

goods24,363Å 17,274Å Inventory\$88,272Å \$73,706Å Property and Equipment, NetProperty and equipment, net consisted of the following (in thousands):June 30,2024December 31,2023Land\$36,765Å \$36,765Å Building146,750Å 146,044Å Laboratory equipment and machinery 70,093Å 69,238Å Computer equipment and software15,631Å 16,379Å Furniture and fixtures10,481Å 10,979Å Leasehold improvements95,307Å 96,405Å Construction in progress\$3,717Å 7,252Å Total property and equipment\$378,744Å 383,062Å Less: accumulated depreciation and amortization (115,459)Å(103,491)Property and equipment, net\$263,285Å \$279,571Å During the six months ended JuneÅ 30, 2024, the Company recorded impairment charges of \$2.1Å million related to computer equipment and software of which \$0.3Å million, \$0.7Å million and \$1.1Å million was classified in cost of revenue, research and 10Table of Contents10x Genomics, Inc.Notes to Unaudited Condensed Consolidated Financial Statementsdevelopment, and selling, general and administrative expenses, respectively, in the condensed consolidated statement of operations. The impairment charge was triggered by a decision to discontinue a productivity engineering project.Accrued Compensation and Related BenefitsAccrued compensation and related benefits were comprised of the following as of the dates indicated (in thousands):June 30,2024December 31,2023Accrued payroll and related costs\$1,602Å \$2,262Å Accrued bonus11,886Å 18,254Å Accrued commissions\$3,637Å 6,410Å Other2,953Å 3,179Å Accrued compensation and related benefits\$20,078Å \$30,105Å Accrued Expenses and Other Current LiabilitiesAccrued expenses and other current liabilities were comprised of the following as of the dates indicated (in thousands):June 30,2024December 31,2023Accrued purchase consideration\$Å \$20,000Å Accrued legal and related costs7,936Å 3,839Å Accrued royalties for licensed technologies8,311Å 5,455Å Accrued property and equipment1,452Å 3,199Å Accrued professional services4,199Å 6,577Å Product warranties9,454Å 8,116Å Taxes payable5,792Å 5,049Å Other5,293Å 4,413Å Accrued expenses and other current liabilities\$42,437Å \$56,648Å Product WarrantiesChanges in the reserve for product warranties were as follows for the periods indicated (in thousands):Six Months EndedJune 30,20242023Beginning of period\$8,116Å \$3,023Å Amounts charged to cost of revenue5,031Å 3,833Å Repairs and replacements(3,693)Å(2,915)End of period\$9,454Å \$3,941Å Revenue and Deferred RevenueAs of JuneÅ 30, 2024, the aggregate amount of remaining performance obligations related to separately sold extended warranty service agreements or allocated amounts for extended warranty service agreements bundled with sales of instruments was \$27.8 million, of which approximately \$16.4 million is expected to be recognized to revenue in the next 12 months, with the 11Table of Contents10x Genomics, Inc.Notes to Unaudited Condensed Consolidated Financial Statementsremainder thereafter. The contract liabilities of \$27.8 million and \$22.0 million as of JuneÅ 30, 2024 and DecemberÅ 31, 2023, respectively, consisted of deferred revenue related to extended warranty service agreements.The following revenue recognized for the periods were included in contract liabilities as of DecemberÅ 31, 2023 and DecemberÅ 31, 2022, respectively (in thousands):Three Months EndedJune 30,Six Months EndedJune 30,2024202320242023Deferred revenue recognized\$3,146Å \$1,856Å \$6,741Å \$3,963Å The following table represents revenue by source for the periods indicated (in thousands). Spatial products include the Company's Visium and Xenium products:Three Months EndedJune 30,Six Months EndedJune 30,2024202320242023InstrumentsChromium\$8,792Å \$12,859Å \$16,642Å \$24,485Å Spatial15,060Å 18,096Å 32,663Å 25,646Å Total instruments revenue23,852Å 30,955Å 49,305Å 50,131Å ConsumablesChromium94,108Å 100,794Å 178,035Å 201,890Å Spatial29,254Å 11,694Å 55,662Å 22,976Å Total consumables revenue123,362Å 112,488Å 233,697Å 224,866Å Services5,890Å 3,376Å 11,108Å 6,107Å Total revenues153,104Å \$146,819Å \$294,110Å \$281,104Å The following table presents revenue by geography based on the location of the customer for the periods indicated (in thousands):Three Months EndedJune 30,Six Months EndedJune 30,2024202320242023AmericasUnited States\$89,672Å \$88,394Å \$165,309Å \$164,675Å Americas (excluding United States)\$3,419Å 3,149Å 7,412Å 5,664Å Total Americas93,091Å 91,543Å 172,721Å 170,339Å Europe, Middle East and Africa37,362Å 31,246Å 72,083Å 59,668Å Asia-PacificChina13,738Å 12,755Å 27,662Å 26,786Å Asia-Pacific (excluding China)8,913Å 11,275Å 21,644Å 24,311Å Total Asia-Pacific22,651Å 24,030Å 49,306Å 51,097Å Total Revenue\$153,104Å \$146,819Å \$294,110Å \$281,104Å A A A A Commitments and ContingenciesLease AgreementsThe Company leases office, laboratory, manufacturing, distribution and server space in various locations worldwide. 12Table of Contents10x Genomics, Inc.Notes to Unaudited Condensed Consolidated Financial StatementsFuture net lease payments related to the Company's operating lease liabilities as of JuneÅ 30, 2024 is as follows (in thousands):OperatingÅ Leases2024 (excluding the six months ended June 30, 2024)\$8,430Å 202514,811Å 202615,359Å 202715,569Å 202815,736Å Thereafter40,639Å Total lease payments\$110,544Å Less: imputed interest(21,062)Å Present value of operating lease liabilities\$89,482Å Operating lease liabilities, current10,820Å Operating lease liabilities, noncurrent78,662Å Total operating lease liabilities\$89,482Å The following table summarizes additional information related to operating leases as of JuneÅ 30, 2024:June 30,2024December 31, 2023Weighted-average remaining lease term7.1 years7.5 yearsWeighted-average discount rate5.9% 5.9% %LitigationThe Company is regularly subject to lawsuits, claims, arbitration proceedings, administrative actions and other legal and regulatory proceedings involving intellectual property disputes, commercial disputes, competition and other matters, and the Company may become subject to additional types of lawsuits, claims, arbitration proceedings, administrative actions, government investigations and legal and regulatory proceedings in the future.NanoStringOn May 6, 2021, the Company filed suit against NanoString Technologies, Inc. (the "NanoString") in the U.S. District Court for the District of Delaware alleging that NanoString's GeoMx Digital Spatial Profiler and associated instruments and reagents infringe U.S. Patent Nos. 10,472,669, 10,662,467, 10,961,566, 10,983,113 and 10,996,219 (the "GeoMx Action"). On May 19, 2021, the Company filed an amended complaint additionally alleging that the GeoMx products infringe U.S. Patent Nos. 11,001,878 and 11,008,607. On May 4, 2022, the Company filed an amended complaint in the GeoMx Action additionally alleging that the GeoMx products infringe U.S. Patent No. 11,293,917 and withdrawing the Company's claims of infringement of U.S. Patent No. 10,662,467. The Company is seeking, among other relief, injunctive relief and unspecified damages (including attorneys' fees) in relation to NanoString's making, using, selling, offering to sell, exporting and/or importing in the United States the GeoMx Digital Spatial Profiler and associated instruments and reagents. NanoString filed its answer to the GeoMx Action on May 18, 2022. A Markman hearing was held on February 17, 2023 and the Court issued its claim construction order on February 28, 2023. On September 7, 2023, the Court issued an order granting the Company's motion for summary judgment that the asserted patents are not invalid for indefiniteness and denying NanoString's motion for summary judgment that the asserted patents are invalid for indefiniteness and lack of written description. On November 17, 2023, a jury found that NanoString willfully infringed the asserted patents and that the asserted patents are valid. The jury awarded the Company more than \$31Å million in damages, consisting of approximately \$25Å million in lost profits and approximately \$6Å million in royalties. Post-trial motions, including the Company's motions for a permanent injunction, ongoing royalties, enhanced damages, attorneys' fees and pre- and post-judgment interest, are pending. NanoString filed for bankruptcy protection under Chapter 11 of the United States Bankruptcy Code in the U.S. bankruptcy court in Delaware on February 4, 2024, and the Court's consideration of these post-trial motions was stayed due to the bankruptcy filing. In May 2024, Bruker Corporation (the "Bruker") acquired certain assets and assumed certain liabilities of NanoString, including the litigation between the Company and NanoString, and the NanoString product lines at issue. Bruker, Bruker Spatial Biology, Inc. and Bruker Nano, Inc. were substituted as defendants in the GeoMx 13Table of Contents10x Genomics, Inc.Notes to Unaudited Condensed Consolidated Financial StatementsAction. Post-trial briefing is complete following supplementation by the parties. Due to the uncertainties in collecting the jury award, the Company has not recorded a receivable from NanoString as of June 30, 2024. On February 28, 2022, the Company filed a second suit against NanoString in the U.S. District Court for the District of Delaware alleging that NanoString's CosMx Spatial Molecular Imager and associated instruments, reagents and services infringe U.S. Patent Nos. 10,227,639 and 11,021,737 (the "CosMx Action"). On May 12, 2022, the Company filed an amended complaint in the CosMx Action additionally alleging that the CosMx products additionally infringe U.S. Patent Nos. 11,293,051, 11,293,052 and 11,293,054. NanoString filed its answer to the CosMx Action on May 26, 2022. On March 1, 2023, the Company filed a second amended complaint additionally alleging that the CosMx products infringe U.S. Patent No. 11,542,554. The Company is seeking, among other relief, injunctive relief and unspecified damages (including attorneys' fees) in relation to NanoString's making, using, selling, offering to sell, exporting and/or importing in the United States the CosMx Spatial Molecular Imager and associated instruments, reagents and services. NanoString filed its answer to the second amended complaint on March 22, 2023. Discovery is in progress. A Markman hearing was held on January 10, 2024, and the Court issued its claim construction order on February 1, 2024. On August 16, 2022, NanoString filed a counterclaim in the CosMx Action alleging that the Company's Visium products infringe U.S. Patent No. 11,377,689 (the "689 patent"). The Company filed its answer to NanoString's counterclaim in the CosMx Action on August 30, 2022. On November 23, 2022, the Company moved to sever claims relating to NanoString's assertion of the 689 patent and consolidate those claims with the patent case NanoString filed against the Company on October 20, 2022 (discussed below). On January 24, 2023, the Court granted the Company's motion. On May 1, 2023, NanoString filed a motion in the CosMx Action to add antitrust, unfair competition, tort and contract counterclaims. NanoString seeks, among other relief, injunction relief (including that the Company grant NanoString a license to the patents that the Company asserted against NanoString in the CosMx Action) and unspecified damages (including attorneys' fees). On July 10, 2023, the Court denied NanoString's motion for leave to add a contract counterclaim but otherwise granted the motion for leave to amend. On May 24, 2023, NanoString filed a motion to bifurcate its amended counterclaims and a motion for expedited discovery. On June 6, 2023, the Court denied NanoString's motion to bifurcate and granted its motion for expedited discovery. Bruker, Bruker Spatial Biology, Inc. and Bruker Nano, Inc. were substituted as defendants in the CosMx Action. Trial is expected in May 2025. The Company believes Bruker's claims are meritless and intends to vigorously defend itself. On October 20, 2022, NanoString filed suit against the Company in the U.S. District Court for the District of Delaware alleging that the Company's Visium products infringe U.S. Patent No. 11,473,142 (the "142 patent"), a continuation of the 689 patent (the "NanoString Action"). NanoString seeks, among other relief, injunctive relief and unspecified damages (including attorneys' fees) in relation to the Company's making, using, selling, offering to sell, exporting and/or importing in the United States Visium products and associated instruments, reagents and services. On January 24, 2023, the Court severed NanoString's claims with respect to the 689 patent from the CosMx Action and consolidated those claims with this action. NanoString filed an amended complaint on January 27, 2023. The Company filed an answer to the NanoString Action on February 10, 2023. Discovery is in progress. A Markman hearing was held on January 10, 2024, and the Court issued its claim construction order on February 1, 2024. Bruker Spatial Biology, Inc. and Bruker Nano, Inc. were substituted as plaintiffs in the NanoString Action in June 2024. A trial date in the NanoString Action has not yet been set. The Company believes these claims in the NanoString Action are meritless and intends to vigorously defend itself. On August 16 and September 25, 2023, the Company filed petitions for inter partes review (the "IPR") of the 689 patent and the 142 patent, respectively. On February 1, 2024, IPR was instituted for the 689 patent. An institution decision for the IPR against the 142 patent is pending. On January 30, 2024, NanoString filed a petition for IPR of U.S. Patent No. 11,542,554 (the "554 patent"), which is asserted by the Company against NanoString in the CosMx Action. An institution decision for the IPR against the 554 patent is pending. On March 9, 2022, the Company filed suit in the Munich Regional Court in Germany alleging that NanoString's CosMx Spatial Molecular Imager and associated instruments, reagents and services infringe EP Patent No. 2794928B1 (the "EP928 patent") (the "Germany CosMx Action"). A hearing on infringement was held on March 23, 2023. On May 17, 2023, the Munich Regional Court found that the CosMx products infringe the EP928 patent and issued a permanent injunction requiring NanoString to stop selling and supplying CosMx instruments and reagents for RNA detection in Germany. The injunction took effect on June 1, 2023. On May 25, 2023, NanoString filed an appeal of the Germany CosMx Action in the Munich Higher Regional Court. A 14Table of Contents10x Genomics, Inc.Notes to Unaudited Condensed Consolidated Financial Statementshearing date has not yet been set for this appeal. On October 30, 2023, NanoString requested that the Higher Regional Court temporarily stay enforcement of the injunction pending the appeal. On December 20, 2023, the Higher Regional Court granted NanoString's request conditioned upon NanoString posting a 2.3Å million Euro security deposit. On July 29, 2022, NanoString filed a nullity action with the German Federal Patent Court challenging the validity of the EP928 patent. On February 10, 2023, the German Federal Patent Court issued a preliminary opinion upholding the validity of certain claims of the EP928 patent directed to in situ analysis. On May 7, 2024, the German Federal Patent Court reversed its preliminary opinion and revoked the German part of the EP928 patent. The Company strongly disagrees with this decision and will appeal the decision. On June 1, 2023, the Company filed requests for preliminary injunctions in the Munich Local Division of the Unified Patent Court (the "UPC") alleging that NanoString's CosMx Spatial Molecular Imager and associated instruments, reagents and services for RNA detection infringe the EP928 patent and EP Patent No. 4108782 (the "EP782 patent"). Hearings were held for the EP782 and EP928 patents on September 5 and September 19, respectively. On September 19, 2023, the UPC granted the Company's request with respect to the EP782 patent and issued a preliminary injunction requiring NanoString to stop selling and supplying CosMx instruments and reagents for RNA detection in all 17 UPC member states. On October 10, 2023, the UPC denied the Company's preliminary injunction request for the EP928 patent. On October 2, 2023, NanoString filed an appeal of the preliminary injunction for the EP782 patent in the UPC Court of Appeals. A hearing was held before the UPC Court of Appeals on December 18, 2023. The UPC Court of Appeals overturned the preliminary injunction on February 26, 2024. On August 31 and September 18, 2023 the Company filed main requests in the Munich Local Division of the UPC alleging that NanoString's CosMx Spatial Molecular Imager and associated instruments, reagents and services for RNA detection infringe the EP782 and EP928 patents, respectively. No hearings have yet been set for these main requests. On July 18, 2023, NanoString filed an opposition in the European Patent Office challenging the validity of the EP782 patent. An oral hearing for this opposition is scheduled on March 18, 2025. On July 27, 2023, NanoString filed a revocation action in the Munich Central Division of the UPC challenging the validity of the EP928 patent. An oral hearing for this revocation action is scheduled for September 18, 2024. Vizgen On May 3, 2022, the Company filed suit against Vizgen, Inc. (the "Vizgen") in the U.S. District Court for the District of Delaware alleging that Vizgen's MERSCOPE Platform and workflow and/or Vizgen's Lab Services program, including associated instruments and reagents, infringe U.S. Patent Nos. 11,021,737, 11,293,051, 11,293,052, 11,293,054 and 11,299,767. The Company seeks, among other relief, injunction relief and unspecified damages (including attorneys' fees) in relation to Vizgen's making, using, selling, offering to sell, exporting and/or importing in the United States the MERSCOPE Platform and workflow and/or Vizgen's Lab Services program, including associated instruments and reagents. On July 25, 2022, Vizgen filed a motion to dismiss the Company's claims for willful and indirect infringement, which the Court denied on September 19, 2022. Discovery is in progress. A Markman hearing was held on January 10, 2024, and the Court issued its claim construction order on February 1, 2024. On August 30, 2022, Vizgen filed its answer and counterclaims alleging that the Company's Xenium product infringes U.S. Patent No. 11,098,303 (the "303 patent"). Vizgen seeks, among other relief, injunction relief and unspecified damages (including attorneys' fees) in relation to the Company's making, using, selling, offering to sell, exporting and/or importing in the United States Xenium products, including associated instruments and reagents. Vizgen also filed counterclaims alleging that the Company tortiously interfered with Vizgen's contractual and business relationship with Harvard and that the Company engaged in unfair practices under Massachusetts state law. On October 27, 2022, the Company filed a partial answer and motion to dismiss the infringement counterclaim and the tort counterclaims. On February 2, 2023, the Company's motion to dismiss was denied. The Company believes Vizgen's claims are meritless and intends to vigorously defend itself. 15Table of Contents10x Genomics, Inc.Notes to Unaudited Condensed Consolidated Financial StatementsOn March 15, 2023, the Company filed an amended complaint additionally alleging that the MERSCOPE Platform and workflow and Vizgen's Lab Services program infringe U.S. Patent No. 11,549,136 and withdrawing its claim of infringement of U.S. Patent No. 11,293,054. On April 17, 2023, Vizgen filed its answer adding amended counterclaims including antitrust, unfair competition, tort and contract counterclaims. Vizgen seeks, among other relief, injunctive relief (including that the Company grant Vizgen a license to the patents that the Company asserted against Vizgen) and unspecified damages (including attorneys' fees). On May 18, 2023, the Company filed a motion to dismiss Vizgen's amended counterclaims. On July 10, 2023, the Court granted the Company's motion to dismiss Vizgen's contract counterclaim but otherwise denied the Company's motion to dismiss. On April 29, 2024, Vizgen amended its counterclaims to add additional antitrust counterclaims based on alleged bundling and predatory pricing. The Company believes Vizgen's claims are meritless and intends to vigorously defend itself. Trial on the Company's claims and on Vizgen's non-patent counterclaims is scheduled for February 2025. A trial date on Vizgen's counterclaim regarding the 303 patent is expected to be set for the second half of 2024. On August 30, 2023, the Company filed a petition for IPR of the 303 patent. Institution was denied on March 7, 2024. 16Table of Contents10x Genomics, Inc.Notes to Unaudited Condensed Consolidated Financial StatementsOn June 1, 2023, the Company filed suit in the Hamburg Local Division of the UPC alleging that Vizgen's MERSCOPE products infringe the EP782 patent. The Company seeks, among other relief, injunction relief and unspecified damages (including attorneys' fees) in relation to Vizgen's MERSCOPE products in all 17 UPC member states. A hearing for this UPC action has not yet been set. Parse On August 24, 2022, the Company filed suit against Parse Biosciences, Inc. (the "Parse") in the U.S. District Court for the District of Delaware alleging that Parse's Evercode Whole Transcriptomics products and ATAC-seq products infringe U.S. Patent Nos. 10,155,981 (the "981 patent"), 10,697,013 (the "013 patent"), 10,240,197 (the "019 patent"), 10,150,995, 10,619,207 and 10,738,357. The Company seeks, among

other relief, injunction relief and unspecified damages (including attorneys' fees) in relation to Parsec's making, using, selling, offering to sell, exporting and/or importing in the United States Parsec's Evercode Whole Transcriptomics products and ATAC-seq products. On October 17, 2022, Parse filed a motion to dismiss alleging that the asserted claims are directed to patent ineligible subject matter. The Court held a hearing on the motion to dismiss on November 22, 2022, and supplemental briefing was submitted on December 15, 2022. On September 14, 2023, the Court denied the motion. Parse filed its answer on October 6, 2023. A Markman hearing was held on February 21, 2024, and the Court issued its claim construction order on May 3, 2024. Trial is scheduled for December 2024. Between April 20 and June 21, 2023, Parse filed petitions for IPR of all of the patents asserted. On October 13, 2023, IPR was instituted on the 981 patent. Oral argument for the 981 IPR took place on July 24, 2024. A final written decision on the 981 IPR is expected in October 2024. The PTAB denied institution of Parsec's petitions for IPR on the other five asserted patents. On January 2 and 5, 2024, Parse filed rehearing requests with the PTAB for the 197 and 013 patents, respectively. On February 5, 2024, the PTAB instituted IPRs for the 197 and 013 patents on Parsec's requests for rehearing. On November 6, 2023, Parse filed a motion to stay the Delaware action pending the IPRs. On December 21, 2023, the court denied Parsec's motion to stay. On February 8, 2024, Parse filed a renewed motion to stay. On February 20, 2024, the court denied Parsec's renewed motion to stay. Curio On December 1, 2023, the Company filed suit against Curio Bioscience, Inc. (a Curio) in the U.S. District Court for the District of Delaware alleging that the Curio Seeker Spatial Mapping Kit and associated products and services infringe U.S. Patent Nos. 10,480,022, 10,662,468, 11,001,879, 11,549,138, and 11,761,030. On February 1, 2024, Curio filed a motion to dismiss alleging that the asserted claims are directed to patent ineligible subject matter. The Court denied that motion on May 9, 2024. On May 31 and June 20, 2024, Curio answered the Complaint and filed antitrust and unfair competition counterclaims. The Company filed a motion to dismiss Curio's unfair competition and antitrust counterclaims on July 5, 2024. The Company believes Curio's counterclaims are meritless and intends to vigorously defend itself. Trial is scheduled for May 2026. On December 4, 2023, the Company filed a request for a preliminary injunction in the Dusseldorf Local Division of the UPC alleging that the Curio Seeker Spatial Mapping Kit and associated products and services infringe EP Patent No. 2697391 (the EP391 patent). A hearing was held on March 26, 2024. On April 30, 2024, the UPC granted the Company's request and issued a preliminary injunction requiring Curio to stop offering, marketing, using or possessing their Curio Seeker products and services in Germany, France and Sweden. Curio did not appeal the preliminary injunction. On March 25, 2024, the Company filed a main request in the Dusseldorf Local Division of the UPC alleging that the Curio Seeker Spatial Mapping Kit and associated products and services infringe the EP391 patent. As of June 30, 2024, the number of shares of Class A common stock and Class B common stock issued and outstanding were 106,417,334 and 14,056,833, respectively. The following table represents the number of shares of Class B common stock converted to shares of Class A common stock upon the election of the holders of such shares during the periods: Table of Contents 10x Genomics, Inc. Notes to Unaudited Condensed Consolidated Financial Statements Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 Class B common stock converted to Class A common stock 4,010,422 4,610,422 6.6 A A A Equity Incentive Plans Stock-based Compensation The Company recorded stock-based compensation expense in the condensed consolidated statement of operations for the periods presented as follows (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 Cost of revenue 2,247 \$1,835 \$4,280 \$3,296 Research and development 17,862 19,560 34,750 37,340 Selling, general and administrative 18,383 24,301 35,591 47,161 Total stock-based compensation expense 38,492 \$45,696 \$74,621 \$87,797 Restricted Stock Units Restricted stock unit activity for the six months ended June 30, 2024 is as follows: Restricted Stock Units Weighted-Average Grant Date Fair Value (per share) Outstanding as of December 31, 2023 334,134 \$48.26 2,703,666 37.45 Vested (977,388) 56.09 Canceled (447,959) 46.89 Outstanding as of June 30, 2024 6,124,534 \$42.78 Stock Options Stock option activity for the six months ended June 30, 2024 is as follows: Stock Options Weighted-Average Exercise Price Outstanding as of December 31, 2023 946,786 \$42.17 Exercised (208,548) 9.05 Canceled and forfeited (326,334) 47.75 Outstanding as of June 30, 2024 4,119,044 \$43.11 Performance Stock Awards In March 2024, the Company granted 219,168 performance stock units (PSUs) under the 2019 Plan to certain members of management which are subject to the achievement of certain performance conditions established by the Company's Compensation Committee of the Board of Directors as described below: 50% of target PSUs earned will be based on the Company's compound annual growth rate (CAGR) of the Company's Revenue over a two-year performance period from January 1, 2024 to December 31, 2025. Holders may earn from 0% to 175% of the target amount of shares and earned PSUs will then be subject to service-based vesting; and 18% Table of Contents 10x Genomics, Inc. Notes to Unaudited Condensed Consolidated Financial Statements 50% of target PSUs earned will be based on the relative Total Shareholder Return (TSR) of the Company's common stock as compared to the TSR of the members of the Russell 3000 Medical Equipment and Services Sector Index over a three-year performance period from January 1, 2024 to December 31, 2026. Depending on the results relative to the TSR market condition, the holders may earn from 0% to 200% of the target amount of shares which will vest at the end of the performance period. The PSUs will be forfeited if the performance conditions are not achieved at the end of the relative performance periods as described above. The vesting of the PSUs can also be triggered upon certain change in control events or in the event of death or disability. The weighted-average grant date fair values of the PSUs relating to CAGR and TSR components were \$37.43 and \$44.80 per share respectively. Stock-based compensation expense recognized for these awards was approximately \$0.7 million and \$0.8 million for the three and six months ended June 30, 2024, respectively. The Company estimated the fair values of shares granted under the market-based TSR PSUs using a Monte Carlo simulation model with the following assumptions: Expected volatility 66% Risk-free interest rate 4.5% Expected dividend yield 0% In March 2023, the Company granted 172,842 PSUs under the 2019 Plan to certain members of management, which are subject to the achievement of certain stock price thresholds established by the Company's Compensation Committee of the Board of Directors. As of June 30, 2024, the performance periods for the 2024 PSUs were not completed and none of the stock price thresholds for the 2023 PSUs had been met resulting in no shares vesting or becoming exercisable. 2019 Employee Stock Purchase Plan A total of 3,686,671 shares of Class A common stock were reserved for issuance under the 2019 Employee Stock Purchase Plan (the ESPP). The price at which Class A common stock is purchased under the ESPP is equal to 85% of the fair market value of the common stock on the first day of the offering period or purchase date, whichever is lower. During the three months ended June 30, 2024 and 2023, 192,869 and 117,280 shares of Class A common stock, respectively, were issued under the ESPP. There were no shares of Class A common stock were issued under the ESPP during the three months ended March 31, 2024 and 2023. As of June 30, 2024, there were 2,898,194 shares available for issuance under the ESPP. 7. A A A Net Loss Per Share The following outstanding shares of common stock equivalents were excluded from the computation of diluted net loss per share for the periods presented because including them would have had an anti-dilutive effect: Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 Stock options to purchase common stock 5,411,904 7,007,627 5,411,904 7,007,627 Restricted stock units 6,124,534 6,433,832 6,124,534 6,433,832 Shares committed under ESPP 89,193 34,718 89,193 34,718 Total 12,113,550 13,476,177 12,113,550 13,476,177 Table of Contents Item 2. A A Management's Discussion and Analysis of Financial Condition and Results of Operations. You should read the following discussion of our financial condition and results of operations in conjunction with our unaudited condensed consolidated financial statements and the related notes and other financial information included elsewhere in this Quarterly Report and our audited consolidated financial statements and notes thereto and the section titled "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 filed with the SEC on February 15, 2024 (our "Annual Report"). As discussed in the section titled "Special Note Regarding Forward-Looking Statements," the following discussion and analysis, in addition to historical financial information, contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth in the section titled "Risk Factors" in this Quarterly Report and Part I, Item 1A of our Annual Report. In addition, statements that we believe and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this Quarterly Report and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements. Overview We are a life sciences technology company focused on building innovative products and solutions to interrogate, understand and master biology. Our integrated solutions include instruments, consumables and software for analyzing biological systems at resolution and scale that matches the complexity of biology. We have launched multiple products that enable researchers to understand and interrogate biological analytes in their full biological context. Our commercial product portfolio leverages our Chromium X Series and Chromium Connect instruments, which we refer to as Chromium instruments, our Visium CytAssist, an instrument designed to simplify the Visium solution workflow by facilitating the transfer of transcriptomic probes from standard glass slides to Visium slides, and our Xenium Analyzer, an instrument designed for fully automated high-throughput analysis of cells in their tissue environment, which we refer to as Spatial instruments, and our proprietary microfluidic chips, slides, reagents and other consumables for our Chromium, Visium and Xenium solutions, which we refer to as consumables. We bundle our software with these products to guide customers through the workflow, from sample preparation through analysis and visualization. Our products cover a wide variety of applications and allow researchers to analyze biological systems at fundamental resolutions and on massive scale, such as at the single cell level for millions of cells. Customers purchase instruments and consumables from us for use in their experiments. In addition to instrument and consumable sales, we derive revenue from post-warranty service contracts for our instruments. Since our inception in 2012, we have incurred net losses in each year. Our net losses were \$37.9 million and \$97.8 million for the three and six months ended June 30, 2024 and \$62.4 million and \$113.2 million for the three and six months ended June 30, 2023, respectively. As of June 30, 2024, we had an accumulated deficit of \$1.4 billion and cash, cash equivalents and marketable securities totaling \$380.1 million. We expect to continue to incur significant expenses for the foreseeable future and to incur operating losses in the near term. We expect our expenses will increase in connection with our ongoing activities, as we: attract, hire and retain qualified personnel; scale our technology platforms and introduce new products and services; protect and defend our intellectual property; acquire businesses or technologies; and invest in processes, tools and infrastructure to support the growth of our business. Table of Contents Comparison of the Three and Six Months Ended June 30, 2024 and 2023 Revenue Three Months Ended June 30, Change Six Months Ended June 30, Change (dollars in thousands) 2024 2023 % 2024 2023 % Instruments Chromium \$8,792 \$12,859 (4,067) (32)% \$16,642 \$24,485 (\$7,843) (32)% Spatial 15,060 18,096 (3,036) (17)% 32,663 25,646 7,017 27% Total instruments revenue 23,852 30,955 (7,103) (23)% 49,305 50,131 (826) (2)% Consumables Chromium 94,108 100,794 (6,686) (7)% 178,035 201,890 (23,855) (12)% Spatial 29,254 11,694 17,560 150% 55,662 22,976 32,686 142% Total consumables revenue 123,362 112,488 10,874 10% 233,697 224,866 8,831 4% Services 5,890 3,376 2,514 74% 11,108 6,107 5,001 82% Total revenue 153,104 \$146,819 \$6,285 4% \$294,110 \$281,104 \$13,006 5% Revenue increased \$6.3 million, or 4%, to \$153.1 million for the three months ended June 30, 2024 as compared to the three months ended June 30, 2023. Instruments revenue decreased \$7.1 million, or 23%, to \$23.9 million for the three months ended June 30, 2024 as compared to the three months ended June 30, 2023, primarily due to lower volume of Chromium and Spatial instruments sold. Consumables revenue increased \$10.9 million, or 10%, to \$123.4 million for the three months ended June 30, 2024 as compared to the three months ended June 30, 2023, primarily driven by higher Spatial consumables sales. Revenue increased \$13.0 million, or 5%, to \$294.1 million for the six months ended June 30, 2024 as compared to the six months ended June 30, 2023. Instruments revenue decreased \$0.8 million, or 2%, to \$49.3 million for the six months ended June 30, 2024 as compared to the six months ended June 30, 2023, primarily due to lower volume of Chromium instruments sold, partially offset by higher volume of Spatial instruments sold. Consumables revenue increased \$8.8 million, or 4%, to \$233.7 million for the six months ended June 30, 2024 as compared to the six months ended June 30, 2023, primarily driven by growth in Spatial consumables sales partially offset by lower Chromium consumables sales. Cost of revenue, gross profit and gross margin Three Months Ended June 30, Change Six Months Ended June 30, Change (dollars in thousands) 2024 2023 % 2024 2023 % Cost of revenue \$48,884 \$47,207 \$1,677 4% \$96,976 \$83,102 \$13,874 17% Gross profits 104,220 \$99,612 \$4,608 5% \$197,134 \$198,002 (\$868) -4% Gross margin 68% 68% 67% 70% Cost of revenue increased \$1.7 million, or 4%, to \$48.9 million for the three months ended June 30, 2024 as compared to the three months ended June 30, 2023. The increase was primarily driven by higher manufacturing costs of \$2.3 million due to increased sales and higher costs associated with newly introduced products and \$0.9 million of higher warranty charges, partially offset by lower inventory write-downs of \$1.5 million. Gross margin remained flat at 68%. Cost of revenue increased \$13.9 million, or 17%, to \$97.0 million for the six months ended June 30, 2024 as compared to the six months ended June 30, 2023. The increase was primarily driven by higher manufacturing costs of \$12.7 million due to increased sales and higher costs of newly introduced products and \$2.9 million of higher warranty charges, partially offset by lower inventory write-downs of \$1.8 million. Gross margin percentage decreased by 3% points to 67% primarily due to change in product mix and higher royalties. Table of Contents We expect our gross margin to continue to fluctuate due to product mix and the impact of royalty obligations which vary by product. Three Months Ended June 30, Change Six Months Ended June 30, Change (dollars in thousands) 2024 2023 % 2024 2023 % Research and development \$62,918 \$71,460 (\$8,542) (12)% \$131,556 \$138,558 (\$7,002) (5)% Selling, general and administrative 83,039 91,510 (8,471) (9)% 168,813 174,790 (5,977) (3)% Total operating expenses \$145,957 \$162,970 (\$17,013) (10)% \$300,369 \$313,348 (\$12,979) (4)% Research and development expenses decreased \$8.5 million, or 12%, to \$62.9 million for the three months ended June 30, 2024, as compared to the three months ended June 30, 2023. The decrease was primarily driven by \$4.5 million of lower laboratory materials and supplies used to support our research and development efforts, decrease in personnel expenses of \$2.5 million, including a decrease of \$1.7 million in stock-based compensation expense, and decrease in other expenses of \$0.7 million. Research and development expenses decreased \$7.0 million, or 5%, to \$131.6 million for the six months ended June 30, 2024, as compared to the six months ended June 30, 2023. The decrease was primarily driven by lower laboratory materials, supplies and expensed equipment of \$4.5 million used to support our research and development efforts, lower personnel expenses of \$1.8 million, including a decrease of \$2.6 million in stock-based compensation expense, and a decrease in consulting and professional services of \$0.9 million. Selling, general and administrative expenses decreased \$8.5 million, or 9%, to \$83.0 million for the three months ended June 30, 2024, as compared to the three months ended June 30, 2023. The decrease was primarily driven by \$6.9 million of lower personnel expenses, including a decrease of \$5.9 million in stock-based compensation expense, a decrease in facilities and information technology expenses of \$3.5 million and a decrease in marketing expenses related to conferences and seminars of \$2.4 million, partially offset by an increase in outside legal expenses of \$3.5 million. Facilities and information technology costs includes a one-time lease impairment charge of \$2.8 million in the three months ended June 30, 2023. Selling, general and administrative expenses decreased \$6.0 million, or 3%, to \$168.8 million for the six months ended June 30, 2024, as compared to the six months ended June 30, 2023. The decrease was primarily driven by lower personnel expenses of \$12.4 million, including a decrease of \$11.6 million in stock-based compensation expense, a decrease in marketing expenses related to conferences and seminars of \$2.1 million and a decrease in facilities and information technology expenses supporting operational expansion of \$1.5 million, partially offset by an increase in outside legal expenses of \$9.4 million. Facilities and Information Technology costs includes a one-time lease impairment charge of \$2.8 million in the six months ended June 30, 2023. During the six months ended June 30, 2024, the Company recorded impairment charges of \$2.1 million related to computer equipment and software of which \$1.1 million was classified as selling, general and administrative expenses in the condensed consolidated statement of operations. The impairment charge was triggered by a decision to discontinue a software project. Excluding acquisitions, we expect our operating expenditures to continue to increase in 2024 and beyond as we increase our investment in new and existing research and development projects, commercial efforts to support revenue growth and incentives to retain key talent. In addition, we expect increased legal costs in remaining quarters of 2024 to support the protection of our intellectual property portfolio. Other income (expense), net Three Months Ended June 30, Change Six Months Ended June 30, Change (dollars in thousands) 2024 2023 % 2024 2023 % Interest income \$4,715 \$4,100 \$615 15% \$9,451 \$7,969 \$1,482 19% Interest expense (1)(5) (80) (2)(24) 22% Other expense, net (56)(1,504) 1,448 (96)(1,096) (3)(20) 92% Total other income \$4,658 \$2,591 \$2,067 80% \$8,353 \$4,925 \$3,428 70% Table of Contents Interest income increased by \$0.6 million or 15% to \$4.7 million for the three months ended June 30, 2024 as compared to the three months ended June 30, 2023. Interest income increased by \$1.5 million, or 19%, to \$9.5 million for the six months ended June 30, 2024 as compared to the six months ended June 30, 2023. The increase was primarily due to interest income generated from our cash equivalents and marketable securities during the three and six months ended June 30, 2024 reflecting an increase in interest rates. Other expense, net decreased by \$1.4 million, or 96% to

\$0.1 million for the three months ended June 30, 2024 as compared to the three months ended June 30, 2023. Other expense, net decreased by \$1.9 million, or 64% to \$1.1 million for the six months ended June 30, 2024 as compared to the six months ended June 30, 2023. The decrease was driven by realized and unrealized losses from foreign currency rate measurement fluctuations. Provision for Income Taxes The Company's provision for income taxes was \$0.8 million and \$3.0 million, respectively, for the three and six months ended June 30, 2024, and \$1.6 million and \$2.7 million, respectively, for the three and six months ended June 30, 2023. The decrease of \$0.8 million for the three months ended June 30, 2024 as compared to the three months ended June 30, 2023 is primarily due to lower foreign income. The provision for income taxes remained flat for the six months ended June 30, 2024 as compared to the six months ended June 30, 2023. Deferred tax assets related to our domestic operations are fully offset by a valuation allowance. Liquidity and Capital Resources As of June 30, 2024, we had \$380.1 million in cash and cash equivalents and marketable securities. We have generated negative cumulative cash flows from operations since inception through June 30, 2024, and we have generated losses from operations since inception as reflected in our accumulated deficit of \$1.4 billion. We currently anticipate making aggregate capital expenditures of between approximately \$15 million and \$20 million during the next 12 months, which we expect to include, among other expenditures, equipment to be used for manufacturing and research and development. Our future capital requirements will depend on many factors including our revenue growth rate, research and development efforts, investments in or acquisitions of complementary or enhancing technologies or businesses, the timing and extent of additional capital expenditures to invest in existing and new facilities, the expansion of sales and marketing and international activities, legal costs associated with defending and enforcing intellectual property rights and the introduction of new products. We take a long-term view in growing and scaling our business and we regularly review acquisition and investment opportunities, and we may in the future enter into arrangements to acquire or invest in businesses, real estate, services and technologies, including intellectual property rights, and any such acquisitions or investments could significantly increase our capital needs. We regularly review opportunities that meet our long-term growth objectives. We expect to continue to incur operating losses for the foreseeable future. We believe that our existing cash and cash equivalents and cash generated from sales of our products will be sufficient to meet our anticipated cash needs for at least the next 12 months. However, our liquidity assumptions may prove to be incorrect, and we could exhaust our available financial resources sooner than we currently expect. We maintain the majority of our cash and cash equivalents in accounts with major U.S. and multi-national financial institutions, and our deposits at these institutions exceed insured limits. Market conditions can impact the viability of these institutions. In the event of failure of any of the financial institutions where we maintain our cash and cash equivalents, there can be no assurance that we would be able to access uninsured funds in a timely manner or at all. Any inability to access or delay in accessing these funds could adversely affect our business and financial position. We intend to continue to evaluate market conditions and may in the future pursue additional sources of funding, such as mortgage or other financing, to further enhance our financial position and to execute our business strategy. In addition, should prevailing economic, financial, business or other factors adversely affect our ability to meet our operating cash requirements, we could be required to obtain funding through traditional or alternative sources of financing. We cannot be certain that additional funds would be available to us on favorable terms when required, or at all. Sources of liquidity Table of Contents Since our inception, we have financed our operations and capital expenditures primarily through sales of convertible preferred stock and common stock, revenue from sales of our products and the incurrence of indebtedness. The following table summarizes our cash flows for the periods indicated: Six Months Ended June 30, (in thousands) 2024 2023 Net cash provided by (used in): Operating activities \$(8,229) \$(15,651) Investing activities \$2,579 \$115,494 Financing activities \$6,241 \$3,682 Effect of exchange rate changes on cash, cash equivalents, and restricted cash (51) (25) Net increase in cash and cash equivalents \$20,540 \$103,500 Operating activities The net cash used in operating activities of \$8.2 million for the six months ended June 30, 2024 was primarily due to a net loss of \$97.8 million, net cash outflow from changes in operating assets and liabilities of \$10.4 million, primarily offset by stock-based compensation expense of \$74.6 million, depreciation and amortization of \$18.2 million, lease and asset impairment charges of \$2.5 million, amortization of leased right-of-use assets of \$4.2 million, and other non-cash expenses of \$0.5 million. The net cash outflow from operating assets and liabilities was primarily due to a decrease in accrued expenses and other current liabilities of \$12.1 million primarily driven by payments related to purchase consideration and royalty payments, an increase in inventory of \$15.1 million, a decrease in accrued compensation and other related benefits of \$10.0 million related to the prior year annual bonus payments and a decrease in operating lease liability of \$5.6 million. The net cash outflow from operating assets and liabilities was partially offset by an increase in accounts receivable of \$23.6 million due to timing of collections, an increase in accounts payable of \$5.7 million and an increase in deferred revenue of \$5.8 million. The net cash used in operating activities of \$15.7 million for the six months ended June 30, 2023 was primarily due to a net loss of \$113.2 million, net cash outflow from changes in operating assets and liabilities of \$15.9 million, primarily offset by stock-based compensation expense of \$87.8 million, depreciation and amortization of \$16.4 million, amortization of leased right-of-use assets of \$4.1 million, lease impairment charges of \$2.8 million, realized losses on sale of marketable securities of \$1.7 million and other non-cash expenses of \$0.6 million. The net cash outflow from operating assets and liabilities was primarily due to an increase in other noncurrent assets of \$18.1 million primarily due to an upfront payment for an intellectual property license of \$10.0 million and a legal security deposit of \$7.8 million, a decrease in accrued compensation and other related benefits of \$10.3 million primarily related to the prior year annual bonus payments, a decrease in operating lease liability of \$4.5 million, an increase in inventory of \$2.3 million, and a decrease in prepaid expenses and other current assets of \$2.1 million. The net cash outflow from operating assets and liabilities was partially offset by a decrease of accounts receivable of \$16.5 million due to timing of collections, an increase in deferred revenue of \$2.9 million, and an increase in accounts payable of \$1.3 million due to timing of vendor payments. Investing activities The net cash provided by investing activities of \$22.6 million in the six months ended June 30, 2024 was due to proceeds from sales and maturities of marketable securities of \$3.6 million and \$25.8 million, respectively, partially offset by purchases of property and equipment and intangible assets of \$5.8 million and \$1.0 million, respectively. The net cash provided by investing activities of \$115.5 million in the six months ended June 30, 2023 was due to proceeds from sales and maturities of marketable securities of \$94.9 million and \$51.2 million, respectively, partially offset by purchases of property and equipment and intangible assets of \$29.9 million and \$0.7 million, respectively. Financing activities The net cash provided by financing activities of \$6.2 million in the six months ended June 30, 2024 was primarily from proceeds related to the issuance of common stock from the exercise of stock options and employee stock purchase plan. Table of Contents The net cash provided by financing activities of \$3.7 million in the six months ended June 30, 2023 was primarily from proceeds of \$9.5 million from the issuance of common stock from the exercise of stock options and employee stock purchase plan, partially offset by payments on financing arrangements of \$5.8 million. Critical Accounting Estimates Our condensed consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (the GAAP) for interim financial information and the applicable rules and regulations of the SEC. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenues and expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. There have been no significant changes in our critical accounting policies and estimates during the six months ended June 30, 2024 as compared to the critical accounting policies and estimates disclosed in the section titled "Management's Discussion and Analysis of Financial Condition and Results of Operations" included in our most recent Annual Report on Form 10-K filed with the SEC on February 15, 2024. Item 3. Quantitative and Qualitative Disclosures About Market Risk. For financial market risks related to changes in interest rates and foreign currency exchange rates, reference is made to Item 7A "Quantitative and Qualitative Disclosures About Market Risk" contained in Part II of our Annual Report. Our exposure to market risk has not changed materially since December 31, 2023. Item 4. Controls and Procedures. Evaluation of Disclosure Controls and Procedures Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we evaluated the effectiveness of the design and operation of our disclosure controls and procedures pursuant to Rule 13a-15(e) and 15d-15(e) under the Exchange Act as of the end of the period covered by this Quarterly Report. Our disclosure controls and procedures are designed to ensure that information required to be disclosed in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms, and that such information is accumulated and communicated to our management, including the Chief Executive Officer and the Chief Financial Officer, to allow timely decisions regarding required disclosures. Any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objective and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective at a reasonable assurance level as of June 30, 2024. Changes in Internal Control over Financial Reporting There have been no changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) under the Exchange Act) during the quarter ended June 30, 2024 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. Table of Contents 10x Genomics, Inc. PART II OTHER INFORMATION Item 1. Legal Proceedings. We are regularly subject to lawsuits, claims, arbitration proceedings, administrative actions and other legal and regulatory proceedings involving intellectual property disputes, commercial disputes, competition and other matters, and we may become subject to additional types of lawsuits, claims, arbitration proceedings, administrative actions, government investigations and legal and regulatory proceedings in the future and as our business grows, including proceedings related to product liability or our acquisitions, securities issuances or our business practices, including public disclosures about our business. Our success depends in part on our non-infringement of the patents or proprietary rights of third parties. In the past, third parties have asserted and may in the future assert that we are employing their proprietary technology without authorization. We have been involved in multiple patent litigation matters and other proceedings in the past and we expect that given the litigious history of our industry and the high profile of operating as a public company, third parties may claim that our products infringe their intellectual property rights. We have also initiated litigation to defend our technology including technology developed through our significant investments in research and development. It is our general policy not to out-license our patents but to protect our sole right to own and practice them. There are inherent uncertainties in these legal matters, some of which are beyond management's control, making the ultimate outcomes difficult to predict. Refer to Note 4 to our unaudited condensed consolidated financial statements included elsewhere in this Quarterly Report. Item 1A. Risk Factors. There have been no material changes to our risk factors that we believe are material to our business, results of operations and financial condition from the risk factors previously disclosed in our Annual Report, and any documents incorporated by reference therein, which is accessible on the SEC's website at www.sec.gov. Item 5. Other Information. None of our directors or officers adopted, modified or terminated a Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement during the quarter ended June 30, 2024, as such terms are defined under Item 408(a) of Regulation S-K. Table of Contents Item 6. Exhibits. Exhibit Number Incorporated by Reference Exhibit Title Form File No. Exhibit Filing Date Filed Herewith 3.1 Amended and Restated Certificate of Incorporation of the Registrant. 8-K001-390353.19/16/2019.3.2 Amended and Restated Bylaws of the Registrant. 10-Q001-390353.21/13/2024.1 Form of Stock Certificate for Class A common stock of the Registrant. S-1333-233361.4.28/19/2019.1.1 Amended and Restated Non-Employee Director Compensation Policy. X31.1 Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. X31.2 Certification of Principal Financial and Accounting Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. X32.1 Certification of Principal Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. X101.INS Inline XBRL Instance Document. 101.SCH Inline XBRL Taxonomy Extension Schema Document. 101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document. 101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document. 101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document. 101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document. 104 Cover Page Interactive Data File (the Cover Page Interactive Data File does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document). *A This certification is deemed not filed for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act. + A Management contract or compensatory plan or arrangement. 27 Table of Contents Signatures Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. 10x Genomics, Inc. Date: August 8, 2024 By: /s/ Justin J. McAnear Justin J. McAnear Chief Financial Officer (Principal Financial and Accounting Officer) 28 EX-10.1 20240630xex101.htm EX-10.1 Document 6230 Stoneridge Mall Road Pleasanton, CA 94588-3260925 401 730010xgenomics.com Exhibit 10.1 10x Genomics, Inc. Non-Employee Director Compensation Policy (Amended and Restated Effective as of April 26, 2024) Purpose The purpose of this Non-Employee Director Compensation Policy (this Policy) is to establish the cash and equity compensation for non-employee members of the Board of Directors (the Board) of 10x Genomics, Inc. (the Company) in a manner that aligns their interests with those of the Company's shareholders and is competitive with comparable companies. The cash and equity compensation described in this Policy shall be paid or be made, as applicable, automatically and without further action of the Board, or any committee or subcommittee thereof, to each member of the Board who is not an employee of the Company or any parent or subsidiary of the Company (each, a Non-Employee Director) who may be eligible to receive such cash or equity compensation, unless such Non-Employee Director declines the receipt of such cash or equity compensation by written notice to the Company. Effective Date This Policy as amended and restated is effective as of April 26, 2024 (the Effective Date), and shall remain in effect until it is revised or rescinded by further action of the Board. Compensation 1 Cash Compensation. Effective as of the Effective Date: Annual Retainers. Each Non-Employee Director shall receive an annual retainer of \$55,000 for service on the Board. Additional Annual Retainers. In addition to the annual retainer in Section 1(a), the Non-Employee Director serving as the Chair of the Board and each Non-Employee Director serving as a member or chair, as applicable, of the following committees of the Board shall receive an additional annual retainer for such service as follows: Chair of the Board: \$50,000 Audit Committee Chair: \$25,000 Audit Committee Member: \$10,000 Compensation Committee Chair: \$18,250 Compensation Committee Member: \$8,000 Nominating and Corporate Governance Chair: \$12,500 Nominating and Corporate Governance Member: \$5,000 10xgenomics.com Payment of Retainers. The annual retainers described in Section 1(a) and Section 1(b) shall be earned on a quarterly basis based on a calendar quarter and shall be paid by the Company in arrears not later than the fifteenth day following the end of each calendar quarter. In the event a member of the Board does not serve as a Non-Employee Director, or in the applicable positions described in Section 1(b), for an entire calendar quarter, such Non-Employee Director shall receive a prorated portion of the retainer(s) otherwise payable to such Non-Employee Director for such calendar quarter pursuant to Section 1(a) and Section 1(b), as applicable, with such prorated portion determined by multiplying such otherwise payable retainer(s) by a fraction, the numerator of which is the number of days during which the member of the Board serves as a Non-Employee Director or in the applicable positions described in Section 1(b) during the applicable calendar quarter and the denominator of which is the number of days in the applicable calendar quarter. Reimbursement of Expenses. The Company shall reimburse each Non-Employee Director for all reasonable and documented travel and lodging expenses associated with attendance at Board and committee meetings. 2 Equity Compensation. Non-Employee Directors shall be granted the equity awards described below. The awards described below shall be granted under and shall be subject to the terms and provisions of the Company's 2019 Omnibus Incentive Plan or any other applicable Company equity incentive plan then maintained by the Company (such plan, as may be amended from time to time, the 2019 Plan) and shall be granted subject to the execution and delivery of applicable award agreement(s), including any exhibits attached thereto. All applicable terms of the 2019 Plan and any award agreement thereunder shall apply to this Policy as if fully set forth herein. Annual Awards. Each Non-Employee Director who (i) serves on the Board as of the date of any annual meeting of the Company's stockholders (an Annual Meeting) after the Effective Date and (ii) will continue to serve as a Non-Employee Director immediately following such Annual Meeting shall be automatically granted, on the date of such Annual Meeting, a number of restricted stock units that will, upon vesting, settle in shares of Class A Common Stock, which number shall be determined by dividing \$215,000 by the average closing price per share of Class A Common Stock over the 20 trading days commencing on the first day of the most recent open trading window preceding such Annual Meeting (with the number of shares of Class A Common Stock underlying such restricted stock unit award subject to adjustment as provided in the 2019 Plan). The awards described in this Section 2(a) shall be referred to as the Annual Awards. For the avoidance of doubt, a Non-Employee Director elected for the first time to the Board at an Annual Meeting shall only receive an Annual Award in connection with such

election, and shall not receive any Initial Award (as defined below), b)Initial Awards. Each Non-Employee Director who is initially elected or appointed to the Board after the Effective Date on any date other than the date of an Annual Meeting shall be automatically granted, on the last business day of the month that follows the month in which such Non-Employee Director's initial election or appointment occurred (such last business day, the "Initial Award Grant Date"), a number of restricted stock units that will, upon vesting, settle in shares of Class A Common Stock, which number shall be determined by dividing \$400,000 by the average closing price per share of Class A Common Stock over the first 20 trading days of the month that immediately follows the month in which such Non-Employee Director's initial election or appointment occurred (with the number of shares of Class A Common Stock underlying such restricted stock unit award subject to adjustment as provided in the 2019 Plan). The awards described in this Section 2(b) shall be referred to as "Initial Awards." For the avoidance of doubt, no Non-Employee Director shall be granted more than one Initial Award.

210xgenomics.comTermination of Employment of Employee Directors. Members of the Board who are employees of the Company or any parent or subsidiary of the Company who, following the Effective Date, terminate their employment with the Company and any parent or subsidiary of the Company and remain on the Board will not receive an Initial Award pursuant to Section 2(b) above, but to the extent that they are otherwise eligible, will be eligible to receive, after termination from employment with the Company and any parent or subsidiary of the Company, Annual Awards as described in Section 2(a) above.

v)Vesting of Awards Granted to Non-Employee Directors. Subject to the Non-Employee Director continuing in service through each applicable vesting date: i)Annual Award. Each Annual Award of restricted stock units shall vest in four equal quarterly installments following the date of the Annual Meeting on which such Annual Award is granted, with one fourth of such Annual Award of restricted stock units vesting on the first to occur, on or following the date of the Annual Meeting on which such Annual Award is granted, of February 21, May 21, August 21 or November 21 following the date of such Annual Meeting, and one fourth of each Annual Award of restricted stock units vesting quarterly thereafter. ii)Initial Award. Each Initial Award of restricted stock units shall vest as to one-third of such award on the first anniversary of the first to occur, on or following the date on which such Annual Award is granted, of February 21, May 21, August 21 or November 21 following the Initial Award Grant Date and thereafter vest in equal quarterly installments for the following two years. iii)Termination. No portion of an Annual Award or Initial Award that is invested at the time of a Non-Employee Director's termination of service on the Board shall become vested thereafter. iv)Change in Control. All of the Annual Awards and Initial Awards shall vest in full immediately prior to the occurrence of a Change in Control (as defined in the 2019 Plan), to the extent outstanding and unvested at such time. Compensation Limits Notwithstanding anything to the contrary in this Policy, all compensation payable under this Policy will be subject to any limits on the maximum amount of Non-Employee Director compensation set forth in the 2019 Plan, as in effect from time to time. Modifications to the Policy This Policy may be amended, modified or terminated at any time by action by the Board in its sole discretion. The terms and conditions of this Policy shall supersede any prior cash and/or equity compensation arrangements for service as a member of the Board between the Company and any of its Non-Employee Directors and between any subsidiary of the Company and any of its non-employee directors. No Non-Employee Director shall have any rights hereunder, except with respect to equity awards granted pursuant to this Policy following grant thereof. * * * * * EX-31.1 3 txcg-20240630ex311.htm EX-31.1 DocumentExhibit 31.1 CERTIFICATION OF PERIODIC REPORT UNDER SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002I, Serge Saxonov, certify that: 1. I have reviewed this Quarterly Report on Form 10-Q of 10x Genomics, Inc.; 2. I am based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3. I am based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 4. I am the registrant's other certifying officer and I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting. 5. I am the registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. Date: August 8, 2024 By: /s/ Serge Saxonov Serge Saxonov Chief Executive Officer and Director (Principal Executive Officer) EX-31.2 4 txcg-20240630ex312.htm EX-31.2 DocumentExhibit 31.2 CERTIFICATION OF PERIODIC REPORT UNDER SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002I, Justin J. McAnear, certify that: 1. I have reviewed this Quarterly Report on Form 10-Q of 10x Genomics, Inc.; 2. I am based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3. I am based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 4. I am the registrant's other certifying officer and I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting. 5. I am the registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. Date: August 8, 2024 By: /s/ Justin J. McAnear Justin J. McAnear Chief Financial Officer (Principal Financial and Accounting Officer) EX-32.1 5 txcg-20240630ex321.htm EX-32.1 DocumentExhibit 32.1 CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, I, Serge Saxonov, the Chief Executive Officer of 10x Genomics, Inc. (the "Company"), hereby certify, that, to my knowledge: 1. The Quarterly Report on Form 10-Q for the period ended June 30, 2024 (the "Report") of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and 2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Date: August 8, 2024 By: /s/ Serge Saxonov Serge Saxonov Chief Executive Officer and Director (Principal Executive Officer) EX-32.2 6 txcg-20240630ex322.htm EX-32.2 DocumentExhibit 32.2 CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, I, Justin J. McAnear, the Chief Financial Officer of 10x Genomics, Inc. (the "Company"), hereby certify, that, to my knowledge: 1. The Quarterly Report on Form 10-Q for the period ended June 30, 2024 (the "Report") of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and 2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Date: August 8, 2024 By: /s/ Justin J. McAnear Justin J. McAnear Chief Financial Officer (Principal Financial and Accounting Officer) EX-101.SCH 7 txcg-20240630.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page link: presentationLink link: calculationLink link: definitionLink link: definitionLink 9952151 - Statement - Condensed Consolidated Balance Sheets link: presentationLink link: calculationLink link: definitionLink 9952152 - Statement - Condensed Consolidated Statements of Operations link: presentationLink link: calculationLink link: definitionLink 9952153 - Statement - Condensed Consolidated Statements of Comprehensive Loss link: presentationLink link: calculationLink link: definitionLink 9952154 - Statement - Condensed Consolidated Statements of Stockholders' Equity link: presentationLink link: calculationLink link: definitionLink 9952155 - Statement - Condensed Consolidated Statements of Cash Flows link: presentationLink link: calculationLink link: definitionLink 9952156 - Disclosure - Description of Business and Basis of Presentation link: presentationLink link: calculationLink link: definitionLink 9952157 - Disclosure - Summary of Significant Accounting Policies link: presentationLink link: calculationLink link: definitionLink 9952158 - Disclosure - Other Financial Statement Information link: presentationLink link: calculationLink link: definitionLink 9952159 - Disclosure - Commitments and Contingencies link: presentationLink link: calculationLink link: definitionLink 9952160 - Disclosure - Capital Stock link: presentationLink link: calculationLink link: definitionLink 9952161 - Disclosure - Equity Incentive Plans link: presentationLink link: calculationLink link: definitionLink 9952162 - Disclosure - Net Loss Per Share link: presentationLink link: calculationLink link: definitionLink 9954471 - Disclosure - Summary of Significant Accounting Policies (Policies) link: presentationLink link: calculationLink link: definitionLink 9954472 - Disclosure - Other Financial Statement Information (Tables) link: presentationLink link: calculationLink link: definitionLink 9954473 - Disclosure - Commitments and Contingencies (Tables) link: presentationLink link: calculationLink link: definitionLink 9954474 - Disclosure - Capital Stock (Tables) link: presentationLink link: calculationLink link: definitionLink 9954475 - Disclosure - Equity Incentive Plans (Tables) link: presentationLink link: calculationLink link: definitionLink 9954476 - Disclosure - Net Loss Per Share (Tables) link: presentationLink link: calculationLink link: definitionLink 9954477 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail) link: presentationLink link: calculationLink link: definitionLink 9954478 - Disclosure - Other Financial Statement Information - Available-for-Sale Securities (Details) link: presentationLink link: calculationLink link: definitionLink 9954479 - Disclosure - Other Financial Statement Information - Contractual Maturities of Marketable Securities (Details) link: presentationLink link: calculationLink link: definitionLink 9954480 - Disclosure - Other Financial Statement Information - Additional Information (Details) link: presentationLink link: calculationLink link: definitionLink 9954481 - Disclosure - Other Financial Statement Information - Schedule of Inventory (Details) link: presentationLink link: calculationLink link: definitionLink 9954482 - Disclosure - Other Financial Statement Information - Schedule Of Property Plant And Equipment (Detail) link: presentationLink link: calculationLink link: definitionLink 9954483 - Disclosure - Other Financial Statement Information - Schedule of Accrued Compensation and Related Benefits (Details) link: presentationLink link: calculationLink link: definitionLink 9954484 - Disclosure - Other Financial Statement Information - Schedule of Accrued Expense And Other Current Liabilities (Details) link: presentationLink link: calculationLink link: definitionLink 9954485 - Disclosure - Other Financial Statement Information - Schedule of Changes in the Reserve for Product Warranties (Details) link: presentationLink link: calculationLink link: definitionLink 9954486 - Disclosure - Other Financial Statement Information - Schedule of Revenue of Recognized in Contract Liabilities (Details) link: presentationLink link: calculationLink link: definitionLink 9954487 - Disclosure - Other Financial Statement Information - Schedule of Revenue by Source (Details) link: presentationLink link: calculationLink link: definitionLink 9954488 - Disclosure - Other Financial Statement Information - Schedule of Revenue by Geographic Region (Details) link: presentationLink link: calculationLink link: definitionLink 9954489 - Disclosure - Commitments and Contingencies - Schedule of Company's Operating Lease Liabilities (Detail) link: presentationLink link: calculationLink link: definitionLink 9954489 - Disclosure - Commitments and Contingencies - Schedule of Company's Operating Lease Liabilities (Detail) link: presentationLink link: calculationLink link: definitionLink 9954490 - Disclosure - Commitments and Contingencies - Schedule of Additional Information Related to Operating Leases (Detail) link: presentationLink link: calculationLink link: definitionLink 9954491 - Disclosure - Commitments and Contingencies - Additional Information (Detail) link: presentationLink link: calculationLink link: definitionLink 9954492 - Disclosure - Capital Stock - Additional Information (Detail) link: presentationLink link: calculationLink link: definitionLink 9954493 - Disclosure - Capital Stock - Schedule of Common Stock Issued and Outstanding (Details) link: presentationLink link: calculationLink link: definitionLink 9954494 - Disclosure - Equity Incentive Plans - Schedule of Recorded Stock-Based Compensation Expense in the Condensed Consolidated Statement of Operations (Details) link: presentationLink link: calculationLink link: definitionLink 9954495 - Disclosure - Equity Incentive Plans - Schedule of RSU Activity (Detail) link: presentationLink link: calculationLink link: definitionLink 9954496 - Disclosure - Equity Incentive Plans - Schedule of Company's Stock Option Activity (Details) link: presentationLink link: calculationLink link: definitionLink 9954497 - Disclosure - Equity Incentive Plans - Additional Information (Details) link: presentationLink link: calculationLink link: definitionLink 9954498 - Disclosure - Equity Incentive Plans - Fair Values of Shares Under the Performance Stock Options (Details) link: presentationLink link: calculationLink link: definitionLink 9954499 - Disclosure - Net Loss Per Share - Shares of Common Stock Equivalents Were Excluded From The Computation of Diluted Net Loss Per Share (Details) link: presentationLink link: definitionLink EX-101.CAL 8 txcg-20240630.cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 9 txcg-20240630.def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 10 txcg-20240630.lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Operating Leases Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Statistical Measurement [Domain] Statistical Measurement [Domain] Gross Unrealized Losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Cover [Abstract] Cover [Abstract] Net increase in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Schedule of Company's Operating Lease Liabilities Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Other Other Liabilities, Current Trading Symbol Trading Symbol All Trading Arrangements All Trading Arrangements [Member] Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Non-NEOs Non-NEOs [Member] Performance period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Products and Services, Excluding Grant Revenue Products And Services, Excluding Grant Revenue [Member] Products And Services, Excluding Grant Revenue Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Cash paid for taxes Income Taxes Paid, Net Common Class A Common Class A [Member] Proceeds from sales of marketable securities Proceeds from Sale of Held-to-Maturity Securities Pay vs Performance Disclosure [Line Items] Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] Accounts receivable Increase (Decrease) in Accounts Receivable 2019 Plan Two Thousands Nineteen Plan [Member] Two Thousands Nineteen Plan Net Loss Per Share Earnings Per Share, Policy [Policy Text Block] Operating lease liability Increase (Decrease) in Operating Lease Liability Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Accrued payroll and related costs Accrued Payroll And Related Costs Accrued Payroll And Related Costs. Land Land [Member] Unrealized gains on available-for-sale marketable securities OCI,

Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax Award Timing Disclosures [Line Items] Other Performance Measure, Amount Other Performance Measure, Amount Common stock shares outstanding (in shares) Common Stock, Shares, Outstanding Operating lease liabilities, noncurrent Operating lease liabilities, noncurrent Operating Lease, Liability, Noncurrent Debt securities, available-for-sale, realized loss Debt Securities, Available-for-Sale, Realized Loss Deferred revenue Deferred revenue Contract with Customer, Liability, Current Plan Name [Domain] Plan Name [Domain] United States UNITED STATES Other noncurrent assets Other Assets, Noncurrent Entity Tax Identification Number Entity Tax Identification Number Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Money market funds Money Market Funds [Member] Selling, general and administrative Selling, general and administrative Selling, General and Administrative Expenses [Member] Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Taxes payable Taxes Payable, Current Plan Name [Axis] Plan Name [Axis] Equity Components [Axis] Equity Components [Axis] Accrued legal and related costs Accrued Legal And Related Expenses Current Accrued legal expenses current. Share-based Payment Arrangement, Expensed [Line Items] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Award Timing Method Award Timing Method [Text Block] Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Marketable securities, fair value Total marketable securities Debt Securities, Available-for-Sale Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Insider Trading Policies and Procedures [Line Items] Conversion of Stock [Table] Conversion of Stock [Table] Adjustment to Compensation, Amount Adjustment to Compensation Amount Additional paid-in capital Additional Paid in Capital, Common Stock Compensation Amount Outstanding Recovery Compensation Amount Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Entity Small Business Entity Small Business Company Selected Measure Amount Company Selected Measure Amount Geographical [Axis] Geographical [Axis] Proceeds from maturities of marketable securities Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale Tabular List, Table Tabular List [Table Text Block] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Europe, Middle East and Africa EMEA [Member] Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Accrued expenses and other current liabilities Increase Decrease In Accrued Liabilities And Other Current Liabilities Increase decrease in accrued liabilities and other current liabilities. Antidilutive securities excluded from computation of earnings per share, amount (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Spatial Spatial - Instruments [Member] Spatial - Instruments Accrued bonus Accrued Bonuses, Current Cash, cash equivalents, and restricted cash at beginning of period Cash, cash equivalents, and restricted cash at end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Current assets: Assets, Current [Abstract] Goodwill Goodwill Other comprehensive income, net of tax: Other Comprehensive Income (Loss), Net of Tax [Abstract] Repairs and replacements Standard and Extended Product Warranty Accrual, Decrease for Payments Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Product and Service [Domain] Product and Service [Domain] Entity Information [Line Items] Entity Information [Line Items] Stock options to purchase common stock Share-Based Payment Arrangement, Option [Member] Vested (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value 2025 Lessee, Operating Lease, Liability, to be Paid, Year One Antidilutive Security, Excluded EPS Calculation [Table] Antidilutive Security, Excluded EPS Calculation [Table] Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Purchased materials Inventory, Raw Materials and Supplies, Net of Reserves Security Exchange Name Security Exchange Name Award Type [Axis] Award Type [Axis] Corporate debt securities Corporate Debt Securities [Member] Exercised (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Restricted Stock Units Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Work in progress Inventory, Work in Process, Net of Reserves Property and equipment, net Property and equipment, net Property, Plant and Equipment, Net Total liabilities Liabilities Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Shares committed under ESPP Shares Under ESPP Plan [Member] Schedule of Debt Securities, Available-for-sale Debt Securities, Available-for-Sale [Table Text Block] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Expiration Date Trading Arrangement Expiration Date Investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Operating lease liabilities Operating lease liabilities, current Operating Lease, Liability, Current Total Shareholder Return Amount Total Shareholder Return Amount Common stock shares issued (in shares) Common Stock, Shares, Issued Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Computer equipment and software Computer equipment and software Computer Equipment [Member] Spatial Spatial - Consumables [Member] Spatial - Consumables Debt securities, available-for-sale, realized gain Debt Securities, Available-for-Sale, Realized Gain Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Less: accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Total property and equipment Property, Plant and Equipment, Gross Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Weighted-Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Research and development Research and development Research and Development Expense [Member] Chromium Chromium - Instruments [Member] Chromium - Instruments Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Weighted-average shares of common stock used in computing net loss per share, diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Accrued property and equipment Accrued Property And Equipment Current Accrued property and equipment current. MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Total stockholders' equity Beginning balance Ending balance Equity, Attributable to Parent Chromium Chromium - Consumables [Member] Chromium - Consumables Due in one year or less Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One Interest expense Interest Expense, Nonoperating Selling, general and administrative Selling, General and Administrative Expense Other comprehensive income (loss), net of tax Other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Accounts receivable, net Accounts Receivable, after Allowance for Credit Loss, Current Cost of revenue Cost of Sales [Member] Stock Conversion Description [Axis] Stock Conversion Description [Axis] Revenues from External Customers and Long-Lived Assets [Line Items] Revenues from External Customers and Long-Lived Assets [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Document Fiscal Period Focus Document Fiscal Period Focus All Executive Categories All Executive Categories [Member] Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Assets Assets [Abstract] Expected dividend yield Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Document Type Document Type Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Total marketable securities Debt Securities, Available-for-Sale, Amortized Cost Accrued commissions Accrued Commissions Current Accrued commissions, Current Schedule of Revenue of Recognized in Contract Liabilities Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] Risk-free interest rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Maximum Maximum [Member] Contract liability Contract with Customer, Liability Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Payments on financing arrangement Payments of Financing Costs Furniture and fixtures Furniture and fixtures [Member] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Accounts payable Accounts Payable, Current Accounting Policies [Abstract] Accounting Policies [Abstract] Amount of lost profits Gain (Loss) from Litigation Settlement Leasehold improvements Leasehold Improvements [Member] Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Current Fiscal Year End Date Current Fiscal Year End Date Less: imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Statistical Measurement [Axis] Statistical Measurement [Axis] PEO Name PEO Name Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Loss before provision for income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Shares issued in period for previously outstanding awards (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Award Type [Domain] Award Type [Domain] Name Outstanding Recovery, Individual Name Issuance of Class A common stock related to equity awards (in shares) Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Schedule of Shares of Common Stock Equivalents Excluded from Computation of Diluted Net Loss Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Money market funds Money Market Funds, at Carrying Value Non-PEO NEO Non-PEO NEO [Member] Additional Paid-in Capital Additional Paid-in Capital [Member] Award Timing Predetermined Award Timing Predetermined [Flag] Class of Stock [Line Items] Class of Stock [Line Items] Thereafter Lessee, Operating Lease, Liability, Payments, Due After Year Four Lessee, Operating Lease, Liability, Payments, Due After Year Four Recently Issued Accounting Pronouncement and Disclosure Rules New Accounting Pronouncements, Policy [Policy Text Block] Net loss per share, diluted (in dollars per share) Earnings Per Share, Diluted Class of Stock [Axis] Class of Stock [Axis] Revenue Recognition Revenue from Contract with Customer [Policy Text Block] Name Measure Name Entity Interactive Data Current Entity Interactive Data Current Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] PSA target percentage Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] China CHINA Asset-backed securities Asset-Backed Securities [Member] Product warranties Product Warranty Accrual, Current Stock-based compensation expense Share-Based Payment Arrangement, Noncash Expense Provision for income taxes Income Tax Expense (Benefit) Other income (expense): Nonoperating Income (Expense) [Abstract] Schedule of Additional Information Related to Operating Leases Disclosure of Additional Information Related to Operating Leases [Table Text Block] Disclosure of additional information related to operating leases. Marketable securities Debt Securities, Available-for-Sale, Current Supplemental disclosures of cash flow information: Supplemental Cash Flow Information [Abstract] Revenue Total revenue Revenue from Contract with Customer, Excluding Assessed Tax Purchases of intangible assets Payments to Acquire Intangible Assets Services Service [Member] Total other income Nonoperating Income (Expense) Other noncurrent liabilities Increase (Decrease) in Other Noncurrent Liabilities Statement of Comprehensive Income [Abstract] Cash and cash equivalents Cash Equivalents, at Carrying Value Net cash provided by investing activities Net Cash Provided by (Used in) Investing Activities Loss from operations Operating Income (Loss) Research and development Research and Development Expense (Excluding Acquired in Process Cost) Other Other Employee-related Liabilities, Current Total liabilities and stockholders' equity Liabilities and Equity Other Other Operating Activities, Cash Flow Statement Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] All Adjustments to Compensation All Adjustments to Compensation [Member] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Accrued compensation and related benefits Accrued compensation and related benefits Employee-related Liabilities, Current Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Lease and asset impairment charges Operating Lease, Impairment Loss Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Interest income Investment Income, Interest Right-of-use assets obtained in exchange for new operating lease liabilities Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Underlying Security Market Price Change Underlying Security Market Price Change, Percent Individual: Individual [Axis] Revenue recognition, payment due period Revenue From Contract With Customer, Payment Period Revenue From Contract With Customer, Payment Period Accumulated Other Comprehensive Income (Loss) AOCI Attributable to Parent [Member] Cancelled and forfeited (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Expected period of revenue recognition Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period Inventory Inventory Inventory, Net Product and Service [Axis] Product and Service [Axis] Entity Address, State or Province Entity Address, State or Province Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Statement [Line Items] Statement [Line Items] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Operating expenses: Operating Expenses [Abstract] Schedule of Property and Equipment, Net Property, Plant and Equipment [Table Text Block] Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Financial Instruments [Domain] Financial Instruments [Domain] Beginning balance (in dollars per share) Ending balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Liabilities and stockholders' equity Liabilities and Equity [Abstract] Share based payment arrangement recognized Employee Benefits and Share-Based Compensation Asia-Pacific Asia Pacific [Member] Minimum [Member] Restatement Determination Date Restatement Determination Date Adoption Date Trading Arrangement Adoption Date Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Deferred revenue, noncurrent Contract with Customer, Liability, Noncurrent Conversion of Stock [Line Items] Conversion of Stock [Line Items] Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Beginning balance (in dollars per share) Ending balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Concentration Risk [Table] Concentration Risk [Table] Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Beginning balance (in shares) Ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Schedule of Recorded Stock-based Compensation Expense in the Condensed Consolidated Statement of Operations Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block] TSR Total Shareholder Return [Member] Total Shareholder Return Exercise Price Award Exercise Price Other Financial Statement Information Additional Financial Information Disclosure [Text Block] Net Loss Per Share Earnings Per Share [Text Block] Accrued compensation and other related benefits Increase (Decrease) in Employee Related Liabilities Arrangement Duration Trading Arrangement Duration Stockholders' equity: Equity, Attributable to Parent [Abstract] Granted (in dollars per share) Weighted-average grant date fair value, granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Marketable Securities [Table] Marketable Securities [Table] Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] All Individuals All Individuals [Member] Building Building [Member] PEO PEO [Member] Name Trading Arrangement, Individual Name Other expense, net Other Nonoperating Income (Expense) Accrued expenses and other current liabilities Accrued expenses and other current liabilities Accrued Expenses And Other Liabilities Current Accrued Expenses And Other Liabilities Current Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Intangible assets, net Intangible Assets, Net (Excluding Goodwill) Asia-Pacific (excluding China) Asia-Pacific, Excluding China [Member] Asia-Pacific, Excluding China Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Axis] Gross Unrealized Gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Issuance of common stock from exercise of stock options and employee stock purchase plan purchases Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Total available-for-sale securities, amortized cost Debt Securities, Available For Sale, Amortized Cost Including Money Market Funds Debt Securities, Available For Sale, Amortized Cost Including Money Market Funds Common stock reserved for issuance (in shares) Common Stock, Capital Shares Reserved for Future Issuance Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Beginning balance (in shares) Ending balance (in shares) Shares, Outstanding

Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Local Phone Number Local Phone Number Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Total operating expenses Operating Expenses Americas Americas [Member] Expected volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Schedule of RSU Activity Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block] Conversion of stock, shares converted (in shares) Conversion of Stock, Shares Converted Other noncurrent assets Increase (Decrease) in Other Operating Assets Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] PEO Total Compensation Amount PEO Total Compensation Amount Share-based compensation arrangement percent Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent Class B common stock converted to Class A common stock Class B Common Stocks Converted to Class A Common Stock [Member] Class B Common Stocks Converted to Class A Common Stock Long-Lived Tangible Asset [Domain] Long-Lived Tangible Asset [Domain] Statement of Income Location, Balance [Axis] Statement of Income Location, Balance [Axis] Schedule of Accrued Expense and Other Current Liabilities Schedule of Accrued Liabilities And Other Current Liabilities [Table Text Block] Schedule of accrued liabilities and other current liabilities. Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Impairment of long lived assets Impairment, Long-Lived Asset, Held-for-Use Common Stock Common Stock [Member] Measure: Measure [Axis] Issuance of Class A Common stock related to equity awards Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Entity Emerging Growth Company Entity Emerging Growth Company Consumables Consumables [Member] Consumables member. Entity Central Index Key Entity Central Index Key Contingency, damages sought, value Loss Contingency, Damages Sought, Value Schedule of Inventory Schedule of Inventory, Current [Table Text Block] Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Amounts charged to cost of revenue Standard and Extended Product Warranty Accrual, Increase for Warranties Issued Capital Stock Equity [Text Block] Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Equity Component [Domain] Equity Component [Domain] Financial Instrument [Axis] Financial Instrument [Axis] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Stock-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Entity Shell Company Entity Shell Company Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Cost of Revenue Cost of Revenue [Member] Cost of Revenue Common Class B Common Class B Common Class B [Member] Title Trading Arrangement, Individual Title Instruments Instruments [Member] Instruments member. Statement [Table] Statement [Table] Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] City Area Code City Area Code Current liabilities: Liabilities, Current [Abstract] Cash paid for interest Interest Paid, Excluding Capitalized Interest, Operating Activities Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Level 1 Fair Value, Inputs, Level 1 [Member] Total current assets Assets, Current Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Noncash investing and financing activities: Noncash Investing and Financing Items [Abstract] Realized loss on available-for-sale marketable securities reclassified into net loss Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, before Tax Weighted-Average Grant Date Fair Value (per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] 2028 Lessee, Operating Lease, Liability, to be Paid, Year Four Earnings Per Share [Abstract] Earnings Per Share [Abstract] Schedule of Revenue by Source Revenue from External Customers by Products and Services [Table Text Block] Equity [Abstract] Equity [Abstract] Fair Value Debt Securities, Available-for-Sale, Fair Value, Fiscal Year Maturity [Abstract] Accumulated deficit Retained Earnings (Accumulated Deficit) Americas (excluding United States) Americas, Excluding United States [Member] Americas, Excluding United States Class of Stock [Domain] Class of Stock [Domain] Security deposit Security Deposit Inventory Increase (Decrease) in Inventories Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Equity Awards Adjustments Equity Awards Adjustments [Member] Weighted-average discount rate Operating Lease, Weighted Average Discount Rate, Percent Present value of operating lease liabilities Total operating lease liabilities Operating Lease, Liability Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Underlying Securities Award Underlying Securities Amount Performance Stock Units Performance Shares [Member] Conversion of Stock, Name [Domain] Conversion of Stock, Name [Domain] Amendment Flag Amendment Flag Entity Registrant Name Entity Registrant Name Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Depreciation and amortization Depreciation, Depletion and Amortization Gross profit Gross Profit Foreign currency translation adjustment Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent Laboratory equipment and machinery Machinery [Member] Schedule of Changes in the Reserve for Product Warranties Schedule of Product Warranty Liability [Table Text Block] Fair Value as of Grant Date Award Grant Date Fair Value Amortization of right-of-use assets Finance Lease, Right-of-Use Asset, Amortization 2019 Employee Stock Purchase Plan Two Thousands Nineteen Employee Stock Purchase Plan [Member] 2019 Employee Stock Purchase Plan [Member]. Level 2 Fair Value, Inputs, Level 2 [Member] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Geographical [Domain] Geographical [Domain] Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Beginning of period End of period Standard and Extended Product Warranty Accrual Entity Address, Postal Zip Code Entity Address, Postal Zip Code Restatement Determination Date: Restatement Determination Date [Axis] Title of 12(b) Security Title of 12(b) Security Common stock Common Stock, Value, Issued Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Government debt securities US Government Debt Securities [Member] Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] Cancelled (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] Concentration Risk [Line Items] Concentration Risk [Line Items] Preferred stock Preferred Stock, Value, Issued Stock Options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Employee Stock Employee Stock [Member] Net loss per share, basic (in dollars per share) Earnings Per Share, Basic Accounts payable Increase (Decrease) in Accounts Payable Adjustment to PEO Compensation, Footnote Adjustment to PEO Compensation, Footnote [Text Block] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Movement in Standard and Extended Product Warranty Accrual, Increase (Decrease) [Roll Forward] Movement in Standard and Extended Product Warranty Accrual, Increase (Decrease) [Roll Forward] Purchases of property and equipment included in accounts payable and accrued expenses and other current liabilities Capital Expenditures Incurred but Not yet Paid Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Schedule of Stock by Class [Table] Stock, Class of Stock [Table] Total current liabilities Liabilities, Current Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] Total assets Assets Granted (in shares) Restricted stock units, granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Other noncurrent liabilities Other Liabilities, Noncurrent Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Commitments and contingencies (Note 4) Commitments and Contingencies Accrued royalties for licensed technologies Accrued Royalties, Current Termination Date Trading Arrangement Termination Date Description of Business and Basis of Presentation Business Description and Basis of Presentation [Text Block] 2026 Lessee, Operating Lease, Liability, to be Paid, Year Two Equity Incentive Plans Share-Based Payment Arrangement [Text Block] Schedule of Revenue by Geographic Location Revenue from External Customers by Geographic Areas [Table Text Block] Entity Address, City or Town Entity Address, City or Town Due after one year to five years Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five Schedule of the Company's Stock Option Activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Total stock-based compensation expense Share-Based Payment Arrangement, Expense Net loss Net loss Net Income (Loss) Attributable to Parent Trading Arrangement: Trading Arrangement [Axis] Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Cancelled (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Total available-for-sale securities, fair value Debt Securities, Available For Sale, Including Money Market Funds Debt Securities, Available For Sale, Including Money Market Funds Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Entity File Number Entity File Number Realized loss on marketable securities Marketable Security, Realized Gain (Loss) Document Fiscal Year Focus Document Fiscal Year Focus Revenue from External Customers by Products and Services [Table] Segment Reporting, Revenue from External Customer, Product and Service [Table] Income Statement [Abstract] Income Statement [Abstract] Entity Address, Address Line One Entity Address, Address Line One Revenue from External Customer [Line Items] Revenue from External Customer [Line Items] Effect of exchange rate changes on cash, cash equivalents, and restricted cash Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Name Forgone Recovery, Individual Name 2024 (excluding the six months ended June 30, 2024) Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Weighted-average remaining lease term Operating Lease, Weighted Average Remaining Lease Term Document Period End Date Document Period End Date Finished goods Inventory, Finished Goods, Net of Reserves Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Total lease payments Lessee, Operating Lease, Liability, to be Paid Beginning balance (in shares) Ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Deferred revenue Increase (Decrease) in Deferred Revenue CAGR Compound Annual Growth Rate [Member] Compound Annual Growth Rate Insider Trading Arrangements [Line Items] Payments for royalties Payments for Royalties Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount PSA target amount of shares percentage Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Multiplier, Percentage Schedule of Common Stock Issued and Outstanding Schedule of Stock by Class [Table Text Block] 2027 Lessee, Operating Lease, Liability, to be Paid, Year Three PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Schedule of Accrued Compensation and Related Benefits Schedule of Accrued Compensation And Related Benefits [Table Text Block] Schedule of accrued compensation and related benefits Schedule of Marketable Securities Marketable Securities [Table Text Block] Cost of revenue Cost of Revenue Deferred revenue recognized Contract with Customer, Liability, Revenue Recognized Adjustment to Compensation: Adjustment to Compensation [Axis] Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Document Transition Report Document Transition Report Document Quarterly Report Document Quarterly Report Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Entity Current Reporting Status Entity Current Reporting Status Accumulated Deficit Retained Earnings [Member] Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] Market-based Performance Awards Market-based Performance Awards [Member] Market-based Performance Awards Weighted-average shares of common stock used in computing net loss per share, basic (in shares) Weighted Average Number of Shares Outstanding, Basic Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Acquired purchase consideration Acquired Purchase Consideration, Current Acquired Purchase Consideration, Current Marketable Securities [Line Items] Marketable Securities [Line Items] Schedule of Revenues from External Customers and Long-Lived Assets [Table] Schedule of Revenues from External Customers and Long-Lived Assets [Table] Document Information [Table] Document Information [Table] Restricted stock units Restricted Stock Units (RSUs) [Member] Debt securities, available-for-sale, realized gain (loss) Debt Securities, Available-for-Sale, Realized Gain (Loss) Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Acquired professional services Acquired Professional Fees, Current Executive Category: Executive Category [Axis] Name Awards Close in Time to MNPI Disclosures, Individual Name Construction in progress Construction in Progress [Member] Cancelled and forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Entity Filer Category Entity Filer Category Transaction price allocated to remaining performance obligations Revenue, Remaining Performance Obligation, Amount Statement of Income Location, Balance [Domain] Statement of Income Location, Balance [Domain] Company Selected Measure Name Company Selected Measure Name AX-101.PRE 11 txg-20240630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 12 a10x_logoxverticalfullcol.jpg GRAPHIC begin 644 a10x_logoxverticalfullcol.jpg

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|QAHM)=A-M; ;#(Z;/B M #51 K1G#H&@>2%*UJ&OOF.4A[1W]9Y0WAY@!>5!0*!LDF@9!J2F]9R&0; -MN@*?>=S;Zy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t#*#).#T">7WH 13N]5^U M6JUO] [W;^\$ ^>OLG]HV,7/H)PH4LM.]W>?>Q^U;X[SQWX9G3DW /M9V= .!)*>WMY5=1= R>S]BJDQF@NV#1+12@G; ML[G]H2YT6[L.O[]<6]\$.QO-M []N,]P' / KE0V.MW1?>O5]H51M BR6HM, =&L;+>SS\$]01=0+>4R]FY" M>+3\$# =!5G]JNM:589V9TO /BI MR@58X^~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

77RKC/CY&T7T BJKY9F.U2 + \$LVFXRRD/V3 M=7TT+RL H\$;'^:(.0BPW2D 3>?YO-JFDJ%QU4%\$K<39LRQN,VXPXR 4 / MW84P" EQQ?CJFN8\$U/A>V=I|=7C?)Y-
10M5@/H&T@M?>NVEGP2+Y8E0& M .3'O'Z220BQ/KN^E97=Y&[.B.W. !CJ]!>YJNSC1#/#;#*:*!M-.L #7Q MKQ^+[%B? H .:~%\$%
MUOT0R10K6M77Y5/A1J/XB;5^EOKLSIKZ1YF5M1F6HP@4 *NR# 59+8B4% MV9085V2>#7A+R+N19^+4+Y096V.W^!X4Q) Q?TTP&K]=;T5B51\$WAO+& M_EX<Q><< +G2I+EJMS5E+
M(Q,)=5B+K0K71TSCZ*W, J+<=5;KQFN R63:3ZW6J7I6@9A/FMH@E M6B.2D)DU;A3WO=>=>3%UJ &BW 66Z^!OZU3%QVRRVWZ.3D1DTLAAOVQ?S.M.53>> NGR ;88.80
4%5155BMT01L;2.6%6%SO5Q^R-C&N3 M !?Y> MPPOJX. J.\$=*?>#]L]=*7J.1W,7FD9A5<3123 BIED9@#T5\$2X5 W.M.S^ #P1000L.6.&FZ94O.VFRMIVU>A>T=KXO*H^_FEG@NJ-.B8.)_40/7Y9./<
M7U71@& QUS&W0^EQ1 3G;C&3;C+Y4^20@=(ZNS -4:4Q1E1=Q#L R T%# M J. K.OT=8FVZ&B+FI4V0E@W@;S?9Y?/ZBH5Z:3QJ?S?1 014Q?&#K:~? M.&S&S+1CY/O.P
&&I92H#5^CO\$U!%VI%="9*5&\$!0\$4/L^KT\$H)Q" FHV7*@I55AS,P<+]@& I K-AEJR*N \$A(M1F^GKK1,@CESF#E=SJ; MC+Y4Y6!1!U&E9E ?\$0!(7+30 J_7WV!7-0NQM
Q'0;SDVW0@TQFXR..U]!MODS. J?<=<5&K?;(58=)W&J!&80T?>N>W&X5446<<55C2Y. Q;@!(1%#1:2X5 M6?0*P&RNP;C0,@C\$&#&EYSL+FL??Y?7^P @R:846*V_OJR#M&K#M
M @ U [8-S4XD]1.J.Q#>[KEDD;81K%3A. &BDT@LUMAUH<+>?QOLEH4@ M);/O^P^>?Z^QE^E9 %90!(5*15NNO&NNO P&L;Y!FPR&KT ?&@D9V
M6&BH,+K1,]=S, \$&25^F U KJQVDDXXQ;R^D^N*NT51^SG(C LWE)5P^ MZ]H(1-2018R);#K;#N4+&.0+0.F.U]!J?>@R.J550X4 J_HDFD K<5) MB5E\$E_*G73 #Z0<@%#E>.F&KT..?E)
(%!)5CAVJL\$S0@("ONM"<=YUR M9U-1M,*R^&0%&W^/K^<K.Z#2156#=#A5A9;JU^?JZ+8-0#=#ZY>!%?C3 M;(#Z+NG^JG(ZW8?&O!(3!5NNO&ZROH1(KUDV6ED&H@E@6^U7Y4?!"PG
MY&..&D)LD J 7\$*M6M@AOCK=P=6J 72-390 MTO\$!9^GM^GZ!9'O;C^M^#=#GJR;K99;(X018W+OVR&KXHD18 M^\$N5 4V6M4+78=9YX?2; OAP5F(U@G)BSI VV60;<V-VWY**&
G !D;? MFCYQ1="CWIJ3MVM08HTLW9ZJ!P&KML;EHZM?Q@M^XZ^L;(UJZ= K^Q MRR146<(R&S)G&N7A !7!(G-H2Y0!<29&AV10OAO?7%#& .IDG 476&Q876 MP?>6,(K/8W+I3R;5';
<OUP!6]8(AEET&H1V_# M2E0,%2B^DSJ^?C= MP<F^<#2.@!V3 M.C&C^LLU]U^E80XW M9Z09BXEWUBR^K^V.RZ5VA50RP JU^!K.-0=>7F#&I^&=9A7]+#U
M3G>@36M^&V\$!1732@YA=I;^L5Q7215;95K^Z?C[?Z[?S?V]?GGPU?S6;C!X] MN1Y(B@ KGW-5IT;1.N7EXE =G3EH)HWKN@1QRR Y6GEBN*+7V3IXI!(15NNO M\$&L;B)N0)G4+I04ESDD^<B^O
O+R?9&@/L!P!XX?T@ 5.]J[U@GUD??1+MPLV9ZK9Q)!%&C%O^<11NNO&C%#&F&P+S+&M4A;J?>=>9 +&^TEO!K0>J;G+J]MA 3-V>K:ZU62Z**+?M9C@/8Y6PCB>>D(%)Z5U,
(LKHKMF.A@>4GP,K^MCL2P+1+6(GZ%&C3L;C;7!J5]N^KY^7N27^GZ8L J]V1^1 *O#&@D(46 N=F.S. 0(PQX VP2SC%VILJL;^PSO!G?)7]+,RW M9%&K; LNX-S?# L2@C Y6AC2J; M^ \
(L#4>8N85W8R PP+>WPS!J+P;S;PU;RNP;]=V3?2?#E#E*;LY6]T\$ MCV:(O?8992.Y M(G);>7 @!1E.R.?OT->R.LR.55Y4?&B>IXKY60IKHW M^&K Y \$3QJ;UQ&6T<@<0+2!T^AGP!<
(+F4U&OJ K808LUA;?>(YW3 JH MVYF4U!5UIH)EHMS1L.XX08 &ILVM(JAY @<=>122KTXQJ6,@GFW5)<=<#AJITA_44%F286^<@ M?>=&^UN)DJO=>NIZCO,*01;LY6L Z8U<[B]H.MC))&O
M1DR16(FJK+&#&GDI;(K834G=);J;L&Y=16P?0*? O EDIR.=K%O2X)K2! M^S<#?;7LJ;T]U>WUJDE@B<MWR9M[FCSCN.WJL9E.2 /!5A CUD=PH9IC+&M^<
>S^>.C.0H67NZ>L\$90&S+&G.VFUQK08**;&Y&M=FW(L(14F3.2CP="8"E". **%U7R0 *U! P1YXWQRV!/?[?>G^!1-0V>KV6? M.LO:MQ>?VQF42U9^&+!5!QRL;8L&1^8=YP5(P1FNWVQ6W5
Y&@<6DR..!JJO@>750?P)P.Y%V78V&5=9 J-GZ>;=[MTE=12*7M!1LVIMG?P?;WV2 M27B]1+>1;HBD+>];L7L K:98K&BWOOC.LEI 0\$6D10#W.SPITHB@#K85Z7 M1#&L7?<
(WD6CE91D9WRMKTMDY,KYJ]9E)1..1:0&@&6@/(LH^A^XNS+&WZ(LAKUQJGOW6^/U.M.TU=8^Z M.ZU]@<R-!>?29?NBQ1^?7.GA^@ 6DQ@-!/(LH!)SR4B E8 ?<
M]T]B>0?9V9RT2=>OKW=U[JO]P<[?<=[F!S<=<K>K^N^O^P]W?784-V-M V2M208[8H MCI#(1V4\$5(OFH+V! /7FA H7A:2FO)DND!)68M0W&G@B6**** @ 19HWB5 M;.<68 %& @.W@
1000^P^K=(Y15^B86^< 29^? P^Q5Z]Z0O,*00-V>K6370 M.ZL:Q8VQF5EGR<=<6\$J U;7.0P.E\$(<=<3W P)9J)M092W9RMKMDL(K3J]L9E1=; @6DP@U1/(L!;MROGX_2K?MDT^M!2!&
MM0Y&<5^5^5P6\$ JO.1.T4\$5.LM^RG(I J2VAE5^1QP0?T ZE1S^3^IIN MSE.SJOIUBER;E@&=&9?5A NPJ@M38W2871%K 3^9Y?V@ 7.D8L[67M.T]Q>Z8U<[B]H.MC))&O
(AWY4ILOO.1?>0&3&B%&O M^U.#VJ]6]Z]60;9%&!(^9;F]J&3CF%6 G^M^B=8C>D>Y)7PLM<D^Y6T^&L^&L6A0?79WQ4Z(0\$6D JS%&+1R@&S
M)CC1X^5EFWSZ(YV#W1.Z.E.ZVW#45W4<7+& 1+O C<<^&0BP@.A48.6C^B4 M6=FCD>P>MYJM6HQJHH#L)GAN+5JG7PC@+ 2+\$ WP\$6\$!L^*K^R2(F,^@06 M/4T=8CD<Y>Y)?
[19K;LY6L:(.RL8Q8?VQN67.IZ8 NB@.<180%2SR4@% M5CY.X1.T(UUW6]V6>=7(1^MA\$4S=GJFM;];&Y>UW6!< 6DX^6KD(L^M^R8#!.IA\$M3194PCB<""G!A-195P8
24115^&9UW; S1\$A J3K=M@90^G&E.3D0 +&[JK(79#CY1P]X.X;J]T]U.3U]DE!0GZ2FWXWZL(7E9 LMLJ]>#N^OUZJ" R^B;MHM;KJMPD\$M<I<S2O=>B)U+ WSMI3IN^#1L]9IT
M 2WPYNSU+UW D04?MCM@G@H]K15A V6RKF5U;!!V15Q+> WSMIM(C9^2]YMW02 M7.6R,6XOKM,KKF5B;J<C>+ 2>2^8!M@>U C= LIT874?1; @609JK]12M@ M6@<C^F]J=; "RA-
LIRJ RVJ62DA1 H4R-V-WJL3J@>@<JLBM!)&J5RPTOC M-7+2]6\$G(M^W<=<6\$>9Q(UT#H\$X\$644R[1VJL/35^2^10GQO0W&X^F#71S MMJ]P; @<O?Z1?&A07#;VQ.8
"RB3& U\$JMPD\$M&>2>COF,\$ 190CN6Z M(DP31 M-A+6D=C^C^F]M;# "P^APC2]UA; RUJ0.12 [R]JZ T]B]SKJ; ML4J.X]L^12 M^N\$V\$H!%E FVRK8HW4^*!&I]@551P]X.X\$Z;HZ14^*W
M>1+WMUQ>V>K3V5W 1UB.1S>^>R.V6+&0F6 L1E8U;5; ZMA7/&@L9Q M.LT;T]T@>];[T=C= MHFNSSE. :N>Z>LOR:VQNSQ(X)T]P\$6 # W02QO.P>]1+7>EL1-V>K3[4. M1G/1.K5L/>=
190BDYW8@G +73Z0Y4E3\$3M1^Y <6 \$ &1UJ&WX5 <7/6150=>WT1(M^F^?M^B;M^&=MSDWTJ(XFY.5O:HF /HZ1)U; @<?&Z2?)@<?& I!V/&) *M
58^>:U4X2[;JL9:~9WSW1^<QMPQ,W9Z@M#]J;Y;6<I^C?D?1 93%\$H\$ H1^&O?%04)4HT+W+^M:Z M9#=#G]DU6& T(L2S]T]XZ5.6<P+&U^S(4;G.QPN:FAKVQEE[S^>F&KT,D
M]W=<7^J6KJY)@J]WJN3C^I\$>N61UF). =#D^%6HM!%A *KZY\$KFH6^BW:V^ MTTB7+!>V>K3L.RQ=,Z. *B286 [50-G.MK]W#K<+; MS69J!+&H3D(L^:JL99=>^/R2R;=(D\$6
I]U8&2(66]PZW8\$[OK;5;6?TU?A\$M @ M5!<2Z^C^+ M^&Y1%C-HI4PCV=15^VZ TX^RNCN.E.S;R90..05[11@+LRO?22 \$E&\$ E=L.M(C M#Z3\$S3?P WSE]P3J-U
M)N]WT; CW2\$=E]M.H. 5 HDJN.TU70&I37;]J @ M+<17M0TTW9H\$2)83^Q V33.6Z, ZM@TLDP (@.428740?#;A2UM6G0QO2 M-PQ(O3=GJUDU^HE#IY2MEL;ET^+ (D "P 8 F&07%6U?<
>96D;Q7B0A &L. M5E^U6JW53ONBOK4WKBT<2^"; KC9 #J2BMAA;@< QG33G9QJHY6WV M-3^"O69R?>L2@1M0;J?<K1P .&O?&W.V^B^9X=<6 (N2Z]M@>SB]U U ML ^<
(T]W802(WO17QL2])PP[!XZ05^MCT=8CDWY] UACS001;LY6LU@M M.65H9%H^MCKX;<M1W;WKBTU@438 \$ P)U@ER/S+&AOT^!46E M. ">M@GW%<QV.OX #&+!];
MDW @AVC=G]JYG;3M1V0^G?;&Y310?# L@?7<=J R Q MOI=0>#>J]KJ.O)A<[:G?O! ZE=3Z7WR5 44BP (ER)S0 M0&N&L 6.6;IY&APLW9ZE.ME.H^8Q @ 4 #1L#?<
>YH\$WFO=7 Y^O(0U1M#6WR-RY5)D]HWNV>]@UX\$S =.VFIWKNP. M10D^MCLNISE;SE!7 M=ACWS=EJ=NSK^1Q^\$VRV-RZG35^\$5 BP \$C^L;JFL^N1130=T Z+ZIV
MT#=#GJ^R8T @4K@K4AP (\$B5L^X^M6=<=W.V^E38K076@73 M^R(, @!<O W.N;1.9]J]M1F>];/S\$B.LJA:[]U(1?2!) !R(W^WSM]6 M/KHP4;R0P]Z>V>K^UH^H G8WKVCT]HSK10!%<
O^KVAOL^M#69;6P3C.M^ Y):0!%&0&^&FZ+Q^V]V3 J3M^R(, @<9^P\$T=)A! FP F3C.MK^<V6TJ/KD?4^<1=40\$4QX?QON77]I]H50FP \$C7LZ="6Q%>I0B+>PP M^TKU5?<
%V.QN7@LRO\$; #2E47^&M1@M)B\$^L6(MO-G-0BP \$A9: M^049Q0L4@>Y6WUJY#E434^>V-RVDS^SKR/L@& " & &^U^F;D^M4J?>] V4 W0J]P]OZP^4V>ZVNS^>T0>A*618
U:5L^I53R10B5^&6^1!4 MP+>W6G@&MRKA(I=0+4&?&J;@>TUA^7H18 \$&3\$!#<=<SMJ>?7. "9&V\$ M18=8-V^K^051=24?0?YVW1]6]H]H% @<0+5D5557KEEA4@B1^%C%N; IO04
M^L^IDV!M TT18^606D@K^I%&@.0.4>=<0.61N4ZU;(M02.X44^Q0^M!^H]H;E.U^&OAS< "H]P-ZMVO[KG]1S^DP2.H6f_VJUN76@B;#&0>@ M 3PP\$=V^P.L:;#Y; @4H^Z6K\$Y[+F;FJ
<7EJL;SH;UQ?&A @64XM^H^&@.L]9[!KWFDEH]^* M[IR]<EUL.8\$6\$ 9E/4^&NSR<@< 85^BE3^V9V0@SWE8.H.UA;8R7V>Z; M^3A.DF IO 4&H^WCAK K-7?0H^U]^# 1.N+X1]U]P^P
H..&O?&^ MH> /2K%E3X^U-Y; &YI23?SML;EUH^*R !93!6Y!/[@%I,3N]J/EH;:\$20BMA MTWAMATS^KC2? @^ Y;+&I4Q[VSS^N^AEZQBW^#E!1;YRZ] MN#17D#)L #2]L "4F%3B?<
MRF^&2AKUQO@N:=P]V>E6N M9&1^#9^PMP0", "P @#>=>L^UM^G^T]U]9V;UJ^&XJ>V>G]H;ETW? M=9^O^+& L1CMQ@<0^4>=>^MFH=8QV>N+M]M;=&EKLH]W\$.R^!];(SD).
M]R(F;W.S.G.H^O-J+R:AAUV-^NKOR^). \$X^60-K;6^2VN-V^H]T^VUO M7-Y.E^P?U^M^&+1UNH;7MFO?3^!&O;B4;J.V;I]V#W19^66UF+X^L-S
M]R(XWGB2R^G4>I\$Z=V^!)\$%;P@<K.HD]P)6L+5D!A90JH, 2R;MAV=5)WN M8,TSR5U;@=40^E,E ZFR8\$JESV !^428 \$ P]D,QZM)O L6P +&? M27+10@B43046 % 190@&6H/EH(;<
(L)QVQ\$ "B+ LIDT"=6^V^P 4 M1(#K.E^FCXOJY@M^O1U908 2B? @#=(5)9\$5 ^0 *K^R]0^*Z=;=#E^M#%T 18^H^!%E 16V1DIE@<BRM3 M6Q/Q;DP! 0110^70\$>D^* I0 %M\$6
195%E @<K^APD4=<[L J \$V@<010180-FKBP@F E7. 191%V\$]H\$ ^+5! M JQ]V@<@ \$!C"; L@FPFGEA<L;LDF\$O@E]! D]5"; 4LTF(P%631WV MP;P; @<D0180 HW5B @L "B3 E*@"BL^
%5@<C"; M^B-Y156\$14G^" N^<9L1^00^? "TCL-U10^K9^4! 6V @<5! M1KEL=>= /1+1N7L1^/@V.N.OA8>4?7^>#WYZ-CVH=#<3EVL+&A M]1=D=N^YK^;VM^*08
&IR[X7KH:#WIAZ#T0@XK/ &3D>]E^>ND>A4^ M]M?&AGN5)*NMRU= Z? &1]5;AR.V^KR^!A8%&6 MD I51^EXH 1B^V73SW45A^*TEJZ^ M?^7T^>]7#>=9H^70:K7V;@L J5AE869@ :GP9B?<
%U4X2^6?> DX >+1]L^ MJZO^UGZKUJ L^I^J;@4@MYEBGU;B3EQ7^ ULK.M^O^UND.YMV=1^ I^K^R^<=<1@<C52U7?=>=UV V M^&L^PM<J51>=7H1K^O2V^*+<
E^C^R^#=#1]#BLJ_ 91>U]J]K6X\$5%&JZZ^> M52+ 2.B8E8X?K[46P]N30;@J M]Y^&O=MM=WZIEWP]Q^I41%1 5.BGEX\$2^*KOF7Q47U0;=0V0M2A5@<@U0!<
<6.1>M]J]35]7K]@<AR]T]W.OTR#ZG(E;K+T M^XVR^+> U B^M^P^> Q2BTQTK3^108CD(YPP^#& Y JYQV^ "1=&BG? *?&KFH(5EU6L9&L]1=6=M [M]Y;A;A48181^4]6B3J^<
EU4X2^20.G.O PK.B;06125<=<K.G;E^&M.MT+&H^&+!1Y1R;PSK=<2HLH B^6 *O R&U<7-7?>M6=N5?>7W]5WZL(1^3F M035U-L^1];2X838 3I4H65Q1QH A-K;A;J8N^<J^O 4TM
XV694]F]H^<M7]QX^#Z-<C^H^O^+&I%&KRS6 12]7]L RDLG+>S6QW^&KGCN;(KQ;K4O#^*+> 5^D^ MR\$=>5^&K LODIR.L]=K]K;Z]T9@OU3.XD>2T 15^*X23 M42Q(O(L14>3C<
M1P46L^R3 (O)P]T]YXK<=<LAX\$M^&C6S URO6%&E;I@&I@J;[VM5Y70 /M]M@P6 1^2+Q+H8R^N^EM(I I^A=&A;[C]K]U<9RFT^M^&F@P)@1Y2_C0R^P M#&B;B;Y&E(5Y5U= ^6H3?<
NW/(2K%53 O@PWY?9Q@V^ 1.0@<^<0BP@>S>Q MH^EL>N6BYM1M^YR+5L(\$& \$!^1@Y2/ A[+J]T@<^%!)%&M X5]NPP1-46O:T#^>WOG(XW^ *P;(8 1.0:F^YUDW!PMX) %6/GZ7)2K M
E.VM V.59M+2BU@V@G^V[E;KWK.8\$6\$R^R1B;U;K^>X>Y>+&G@&WRY M JF2.KO+BR>D+M@PL6^F<K>K>4P(L(4>Q+O Q DL)R L]U^/B]R]J(M^J]L2+&^&200^&8K)6V>2E
E+G82\$? 1^P^?>O; MU518^N^1^I^?>OSTYH B;T]13.PT^YF IB *OY;@!0X200N;1R^2> %&M40Y^#M;7! 20M]91X2XK&646(3OCGR44\$]M X^Y.M;POZ348X5C_ \$/ M^M+&CZ\$6
!>=>A(1^<ETL<L.MW^>P^Z^N^DM(GE7. =5)JOUT15.BAAX! V5+35AP + M] (#H#D F]N)O>E^L^ "N]X;I5@<0E M;I^&A;L^S]F]H^42^L^7^M^M?7 MQ8L46;5]WJ]K]P M.YR.-V5-4G^P^L-
#M]J!>+>7^G-XAD776W1L=7 [MURAI9N6;.. ^5N^ N^Z<KQO=2I4G +& M^#F^%45 18.5D A6!<COE M.1.TLP+Q46JUNV.M]E;M]K]F#E<H^N<(\$6\$152%W\$T;D]@<6XW;ORJE
M6->0<O)Y\$]H^K Y^T]W]6PR.HN&5IVK M8HQ4^N&1^ ML3P23 U2K B&F^VY^*+> ^IT]R;S.G^P]N]@<662;MKR@R MA;E^<CX J 6 JLU:=@S791;C>U; 9RZ7Z28 190-9]=L5S(
"LVUER\$R5"=?)2]0(U [JL8>3](&?&2=V0G1B^&M]@L!5A]!&J);P8 190^1(U .O^OR#R]J_SG;AF(I N D8K E96;>7.NBA0J M.O;Y]E]S]LW;@<3^;PKU<U.9SNUPX^T. 15!>]B]X<5RV>Q]T]W98
>S]DYZ? MZBN2=<=?7RL+G]ZYX^83^850L7;6SF5P.H.\$Q FP@.H) #Q7F >3SNM= MV%T%<E<Y>E^\$] J_6]U;K]1<5B^+E!\$P\$L]E\$B/T; M=57Q;\$D(##;][17?>D7FE/!T(4SU6I4N
1525AXO(GO>G^<70T^P^K^Q. M9V1MZH<+&5TU= :5C49\$=ZS1\$R^>A^L^M JSC>K1Q. =3 D2! 5%5%&XN<CL MZN7FX14;JL=;9%&N#KJO^N7E!O]FN^EMK@H]HSI^<CR]JSK=OUK^+H;[;#J4
M2M1(F2)5)F^C/S>AADD0(H^YZ^WQ;^I4G4PCN^ON\$54C^). ^&0D80(L [M]Y Q^P^Q^H AN^KNN=V^IN.DAWD3U=];>R^W^J+7+G46@<O=UZH=]; V.M>8R
M/R1P^*WV>NSPZOXY(O(LH^+T\$<L^&SMH^G WJ &V@<=>];>R=M^ ?78\$H3Q04.M.OB]T]X]XFM^U^>=>R;RN^TKO^<F+D H!%E]UJ^KRRX;Y>Y80P^F?#Y^4R3B #6. M]K8.1;^5.B
+J]H/W;_18\$%>#1#&S; =JEH?OT5 V29M1+L M^W;Q4;]L^OAT^?T@O05PZGUC] BRG1T01SNUEISMX5%;C!A^C^FH^KV13 MBJO^5O! [J1 Y^V]B]H-B;]L^L;L^CN;RHN1T4->5D^>#<
&5&^1O46 M^PQ@V^"GH \$?J]FQ^9Y&R^M^W^X6R9V N]P^W;ZOX;HX1 M\$S U3 L/ 1@9=67ZAM^2E18(G@S6T 1^<1-7>B]6(2A5T^MOXN]MIO 46Z2F M^W^YBCV7XV/C+&[I]M^WZQ;P
M4^32MGKE<I^P])!%A W7E86<QK820^J]B[N8349VA^P5 YM+&#<^W0! M^B=M^E M;+&O.+L>F41M1Z2E18(G@S6T 1^<1-7>B]6(2A5T^MOXN]MIO 46Z2F M^W^YBCV7XV/C+&[I]M^WZQ;P
P4^32MGKE<I^P])!%A W7E86<QK820^J]B[N8349VA^P5 YM+&#<^W0! M^B=M^E M;+&O.+L>F41M1Z2E18(G@S6T 1^<1-7>B]6(2A5T^MOXN]MIO 46Z2F M^W^YBCV7XV/C+&[I]M^WZQ;P
M4^32MGKE<I^P])!%A W7E86<QK820^J]B[N8349VA^P5 YM+&#<^W0! M^B=M^E M;+&O.+L>F41M1Z2E18(G@S6T 1^<1-7>B]6(2A5T^MOXN]MIO 46Z2F M^W^YBCV7XV/C+&[I]M^WZQ;P
P4^32MGKE<I^P])!%A W7E86<QK820^J]B[N8349VA^P5 YM+&#<^W0! M^B=M^E M;+&O.+L>F41M1Z2E18(G@S6T 1^<1-7>B]6(2A5T^MOXN]MIO 46Z2F M^W^YBCV7XV/C+&[I]M^WZQ;P
M4^32MGKE<I^P])!%A W7E86<QK820^J]B[N8349VA^P5 YM+&#<^W0! M^B=M^E M;+&O.+L>F41M1Z2E18(G@S6T 1^<1-7>B]6(2A5T^MOXN]MIO 46Z2F M^W^YBCV7XV/C+&[I]M^WZQ;P
P4^32MGKE<I^P])!%A W7E86<QK820^J]B[N8349VA^P5 YM+&#<^W0! M^B=M^E M;+&O.+L>F41M1Z2E18(G@S6T 1^<1-7>B]6(2A5T^MOXN]MIO 46Z2F M^W^YBCV7XV/C+&[I]M^WZQ;P
M4^32MGKE<I^P])!%A W7E86<QK820^J]B[N8349VA^P5 YM+&#<^W0! M^B=M^E M;+&O.+L>F41M1Z2E18(G@S6T 1^<1-7>B]6(2A5T^MOXN]MIO 46Z2F M^W^YBCV7XV/C+&[I]M^WZQ;P
P4^32MGKE<I^P])!%A W7E86<QK820^J]B[N8349VA^P5 YM+&#<^W0! M^B=M^E M;+&O.+L>F41M1Z2E18(G@S6T 1^<1-7>B]6(2A5T^MOXN]MIO 46Z2F M^W^YBCV7XV/C+&[I]M^WZQ;P
M4^32MGKE<I^P])!%A W7E86<QK820^J]B[N8349VA^P5 YM+&#<^W0! M^B=M^E M;+&O.+L>F41M1Z2E18(G@S6T 1^<1-7>B]6(2A5T^MOXN]MIO 46Z2F M^W^YBCV7XV/C+&[I]M^WZQ;P
P4^32MGKE<I^P])!%A W7E86<QK820^J]B[N8349VA^P5 YM+&#<^W0! M^B=M^E M;+&O.+L>F41M1Z2E18(G@S6T 1^<1-7>B]6(2A5T^MOXN]MIO 46Z2F M^W^YBCV7XV/C+&[I]M^WZQ;P
M4^32MGKE<I^P])!%A W7E86<QK820^J]B[N8349VA^P5 YM+&#<^W0! M^B=M^E M;+&O.+L>F41M1Z2E18(G@S6T 1^<1-7>B]6(2A5T^MOXN]MIO 46Z2F M^W^YBCV7XV/C+&[I]M^WZQ;P
P4^32MGKE<I^P])!%A W7E86<QK820^J]B[N8349VA^P5 YM+&#<^W0! M^B=M^E M;+&O.+L>F41M1Z2E18(G@S6T 1^<1-7>B]6(2A5T^MOXN]MIO 46Z2F M^W^YBCV7XV/C+&[I]M^WZQ;P
M4^32MGKE<I^P])!%A W7E86<QK820^J]B[N8349VA^P5 YM+&#<^W0! M^B=M^E M;+&O.+L>F41M1Z2E18(G@S6T 1^<1-7>B]6(2A5T^MOXN]MIO 46Z2F M^W^YBCV7XV/C+&[I]M^WZQ;P
P4^32MGKE<I^P])!%A W7E86<QK820^J]B[N8349VA^P5 YM+&#<^W0! M^B=M^E M;+&O.+L>F41M1Z2E18(G@S6T 1^<1-7>B]6(2A5T^MOXN]MIO 46Z2F M^W^YBCV7XV/C+&[I]M^WZQ;P
M4^32MGKE<I^P])!%A W7E86<QK820^J]B[N8349VA^P5 YM+&#<^W0! M^B=M^E M;+&O.+L>F41M1Z2E18(G@S6T 1^<1-7>B]6(2A5T^MOXN]MIO 46Z2F M^W^YBCV7XV/C+&[I]M^WZQ;P
P4^32MGKE<I^P])!%A W7E86<QK820^J]B[N8349VA^P5 YM+&#<^W0! M^B=M^E M;+&O.+L>F41M1Z2E18(G@S6T 1^<1-7>B]6(2A5T^MOXN]MIO 46Z2F M^W^YBCV7XV/C+&[I]M^WZQ;P
M4^32MGKE<I^P])!%A W7E86<QK820^J]B[N8349VA^P5 YM+&#<^W0! M^B=M^E M;+&O.+L>F41M1Z2E18(G@S6T 1^<1-7>B]6(2A5T^MOXN]MIO 46Z2F M^W^YBCV7XV/C+&[I]M^WZQ;P
P4^32MGKE<I^P])!%A W7E86<QK820^J]B[N8349VA^P5 YM+&#<^W0! M^B=M^E M;+&O.+L>F41M1Z2E18(G@S6T 1^<1-7>B]6(2A5T^MOXN]MIO 46Z2F M^W^YBCV7XV/C+&[I]M^WZQ;P
M4^32MGKE<I

% QJ[4]C*N; % M:5Y6UOQOKO>#7<7?1P[1]QJV3A M G4J3R,]]>8A/IMGYX=OJ#B*5*;AO=EA3Z]S#B=1K=OU=UIJ5, M, DN2;>:NLU:K5<=CCWV#+D+OSGL7*U@)=^=KOOT_Q,VP38>A-
\$XFUANM,%U_Mi>ZU'9LVSF29>K<8LKBXM;2R2D3YNI64*E*AN+UO,]]22GM2GNZ5*]] MS3(=>=>RYIS,I4O>Q;IR222V);\$CK,CM>+OS6=K,1YM&(8+V58MOC.VL87 M\$H.& .OOE. #/X+?
=AU'14];N2I'Z=>IYGXS+PR/7? MQ1[0 "94 XJED68W>6*9G,8W,+>+>OPS,KM+J]R<E<NHL;OVQMDW%YT'2973R;1 M,74V/<@X/GVTWMM+KR;XF@N HO.
Z>8WU2U,6G<45LBNLL>7>?>11E3H[0 M \$POVD6A>+>?9%R8UCUV31*+XKWBZ=1,]WIES4A*UOQ, -Z4M= # MK'D-FGEOQL^<@OH4Z;R. #61Y4ZD5Z.V]S]Z7DAIL+N=3;>85<8TX7'-KB
MCBNVINEOPSVGLFEFIA%66E\$S?>BN671%0%1Y18M7@.81C./89A]5X5B>]] MTM7?C.XY20FZFHF;DA,UM13U4^,AN]KJVI&;99:0DD-MH(B+HOUN)U;E.I
M#M5DY592.;>UMO;VWPLMN64S(4*3C32BDEN26Y<V^@^@ M. E24K2I]T16A.32M]B25]47.125]J2D]I^AD2X0I;G8+H3D;B/P0W^OR9T9CBH7+3;U M (18T=>.&4FLT_MN;B7 M9V*.
MDIN% A^81X5UC2I7I.C.HEP4H.9C0?%O]06I%G]7L1L?C?RI MGYVL+8M.VHYSFJ<IL5MHV2MF/DXJEG/N\$5-8/K5WBIBR95S31^IZNGKKR M.PW+*JLESX^I8]W/BNV7R?>
<1<10Y3#3>AY2EA&^>N2YME167K/7^V19K6 M=8-F/L1SRG7>P<M/VS/C^ZSOC+>60X.M2V. H1M^D216XN+OD. MO^>LJ1R T -L+&#=->2TRRRA;CKBB2E]F9S/FO)< M49^OC^WV
MIW2+>R>2^6WFRQ>14 7G^C]IA]OAS-14PHM;5U=;%88;UO; M706&LX&OK;5M]_>A0X526VFF21^>224D1\$1^HY2E.3G-MS-Q;UMO>V^L I
M]1)2C%12V(S44% B]WK<^>1 C.LBOS;S'1OV6H>4.2?>U=Z=] # #0403?>.42: -8WRG2AGV%ONPZC^J5>7=4.]^6^OXY M4Y1L^3^N]3S]F7V2;0]J61R;]^U]2J20]N]R/R-
LB5871SE?G^>^I M+&A.OYWXL15#L=U+UO15M8Y4KEOFL^A5KO#158.79V1ZC9G3B BIP M #1.5.KLZLW-L4U-0ZQO^9E.P#>R32338;H]O8LKRIFM0(C32W5FEF M\$);
>>2](<=4AB.PA.KJDMH4HN^>NL:6E.SNIF2FCO1)S?>0ZTWJWVJWY4+40XK^#4UE.F#P;SIOJGV9U.PK8J#>^C^T@N]M]MCU>6^&7)M]=V4Y;2]R]A(4V);9V]TGO7K+B22<88P]D<M
>2>2^W6W^P2>SN]V>F.E.Q&G. M7N6G8S5?>1]=6NNIDDFR.E=DLR&8>1XK=OHUE6R#00W>=%>UOZWR<^N]NFEXT.S;NS#9B4S]2S.E2.C.IRGY^>M]U^12E]Y1N^&R;B.K P
O8S19ONZ.L5X.L7ZDL>RD6F169-0 M M*X^GK^>2]6Vf=Y=^A.3.2FB^*C&&^T7C(9E91^F^2R2368UCTU@U-UYI?B/NIK\$9M^2XTRYC MLTS;PR:U=YF%10I+>PN3]K%;VWR;MIP6+ .Y8V%UF-
=61]R]J?O>=>1 M1808-(WE8>2)OZNFNFK, P A-K=THZ..3AXI M]YU.NVKJ3MYZ#7W+CL. #1061M19W^H]NA30HY8GL@GME0.HUO?>S>]7U]B6 MDMFG+3^8TK^I^>X.9OY%Z^>L+&1LT M
9: AX-3]I] 5W1VKX, %!]] J1H UC?*=^&P6^f#]JZ MI5XU=U3IHWYS/QF7AD?H>V^1 CVB0@8SRH IF M] H\$Y<+>Y58 M613660^>N.]&^<N#H9<4]R744L^U]U:2T90GWI^>R^K^T81
M2.SD0<3Y1H0/D]Z\$RZK.T]2E-87%Q]U+0%U]H\$.S?>93F]._>S;B.M.5+>N9]U<O=O8D0^8D=>+H7I;+>U]E0F(O;LH53^&S= MZXO]XGM;FY^U\$6;U-
EP42;OBOTL^P^T]D]RFX.6@U]TM=0?>E?8^&+6]M M^>SZV^9A1^_>X^*6%HO]U=>F9U<?>E+U^2C%U.4I6& M 5< 4>^>XO?V?CESN]^&= MZG^F^BC52]Y2O5450D+UCE7G-HLPI+X>BNZY8-
F_O;U]SIA M>15P^+17Y(1+7^S?>#S=92V]J]=HVOZ%Y;J3OL1^?074R MOJZRBLG5/LMLUN+Y^I]K3E0M+]++>L3R3W=**>SROZG2]7116>DO^*P^&A;F
M7^X]ZV96S93EYAFI^HWA2E^9+J2V+L2P6-2H.T%T@ M M I4T. OR2BWM6Y.S.M=CX8?W.NI]H3E0M+]++>L3R3W=**>SROZG2]7116>DO^*P^&A;F
M^>L^>R^>O^>N^>L^>I^>R^>9_P3>=%]0% A@^T? 8/2W>P.5&G/4AOL^Q*6.X MI<^>O>+W2X5D]TA=O69.] M F@>K7R5.1^F07<#>9+>#>TMA^>2]J.R3V5?#R17^>7B9AO^X9<=>N#>I]Z[30^>?7A
MF<L>1^*OKAPFY^99Y>M. ^I^E<^>Y.MEN?DEI((S)S^G/V]S.F(C.>AME^% YKF M#89U=]S^HYU;L;H07M80W)>]]>]]>TM>PR^>TRV<K>T@HPX7PR^>N+H68]I M2C&^#=#-
#12+16G<OY%Z^>R+&1LT 7?>9:AX-3]I] 5W1VKX, %!]] J1H UC?*=^&P6^f#]JZ MI5XU=U3IHWYS/QF7AD?H>V^1 CVB0@8SRH IF M] H\$Y<+>Y58 M613660^>N.]&^<N#H9<4]R744L^U]U:2T90GWI^>R^K^T81
M2.SD0<3Y1H0/D]Z\$RZK.T]2E-87%Q]U+0%U]H\$.S?>93F]._>S;B.M.5+>N9]U<O=O8D0^8D=>+H7I;+>U]E0F(O;LH53^&S= MZXO]XGM;FY^U\$6;U-
EP42;OBOTL^P^T]D]RFX.6@U]TM=0?>E?8^&+6]M M^>SZV^9A1^_>X^*6%HO]U=>F9U<?>E+U^2C%U.4I6& M 5< 4>^>XO?V?CESN]^&= MZG^F^BC52]Y2O5450D+UCE7G-HLPI+X>BNZY8-
F_O;U]SIA M>15P^+17Y(1+7^S?>#S=92V]J]=HVOZ%Y;J3OL1^?074R MOJZRBLG5/LMLUN+Y^I]K3E0M+]++>L3R3W=**>SROZG2]7116>DO^*P^&A;F
M7^X]ZV96S93EYAFI^HWA2E^9+J2V+L2P6-2H.T%T@ M M I4T. OR2BWM6Y.S.M=CX8?W.NI]H3E0M+]++>L3R3W=**>SROZG2]7116>DO^*P^&A;F
M^>L^>R^>O^>N^>L^>I^>R^>9_P3>=%]0% A@^T? 8/2W>P.5&G/4AOL^Q*6.X MI<^>O>+W2X5D]TA=O69.] M F@>K7R5.1^F07<#>9+>#>TMA^>2]J.R3V5?#R17^>7B9AO^X9<=>N#>I]Z[30^>?7A
MF<L>1^*OKAPFY^99Y>M. ^I^E<^>Y.MEN?DEI((S)S^G/V]S.F(C.>AME^% YKF M#89U=]S^HYU;L;H07M80W)>]]>]]>TM>PR^>TRV<K>T@HPX7PR^>N+H68]I M2C&^#=#-
#12+16G<OY%Z^>R+&1LT 7?>9:AX-3]I] 5W1VKX, %!]] J1H UC?*=^&P6^f#]JZ MI5XU=U3IHWYS/QF7AD?H>V^1 CVB0@8SRH IF M] H\$Y<+>Y58 M613660^>N.]&^<N#H9<4]R744L^U]U:2T90GWI^>R^K^T81
M2.SD0<3Y1H0/D]Z\$RZK.T]2E-87%Q]U+0%U]H\$.S?>93F]._>S;B.M.5+>N9]U<O=O8D0^8D=>+H7I;+>U]E0F(O;LH53^&S= MZXO]XGM;FY^U\$6;U-
EP42;OBOTL^P^T]D]RFX.6@U]TM=0?>E?8^&+6]M M^>SZV^9A1^_>X^*6%HO]U=>F9U<?>E+U^2C%U.4I6& M 5< 4>^>XO?V?CESN]^&= MZG^F^BC52]Y2O5450D+UCE7G-HLPI+X>BNZY8-
F_O;U]SIA M>15P^+17Y(1+7^S?>#S=92V]J]=HVOZ%Y;J3OL1^?074R MOJZRBLG5/LMLUN+Y^I]K3E0M+]++>L3R3W=**>SROZG2]7116>DO^*P^&A;F
M7^X]ZV96S93EYAFI^HWA2E^9+J2V+L2P6-2H.T%T@ M M I4T. OR2BWM6Y.S.M=CX8?W.NI]H3E0M+]++>L3R3W=**>SROZG2]7116>DO^*P^&A;F
M^>L^>R^>O^>N^>L^>I^>R^>9_P3>=%]0% A@^T? 8/2W>P.5&G/4AOL^Q*6.X MI<^>O>+W2X5D]TA=O69.] M F@>K7R5.1^F07<#>9+>#>TMA^>2]J.R3V5?#R17^>7B9AO^X9<=>N#>I]Z[30^>?7A
MF<L>1^*OKAPFY^99Y>M. ^I^E<^>Y.MEN?DEI((S)S^G/V]S.F(C.>AME^% YKF M#89U=]S^HYU;L;H07M80W)>]]>]]>TM>PR^>TRV<K>T@HPX7PR^>N+H68]I M2C&^#=#-
#12+16G<OY%Z^>R+&1LT 7?>9:AX-3]I] 5W1VKX, %!]] J1H UC?*=^&P6^f#]JZ MI5XU=U3IHWYS/QF7AD?H>V^1 CVB0@8SRH IF M] H\$Y<+>Y58 M613660^>N.]&^<N#H9<4]R744L^U]U:2T90GWI^>R^K^T81
M2.SD0<3Y1H0/D]Z\$RZK.T]2E-87%Q]U+0%U]H\$.S?>93F]._>S;B.M.5+>N9]U<O=O8D0^8D=>+H7I;+>U]E0F(O;LH53^&S= MZXO]XGM;FY^U\$6;U-
EP42;OBOTL^P^T]D]RFX.6@U]TM=0?>E?8^&+6]M M^>SZV^9A1^_>X^*6%HO]U=>F9U<?>E+U^2C%U.4I6& M 5< 4>^>XO?V?CESN]^&= MZG^F^BC52]Y2O5450D+UCE7G-HLPI+X>BNZY8-
F_O;U]SIA M>15P^+17Y(1+7^S?>#S=92V]J]=HVOZ%Y;J3OL1^?074R MOJZRBLG5/LMLUN+Y^I]K3E0M+]++>L3R3W=**>SROZG2]7116>DO^*P^&A;F
M7^X]ZV96S93EYAFI^HWA2E^9+J2V+L2P6-2H.T%T@ M M I4T. OR2BWM6Y.S.M=CX8?W.NI]H3E0M+]++>L3R3W=**>SROZG2]7116>DO^*P^&A;F
M^>L^>R^>O^>N^>L^>I^>R^>9_P3>=%]0% A@^T? 8/2W>P.5&G/4AOL^Q*6.X MI<^>O>+W2X5D]TA=O69.] M F@>K7R5.1^F07<#>9+>#>TMA^>2]J.R3V5?#R17^>7B9AO^X9<=>N#>I]Z[30^>?7A
MF<L>1^*OKAPFY^99Y>M. ^I^E<^>Y.MEN?DEI((S)S^G/V]S.F(C.>AME^% YKF M#89U=]S^HYU;L;H07M80W)>]]>]]>TM>PR^>TRV<K>T@HPX7PR^>N+H68]I M2C&^#=#-
#12+16G<OY%Z^>R+&1LT 7?>9:AX-3]I] 5W1VKX, %!]] J1H UC?*=^&P6^f#]JZ MI5XU=U3IHWYS/QF7AD?H>V^1 CVB0@8SRH IF M] H\$Y<+>Y58 M613660^>N.]&^<N#H9<4]R744L^U]U:2T90GWI^>R^K^T81
M2.SD0<3Y1H0/D]Z\$RZK.T]2E-87%Q]U+0%U]H\$.S?>93F]._>S;B.M.5+>N9]U<O=O8D0^8D=>+H7I;+>U]E0F(O;LH53^&S= MZXO]XGM;FY^U\$6;U-
EP42;OBOTL^P^T]D]RFX.6@U]TM=0?>E?8^&+6]M M^>SZV^9A1^_>X^*6%HO]U=>F9U<?>E+U^2C%U.4I6& M 5< 4>^>XO?V?CESN]^&= MZG^F^BC52]Y2O5450D+UCE7G-HLPI+X>BNZY8-
F_O;U]SIA M>15P^+17Y(1+7^S?>#S=92V]J]=HVOZ%Y;J3OL1^?074R MOJZRBLG5/LMLUN+Y^I]K3E0M+]++>L3R3W=**>SROZG2]7116>DO^*P^&A;F
M7^X]ZV96S93EYAFI^HWA2E^9+J2V+L2P6-2H.T%T@ M M I4T. OR2BWM6Y.S.M=CX8?W.NI]H3E0M+]++>L3R3W=**>SROZG2]7116>DO^*P^&A;F
M^>L^>R^>O^>N^>L^>I^>R^>9_P3>=%]0% A@^T? 8/2W>P.5&G/4AOL^Q*6.X MI<^>O>+W2X5D]TA=O69.] M F@>K7R5.1^F07<#>9+>#>TMA^>2]J.R3V5?#R17^>7B9AO^X9<=>N#>I]Z[30^>?7A
MF<L>1^*OKAPFY^99Y>M. ^I^E<^>Y.MEN?DEI((S)S^G/V]S.F(C.>AME^% YKF M#89U=]S^HYU;L;H07M80W)>]]>]]>TM>PR^>TRV<K>T@HPX7PR^>N+H68]I M2C&^#=#-
#12+16G<OY%Z^>R+&1LT 7?>9:AX-3]I] 5W1VKX, %!]] J1H UC?*=^&P6^f#]JZ MI5XU=U3IHWYS/QF7AD?H>V^1 CVB0@8SRH IF M] H\$Y<+>Y58 M613660^>N.]&^<N#H9<4]R744L^U]U:2T90GWI^>R^K^T81
M2.SD0<3Y1H0/D]Z\$RZK.T]2E-87%Q]U+0%U]H\$.S?>93F]._>S;B.M.5+>N9]U<O=O8D0^8D=>+H7I;+>U]E0F(O;LH53^&S= MZXO]XGM;FY^U\$6;U-
EP42;OBOTL^P^T]D]RFX.6@U]TM=0?>E?8^&+6]M M^>SZV^9A1^_>X^*6%HO]U=>F9U<?>E+U^2C%U.4I6& M 5< 4>^>XO?V?CESN]^&= MZG^F^BC52]Y2O5450D+UCE7G-HLPI+X>BNZY8-
F_O;U]SIA M>15P^+17Y(1+7^S?>#S=92V]J]=HVOZ%Y;J3OL1^?074R MOJZRBLG5/LMLUN+Y^I]K3E0M+]++>L3R3W=**>SROZG2]7116>DO^*P^&A;F
M7^X]ZV96S93EYAFI^HWA2E^9+J2V+L2P6-2H.T%T@ M M I4T. OR2BWM6Y.S.M=CX8?W.NI]H3E0M+]++>L3R3W=**>SROZG2]7116>DO^*P^&A;F
M^>L^>R^>O^>N^>L^>I^>R^>9_P3>=%]0% A@^T? 8/2W>P.5&G/4AOL^Q*6.X MI<^>O>+W2X5D]TA=O69.] M F@>K7R5.1^F07<#>9+>#>TMA^>2]J.R3V5?#R17^>7B9AO^X9<=>N#>I]Z[30^>?7A
MF<L>1^*OKAPFY^99Y>M. ^I^E<^>Y.MEN?DEI((S)S^G/V]S.F(C.>AME^% YKF M#89U=]S^HYU;L;H07M80W)>]]>]]>TM>PR^>TRV<K>T@HPX7PR^>N+H68]I M2C&^#=#-
#12+16G<OY%Z^>R+&1LT 7?>9:AX-3]I] 5W1VKX, %!]] J1H UC?*=^&P6^f#]JZ MI5XU=U3IHWYS/QF7AD?H>V^1 CVB0@8SRH IF M] H\$Y<+>Y58 M613660^>N.]&^<N#H9<4]R744L^U]U:2T90GWI^>R^K^T81
M2.SD0<3Y1H0/D]Z\$RZK.T]2E-87%Q]U+0%U]H\$.S?>93F]._>S;B.M.5+>N9]U<O=O8D0^8D=>+H7I;+>U]E0F(O;LH53^&S= MZXO]XGM;FY^U\$6;U-
EP42;OBOTL^P^T]D]RFX.6@U]TM=0?>E?8^&+6]M M^>SZV^9A1^_>X^*6%HO]U=>F9U<?>E+U^2C%U.4I6& M 5< 4>^>XO?V?CESN]^&= MZG^F^BC52]Y2O5450D+UCE7G-HLPI+X>BNZY8-
F_O;U]SIA M>15P^+17Y(1+7^S?>#S=92V]J]=HVOZ%Y;J3OL1^?074R MOJZRBLG5/LMLUN+Y^I]K3E0M+]++>L3R3W=**>SROZG2]7116>DO^*P^&A;F
M7^X]ZV96S93EYAFI^HWA2E^9+J2V+L2P6-2H.T%T@ M M I4T. OR2BWM6Y.S.M=CX8?W.NI]H3E0M+]++>L3R3W=**>SROZG2]7116>DO^*P^&A;F
M^>L^>R^>O^>N^>L^>I^>R^>9_P3>=%]0% A@^T? 8/2W>P.5&G/4AOL^Q*6.X MI<^>O>+W2X5D]TA=O69.] M F@>K7R5.1^F07<#>9+>#>TMA^>2]J.R3V5?#R17^>7B9AO^X9<=>N#>I]Z[30^>?7A
MF<L>1^*OKAPFY^99Y>M. ^I^E<^>Y.MEN?DEI((S)S^G/V]S.F(C.>AME^% YKF M#89U=]S^HYU;L;H07M80W)>]]>]]>TM>PR^>TRV<K>T@HPX7PR^>N+H68]I M2C&^#=#-
#12+16G<OY%Z^>R+&1LT 7?>9:AX-3]I] 5W1VKX, %!]] J1H UC?*=^&P6^f#]JZ MI5XU=U3IHWYS/QF7AD?H>V^1 CVB0@8SRH IF M] H\$Y<+>Y58 M613660^>N.]&^<N#H9<4]R744L^U]U:2T90GWI^>R^K^T81
M2.SD0<3Y1H0/D]Z\$RZK.T]2E-87%Q]U+0%U]H\$.S?>93F]._>S;B.M.5+>N9]U<O=O8D0^8D=>+H7I;+>U]E0F(O;LH53^&S= MZXO]XGM;FY^U\$6;U-
EP42;OBOTL^P^T]D]RFX.6@U]TM=0?>E?8^&+6]M M^>SZV^9A1^_>X^*6%HO]U=>F9U<?>E+U^2C%U.4I6& M 5< 4>^>XO?V?CESN]^&= MZG^F^BC52]Y2O5450D+UCE7G-HLPI+X>BNZY8-
F_O;U]SIA M>15P^+17Y(1+7^S?>#S=92V]J]=HVOZ%Y;J3OL1^?074R MOJZRBLG5/LMLUN+Y^I]K3E0M+]++>L3R3W=**>SROZG2]7116>DO^*P^&A;F
M7^X]ZV96S93EYAFI^HWA2E^9+J2V+L2P6-2H.T%T@ M M I4T. OR2BWM6Y.S.M=CX8?W.NI]H3E0M+]++>L3R3W=**>SROZG2]7116>DO^*P^&A;F
M^>L^>R^>O^>N^>L^>I^>R^>9_P3>=%]0% A@^T? 8/2W>P.5&G/4AOL^Q*6.X MI<^>O>+W2X5D]TA=O69.] M F@>K7R5.1^F07<#>9+>#>TMA^>2]J.R3V5?#R17^>7B9AO^X9<=>N#>I]Z[30^>?7A
MF<L>1^*OKAPFY^99Y>M. ^I^E<^>Y.MEN?DEI((S)S^G/V]S.F(C.>AME^% YKF M#89U=]S^HYU;L;H07M80W)>]]>]]>TM>PR^>TRV<K>T@HPX7PR^>N+H68]I M2C&^#=#-
#12+16G<OY%Z^>R+&1LT 7?>9:AX-3]I] 5W1VKX, %!]] J1H UC?*=^&P6^f#]JZ MI5XU=U3IHWYS/QF7AD?H>V^1 CVB0@8SRH IF M] H\$Y<+>Y58 M613660^>N.]&^<N#H9<4]R744L^U]U:2T90GWI^>R^K^T81
M2.SD0<3Y1H0/D]Z\$RZK.T]2E-87%Q]U+0%U]H\$.S?>93F]._>S;B.M.5+>N9]U<O=O8D0^8D=>+H7I;+>U]E0F(O;LH53^&S= MZXO]XGM;FY^U\$6;U-
EP42;OBOTL^P^T]D]RFX.6@U]TM=0?>E?8^&+6]M M^>SZV^9A1^_>X^*6%HO]U=>F9U<?>E+U^2C%U.4I6& M 5< 4>^>XO?V?CESN]^&= MZG^F^BC52]Y2O5450D+UCE7G-HLPI+X>BNZY8-
F_O;U]SIA M>15P^+17Y(1+7^S?>#S=92V]J]=HVOZ%Y;J3OL1^?074R MOJZRBLG5/LMLUN+Y^I]K3E0M+]++>L3R3W=**>SROZG2]7116>DO^*P^&A;F
M7^X]ZV96S93EYAFI^HWA2E^9+J2V+L2P6-2H.T%T@ M M I4T. OR2BWM6Y.S.M=CX8?W.NI]H3E0M+]++>L3R3W=**>SROZG2]7116>DO^*P^&A;F
M^>L^>R^>O^>N^>L^>I^>R^>9_P3>=%]0% A@^T? 8/2W>P.5&G/4AOL^Q*6.X MI<^>O>+W2X5D]TA=O69.] M F@>K7R5.1^F07<#>9+>#>TMA^>2]J.R3V5?#R17^>7B9AO^X9<=>N#>I]Z[30^>?7A
MF<L>1^*OKAPFY^99Y>M. ^I^E<^>Y.MEN?DEI((S)S^G/V]S.F(C.>AME^% YKF M#89U=]S^HYU;L;H07M80W)>]]>]]>TM>PR^>TRV<K>T@HPX7PR^>N+H68]I M2C&^#=#-
#12+16G<OY%Z^>R+&1LT 7?>9:AX-3]I] 5W1VKX, %!]] J1H UC?*=^&P6^f#]JZ MI5XU=U3IHWYS/QF7AD?H>V^1 CVB0@8SRH IF M] H\$Y<+>Y58 M613660^>N.]&^<N#H9<4]R744L^U]U:2T90GWI^>R^K^T81
M2.SD0<3Y1H0/D]Z\$RZK.T]2E-87%Q]U+0%U]H\$.S?>93F]._>S;B.M.5+>N9]U<O=O8D0^8D=>+H7I;+>U]E0F(O;LH53^&S= MZXO]XGM;FY^U\$6;U-
EP42;OBOTL^P^T]D]RFX.6@U]TM=0?>E?8^&+6]M M^>SZV^9A1^_>X^*6%HO]U=>F9U<?>E+U^2C%U.4I6& M 5< 4>^>XO?V?CESN]^&= MZG^F^BC52]Y2O5450D+UCE7G-HLPI+X>BNZY8-
F_O;U]SIA M>15P^+17Y(1+7^S?>#S=92V]J]=HVOZ%Y;J3OL1^?074R MOJZRBLG5/LMLUN+Y^I]K3E0M+]++>L3R3W=**>SROZG2]7116>DO^*P^&A;F
M7^X]ZV96S93EYAFI^HWA2E^9+J2V+L2P6-2H.T%T@ M M I4T. OR2BWM6Y.S.M=CX8?W.NI]H3E0M+]++>L3R3W=**>SROZG2]7116>DO^*P^&A;F
M^>L^>R^>O^>N^>L^>I^>R^>9_P3>=%]0% A@^T? 8/2W>P.5&G/4AOL^Q*6.X MI<^>O>+W2X5D]TA=O69.] M F@>K7R5.1^F07<#>9+>#>TMA^>2]J.R3V5?#R17^>7B9AO^X9<=>N#>I]Z[30^>?7A
MF<L>1^*OKAPFY^99Y>M. ^I^E<^>Y.MEN?DEI((S)S^G/V]S.F(C.>AME^% YKF M#89U=]S^HYU;L;H07M80W)>]]>]]>TM>PR^>TRV<K>T@HPX7PR^>N+H68]I M2C&^#=#-
#12+16G<OY%Z^>R+&1LT 7?>9:AX-3]I] 5W1VKX, %!]] J1H UC?*=^&P6^f#]JZ MI5XU=U3IHWYS/QF7AD?H>V^1 CVB0@8SRH IF M] H\$Y<+>Y58 M613660^>N.]&^<N#H9<4]R744L^U]U:2T90GWI^>R^K^T81
M2.SD0<3Y1H0/D]Z\$RZK.T]2E-87%Q]U+0%U]H\$.S?>93F]._>S;B.M.5+>N9]U<O=O8D0^8D=>+H7I;+>U]E0F(O;LH53^&S= MZXO]XGM;FY^U\$6;U-
EP42;OBOTL^P^T]D]RFX.6@U]TM=0?>E?8^&+6]M M^>SZV^9A1^_>X^*6%HO]U=>F9U<?>E+U^2C%U.4I6& M 5< 4>^>XO?V?CESN]^&= MZG^F^BC52]Y2O5450D+UCE7G-HLPI+X>BNZY8-
F_O;U]SIA M>15P^+17Y(1+7^S?>#S=92V]J]=HVOZ%Y;J3OL1^?074R MOJZRBLG5/LMLUN+Y^I]K3E0M+]++>L3R3W=**>SROZG2]7116>DO^*P^&A;F
M7^X]ZV96S93EYAFI^HWA2E^9+J2V+L2P6-2H.T%T@ M M I4T. OR2BWM6Y.S.M=CX8?W.NI]H3E0M+]++>L3R3W=**>SROZG2]7116>DO^*P^&A;F
M^>L^>R^>O^>N^>L^>I^>R^>9_P3>=%]0% A@^T? 8/2W>P.5&G/4AOL^Q*6.X MI<^>O>+W2X5D]TA=O69.] M F@>K7R5.1^F07<#>9+>#>TMA^>2]J.R3V5?#R17^

Deferred revenue	16,436	13,150
Operating lease liabilities	10,820	11,521
Total current liabilities	111,019	127,162
Operating lease liabilities, noncurrent	78,662	83,849
Deferred revenue, noncurrent	11,358	8,814
Other noncurrent liabilities	4,571	4,275
Total liabilities	205,610	224,100
Commitments and contingencies (Note 4)		
Stockholders' equity:		
Preferred stock	0	0
Common stock	2	2
Additional paid-in capital	2,106,752	2,025,890
Accumulated deficit	(1,382,266)	(1,284,420)
Accumulated other comprehensive loss	(430)	(429)
Total stockholders' equity	724,058	741,043
Total liabilities and stockholders' equity	\$ 929,668	\$ 965,143

[XML 17 R3.htm IDEA- XBRL DOCUMENT](#)

	3 Months Ended		6 Months Ended	
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023

Income Statement [Abstract]

	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Revenue	\$ 153,104	\$ 146,819	\$ 294,110	\$ 281,104
Cost of revenue	48,884	47,207	96,976	83,102
Gross profit	104,220	99,612	197,134	198,002
Operating expenses:				
Research and development	62,918	71,460	131,556	138,558
Selling, general and administrative	83,039	91,510	168,813	174,790
Total operating expenses	145,957	162,970	300,369	313,348
Loss from operations	(41,737)	(63,358)	(103,235)	(115,346)
Other income (expense):				
Interest income	4,715	4,100	9,451	7,969
Interest expense	(1)	(5)	(2)	(24)
Other expense, net	(56)	(1,504)	(1,096)	(3,020)
Total other income	4,658	2,591	8,353	4,925
Loss before provision for income taxes	(37,079)	(60,767)	(94,882)	(110,421)
Provision for income taxes	818	1,647	2,964	2,740
Net loss	\$ (37,897)	\$ (62,414)	\$ (97,846)	\$ (113,161)
Net loss per share, basic (in dollars per share)	\$ (0.32)	\$ (0.53)	\$ (0.82)	\$ (0.97)
Net loss per share, diluted (in dollars per share)	\$ (0.32)	\$ (0.53)	\$ (0.82)	\$ (0.97)
Weighted-average shares of common stock used in computing net loss per share, basic (in shares)	120,066,972	116,707,672	119,461,485	116,166,776
Weighted-average shares of common stock used in computing net loss per share, diluted (in shares)	120,066,972	116,707,672	119,461,485	116,166,776

[XML 18 R4.htm IDEA- XBRL DOCUMENT](#)

	3 Months Ended		6 Months Ended	
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023

Statement of Comprehensive Income [Abstract]

	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Net loss	\$ (37,897)	\$ (62,414)	\$ (97,846)	\$ (113,161)
Other comprehensive income, net of tax:				
Unrealized gains on available-for-sale marketable securities	48	379	185	1,496
Realized loss on available-for-sale marketable securities reclassified into net loss	0	0	0	1,715
Foreign currency translation adjustment	(22)	131	(186)	155
Other comprehensive income (loss), net of tax	26	510	(1)	3,366
Comprehensive loss	\$ (37,871)	\$ (61,904)	\$ (97,847)	\$ (109,795)

[XML 19 R5.htm IDEA- XBRL DOCUMENT](#)

	Total	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Accumulated Other Comprehensive Income (Loss)	Common Class A	Common Class A Common Stock	Common Class A Additional Paid-in Capital
Statements of Stockholders' Equity - USD (\$)								
\$ in Thousands								
Beginning balance (in shares) at Dec. 31, 2022		115,195,009						
Beginning balance at Dec. 31, 2022	\$ 805,743	\$ 2	\$ 1,839,397	\$ (1,029,321)	\$ (4,335)			
Increase (Decrease) in Stockholders' Equity [Roll Forward]								
Issuance of Class A common stock related to equity awards (in shares)							978,333	
Issuance of Class A common stock related to equity awards						\$ 2,400		\$ 2,400
Stock-based compensation	42,133		42,133					
Net loss	(50,747)			(50,747)				
Other comprehensive income (loss)	2,856				2,856			
Ending balance (in shares) at Mar. 31, 2023		116,173,342						
Ending balance at Mar. 31, 2023	802,385	\$ 2	1,883,930	(1,080,068)	(1,479)			
Beginning balance (in shares) at Dec. 31, 2022		115,195,009						
Beginning balance at Dec. 31, 2022	805,743	\$ 2	1,839,397	(1,029,321)	(4,335)			
Increase (Decrease) in Stockholders' Equity [Roll Forward]								
Net loss	(113,161)							
Other comprehensive income (loss)	3,366							
Ending balance (in shares) at Jun. 30, 2023		117,323,435						
Ending balance at Jun. 30, 2023	793,301	\$ 2	1,936,750	(1,142,482)	(969)			
Beginning balance (in shares) at Mar. 31, 2023		116,173,342						
Beginning balance at Mar. 31, 2023	802,385	\$ 2	1,883,930	(1,080,068)	(1,479)			
Increase (Decrease) in Stockholders' Equity [Roll Forward]								
Issuance of Class A common stock related to equity awards (in shares)							1,150,093	
Issuance of Class A common stock related to equity awards						7,096		7,096
Stock-based compensation	45,724		45,724					
Net loss	(62,414)			(62,414)				
Other comprehensive income (loss)	510				510			
Ending balance (in shares) at Jun. 30, 2023		117,323,435						
Ending balance at Jun. 30, 2023	793,301	\$ 2	1,936,750	(1,142,482)	(969)			
Beginning balance (in shares) at Dec. 31, 2023		119,095,362						

Beginning balance at Dec. 31, 2023	741,043	\$ 2	2,025,890	(1,284,420)	(429)		
Increase (Decrease) in Stockholders' Equity [Roll Forward]							
Issuance of Class A common stock related to equity awards (in shares)						605,487	
Issuance of Class A common stock related to equity awards						1,638	1,638
Stock-based compensation	36,129		36,129				
Net loss	(59,949)			(59,949)			
Other comprehensive income (loss)	(27)				(27)		
Ending balance (in shares) at Mar. 31, 2024			119,700,849				
Ending balance at Mar. 31, 2024	718,834	\$ 2	2,063,657	(1,344,369)	(456)		
Beginning balance (in shares) at Dec. 31, 2023			119,095,362				
Beginning balance at Dec. 31, 2023	741,043	\$ 2	2,025,890	(1,284,420)	(429)		
Increase (Decrease) in Stockholders' Equity [Roll Forward]							
Net loss	(97,846)						
Other comprehensive income (loss)	(1)						
Ending balance (in shares) at Jun. 30, 2024			120,474,167				
Ending balance at Jun. 30, 2024	724,058	\$ 2	2,106,752	(1,382,266)	(430)		
Beginning balance (in shares) at Mar. 31, 2024			119,700,849				
Beginning balance at Mar. 31, 2024	718,834	\$ 2	2,063,657	(1,344,369)	(456)		
Increase (Decrease) in Stockholders' Equity [Roll Forward]							
Issuance of Class A common stock related to equity awards (in shares)						773,318	
Issuance of Class A common stock related to equity awards						\$ 4,603	\$ 4,603
Stock-based compensation	38,492		38,492				
Net loss	(37,897)			(37,897)			
Other comprehensive income (loss)	26				26		
Ending balance (in shares) at Jun. 30, 2024			120,474,167				
Ending balance at Jun. 30, 2024	\$ 724,058	\$ 2	\$ 2,106,752	\$ (1,382,266)	\$ (430)		

[XML 20 R6.htm IDEA XBRL DOCUMENT](#)

Condensed Consolidated Statements of Cash Flows - USD (\$) \$ in Thousands	6 Months Ended	
	Jun. 30, 2024	Jun. 30, 2023
Operating activities:		
Net loss	\$ (97,846)	\$ (113,161)
Adjustments to reconcile net loss to net cash used in operating activities:		
Stock-based compensation expense	74,621	87,797
Depreciation and amortization	18,165	16,423
Amortization of right-of-use assets	4,229	4,070
Lease and asset impairment charges	2,454	2,785
Realized loss on marketable securities	1	1,715
Other	509	613
Changes in operating assets and liabilities:		
Accounts receivable	23,638	16,526
Inventory	(15,134)	(2,311)
Prepaid expenses and other current assets	(898)	(2,123)
Other noncurrent assets	(2,133)	(18,073)
Accounts payable	5,705	1,314
Accrued compensation and other related benefits	(9,960)	(10,313)
Deferred revenue	5,832	2,885
Accrued expenses and other current liabilities	(12,127)	494
Operating lease liability	(5,599)	(4,540)
Other noncurrent liabilities	314	248
Net cash used in operating activities	(8,229)	(15,651)
Investing activities:		
Purchases of property and equipment	(5,788)	(29,915)
Purchases of intangible assets	(1,000)	(723)
Proceeds from sales of marketable securities	3,585	94,947
Proceeds from maturities of marketable securities	25,782	51,185
Net cash provided by investing activities	22,579	115,494
Financing activities:		
Payments on financing arrangement	0	(5,814)
Issuance of common stock from exercise of stock options and employee stock purchase plan purchases	6,241	9,496
Net cash provided by financing activities	6,241	3,682
Effect of exchange rate changes on cash, cash equivalents, and restricted cash	(51)	(25)
Net increase in cash and cash equivalents	20,540	103,500
Cash, cash equivalents, and restricted cash at beginning of period	359,284	227,353
Cash, cash equivalents, and restricted cash at end of period	379,824	330,853
Supplemental disclosures of cash flow information:		
Cash paid for interest	0	436
Cash paid for taxes	2,040	3,852
Noncash investing and financing activities:		
Purchases of property and equipment included in accounts payable and accrued expenses and other current liabilities	1,452	9,317
Right-of-use assets obtained in exchange for new operating lease liabilities	\$ 0	\$ 6,893

[XML 21 R7.htm IDEA XBRL DOCUMENT](#)

Description of Business and Basis of Presentation	6 Months Ended	
	Jun. 30, 2024	

Organization, Consolidation and Presentation of Financial Statements [Abstract]

[Description of Business and Basis of Presentation](#)

Organization and Description of Business

10x Genomics, Inc. (the "Company") is a life sciences technology company focused on building innovative products and solutions to interrogate, understand and master biological systems at resolution and scale that matches the complexity of biology. The Company's integrated solutions include the Company's Chromium X Series and Chromium Connect instruments, which the Company refers to as "Chromium instruments," the Company's Visium CytoAssist and Xenium Analyzer instruments, which the Company refers to as "Spatial instruments," and the Company's proprietary microfluidic chips, slides, reagents and other consumables for the Company's Chromium, Visium and Xenium solutions, which the Company refers to as "consumables." The Company bundles its software with these products to guide customers through the workflow, from sample preparation through analysis and visualization. The Company was incorporated in the state of Delaware in July 2012 and began commercial and manufacturing operations and selling its instruments and consumables in 2015. The Company is headquartered in Pleasanton, California and has wholly-owned subsidiaries in Asia, Europe, Oceania and North America.

Basis of Presentation

The accompanying condensed consolidated financial statements, which include the Company's accounts and the accounts of its wholly-owned subsidiaries, are unaudited and have been prepared in accordance with U.S. generally accepted accounting principles ("GAAP"). The condensed consolidated balance sheet at December 31, 2023 has been derived from the audited consolidated financial statements of the Company at that date. Certain information and footnote disclosures typically included in the Company's audited consolidated financial statements have been condensed or omitted. The accompanying unaudited condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments,

which include only normal recurring adjustments, necessary to state fairly the Company's financial position, results of operations, comprehensive loss and cash flows for the periods presented, but are not necessarily indicative of the results of operations to be anticipated for any future annual or interim period. All intercompany transactions and balances have been eliminated. The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosure of contingent assets and liabilities. Actual results could differ from those estimates.

The accompanying unaudited condensed consolidated financial statements and notes should be read in conjunction with the audited consolidated financial statements and related notes for the year ended December 31, 2023 included in the Company's Annual Report on Form 10-K filed with the SEC on February 15, 2024 (our "Annual Report").

[XML 22-R8.htm IDEA- XBRL DOCUMENT](#)

Summary of Significant Accounting Policies
[Accounting Policies \[Abstract\]](#)
[Summary of Significant Accounting Policies](#)

6 Months Ended
Jun. 30, 2024

Summary of Significant Accounting Policies

There were no material changes in the Company's significant accounting policies during the six months ended June 30, 2024. See Note 2 - Summary of Significant Accounting Policies to the consolidated financial statements included in the Company's Annual Report for information regarding the Company's significant accounting policies.

Revenue Recognition

The Company generates revenue from sales of products and services, and its products consist of instruments and consumables. Revenue from product sales is recognized when control of the product is transferred, which is generally upon shipment to the customer. Instrument service agreements, which relate to extended warranties, are typically entered into for one-year terms, following the expiration of the standard one-year warranty period. Revenue for extended warranties is recognized ratably over the term of the extended warranty period as a stand ready performance obligation. Revenue is recorded net of discounts, distributor commissions and sales taxes collected on behalf of governmental authorities. Customers are invoiced generally upon shipment, or upon order for services, and payment is typically due within 30 days. Cash received from customers in advance of product shipment or providing services is recorded as a contract liability. The Company's contracts with its customers generally do not include rights of return or a significant financing component.

The Company regularly enters into contracts that include various combinations of products and services which are generally distinct and accounted for as separate performance obligations. The transaction price is allocated to each performance obligation in proportion to its standalone selling price. The Company determines standalone selling price using average selling

prices with consideration of current market conditions. If the product or service has no history of sales or if the sales volume is not sufficient, the Company relies upon prices set by management, adjusted for applicable discounts.

Net Loss Per Share

Net loss per share is computed using the two-class method required for multiple classes of common stock and participating securities. The rights, including the liquidation and dividend rights and sharing of losses, of the Class A common stock and Class B common stock are identical, other than voting rights. As the liquidation and dividend rights and sharing of losses are identical, the undistributed earnings are allocated on a proportionate basis and the resulting net loss per share will, therefore, be the same for both Class A and Class B common stock on an individual or combined basis.

Basic net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period, adjusted for outstanding shares that are subject to repurchase.

For the calculation of diluted net loss per share, basic net loss per share is adjusted by the effect of dilutive securities including awards under the Company's equity compensation plans. Diluted net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding. For periods in which the Company reports net losses, diluted net loss per share is the same as basic net loss per share because potentially dilutive shares of common stock are not assumed to have been issued if their effect is anti-dilutive.

Recently Issued Accounting Pronouncement and Disclosure Rules

In December 2023, the FASB issued ASU No. 2023-09, Income Taxes, which prescribes standardized categories and disaggregation of information in the reconciliation of provision for income taxes, requires disclosure of disaggregated income taxes paid, and modifies other income tax-related disclosure requirements. The updated standard is effective beginning with the Company's fiscal year 2025 annual reporting period. Early adoption is permitted. The Company is currently evaluating the impact that the updated standard will have on its related disclosures.

In March 2024, the Securities and Exchange Commission (SEC) issued Final Rule No. 33-11275, The Enhancement and Standardization of Climate-Related Disclosures for Investors. If effected as issued, the rule would require registrants to provide certain climate related disclosures in their annual reports. While in April 2024 the SEC stayed Final Rule No. 33-11275 in connection with legal challenges to the rule, the Company is in the process of analyzing the impact of the rule on its related disclosures.

[XML 23-R9.htm IDEA- XBRL DOCUMENT](#)

Other Financial Statement Information
[Organization, Consolidation and Presentation of Financial Statements \[Abstract\]](#)
[Other Financial Statement Information](#)

6 Months Ended
Jun. 30, 2024

Other Financial Statement Information

Available-for-sale Securities

Available-for-sale securities consisted of the following (in thousands):

	June 30, 2024				December 31, 2023				Fair Value Measurement
	Amortized Cost	Gross Unrealized Gains	Gross Unrealized Losses	Fair Value	Amortized Cost	Gross Unrealized Gains	Gross Unrealized Losses	Fair Value	
Cash equivalents:									
Money market funds	\$ 365,906	\$ —	\$ —	\$ 365,906	\$ 348,539	\$ —	\$ —	\$ 348,539	Level 1
Marketable securities:									
Corporate debt securities	—	—	—	—	10,022	—	(51)	9,971	Level 2
Government debt securities	—	—	—	—	18,152	—	(125)	18,027	Level 2
Asset-backed securities	272	—	(3)	269	1,425	—	(12)	1,413	Level 2
Total available-for-sale securities	\$ 366,178	\$ —	\$ (3)	\$ 366,175	\$ 378,138	\$ —	\$ (188)	\$ 377,950	

The contractual maturities of marketable securities as of June 30, 2024 were as follows (in thousands):

	Fair Value
Due in one year or less	\$ —
Due after one year to five years	269
Total marketable securities	\$ 269

The Company incurred no material gross realized gains or losses from available-for-sales debt securities during the three and six months ended June 30, 2024. The Company incurred gross realized losses of \$1.7 million and no gross realized gains from the sale of available-for-sales debt securities during the three and six months ended June 30, 2023. Realized gains (losses) on the sale of marketable securities are recorded in "Other expense, net" in the condensed consolidated statements of operations.

The available-for-sale debt securities are subject to a periodic impairment review. For investments in an unrealized loss position, the Company determines whether a credit loss exists by considering information about the collectability of the instrument, current market conditions and reasonable and supportable forecasts of economic conditions. The Company recognizes an allowance for credit losses, up to the amount of the unrealized loss when appropriate, and writes down the amortized cost basis of the investment if it is more likely than not that the Company will be required or will intend to sell the investment before recovery of its amortized cost basis. Allowances for credit losses and write-downs are recognized in "Other expense, net," and unrealized losses not related to credit losses are recognized in "Accumulated other comprehensive loss." There are no allowances for credit losses for the periods presented. As of June 30, 2024, the gross unrealized losses on available-for-sale securities are related to market interest rate changes and not attributable to credit.

Inventory

Inventory was comprised of the following (in thousands):

	June 30, 2024	December 31, 2023
Purchased materials	\$ 38,873	\$ 34,484
Work in progress	25,036	21,975
Finished goods	24,363	17,247
Inventory	\$ 88,272	\$ 73,706

Property and Equipment, Net

Property and equipment, net consisted of the following (in thousands):

	June 30, 2024	December 31, 2023
Land	\$ 36,765	\$ 36,765
Building	146,750	146,044
Laboratory equipment and machinery	70,093	69,238
Computer equipment and software	15,631	16,379
Furniture and fixtures	10,481	10,979
Leasehold improvements	95,307	96,405
Construction in progress	3,717	7,252
Total property and equipment	378,744	383,062
Less: accumulated depreciation and amortization	(115,459)	(103,491)
Property and equipment, net	\$ 263,285	\$ 279,571

During the six months ended June 30, 2024, the Company recorded impairment charges of \$2.1 million related to computer equipment and software of which \$0.3 million, \$0.7 million and \$1.1 million was classified in cost of revenue, research and development, and selling, general and administrative expenses, respectively, in the condensed consolidated statement of operations. The impairment charge was triggered by a decision to discontinue a productivity engineering project.

Accrued Compensation and Related Benefits

Accrued compensation and related benefits were comprised of the following as of the dates indicated (in thousands):

	June 30, 2024	December 31, 2023
Accrued payroll and related costs	\$ 1,602	\$ 2,262
Accrued bonus	11,886	18,254
Accrued commissions	3,637	6,410
Other	2,953	3,179
Accrued compensation and related benefits	<u>\$ 20,078</u>	<u>\$ 30,105</u>

Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities were comprised of the following as of the dates indicated (in thousands):

	June 30, 2024	December 31, 2023
Accrued purchase consideration	\$ —	\$ 20,000
Accrued legal and related costs	7,936	3,839
Accrued royalties for licensed technologies	8,311	5,455
Accrued property and equipment	1,452	3,199
Accrued professional services	4,199	6,577
Product warranties	9,454	8,116
Taxes payable	5,792	5,049
Other	5,293	4,413
Accrued expenses and other current liabilities	<u>\$ 42,437</u>	<u>\$ 56,648</u>

Product Warranties

Changes in the reserve for product warranties were as follows for the periods indicated (in thousands):

	Six Months Ended June 30,	
	2024	2023
Beginning of period	\$ 8,116	\$ 3,023
Amounts charged to cost of revenue	5,031	3,833
Repairs and replacements	(3,693)	(2,915)
End of period	<u>\$ 9,454</u>	<u>\$ 3,941</u>

Revenue and Deferred Revenue

As of June 30, 2024, the aggregate amount of remaining performance obligations related to separately sold extended warranty service agreements or allocated amounts for extended warranty service agreements bundled with sales of instruments was \$27.8 million, of which approximately \$16.4 million is expected to be recognized to revenue in the next 12 months, with the remainder thereafter. The contract liabilities of \$27.8 million and \$22.0 million as of June 30, 2024 and December 31, 2023, respectively, consisted of deferred revenue related to extended warranty service agreements.

The following revenue recognized for the periods were included in contract liabilities as of December 31, 2023 and December 31, 2022, respectively (in thousands):

	Three Months Ended June 30,		Six Months Ended June 30,	
	2024	2023	2024	2023
Deferred revenue recognized	\$ 3,146	\$ 1,856	\$ 6,741	\$ 3,963

The following table represents revenue by source for the periods indicated (in thousands). Spatial products include the Company's Visium and Xenium products:

	Three Months Ended June 30,		Six Months Ended June 30,	
	2024	2023	2024	2023
Instruments				
Chromium	\$ 8,792	\$ 12,859	\$ 16,642	\$ 24,485
Spatial	15,060	18,096	32,663	25,646
Total instruments revenue	23,852	30,955	49,305	50,131
Consumables				
Chromium	94,108	100,794	178,035	201,890
Spatial	29,254	11,694	55,662	22,976
Total consumables revenue	123,362	112,488	233,697	224,866
Services	5,890	3,376	11,108	6,107
Total revenue	<u>\$ 153,104</u>	<u>\$ 146,819</u>	<u>\$ 294,110</u>	<u>\$ 281,104</u>

The following table presents revenue by geography based on the location of the customer for the periods indicated (in thousands):

	Three Months Ended June 30,		Six Months Ended June 30,	
	2024	2023	2024	2023
Americas				
United States	\$ 89,672	\$ 88,394	\$ 165,309	\$ 164,675
Americas (excluding United States)	3,419	3,149	7,412	5,664
Total Americas	93,091	91,543	172,721	170,339
Europe, Middle East and Africa	37,362	31,246	72,083	59,668
Asia-Pacific				
China	13,738	12,755	27,662	26,786
Asia-Pacific (excluding China)	8,913	11,275	21,644	24,311
Total Asia-Pacific	22,651	24,030	49,306	51,097
Total Revenue	<u>\$ 153,104</u>	<u>\$ 146,819</u>	<u>\$ 294,110</u>	<u>\$ 281,104</u>

[XML 24 R10.htm IDEA XBRL DOCUMENT](#)

Commitments and Contingencies

[Commitments and Contingencies Disclosure \[Abstract\]](#)
[Commitments and Contingencies](#)

Commitments and Contingencies

Lease Agreements

The Company leases office, laboratory, manufacturing, distribution and server space in various locations worldwide.

Future net lease payments related to the Company's operating lease liabilities as of June 30, 2024 is as follows (in thousands):

	Operating Leases
2024 (excluding the six months ended June 30, 2024)	\$ 8,430
2025	14,811
2026	15,359
2027	15,569
2028	15,736
Thereafter	40,639
Total lease payments	\$ 110,544
Less: imputed interest	(21,062)
Present value of operating lease liabilities	<u>\$ 89,482</u>
Operating lease liabilities, current	\$ 10,820
Operating lease liabilities, noncurrent	78,662
Total operating lease liabilities	<u>\$ 89,482</u>

The following table summarizes additional information related to operating leases as of June 30, 2024:

	June 30, 2024	December 31, 2023
Weighted-average remaining lease term	7.1 years	7.5 years
Weighted-average discount rate	5.9 %	5.9 %

Litigation

The Company is regularly subject to lawsuits, claims, arbitration proceedings, administrative actions and other legal and regulatory proceedings involving intellectual property disputes, commercial disputes, competition and other matters, and the Company may become subject to additional types of lawsuits, claims, arbitration proceedings, administrative actions, government investigations and legal and regulatory proceedings in the future.

NanoString

On May 6, 2021, the Company filed suit against NanoString Technologies, Inc. ("NanoString") in the U.S. District Court for the District of Delaware alleging that NanoString's GeoMx Digital Spatial Profiler and associated instruments and reagents infringe U.S. Patent Nos. 10,472,669, 10,662,467, 10,961,566, 10,983,113 and 10,996,219 (the "GeoMx Action"). On May 19, 2021, the Company filed an amended complaint additionally alleging that the GeoMx products infringe U.S. Patent Nos. 11,001,878 and 11,008,607. On May 4, 2022, the Company filed an amended complaint in the GeoMx Action additionally alleging that the GeoMx products infringe U.S. Patent No. 11,293,917 and withdrawing the Company's claims of infringement of U.S. Patent No. 10,662,467. The Company is seeking, among other relief, injunctive relief and unspecified damages (including attorneys' fees) in relation to NanoString's making, using, selling, offering to sell, exporting and/or importing in the United States the GeoMx Digital Spatial Profiler and associated instruments and reagents. NanoString filed its answer to the GeoMx Action on May 18, 2022. A Markman hearing was held on February 17, 2023 and the Court issued its claim construction order on February 28, 2023. On September 7, 2023, the Court issued an order granting the Company's motion for summary judgment that the asserted patents are not invalid for indefiniteness and denying NanoString's motion for summary judgment that the asserted patents are invalid for indefiniteness and lack of written description. On November 17, 2023, a jury found that NanoString willfully infringed the asserted patents and that the asserted patents are valid. The jury awarded the Company more than \$31 million in damages, consisting of approximately \$25 million in lost profits and approximately \$6 million in royalties. Post-trial motions, including the Company's motions for a permanent injunction, ongoing royalties, enhanced damages, attorneys' fees and pre- and post-judgment interest, are pending. NanoString filed for bankruptcy protection under Chapter 11 of the United States Bankruptcy Code in the U.S. bankruptcy court in Delaware on February 4, 2024, and the Court's consideration of these post-trial motions was stayed due to the bankruptcy filing. In May 2024, Bruker Corporation ("Bruker") acquired certain assets and assumed certain liabilities of NanoString, including the

litigation between the Company and NanoString, and the NanoString product lines at issue. Bruker, Bruker Spatial Biology, Inc. and Bruker Nano, Inc. were substituted as defendants in the GeoMx Action. Post-trial briefing is complete following supplementation by the parties. Due to the uncertainties in collecting the jury award, the Company has not recorded a receivable from NanoString as of June 30, 2024.

On February 28, 2022, the Company filed a second suit against NanoString in the U.S. District Court for the District of Delaware alleging that NanoString's CosMx Spatial Molecular Imager and associated instruments, reagents and services infringe U.S. Patent Nos. 10,227,639 and 11,021,737 (the "CosMx Action"). On May 12, 2022, the Company filed an amended complaint in the CosMx Action additionally alleging that the CosMx products additionally infringe U.S. Patent Nos. 11,293,051, 11,293,052 and 11,293,054. NanoString filed its answer to the CosMx Action on May 26, 2022. On March 1, 2023, the Company filed a second amended complaint additionally alleging that the CosMx products infringe U.S. Patent No. 11,542,554. The Company is seeking, among other relief, injunctive relief and unspecified damages (including attorneys' fees) in relation to NanoString's making, using, selling, offering to sell, exporting and/or importing in the United States the CosMx Spatial Molecular Imager and associated instruments, reagents and services. NanoString filed its answer to the second amended complaint on March 22, 2023. Discovery is in progress. A Markman hearing was held on January 10, 2024, and the Court issued its claim construction order on February 1, 2024.

On August 16, 2022, NanoString filed a counterclaim in the CosMx Action alleging that the Company's Visium products infringe U.S. Patent No. 11,377,689 (the "689 patent"). The Company filed its answer to NanoString's counterclaim in the CosMx Action on August 30, 2022. On November 23, 2022, the Company moved to sever claims relating to NanoString's assertion of the 689 patent and consolidate those claims with the patent case NanoString filed against the Company on October 20, 2022 (discussed below). On January 24, 2023, the Court granted the Company's motion.

On May 1, 2023, NanoString filed a motion in the CosMx Action to add antitrust, unfair competition, tort and contract counterclaims. NanoString seeks, among other relief, injunctive relief (including that the Company grant NanoString a license to the patents that the Company asserted against NanoString in the CosMx Action) and unspecified damages (including attorneys' fees). On July 10, 2023, the Court denied NanoString's motion for leave to add a contract counterclaim but otherwise granted the motion for leave to amend. On May 24, 2023, NanoString filed a motion to bifurcate its amended counterclaims and a motion for expedited discovery. On June 6, 2023, the Court denied NanoString's motion to bifurcate and granted its motion for expedited discovery. Bruker, Bruker Spatial Biology, Inc. and Bruker Nano, Inc. were substituted as defendants in the CosMx Action. Trial is expected in May 2025. The Company believes Bruker's claims are meritless and intends to vigorously defend itself.

On October 20, 2022, NanoString filed suit against the Company in the U.S. District Court for the District of Delaware alleging that the Company's Visium products infringe U.S. Patent No. 11,473,142 (the "142 patent"), a continuation of the 689 patent (the "NanoString Action"). NanoString seeks, among other relief, injunctive relief and unspecified damages (including attorneys' fees) in relation to the Company's making, using, selling, offering to sell, exporting and/or importing in the United States Visium products and associated instruments, reagents and services. On January 24, 2023, the Court severed NanoString's claims with respect to the 689 patent from the CosMx Action and consolidated those claims with this action. NanoString filed an amended complaint on January 27, 2023. The Company filed an answer to the NanoString Action on February 10, 2023. Discovery is in progress. A Markman hearing was held on January 10, 2024, and the Court issued its claim construction order on February 1, 2024. Bruker Spatial Biology, Inc. and Bruker Nano, Inc. were substituted as plaintiffs in the NanoString Action in June 2024. A trial date in the NanoString Action has not yet been set. The Company believes these claims in the NanoString Action are meritless and intends to vigorously defend itself.

On August 16 and September 25, 2023, the Company filed petitions for inter partes review ("IPR") of the 689 patent and the 142 patent, respectively. On February 1, 2024, IPR was instituted for the 689 patent. An institution decision for the IPR against the 142 patent is pending.

On January 30, 2024, NanoString filed a petition for IPR of U.S. Patent No. 11,542,554 (the "554 patent"), which is asserted by the Company against NanoString in the CosMx Action. An institution decision for the IPR against the 554 patent is pending.

On March 9, 2022, the Company filed suit in the Munich Regional Court in Germany alleging that NanoString's CosMx Spatial Molecular Imager and associated instruments, reagents and services infringe EP Patent No. 2794928B1 (the "EP928 patent") (the "Germany CosMx Action"). A hearing on infringement was held on March 23, 2023. On May 17, 2023, the Munich Regional Court found that the CosMx products infringe the EP928 patent and issued a permanent injunction requiring NanoString to stop selling and supplying CosMx instruments and reagents for RNA detection in Germany. The injunction took effect on June 1, 2023. On May 25, 2023, NanoString filed an appeal of the Germany CosMx Action in the Munich Higher Regional Court. A

hearing date has not yet been set for this appeal. On October 30, 2023, NanoString requested that the Higher Regional Court temporarily stay enforcement of the injunction pending the appeal. On December 20, 2023, the Higher Regional Court granted NanoString's request conditioned upon NanoString posting a 2.3 million Euro security deposit.

On July 29, 2022, NanoString filed a nullity action with the German Federal Patent Court challenging the validity of the EP928 patent. On February 10, 2023, the German Federal Patent Court issued a preliminary opinion upholding the validity of certain claims of the EP928 patent directed to in situ analysis. On May 7, 2024, the German Federal Patent Court reversed its preliminary opinion and revoked the German part of the EP928 patent. The Company strongly disagrees with this decision and will appeal the decision.

On June 1, 2023, the Company filed requests for preliminary injunctions in the Munich Local Division of the Unified Patent Court ("UPC") alleging that NanoString's CosMx Spatial Molecular Imager and associated instruments, reagents and services for RNA detection infringe the EP928 patent and EP Patent No. 4108782 (the "EP782 patent"). Hearings were held for the EP782 and EP928 patents on September 5 and September 19, respectively. On September 19, 2023, the UPC granted the Company's request with respect to the EP782 patent and issued a preliminary injunction requiring NanoString to stop selling and supplying CosMx instruments and reagents for RNA detection in all 17 UPC member states. On October 10, 2023, the UPC denied the Company's preliminary injunction request for the EP928 patent. On October 2, 2023, NanoString filed an appeal of the preliminary injunction for the EP782 patent in the UPC Court of Appeals. A hearing was held before the UPC Court of Appeals on December 18, 2023. The UPC Court of Appeals overturned the preliminary injunction on February 26, 2024.

On August 31 and September 18, 2023 the Company filed main requests in the Munich Local Division of the UPC alleging that NanoString's CosMx Spatial Molecular Imager and associated instruments, reagents and services for RNA detection infringe the EP782 and EP928 patents, respectively. No hearings have yet been set for these main requests.

On July 18, 2023, NanoString filed an opposition in the European Patent Office challenging the validity of the EP782 patent. An oral hearing for this opposition is scheduled on March 18, 2025. On July 27, 2023, NanoString filed a revocation action in the Munich Central Division of the UPC challenging the validity of the EP928 patent. An oral hearing for this revocation action is scheduled for September 18, 2024.

Vizgen

On May 3, 2022, the Company filed suit against Vizgen, Inc. ("Vizgen") in the U.S. District Court for the District of Delaware alleging that Vizgen's MERSCOPE Platform and workflow and/or Vizgen's Lab Services program, including associated instruments and reagents, infringe U.S. Patent Nos. 11,021,737, 11,293,051, 11,293,052, 11,293,054 and 11,299,767. The Company seeks, among other relief, injunctive relief and unspecified damages (including attorneys' fees) in relation to Vizgen's making, using, selling, offering to sell, exporting and/or importing in the United States the MERSCOPE Platform and workflow and/or Vizgen's Lab Services program, including associated instruments and reagents. On July 25, 2022, Vizgen filed a motion to dismiss the Company's claims for willful and indirect infringement, which the Court denied on September 19, 2022. Discovery is in progress. A Markman hearing was held on January 10, 2024, and the Court issued its claim construction order on February 1, 2024.

On August 30, 2022, Vizgen filed its answer and counterclaims alleging that the Company's Xenium product infringes U.S. Patent No. 11,098,303 (the "303 patent"). Vizgen seeks, among other relief, injunctive relief and unspecified damages (including attorneys' fees) in relation to the Company's making, using, selling, offering to sell, exporting and/or importing in the United States Xenium products, including associated instruments and reagents. Vizgen also filed counterclaims alleging that the Company tortiously interfered with Vizgen's contractual and business relationship with Harvard and that the Company engaged in unfair practices under Massachusetts state law. On October 27, 2022, the Company filed a partial answer and motion to dismiss the infringement counterclaim and the tort counterclaims. On February 2, 2023, the Company's motion to dismiss was denied. The Company believes Vizgen's claims are meritless and intends to vigorously defend itself.

On March 15, 2023, the Company filed an amended complaint additionally alleging that the MERSCOPE Platform and workflow and Vizgen's Lab Services program infringe U.S. Patent No. 11,549,136 and withdrawing its claim of infringement of U.S. Patent No. 11,293,054. On April 17, 2023, Vizgen filed its answer adding amended counterclaims including antitrust, unfair competition, tort and contract counterclaims. Vizgen seeks, among other relief, injunctive relief (including that the Company grant Vizgen a license to the patents that the Company asserted against Vizgen) and unspecified damages (including attorneys' fees). On May 18, 2023, the Company filed a motion to dismiss Vizgen's amended counterclaims. On July 10, 2023, the Court granted the Company's motion to dismiss Vizgen's contract counterclaim but otherwise denied the Company's motion to dismiss. On April 29, 2024, Vizgen amended its counterclaims to add additional antitrust counterclaims based on alleged bundling and predatory pricing. The Company believes Vizgen's claims are meritless and intends to vigorously defend itself.

Trial on the Company's claims and on Vizgen's non-patent counterclaims is scheduled for February 2025. A trial date on Vizgen's counterclaim regarding the 303 patent is expected to be set for the second half of 2024.

On August 30, 2023, the Company filed a petition for IPR of the 303 patent. Institution was denied on March 7, 2024.

On June 1, 2023, the Company filed suit in the Hamburg Local Division of the UPC alleging that Vizgen's MERSCOPE products infringe the EP782 patent. The Company seeks, among other relief, injunctive relief and unspecified damages (including attorneys' fees) in relation to Vizgen's MERSCOPE products in all 17 UPC member states. A hearing for this UPC action has not yet been set.

Parse

On August 24, 2022, the Company filed suit against Parse Biosciences, Inc. ("Parse") in the U.S. District Court for the District of Delaware alleging that Parse's Evercode Whole Transcriptomics products and ATAC-seq products infringe U.S. Patent Nos. 10,155,981 (the "981 patent"), 10,697,013 (the "013 patent"), 10,240,197 (the "197 patent"), 10,150,995, 10,619,207 and 10,738,357. The Company seeks, among other relief, injunctive relief and unspecified damages (including attorneys' fees) in relation to Parse's making, using, selling, offering to sell, exporting and/or importing in the United States Parse's Evercode Whole Transcriptomics products and ATAC-seq products. On October 17, 2022, Parse filed a motion to dismiss alleging that the asserted claims are directed to patent ineligible subject matter. The Court held a hearing on the motion to dismiss on November 22, 2022, and supplemental briefing was submitted on December 15, 2022. On September 14, 2023, the Court denied the motion. Parse filed its answer on October 6, 2023. A Markman hearing was held on February 21, 2024, and the Court issued its claim construction order on May 3, 2024. Trial is scheduled for December 2024.

Between April 20 and June 21, 2023, Parse filed petitions for IPR of all of the patents asserted. On October 13, 2023, IPR was instituted on the 981 patent. Oral argument for the 981 IPR took place on July 24, 2024. A final written decision on the 981 IPR is expected in October 2024. The PTAB denied institution of Parse's petitions for IPR on the other five asserted patents. On January 2 and 5, 2024, Parse filed rehearing requests with the PTAB for the 197 and 013 patents, respectively. On February 5, 2024, the PTAB instituted IPRs for the 197 and 013 patents on Parse's requests for rehearing.

On November 6, 2023, Parse filed a motion to stay the Delaware action pending the IPRs. On December 21, 2023, the court denied Parse's motion to stay. On February 8, 2024, Parse filed a renewed motion to stay. On February 20, 2024, the court denied Parse's renewed motion to stay.

Curio

On December 1, 2023, the Company filed suit against Curio Bioscience, Inc. ("Curio") in the U.S. District Court for the District of Delaware alleging that the Curio Seeker Spatial Mapping Kit and associated products and services infringe U.S. Patent Nos. 10,480,022, 10,662,468, 11,001,879, 11,549,138, and 11,761,030. On February 1, 2024, Curio filed a motion to dismiss alleging that the asserted claims are directed to patent ineligible subject matter. The Court denied that motion on May 9, 2024. On May 31 and June 20, 2024, Curio answered the Complaint and filed antitrust and unfair competition counterclaims. The Company filed a motion to dismiss Curio's unfair competition and antitrust counterclaims on July 5, 2024. The Company believes Curio's counterclaims are meritless and intends to vigorously defend itself. Trial is scheduled for May 2026.

On December 4, 2023, the Company filed a request for a preliminary injunction in the Dusseldorf Local Division of the UPC alleging that the Curio Seeker Spatial Mapping Kit and associated products and services infringe EP Patent No. 2697391 (the "EP391 patent"). A hearing was held on March 26, 2024. On April 30, 2024, the UPC granted the Company's request and issued a preliminary injunction requiring Curio to stop offering, marketing, using or possessing these Curio Seeker products and services in Germany, France and Sweden. Curio did not appeal the preliminary injunction. On March 25, 2024, the Company filed a main request in the Dusseldorf Local Division of the UPC alleging that the Curio Seeker Spatial Mapping Kit and associated products and services infringe the EP391 patent.

[XML 25 R11.htm IDEA XBRL DOCUMENT](#)

Capital Stock

6 Months Ended Jun. 30, 2024

[Equity \[Abstract\]](#) [Capital Stock](#)

Capital Stock

As of June 30, 2024, the number of shares of Class A common stock and Class B common stock issued and outstanding were 106,417,334 and 14,056,833, respectively.

The following table represents the number of shares of Class B common stock converted to shares of Class A common stock upon the election of the holders of such shares during the periods:

	Three Months Ended June 30,		Six Months Ended June 30,	
	2024	2023	2024	2023
Class B common stock converted to Class A common stock	—	4,010,422	—	4,610,422

[XML 26 R12.htm IDEA XBRL DOCUMENT](#)

[Equity Incentive Plans](#) [Share-Based Payment Arrangement](#)

6 Months Ended Jun. 30, 2024

The Company regularly enters into contracts that include various combinations of products and services which are generally distinct and accounted for as separate performance obligations. The transaction price is allocated to each performance obligation in proportion to its standalone selling price. The Company determines standalone selling price using average selling

prices with consideration of current market conditions. If the product or service has no history of sales or if the sales volume is not sufficient, the Company relies upon prices set by management, adjusted for applicable discounts.

Net Loss Per Share

Net Loss Per Share

Net loss per share is computed using the two-class method required for multiple classes of common stock and participating securities. The rights, including the liquidation and dividend rights and sharing of losses, of the Class A common stock and Class B common stock are identical, other than voting rights. As the liquidation and dividend rights and sharing of losses are identical, the undistributed earnings are allocated on a proportionate basis and the resulting net loss per share will, therefore, be the same for both Class A and Class B common stock on an individual or combined basis.

Basic net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period, adjusted for outstanding shares that are subject to repurchase.

For the calculation of diluted net loss per share, basic net loss per share is adjusted by the effect of dilutive securities including awards under the Company's equity compensation plans. Diluted net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding. For periods in which the Company reports net losses, diluted net loss per share is the same as basic net loss per share because potentially dilutive shares of common stock are not assumed to have been issued if their effect is anti-dilutive.

Recently Issued

Accounting Pronouncement and Disclosure Rules

In December 2023, the FASB issued ASU No. 2023-09, Income Taxes, which prescribes standardized categories and disaggregation of information in the reconciliation of provision for income taxes, requires disclosure of disaggregated income taxes paid, and modifies other income tax-related disclosure requirements. The updated standard is effective beginning with the Company's fiscal year 2025 annual reporting period. Early adoption is permitted. The Company is currently evaluating the impact that the updated standard will have on its related disclosures.

In March 2024, the Securities and Exchange Commission (SEC) issued Final Rule No. 33-11275, The Enhancement and Standardization of Climate-Related Disclosures for Investors. If effected as issued, the rule would require registrants to provide certain climate related disclosures in their annual reports. While in April 2024 the SEC stayed Final Rule No. 33-11275 in connection with legal challenges to the rule, the Company is in the process of analyzing the impact of the rule on its related disclosures.

[XML 31-R17.htm IDEA XBRL DOCUMENT](#)

Other Financial Statement Information (Tables)

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Schedule of Marketable Securities

6 Months Ended

Jun. 30, 2024

Available-for-sale securities consisted of the following (in thousands):

	June 30, 2024				December 31, 2023				Fair Value Measurement
	Amortized Cost	Gross Unrealized Gains	Gross Unrealized Losses	Fair Value	Amortized Cost	Gross Unrealized Gains	Gross Unrealized Losses	Fair Value	
Cash equivalents:									
Money market funds	\$ 365,906	\$ —	\$ —	\$ 365,906	\$ 348,539	\$ —	\$ —	\$ 348,539	Level 1
Marketable securities:									
Corporate debt securities	—	—	—	—	10,022	—	(51)	9,971	Level 2
Government debt securities	—	—	—	—	18,152	—	(125)	18,027	Level 2
Asset-backed securities	272	—	(3)	269	1,425	—	(12)	1,413	Level 2
Total available-for-sale securities	\$ 366,178	\$ —	\$ (3)	\$ 366,175	\$ 378,138	\$ —	\$ (188)	\$ 377,950	

Schedule of Debt Securities, Available-for-sale

The contractual maturities of marketable securities as of June 30, 2024 were as follows (in thousands):

	Fair Value
Due in one year or less	\$ —
Due after one year to five years	269
Total marketable securities	\$ 269

Schedule of Inventory

Inventory was comprised of the following (in thousands):

	June 30, 2024	December 31, 2023
Purchased materials	\$ 38,873	\$ 34,484
Work in progress	25,036	21,975
Finished goods	24,363	17,247
Inventory	\$ 88,272	\$ 73,706

Schedule of Property and Equipment, Net

Property and equipment, net consisted of the following (in thousands):

	June 30, 2024	December 31, 2023
Land	\$ 36,765	\$ 36,765
Building	146,750	146,044
Laboratory equipment and machinery	70,093	69,238
Computer equipment and software	15,631	16,379
Furniture and fixtures	10,481	10,979
Leasehold improvements	95,307	96,405
Construction in progress	3,717	7,252
Total property and equipment	378,744	383,062
Less: accumulated depreciation and amortization	(115,459)	(103,491)
Property and equipment, net	\$ 263,285	\$ 279,571

Schedule of Accrued Compensation and Related Benefits

Accrued compensation and related benefits were comprised of the following as of the dates indicated (in thousands):

	June 30, 2024	December 31, 2023
Accrued payroll and related costs	\$ 1,602	\$ 2,262
Accrued bonus	11,886	18,254
Accrued commissions	3,637	6,410
Other	2,953	3,179
Accrued compensation and related benefits	\$ 20,078	\$ 30,105

Schedule of Accrued Expense and Other Current Liabilities

Accrued expenses and other current liabilities were comprised of the following as of the dates indicated (in thousands):

	June 30, 2024	December 31, 2023
Accrued purchase consideration	\$ —	\$ 20,000
Accrued legal and related costs	7,936	3,839
Accrued royalties for licensed technologies	8,311	5,455
Accrued property and equipment	1,452	3,199
Accrued professional services	4,199	6,577
Product warranties	9,454	8,116
Taxes payable	5,792	5,049
Other	5,293	4,413
Accrued expenses and other current liabilities	\$ 42,437	\$ 56,648

Schedule of Changes in the Reserve for Product Warranties

Changes in the reserve for product warranties were as follows for the periods indicated (in thousands):

	Six Months Ended June 30,	
	2024	2023
Beginning of period	\$ 8,116	\$ 3,023
Amounts charged to cost of revenue	5,031	3,833
Repairs and replacements	(3,693)	(2,915)
End of period	\$ 9,454	\$ 3,941

Schedule of Revenue of Recognized in Contract Liabilities

The following revenue recognized for the periods were included in contract liabilities as of December 31, 2023 and December 31, 2022, respectively (in thousands):

	Three Months Ended June 30,		Six Months Ended June 30,	
	2024	2023	2024	2023
Deferred revenue recognized	\$ 3,146	\$ 1,856	\$ 6,741	\$ 3,963

Schedule of Revenue by Source

The following table represents revenue by source for the periods indicated (in thousands). Spatial products include the Company's Visium and Xenium products:

	Three Months Ended		Six Months Ended	
	2024	2023	2024	2023
Instruments				
Chromium	\$ 8,792	\$ 12,859	\$ 16,642	\$ 24,485
Spatial	15,060	18,096	32,663	25,646
Total instruments revenue	23,852	30,955	49,305	50,131
Consumables				
Chromium	94,108	100,794	178,035	201,890
Spatial	29,254	11,694	55,662	22,976
Total consumables revenue	123,362	112,488	233,697	224,866
Services	5,890	3,376	11,108	6,107
Total revenue	\$ 153,104	\$ 146,819	\$ 294,110	\$ 281,104

[Schedule of Revenue by Geographic Location](#)

The following table presents revenue by geography based on the location of the customer for the periods indicated (in thousands):

	Three Months Ended		Six Months Ended	
	2024	2023	2024	2023
Americas				
United States	\$ 89,672	\$ 88,394	\$ 165,309	\$ 164,675
Americas (excluding United States)	3,419	3,149	7,412	5,664
Total Americas	93,091	91,543	172,721	170,339
Europe, Middle East and Africa	37,362	31,246	72,083	59,668
Asia-Pacific				
China	13,738	12,755	27,662	26,786
Asia-Pacific (excluding China)	8,913	11,275	21,644	24,311
Total Asia-Pacific	22,651	24,030	49,306	51,097
Total Revenue	\$ 153,104	\$ 146,819	\$ 294,110	\$ 281,104

[XML 32 R18.htm IDEA: XBRL DOCUMENT](#)

Commitments and Contingencies (Tables)

**6 Months Ended
Jun. 30, 2024**

[Commitments and Contingencies Disclosure \[Abstract\]](#)
[Schedule of Company's Operating Lease Liabilities](#)

Future net lease payments related to the Company's operating lease liabilities as of June 30, 2024 is as follows (in thousands):

	Operating Leases
2024 (excluding the six months ended June 30, 2024)	\$ 8,430
2025	14,811
2026	15,359
2027	15,569
2028	15,736
Thereafter	40,639
Total lease payments	\$ 110,544
Less: imputed interest	(21,062)
Present value of operating lease liabilities	\$ 89,482
Operating lease liabilities, current	\$ 10,820
Operating lease liabilities, noncurrent	78,662
Total operating lease liabilities	\$ 89,482

[Schedule of Additional Information Related to Operating Leases](#)

The following table summarizes additional information related to operating leases as of June 30, 2024:

	June 30, 2024	December 31, 2023
Weighted-average remaining lease term	7.1 years	7.5 years
Weighted-average discount rate	5.9 %	5.9 %

[XML 33 R19.htm IDEA: XBRL DOCUMENT](#)

Capital Stock (Tables)

**6 Months Ended
Jun. 30, 2024**

[Equity \[Abstract\]](#)
[Schedule of Common Stock Issued and Outstanding](#)

The following table represents the number of shares of Class B common stock converted to shares of Class A common stock upon the election of the holders of such shares during the periods:

	Three Months Ended		Six Months Ended	
	2024	2023	2024	2023
Class B common stock converted to Class A common stock	—	4,010,422	—	4,610,422

[XML 34 R20.htm IDEA: XBRL DOCUMENT](#)

Equity Incentive Plans (Tables)

**6 Months Ended
Jun. 30, 2024**

[Share-Based Payment Arrangement \[Abstract\]](#)

[Schedule of Recorded Stock-based Compensation Expense in the Condensed Consolidated Statement of Operations](#)

The Company recorded stock-based compensation expense in the condensed consolidated statement of operations for the periods presented as follows (in thousands):

	Three Months Ended		Six Months Ended	
	2024	2023	2024	2023
Cost of revenue	\$ 2,247	\$ 1,835	\$ 4,280	\$ 3,296
Research and development	17,862	19,560	34,750	37,340
Selling, general and administrative	18,383	24,301	35,591	47,161
Total stock-based compensation expense	\$ 38,492	\$ 45,696	\$ 74,621	\$ 87,797

[Schedule of RSU Activity](#)

Restricted stock unit activity for the six months ended June 30, 2024 is as follows:

	Restricted Stock Units	Weighted-Average Grant Date Fair Value (per share)
Outstanding as of December 31, 2023	5,334,134	\$ 48.26
Granted	2,703,666	37.45
Vested	(977,388)	56.09
Cancelled	(447,959)	46.89
Outstanding as of June 30, 2024	6,612,453	\$ 42.78

[Schedule of the Company's Stock Option Activity](#)

Stock option activity for the six months ended June 30, 2024 is as follows:

	Stock Options	Weighted-Average Exercise Price
Outstanding as of December 31, 2023	5,946,786	\$ 42.17
Exercised	(208,548)	9.05
Cancelled and forfeited	(326,334)	47.75
Outstanding as of June 30, 2024	5,411,904	\$ 43.11

[Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions](#)

The Company estimated the fair values of shares granted under the market-based TSR PSUs using a Monte Carlo simulation model with the following assumptions:

Expected volatility	66%
Risk-free interest rate	4.5%
Expected dividend yield	—%

[XML 35 R21.htm IDEA: XBRL DOCUMENT](#)

Net Loss Per Share (Tables)

**6 Months Ended
Jun. 30, 2024**

[Earnings Per Share \[Abstract\]](#)

[Schedule of Shares of Common Stock Equivalents Excluded from Computation of Diluted Net Loss Per Share](#)

The following outstanding shares of common stock equivalents were excluded from the computation of diluted net loss per share for the periods presented because including them would have had an anti-dilutive effect:

	Three Months Ended		Six Months Ended	
	2024	2023	2024	2023
Stock options to purchase common stock	5,411,904	7,007,627	5,411,904	7,007,627
Restricted stock units	6,612,453	6,433,832	6,612,453	6,433,832
Shares committed under ESPP	89,193	34,718	89,193	34,718
Total	12,113,550	13,476,177	12,113,550	13,476,177

[XML 36 R22.htm IDEA: XBRL DOCUMENT](#)

Summary of Significant Accounting Policies -

6 Months Ended

Additional Information (Detail) Jun. 30, 2024

[Accounting Policies \[Abstract\]](#)

Revenue recognition, payment due period 30 days

[XML 37 R23.htm IDEA: XBRL DOCUMENT](#)

Other Financial Statement Information -

Available-for-Sale Securities (Details) -

USD (\$)

Jun. 30, 2024 Dec. 31, 2023

\$ in Thousands

[Marketable Securities \[Line Items\]](#)

Gross Unrealized Gains	\$ 0	\$ 0
Gross Unrealized Losses	(3)	(188)
Marketable securities, fair value	269	
Total available-for-sale securities, amortized cost	366,178	378,138
Total available-for-sale securities, fair value	366,175	377,950

Money market funds | Level 1

[Marketable Securities \[Line Items\]](#)

Money market funds	365,906	348,539
--------------------	---------	---------

Corporate debt securities | Level 2

[Marketable Securities \[Line Items\]](#)

Total marketable securities	0	10,022
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	(51)
Marketable securities, fair value	0	9,971

Government debt securities | Level 2

[Marketable Securities \[Line Items\]](#)

Total marketable securities	0	18,152
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	(125)
Marketable securities, fair value	0	18,027

Asset-backed securities | Level 2

[Marketable Securities \[Line Items\]](#)

Total marketable securities	272	1,425
Gross Unrealized Gains	0	0
Gross Unrealized Losses	(3)	(12)
Marketable securities, fair value	\$ 269	\$ 1,413

[XML 38 R24.htm IDEA: XBRL DOCUMENT](#)

Other Financial Statement Information -

Contractual Maturities of

Marketable Securities (Details)

USD (\$)

\$ in Thousands

[Fair Value](#)

Due in one year or less	\$ 0
Due after one year to five years	269
Total marketable securities	\$ 269

[XML 39 R25.htm IDEA: XBRL DOCUMENT](#)

Other Financial Statement Information -

Additional Information (Details)

USD (\$)

3 Months Ended

6 Months Ended

Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Dec. 31, 2023

[Concentration Risk \[Line Items\]](#)

Debt securities, available-for-sale, realized gain (loss)	\$ 0	\$ 0		
Debt securities, available-for-sale, realized loss		\$ 1,700,000		\$ 1,700,000
Debt securities, available-for-sale, realized gain		\$ 0		\$ 0
Transaction price allocated to remaining performance obligations	27,800,000		27,800,000	
Deferred revenue	16,436,000		16,436,000	\$ 13,150,000
Contract liability	\$ 27,800,000		\$ 27,800,000	\$ 22,000,000.0

Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-07-01

[Concentration Risk \[Line Items\]](#)

Expected period of revenue recognition	12 months	12 months
--	-----------	-----------

Computer equipment and software

[Concentration Risk \[Line Items\]](#)

Impairment of long lived assets		\$ 2,100,000
---------------------------------	--	--------------

Cost of Revenue

[Concentration Risk \[Line Items\]](#)

Impairment of long lived assets		300,000
---------------------------------	--	---------

Research and development

[Concentration Risk \[Line Items\]](#)

Impairment of long lived assets		700,000
---------------------------------	--	---------

Selling, general and administrative

[Concentration Risk \[Line Items\]](#)

Impairment of long lived assets		1,100,000
---------------------------------	--	-----------

Products and Services, Excluding Grant Revenue

[Concentration Risk \[Line Items\]](#)

Deferred revenue	\$ 16,400,000	\$ 16,400,000
------------------	---------------	---------------

[XML 40 R26.htm IDEA: XBRL DOCUMENT](#)

Other Financial Statement Information -

Schedule of Inventory

(Details) - USD (\$)

\$ in Thousands

Jun. 30, 2024 Dec. 31, 2023

[Organization, Consolidation and Presentation of Financial Statements \[Abstract\]](#)

Purchased materials	\$ 38,873	\$ 34,484
Work in progress	25,036	21,975
Finished goods	24,363	17,247
Inventory	\$ 88,272	\$ 73,706

[XML 41 R27.htm IDEA: XBRL DOCUMENT](#)

Other Financial Statement Information -

Schedule Of Property

Plant And Equipment

Jun. 30, 2024 Dec. 31, 2023

(Detail) - USD (\$)
\$ in Thousands

[Property, Plant and Equipment \[Line Items\]](#)

Total property and equipment	\$ 378,744	\$ 383,062
Less: accumulated depreciation and amortization	(115,459)	(103,491)
Property and equipment, net	263,285	279,571

[Land](#)

[Property, Plant and Equipment \[Line Items\]](#)

Total property and equipment	36,765	36,765
------------------------------	--------	--------

[Building](#)

[Property, Plant and Equipment \[Line Items\]](#)

Total property and equipment	146,750	146,044
------------------------------	---------	---------

[Laboratory equipment and machinery](#)

[Property, Plant and Equipment \[Line Items\]](#)

Total property and equipment	70,093	69,238
------------------------------	--------	--------

[Computer equipment and software](#)

[Property, Plant and Equipment \[Line Items\]](#)

Total property and equipment	15,631	16,379
------------------------------	--------	--------

[Furniture and fixtures](#)

[Property, Plant and Equipment \[Line Items\]](#)

Total property and equipment	10,481	10,979
------------------------------	--------	--------

[Leasehold improvements](#)

[Property, Plant and Equipment \[Line Items\]](#)

Total property and equipment	95,307	96,405
------------------------------	--------	--------

[Construction in progress](#)

[Property, Plant and Equipment \[Line Items\]](#)

Total property and equipment	\$ 3,717	\$ 7,252
------------------------------	----------	----------

[XML 42 R29.htm IDEA: XBRL DOCUMENT](#)

Other Financial

Statement

Information -

Schedule of Accrued

Compensation and

Related Benefits

(Details) - USD (\$)

\$ in Thousands

Jun. 30, 2024 Dec. 31, 2023

[Organization, Consolidation and Presentation of Financial Statements \[Abstract\]](#)

Accrued payroll and related costs	\$ 1,602	\$ 2,262
Accrued bonus	11,886	18,254
Accrued commissions	3,637	6,410
Other	2,953	3,179
Accrued compensation and related benefits	\$ 20,078	\$ 30,105

[XML 43 R29.htm IDEA: XBRL DOCUMENT](#)

Other Financial

Statement

Information -

Schedule of Accrued

Expense And Other

Current Liabilities

(Details) - USD (\$)

\$ in Thousands

Jun. 30, 2024 Dec. 31, 2023

[Organization, Consolidation and Presentation of Financial Statements \[Abstract\]](#)

Accrued purchase consideration	\$ 0	\$ 20,000
Accrued legal and related costs	7,936	3,839
Accrued royalties for licensed technologies	8,311	5,455
Accrued property and equipment	1,452	3,199
Accrued professional services	4,199	6,577
Product warranties	9,454	8,116
Taxes payable	5,792	5,049
Other	5,293	4,413
Accrued expenses and other current liabilities	\$ 42,437	\$ 56,648

[XML 44 R30.htm IDEA: XBRL DOCUMENT](#)

Other Financial

Statement

Information -

Schedule of Changes

in the Reserve for

Product Warranties

(Details) - USD (\$)

\$ in Thousands

6 Months Ended

Jun. 30, 2024 Jun. 30, 2023

[Movement in Standard and Extended Product Warranty Accrual, Increase \(Decrease\) \[Roll Forward\]](#)

Beginning of period	\$ 8,116	\$ 3,023
Amounts charged to cost of revenue	5,031	3,833
Repairs and replacements	(3,693)	(2,915)
End of period	\$ 9,454	\$ 3,941

[XML 45 R31.htm IDEA: XBRL DOCUMENT](#)

Other Financial

Statement

Information -

Schedule of Revenue

of Recognized in

Contract Liabilities

(Details) - USD (\$)

\$ in Thousands

3 Months Ended 6 Months Ended

Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023

[Organization, Consolidation and Presentation of Financial Statements \[Abstract\]](#)

Deferred revenue recognized	\$ 3,146	\$ 1,856	\$ 6,741	\$ 3,963
-----------------------------	----------	----------	----------	----------

[XML 46 R32.htm IDEA: XBRL DOCUMENT](#)

Other Financial

Statement

Information -

Schedule of Revenue

by Source (Details) -

USD (\$)

\$ in Thousands

3 Months Ended 6 Months Ended

Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023

[Revenue from External Customer \[Line Items\]](#)

Total revenue	\$ 153,104	\$ 146,819	\$ 294,110	\$ 281,104
---------------	------------	------------	------------	------------

[Instruments](#)

[Revenue from External Customer \[Line Items\]](#)

Total revenue	23,852	30,955	49,305	50,131
---------------	--------	--------	--------	--------

[Chromium](#)

[Revenue from External Customer \[Line Items\]](#)

Total revenue	8,792	12,859	16,642	24,485
---------------	-------	--------	--------	--------

[Spatial](#)

Revenue from External Customer [Line Items]				
Total revenue	15,060	18,096	32,663	25,646
Consumables				
Revenue from External Customer [Line Items]				
Total revenue	123,362	112,488	233,697	224,866
Chromium				
Revenue from External Customer [Line Items]				
Total revenue	94,108	100,794	178,035	201,890
Spatial				
Revenue from External Customer [Line Items]				
Total revenue	29,254	11,694	55,662	22,976
Services				
Revenue from External Customer [Line Items]				
Total revenue	\$ 5,890	\$ 3,376	\$ 11,108	\$ 6,107

[XML 47-R33.htm-IDEA: XBRL DOCUMENT](#)

Other Financial Statement - Information - Schedule of Revenue by Geographic Region (Details) - USD (\$)	3 Months Ended		6 Months Ended	
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
\$ in Thousands				

Revenues from External Customers and Long-Lived Assets [Line Items]					
Total revenue		\$ 153,104	\$ 146,819	\$ 294,110	\$ 281,104
Americas					
Revenues from External Customers and Long-Lived Assets [Line Items]					
Total revenue	93,091	91,543	172,721	170,339	
United States					
Revenues from External Customers and Long-Lived Assets [Line Items]					
Total revenue	89,672	88,394	165,309	164,675	
Americas (excluding United States)					
Revenues from External Customers and Long-Lived Assets [Line Items]					
Total revenue	3,419	3,149	7,412	5,664	
Europe, Middle East and Africa					
Revenues from External Customers and Long-Lived Assets [Line Items]					
Total revenue	37,362	31,246	72,083	59,668	
Asia-Pacific					
Revenues from External Customers and Long-Lived Assets [Line Items]					
Total revenue	22,651	24,030	49,306	51,097	
China					
Revenues from External Customers and Long-Lived Assets [Line Items]					
Total revenue	13,738	12,755	27,662	26,786	
Asia-Pacific (excluding China)					
Revenues from External Customers and Long-Lived Assets [Line Items]					
Total revenue	\$ 8,913	\$ 11,275	\$ 21,644	\$ 24,311	

[XML 48-R34.htm-IDEA: XBRL DOCUMENT](#)

Commitments and Contingencies - Schedule of Company's Operating Lease Liabilities (Detail) - USD (\$)	Jun. 30, 2024		Dec. 31, 2023	
	\$ in Thousands			

Operating Leases				
2024 (excluding the six months ended June 30, 2024)	\$ 8,430			
2025	14,811			
2026	15,359			
2027	15,569			
2028	15,736			
Thereafter	40,639			
Total lease payments	110,544			
Less: imputed interest	(21,062)			
Present value of operating lease liabilities	89,482			
Operating lease liabilities, current	10,820	\$ 11,521		
Operating lease liabilities, noncurrent	78,662	\$ 83,849		
Total operating lease liabilities	\$ 89,482			

[XML 49-R35.htm-IDEA: XBRL DOCUMENT](#)

Commitments and Contingencies - Schedule of Additional Information Related to Operating Leases (Detail)	Jun. 30, 2024		Dec. 31, 2023	
--	----------------------	--	----------------------	--

Commitments and Contingencies Disclosure [Abstract]				
Weighted-average remaining lease term	7 years 1 month 6 days	7 years 6 months		
Weighted-average discount rate	5.90%	5.90%		

[XML 50-R36.htm-IDEA: XBRL DOCUMENT](#)

Commitments and Contingencies - Additional Information (Detail) - USD (\$)	Nov. 17, 2023		Dec. 20, 2023	
	\$ in Millions			

Commitments and Contingencies Disclosure [Abstract]				
Contingency, damages sought, value	\$ 31.0			
Amount of lost profits	25.0			
Payments for royalties	\$ 6.0			
Security deposit		\$ 2.3		

[XML 51-R37.htm-IDEA: XBRL DOCUMENT](#)

Capital Stock - Additional Information (Detail)	Jun. 30, 2024	
	shares	
Common Class A		
Class of Stock [Line Items]		
Common stock shares issued (in shares)	106,417,334	
Common stock shares outstanding (in shares)	106,417,334	
Common Class B		
Class of Stock [Line Items]		
Common stock shares issued (in shares)	14,056,833	
Common stock shares outstanding (in shares)	14,056,833	

[XML 52-R38.htm-IDEA: XBRL DOCUMENT](#)

Capital Stock - Schedule of Common Stock Issued and Outstanding (Details) - shares	3 Months Ended		6 Months Ended	
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023

[Class B common stock converted to Class A common stock](#)

Conversion of Stock [Line Items]

Conversion of stock, shares converted (in shares)	0	4,010,422	0	4,610,422
---	---	-----------	---	-----------

[XML 53-R39.htm IDEA: XBRL DOCUMENT](#)

Equity Incentive Plans - Schedule of Recorded Stock- Based Compensation Expense in the Condensed Consolidated Statement of Operations (Details) - USD (\$) \$ in Thousands	3 Months Ended		6 Months Ended	
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023

Share-based Payment Arrangement, Expensed [Line Items]

Total stock-based compensation expense	\$ 38,492	\$ 45,696	\$ 74,621	\$ 87,797
--	-----------	-----------	-----------	-----------

[Cost of revenue](#)

Share-based Payment Arrangement, Expensed [Line Items]

Total stock-based compensation expense	2,247	1,835	4,280	3,296
--	-------	-------	-------	-------

[Research and development](#)

Share-based Payment Arrangement, Expensed [Line Items]

Total stock-based compensation expense	17,862	19,560	34,750	37,340
--	--------	--------	--------	--------

[Selling, general and administrative](#)

Share-based Payment Arrangement, Expensed [Line Items]

Total stock-based compensation expense	\$ 18,383	\$ 24,301	\$ 35,591	\$ 47,161
--	-----------	-----------	-----------	-----------

[XML 54-R40.htm IDEA: XBRL DOCUMENT](#)

Equity Incentive Plans - Schedule of RSU Activity (Detail)	6 Months Ended	
	Jun. 30, 2024	\$ / shares

Restricted Stock Units

Beginning balance (in shares) shares	5,334,134
--	-----------

Granted (in shares) shares	2,703,666
------------------------------	-----------

Vested (in shares) shares	(977,388)
-----------------------------	-----------

Cancelled (in shares) shares	(447,959)
--------------------------------	-----------

Ending balance (in shares) shares	6,612,453
-------------------------------------	-----------

Weighted-Average Grant Date Fair Value (per share)

Beginning balance (in dollars per share) \$ / shares	\$ 48.26
--	----------

Granted (in dollars per share) \$ / shares	37.45
--	-------

Vested (in dollars per share) \$ / shares	56.09
---	-------

Cancelled (in dollars per share) \$ / shares	46.89
--	-------

Ending balance (in dollars per share) \$ / shares	\$ 42.78
---	----------

[XML 55-R41.htm IDEA: XBRL DOCUMENT](#)

Equity Incentive Plans - Schedule of Company's Stock Option Activity (Details)	6 Months Ended	
	Jun. 30, 2024	\$ / shares

Stock Options

Beginning balance (in shares) shares	5,946,786
--	-----------

Exercised (in shares) shares	(208,548)
--------------------------------	-----------

Cancelled and forfeited (in shares) shares	(326,334)
--	-----------

Ending balance (in shares) shares	5,411,904
-------------------------------------	-----------

Weighted-Average Exercise Price

Beginning balance (in dollars per share) \$ / shares	\$ 42.17
--	----------

Exercised (in dollars per share) \$ / shares	9.05
--	------

Cancelled and forfeited (in dollars per share) \$ / shares	47.75
--	-------

Ending balance (in dollars per share) \$ / shares	\$ 43.11
---	----------

[XML 56-R42.htm IDEA: XBRL DOCUMENT](#)

Equity Incentive Plans - Additional Information (Details) - USD (\$) \$ / shares in Units, \$ in Millions	1 Months Ended		3 Months Ended		6 Months Ended	
	Mar. 31, 2024	Mar. 31, 2023	Jun. 30, 2024	Mar. 31, 2024	Jun. 30, 2023	Mar. 31, 2023

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Restricted stock units, granted (in shares)						2,703,666
---	--	--	--	--	--	-----------

Weighted-average grant date fair value, granted (in dollars per share)						\$ 37.45
--	--	--	--	--	--	----------

[Market-based Performance Awards](#)

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share based payment arrangement recognized			\$ 0.7			\$ 0.8
--	--	--	--------	--	--	--------

[Performance Stock Units | 2019 Plan](#)

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Restricted stock units, granted (in shares)	219,168	172,842				
---	---------	---------	--	--	--	--

[CAGR](#)

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

PSA target percentage						50.00%
-----------------------	--	--	--	--	--	--------

[Performance period](#)

CAGR Minimum						2 years
----------------	--	--	--	--	--	---------

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

PSA target amount of shares percentage						0.00%
--	--	--	--	--	--	-------

[CAGR | Maximum](#)

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

PSA target amount of shares percentage						175.00%
--	--	--	--	--	--	---------

[CAGR | Market-based Performance Awards](#)

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Weighted-average grant date fair value, granted (in dollars per share)						\$ 37.43
--	--	--	--	--	--	----------

[TSR](#)

Share-based Compensation Arrangement by Share-based Payment Award

(Detail)Sheethhttp://www.10xgenomics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetailSummaryofSignificantAccountingPolicies-AdditionalInformation-(Detail)Details22 falsefalseR23.htm9954478-Disclosure-Other Financial Statement Information-Available-for-Sale Securities
(Details)Sheethhttp://www.10xgenomics.com/role/OtherFinancialStatementInformationAvailableforSaleSecuritiesDetailsOther Financial Statement Information - Available-for-Sale Securities (Details)Details23 falsefalseR24.htm9954479-Disclosure-Other Financial Statement Information-Contractual Maturities of Marketable Securities
(Details)Sheethhttp://www.10xgenomics.com/role/OtherFinancialStatementInformationContractualMaturitiesofMarketableSecuritiesDetailsOther Financial Statement Information-Contractual Maturities of Marketable Securities (Details)Details24 falsefalseR25.htm9954480-Disclosure-Other Financial Statement Information-Additional Information-(Details)Sheethhttp://www.10xgenomics.com/role/OtherFinancialStatementInformationAdditionalInformationDetailsOther Financial Statement Information-Additional Information-(Details)Details25 falsefalseR26.htm9954481-Disclosure-Other Financial Statement Information-Schedule of Inventory
(Details)Sheethhttp://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofInventoryDetailsOther Financial Statement Information-Schedule of Inventory (Details)Details26 falsefalseR27.htm9954482-Disclosure-Other Financial Statement Information-Schedule of Property Plant And Equipment
(Detail)Sheethhttp://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofPropertyPlantAndEquipmentDetailOther Financial Statement Information-Schedule of Property Plant And Equipment (Detail)Details27 falsefalseR28.htm9954483-Disclosure-Other Financial Statement Information-Schedule of Accrued Compensation and Related Benefits
(Details)Sheethhttp://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofAccruedCompensationandRelatedBenefitsDetailsOther Financial Statement Information-Schedule of Accrued Compensation and Related Benefits (Details)Details28 falsefalseR29.htm9954484-Disclosure-Other Financial Statement Information-Schedule of Accrued Expense And Other Current Liabilities
(Details)Sheethhttp://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofAccruedExpenseAndOtherCurrentLiabilitiesDetailsOther Financial Statement Information-Schedule of Accrued Expense And Other Current Liabilities (Details)Details29 falsefalseR30.htm9954485-Disclosure-Other Financial Statement Information-Schedule of Changes in the Reserve for Product Warranties
(Details)Sheethhttp://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofChangesintheReserveforProductWarrantiesDetailsOther Financial Statement Information-Schedule of Changes in the Reserve for Product Warranties (Details)Details30 falsefalseR31.htm9954486-Disclosure-Other Financial Statement Information-Schedule of Revenue of Recognized in Contract Liabilities
(Details)Sheethhttp://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofRevenueofRecognizedinContractLiabilitiesDetailsOther Financial Statement Information-Schedule of Revenue of Recognized in Contract Liabilities (Details)Details31 falsefalseR32.htm9954487-Disclosure-Other Financial Statement Information-Schedule of Revenue by Source (Details)Sheethhttp://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofRevenuebySourceDetailsOther Financial Statement Information-Schedule of Revenue by Source (Details)Details32 falsefalseR33.htm9954488-Disclosure-Other Financial Statement Information-Schedule of Revenue by Geographic Region (Details)Sheethhttp://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofRevenuebyGeographicRegionDetailsOther Financial Statement Information-Schedule of Revenue by Geographic Region (Details)Details33 falsefalseR34.htm9954489-Disclosure-Commitments and Contingencies
(Detail)Sheethhttp://www.10xgenomics.com/role/CommitmentsandContingenciesScheduleofCompanysOperatingLeaseLiabilitiesDetailCommitments and Contingencies-Schedule of Company's Operating Lease Liabilities (Detail)Details34 falsefalseR35.htm9954490-Disclosure-Commitments and Contingencies-Schedule of Additional Information Related to Operating Leases
(Detail)Sheethhttp://www.10xgenomics.com/role/CommitmentsandContingenciesScheduleofAdditionalInformationRelatedtoOperatingLeasesDetailCommitments and Contingencies-Additional Information (Detail)Details35 falsefalseR36.htm9954491-Disclosure-Commitments and Contingencies-Additional Information (Detail)Details36 falsefalseR37.htm9954492-Disclosure-Capital Stock-Additional Information
(Detail)Sheethhttp://www.10xgenomics.com/role/CapitalStockAdditionalInformationDetailCapital Stock-Additional Information (Detail)Details37 falsefalseR38.htm9954493-Disclosure-Capital Stock-Schedule of Common Stock Issued and Outstanding
(Details)Sheethhttp://www.10xgenomics.com/role/CapitalStockScheduleofCommonStockIssuedandOutstandingDetailsCapital Stock-Schedule of Common Stock Issued and Outstanding (Details)Details38 falsefalseR39.htm9954494-Disclosure-Equity Incentive Plans-Schedule of Recorded Stock-Based Compensation Expense in the Condensed Consolidated Statement of Operations
(Details)Sheethhttp://www.10xgenomics.com/role/EquityIncentivePlansScheduleofRecordedStockBasedCompensationExpenseintheCondensedConsolidatedStatementofOperations-Incentive Plans-Schedule of Recorded Stock-Based Compensation Expense in the Condensed Consolidated Statement of Operations (Details)Details39 falsefalseR40.htm9954495-Disclosure-Equity Incentive Plans-Schedule of RSU Activity
(Detail)Sheethhttp://www.10xgenomics.com/role/EquityIncentivePlansScheduleofRSUActivityDetailEquity Incentive Plans-Schedule of RSU Activity (Detail)Details40 falsefalseR41.htm9954496-Disclosure-Equity Incentive Plans-Schedule of Company's Stock Option Activity
(Details)Sheethhttp://www.10xgenomics.com/role/EquityIncentivePlansScheduleofCompanysStockOptionActivityDetailsEquity Incentive Plans-Schedule of Company's Stock Option Activity (Details)Details41 falsefalseR42.htm9954497-Disclosure-Equity Incentive Plans-Additional Information
(Details)Sheethhttp://www.10xgenomics.com/role/EquityIncentivePlansAdditionalInformationDetailsEquity Incentive Plans-Additional Information (Details)Details42 falsefalseR43.htm9954498-Disclosure-Equity Incentive Plans-Fair Values of Shares Under the Performance Stock Options
(Details)Sheethhttp://www.10xgenomics.com/role/EquityIncentivePlansFairValuesofSharesUnderthePerformanceStockOptionsDetailsEquity Incentive Plans-Fair Values of Shares Under the Performance Stock Options (Details)Details43 falsefalseR44.htm9954499-Disclosure-Net Loss Per Share-Shares of Common Stock Equivalents Were Excluded From The Computation of Diluted Net Loss Per Share
(Details)Sheethhttp://www.10xgenomics.com/role/NetLossPerShareSharesofCommonStockEquivalentsWereExcludedFromTheComputationofDilutedNetLossPerShareDetailsNet Loss Per Share-Shares of Common Stock Equivalents Were Excluded From The Computation of Diluted Net Loss Per Share (Details)Details44 falsefalseAll Reports Book All Reports txg-20240630.htmtxg-20240630.xsdtxg-20240630-cal.xmltxg-20240630-def.xmltxg-20240630-lab.xmltxg-20240630-pre.xmltxg-20240630-g1.jpg http://fasb.org/us-gaap/2024/txg/xbrl.sec.gov/doi/2024http://xbrl.sec.gov/ecd/2024truetrue JSON 6 MetaLinks.json IDEA XBRL DOCUMENT { "version": "2.2", "instance": { "txg-20240630.htm": { "isPrefix": "txg", "isURI": "http://www.10xgenomics.com/20240630", "dts": { "inline": { "local": { "txg-20240630.htm": { "schema": { "local": { "txg-20240630.xsd": { "remote": { "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd": { "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd": { "http://www.xbrl.org/2003/xl-2003-12-31.xsd": { "http://www.xbrl.org/2003/xlink-2003-12-31.xsd": { "http://www.xbrl.org/2005/xbrldt-2005.xsd": { "http://www.xbrl.org/2006/ref-2006-02-27.xsd": { "http://www.xbrl.org/rr/role/negated-2009-12-16.xsd": { "http://www.xbrl.org/rr/role/net-2009-12-16.xsd": { "http://www.xbrl.org/rr/role/reference-2009-12-16.xsd": { "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd": { "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd": { "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd": { "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd": { "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd": { "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd": { "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd": { "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd": { "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd": { "https://xbrl.sec.gov/country/2024/country-2024.xsd": { "https://xbrl.sec.gov/dei/2024/dei-2024.xsd": { "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd": { "https://xbrl.sec.gov/srtptr/2024/srtptr-2024.xsd": { "calculationLink": { "local": { "txg-20240630-cal.xml": { "definitionLink": { "local": { "txg-20240630-def.xml": { "labelLink": { "local": { "txg-20240630-lab.xml": { "presentationLink": { "local": { "txg-20240630-pre.xml": { "keyStandard": "218", "keyCustom": "15", "axisStandard": "14", "axisCustom": "0", "memberStandard": "35", "memberCustom": "17", "hidden": { "total": "5", "http://xbrl.sec.gov/dei/2024": "5" }, "contextCount": "198", "entityCount": "1", "segmentCount": "54", "elementCount": "471", "unitCount": "4", "baseTaxonomies": { "http://fasb.org/us-gaap/2024": "585", "http://xbrl.sec.gov/dei/2024": "30", "http://xbrl.sec.gov/ecd/2024": "4" }, "report": { "R1": { "role": "http://www.10xgenomics.com/role/CoverPage", "longName": "0000001-Documents-Cover Page", "shortName": "Cover Page", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body", "html": "1", "reportCount": "1", "baseRef": "txg-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body", "html": "1", "reportCount": "1", "baseRef": "txg-20240630.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.10xgenomics.com/role/CondensedConsolidatedBalanceSheets", "longName": "9952151-Statement-Condensed Consolidated Balance Sheets", "shortName": "Condensed Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:CashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr", "table": "div", "body", "html": "1", "reportCount": "1", "baseRef": "txg-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:CashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr", "table": "div", "body", "html": "1", "reportCount": "1", "baseRef": "txg-20240630.htm", "first": true, "unique": true } }, "R3": { "role": "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofOperations", "longName": "9952152-Statement-Condensed Consolidated Statements of Operations", "shortName": "Condensed Consolidated Statements of Operations", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr", "table": "div", "body", "html": "1", "reportCount": "1", "baseRef": "txg-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr", "table": "div", "body", "html": "1", "reportCount": "1", "baseRef": "txg-20240630.htm", "first": true } }, "R4": { "role": "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofComprehensiveLoss", "longName": "9952153-Statement-Condensed Consolidated Statements of Comprehensive Loss", "shortName": "Condensed Consolidated Statements of Comprehensive Loss", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr", "table": "div", "body", "html": "1", "reportCount": "1", "baseRef": "txg-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr", "table": "div", "body", "html": "1", "reportCount": "1", "baseRef": "txg-20240630.htm", "first": true } }, "R5": { "role": "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofStockholdersEquity", "longName": "9952154-Statement-Condensed Consolidated Statements of Stockholders Equity", "shortName": "Condensed Consolidated Statements of Stockholders Equity", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-35", "name": "us-gaap:SharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": { "span": "td", "tr", "table": "div", "body", "html": "1", "reportCount": "1", "baseRef": "txg-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-35", "name": "us-gaap:SharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": { "span": "td", "tr", "table": "div", "body", "html": "1", "reportCount": "1", "baseRef": "txg-20240630.htm", "first": true } }, "R6": { "role": "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsofCashFlows", "longName": "9952155-Statement-Condensed Consolidated Statements of Cash Flows", "shortName": "Condensed Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr", "table": "div", "body", "html": "1", "reportCount": "1", "baseRef": "txg-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr", "table": "div", "body", "html": "1", "reportCount": "1", "baseRef": "txg-20240630.htm", "first": true, "unique": true } }, "R7": { "role": "http://www.10xgenomics.com/role/DescriptionofBusinessandBasisofPresentation", "longName": "9952156-Disclosure-Description of Business and Basis of Presentation", "shortName": "Description of Business and Basis of Presentation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body", "html": "1", "reportCount": "1", "baseRef": "txg-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body", "html": "1", "reportCount": "1", "baseRef": "txg-20240630.htm", "first": true, "unique": true } }, "R8": { "role": "http://www.10xgenomics.com/role/SummaryofSignificantAccountingPolicies", "longName": "9952157-Disclosure-Summary of Significant Accounting Policies", "shortName": "Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body", "html": "1", "reportCount": "1", "baseRef": "txg-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body", "html": "1", "reportCount": "1", "baseRef": "txg-20240630.htm", "first": true, "unique": true } } } }

"http://www.10xgenomics.com/role/EquityIncentivePlansAdditionalInformationDetails", "longName": "9954497 - Disclosure - Equity Incentive Plans - Additional Information (Details)", "shortName": "Equity Incentive Plans - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "txg-20240630.htm", "first": true, "uniqueAnchor": { "contextRef": "c-176", "name": "us-gaap:EmployeeBenefitsAndShareBasedCompensation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "5", "ancestors": ["span", "div", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "txg-20240630.htm", "unique": true }, "R43": { "role": "http://www.10xgenomics.com/role/EquityIncentivePlansFairValuesOfSharesUnderThePerformanceStockOptionsDetails", "longName": "9954498 - Disclosure - Equity Incentive Plans - Fair Values of Shares Under the Performance Stock Options (Details)", "shortName": "Equity Incentive Plans - Fair Values of Shares Under the Performance Stock Options (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c-178", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "txg-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-178", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "txg-20240630.htm", "first": true, "unique": true }, "R44": { "role": "http://www.10xgenomics.com/role/NetLossPerShareSharesOfCommonStockEquivalentsWereExcludedFromTheComputationOfDilutedNetLossPerShareDetails", "longName": "9954499 - Disclosure - Net Loss Per Share - Shares of Common Stock Equivalents Were Excluded From The Computation of Diluted Net Loss Per Share (Details)", "shortName": "Net Loss Per Share - Shares of Common Stock Equivalents Were Excluded From The Computation of Diluted Net Loss Per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "body", "html"] }, "reportCount": 1, "baseRef": "txg-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "body", "html"] }, "reportCount": 1, "baseRef": "txg-20240630.htm", "first": true, "unique": true }, "tag": { "xbrltype": "us-gaap:AccountingPoliciesAbstract", "stringItemType": "nsuri", "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": "en-us", "role": "terseLabel", "AccountingPoliciesAbstract", "label": "Accounting Policies [Abstract] } }", "auth_ref": { "us-gaap:AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "parentTag": "us-gaap:LiabilitiesCurrent", "weight": -1.0, "order": 5.0 } }, "presentation": { "http://www.10xgenomics.com/role/CondensedConsolidatedBalanceSheets", "lang": "en-us", "role": "verboseLabel": "Accounts payable", "label": "Accounts Payable, Current", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). } }", "auth_ref": { "r52", "r66" } }, "us-gaap:AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "parentTag": "us-gaap:AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.10xgenomics.com/role/CondensedConsolidatedBalanceSheets", "lang": "en-us", "role": "verboseLabel": "Accounts receivable, net", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. } }", "auth_ref": { "r81" } }, "us-gaap:AccruedBonusesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedBonusesCurrent", "crdr": "credit", "calculation": { "parentTag": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleOfAccruedCompensationandRelatedBenefitsDetails", "lang": "en-us", "role": "terseLabel": "Accrued bonus", "label": "Accrued Bonuses, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). } }", "auth_ref": { "r54" } }, "txg:AccruedCommissionsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.10xgenomics.com/20240630", "localname": "AccruedCommissionsCurrent", "crdr": "credit", "calculation": { "parentTag": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleOfAccruedCompensationandRelatedBenefitsDetails", "lang": "en-us", "role": "terseLabel": "Accrued commissions", "label": "Accrued Commissions, Current", "documentation": "Accrued commissions, Current", "auth_ref": { "txg:AccruedExpensesAndOtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.10xgenomics.com/20240630", "localname": "AccruedExpensesAndOtherLiabilitiesCurrent", "crdr": "credit", "calculation": { "parentTag": "us-gaap:LiabilitiesCurrent", "weight": -1.0, "order": 2.0 } }, "presentation": { "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleOfAccruedExpenseAndOtherCurrentLiabilitiesDetails", "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.10xgenomics.com/role/CondensedConsolidatedBalanceSheets", "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleOfAccruedExpenseAndOtherCurrentLiabilitiesDetails", "lang": "en-us", "role": "verboseLabel": "Accrued expenses and other current liabilities", "totalLabel": "Accrued expenses and other current liabilities", "label": "Accrued Expenses And Other Liabilities Current", "documentation": "Accrued Expenses And Other Liabilities Current", "auth_ref": { "txg:AccruedLegalAndRelatedExpensesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.10xgenomics.com/20240630", "localname": "AccruedLegalAndRelatedExpensesCurrent", "crdr": "credit", "calculation": { "parentTag": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": { "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleOfAccruedExpenseAndOtherCurrentLiabilitiesDetails", "lang": "en-us", "role": "verboseLabel": "Accrued legal and related costs", "label": "Accrued Legal And Related Expenses Current", "documentation": "Accrued legal expenses current. } }", "auth_ref": { "txg:AccruedPayrollAndRelatedCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.10xgenomics.com/20240630", "localname": "AccruedPayrollAndRelatedCosts", "crdr": "credit", "calculation": { "parentTag": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleOfAccruedCompensationandRelatedBenefitsDetails", "lang": "en-us", "role": "verboseLabel": "Accrued payroll and related costs", "label": "Accrued Payroll And Related Costs", "documentation": "Accrued Payroll And Related Costs. } }", "auth_ref": { "us-gaap:AccruedProfessionalFeesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedProfessionalFeesCurrent", "crdr": "credit", "calculation": { "parentTag": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleOfAccruedExpenseAndOtherCurrentLiabilitiesDetails", "lang": "en-us", "role": "terseLabel": "Accrued professional services", "label": "Accrued Professional Fees, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). } }", "auth_ref": { "txg:AccruedPropertyAndEquipmentCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.10xgenomics.com/20240630", "localname": "AccruedPropertyAndEquipmentCurrent", "crdr": "credit", "calculation": { "parentTag": "us-gaap:AccruedExpensesAndOtherLiabilitiesCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": { "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleOfAccruedExpenseAndOtherCurrentLiabilitiesDetails", "lang": "en-us", "role": "terseLabel": "Accrued property and equipment", "label": "Accrued Property And Equipment Current", "documentation": "Accrued property and equipment current. } }", "auth_ref": { "us-gaap:AccruedPurchaseConsiderationCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.10xgenomics.com/20240630", "localname": "AccruedPurchaseConsiderationCurrent", "crdr": "credit", "calculation": { "parentTag": "us-gaap:AccruedExpensesAndOtherLiabilitiesCurrent", "weight": 1.0, "order": 8.0 } }, "presentation": { "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleOfAccruedExpenseAndOtherCurrentLiabilitiesDetails", "lang": "en-us", "role": "terseLabel": "Accrued purchase consideration", "label": "Accrued Purchase Consideration, Current", "documentation": "Accrued Purchase Consideration, Current", "auth_ref": { "us-gaap:AccruedRoyaltiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedRoyaltiesCurrent", "crdr": "credit", "calculation": { "parentTag": "us-gaap:AccruedExpensesAndOtherLiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleOfAccruedExpenseAndOtherCurrentLiabilitiesDetails", "lang": "en-us", "role": "terseLabel": "Accrued royalties for licensed technologies", "label": "Accrued Royalties, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). } }", "auth_ref": { "r54", "r63" } }, "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "parentTag": "us-gaap:PropertyPlantAndEquipmentNet", "weight": -1.0, "order": 2.0 } }, "presentation": { "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleOfPropertyPlantAndEquipmentDetail", "lang": "en-us", "role": "negatedLabel": "Less: accumulated depreciation and amortization", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services. } }", "auth_ref": { "r37", "r120", "r49" } }, "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "parentTag": "us-gaap:StockholdersEquity", "weight": -1.0, "order": 2.0 } }, "presentation": { "http://www.10xgenomics.com/role/CondensedConsolidatedBalanceSheets", "lang": "en-us", "role": "verboseLabel": "Accumulated other comprehensive loss", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source. } }", "auth_ref": { "r18", "r19", "r70", "r127", "r490", "r518", "r519" } }, "us-gaap:AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": { "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsOfStockholdersEquity", "lang": "en-us", "role": "verboseLabel": "Accumulated Other Comprehensive Income (Loss)", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. } }", "auth_ref": { "r1", "r10", "r19", "r37", "r413", "r514", "r515", "r70", "r79", "r794", "r800", "r801", "r802", "r803" } }, "eccd:Additional402rDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/eccd/2024", "localname": "Additional402rDisclosureTextBlock" } }

"http://www.10xgenomics.com/role/CondensedConsolidatedBalanceSheets", "lang": "en-us", "role": "terseLabel", "Current assets", "label": "Assets, Current [Abstract]", "auth_ref": "I", "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "crdr": "credit", "calculation": "http://www.10xgenomics.com/role/OtherFinancialStatementInformationAvailableForSaleSecuritiesDetails", "parentTag": "txg_DebtSecuritiesAvailableForSaleAmortizedCostIncludingMoneyMarketFunds", "weight": -1.0, "order": 1.0, "presentation": "http://www.10xgenomics.com/role/OtherFinancialStatementInformationAvailableForSaleSecuritiesDetails", "lang": "en-us", "role": "terseLabel", "Gross Unrealized Gains", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax", "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOIC) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)", "auth_ref": "r207", "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "crdr": "debit", "calculation": "http://www.10xgenomics.com/role/OtherFinancialStatementInformationAvailableForSaleSecuritiesDetails", "parentTag": "txg_DebtSecuritiesAvailableForSaleAmortizedCostIncludingMoneyMarketFunds", "weight": -1.0, "order": 2.0, "presentation": "http://www.10xgenomics.com/role/OtherFinancialStatementInformationAvailableForSaleSecuritiesDetails", "lang": "en-us", "role": "negatedTerseLabel", "Gross Unrealized Losses", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax", "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOIC) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)", "auth_ref": "r208", "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "crdr": "debit", "calculation": "http://www.10xgenomics.com/role/OtherFinancialStatementInformationAvailableForSaleSecuritiesDetails", "parentTag": null, "weight": null, "order": null, "root": true, "presentation": "http://www.10xgenomics.com/role/OtherFinancialStatementInformationAvailableForSaleSecuritiesDetails", "lang": "en-us", "role": "totalLabel", "Total marketable securities", "label": "Debt Securities, Available-for-Sale, Amortized Cost", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)", "auth_ref": "r204, r243, r405", "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue", "crdr": "debit", "calculation": "http://www.10xgenomics.com/role/OtherFinancialStatementInformationContractualMaturitiesOfMarketableSecuritiesDetails", "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": -1.0, "order": 2.0, "presentation": "http://www.10xgenomics.com/role/OtherFinancialStatementInformationContractualMaturitiesOfMarketableSecuritiesDetails", "lang": "en-us", "role": "terseLabel", "Due after one year to five years", "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five", "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)", "auth_ref": "r212, r403", "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract", "presentation": "http://www.10xgenomics.com/role/OtherFinancialStatementInformationContractualMaturitiesOfMarketableSecuritiesDetails", "lang": "en-us", "role": "terseLabel", "Fair Value", "label": "Debt Securities, Available-for-Sale, Fair Value, Fiscal Year Maturity [Abstract]", "auth_ref": "I", "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "crdr": "debit", "calculation": "http://www.10xgenomics.com/role/OtherFinancialStatementInformationContractualMaturitiesOfMarketableSecuritiesDetails", "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": -1.0, "order": 1.0, "presentation": "http://www.10xgenomics.com/role/OtherFinancialStatementInformationContractualMaturitiesOfMarketableSecuritiesDetails", "lang": "en-us", "role": "terseLabel", "Due in one year or less", "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One", "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)", "auth_ref": "r211, r402", "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtSecurities", "crdr": "debit", "calculation": "http://www.10xgenomics.com/role/OtherFinancialStatementInformationAvailableForSaleSecuritiesDetails", "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0, "order": 3.0, "presentation": "http://www.10xgenomics.com/role/OtherFinancialStatementInformationContractualMaturitiesOfMarketableSecuritiesDetails", "parentTag": null, "weight": null, "order": null, "root": true, "presentation": "http://www.10xgenomics.com/role/OtherFinancialStatementInformationAvailableForSaleSecuritiesDetails", "lang": "en-us", "role": "terseLabel", "Marketable securities, fair value", "totalLabel": "Total marketable securities", "label": "Debt Securities, Available-for-Sale", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)", "auth_ref": "r205, r243, r302, r470, r653, r659, r811, r891, r892, r893", "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent", "crdr": "debit", "calculation": "http://www.10xgenomics.com/role/CondensedConsolidatedBalanceSheets", "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0, "presentation": "http://www.10xgenomics.com/role/CondensedConsolidatedBalanceSheets", "lang": "en-us", "role": "terseLabel", "Marketable securities", "label": "Debt Securities, Available-for-Sale, Current", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current", "auth_ref": "r202, r243", "ecd_AwardExrcPrice", "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": "en-us", "role": "terseLabel", "Exercise Price", "label": "Award Exercise Price", "auth_ref": "r764", "ecd_AwardGrantDateFairValue", "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": "en-us", "role": "terseLabel", "Fair Value as of Grant Date", "label": "Award Grant Date Fair Value", "auth_ref": "r765", "ecd_AwardTmgDiscInclntems", "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscInclntems", "lang": "en-us", "role": "label", "Award Timing Disclosures [Line Items]", "auth_ref": "r760", "ecd_AwardTmgHowMnpiCnsdrdTextBlock", "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": "en-us", "role": "terseLabel", "Award Timing, How MNPI Considered", "label": "Award Timing, How MNPI Considered [Text Block]", "auth_ref": "r760", "ecd_AwardTmgMethodTextBlock", "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": "en-us", "role": "terseLabel", "Award Timing Method", "label": "Award Timing Method [Text Block]", "auth_ref": "r760", "ecd_AwardTmgMnpiCnsdrdFlag", "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": "en-us", "role": "terseLabel", "Award Timing MNPI Considered", "label": "Award Timing MNPI Considered [Flag]", "auth_ref": "r760", "ecd_AwardTmgMnpiDiscTextBlock", "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": "en-us", "role": "terseLabel", "Award Timing MNPI Disclosure", "label": "Award Timing MNPI Disclosure [Text Block]", "auth_ref": "r760", "ecd_AwardTmgPredtrmndFlag", "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": "en-us", "role": "terseLabel", "Award Timing Predetermined", "label": "Award Timing Predetermined [Flag]", "auth_ref": "r760", "us-gaap_AwardTypeAxis", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": "http://www.10xgenomics.com/role/EquityIncentivePlansAdditionalInformationDetails", "http://www.10xgenomics.com/role/EquityIncentivePlansFairValuesOfSharesUnderThePerformanceStockOptionsDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": "en-us", "role": "terseLabel", "Award Type [Axis]", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement", "auth_ref": "r320, r321, r322, r323, r324, r325, r326, r327, r328, r329, r330, r331, r332, r333, r334, r335, r336, r337, r338, r339, r340, r341, r342, r343, r344, r345", "ecd_AwardUndrlygSecuritiesAmt", "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": "en-us", "role": "terseLabel", "Underlying Securities", "label": "Award Underlying Securities Amount", "auth_ref": "r763", "ecd_AwardsCloseToMnpiDiscIndName", "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": "en-us", "role": "terseLabel", "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name", "auth_ref": "r762", "ecd_AwardsCloseToMnpiDiscTable", "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": "en-us", "role": "terseLabel", "Awards Close in Time to MNPI Disclosures", "label": "Awards Close in Time to MNPI Disclosures [Table]", "auth_ref": "r761", "ecd_AwardsCloseToMnpiDiscTableTextBlock", "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": "en-us", "role": "terseLabel", "Awards Close in Time to MNPI Disclosures, Table", "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "auth_ref": "r761", "us-gaap_BasisOfAccountingPolicyTextBlock", "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfAccountingPolicyTextBlock", "presentation": "http://www.10xgenomics.com/role/SummaryOfSignificantAccountingPolicies", "lang": "en-us", "role": "terseLabel", "Basis of Presentation", "label": "Basis of Presentation", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)", "auth_ref": "I", "us-gaap_BuildingMember", "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BuildingMember", "presentation": "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleOfPropertyPlantAndEquipmentDetail", "lang": "en-us", "role": "verboseLabel", "Building", "label": "Building [Member]", "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities", "auth_ref": "r87", "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock", "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "presentation": "http://www.10xgenomics.com/role/DescriptionOfBusinessAndBasisOfPresentation", "lang": "en-us", "role": "terseLabel", "Description of Business and Basis of Presentation", "label": "Business Description and Basis of Presentation [Text Block]", "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)", "auth_ref": "r51, r82, r83", "country_CN", "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "CN", "presentation": "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleOfRevenueByGeographicRegionDetails", "lang": "en-us", "role": "terseLabel", "China", "label": "CHINA", "auth_ref": "I", "us-gaap_CapitalExpendituresIncurredButNotYetPaid", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CapitalExpendituresIncurredButNotYetPaid", "crdr": "credit", "presentation": "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsOfCashFlows", "lang": "en-us", "role": "terseLabel", "Purchases of property and equipment included in accounts payable and accrued expenses and other current liabilities", "label": "Capital Expenditures Incurred but Not yet Paid", "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred", "auth_ref": "r25, r26, r27", "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsOfCashFlows", "lang": "en-us", "role": "periodStartLabel", "Cash, cash equivalents, and restricted

cash at beginning of period", "periodEndLabel": "Cash, cash equivalents, and restricted cash at end of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } , "auth_ref": "r23", "r79", "r150" } } , "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage, including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } , "auth_ref": "r70", "r79" } } , "us-gaap_CashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.10xgenomics.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } } , "presentation": { "http://www.10xgenomics.com/role/CondensedConsolidatedBalanceSheets": { "lang": "en-us", "role": "verboseLabel": "Cash and cash equivalents", "label": "Cash Equivalents at Carrying Value", "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } , "auth_ref": "r700", "r899" } } , "ecd_ChngInFrValAsOfVstngDtOfPrYrEqtyAwrdsVstDnInCvrdYrMember": { "presentation": { "http://xbrl.sec.gov/ecd/2024", "lang": "en-us", "role": "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year", "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]", "documentation": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]" } } , "auth_ref": "r737" } } , "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrYrsMember": { "presentation": { "http://xbrl.sec.gov/ecd/2024", "lang": "en-us", "role": "terseLabel": "Change in Fair Value of Outstanding and Unvested Equity Awards Granted in Prior Years That are Outstanding and Unvested", "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]", "documentation": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]" } } , "auth_ref": "r735" } } , "txg_ChromiumConsumablesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.10xgenomics.com/20240630", "localname": "ChromiumConsumablesMember", "presentation": { "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofRevenuebySourceDetails": { "lang": "en-us", "role": "terseLabel": "Chromium", "label": "Chromium - Consumables [Member]", "documentation": "Chromium - Consumables [Member]" } } , "auth_ref": "r740" } } , "txg_ChromiumInstrumentsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.10xgenomics.com/20240630", "localname": "ChromiumInstrumentsMember", "presentation": { "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofRevenuebySourceDetails": { "lang": "en-us", "role": "terseLabel": "Chromium", "label": "Chromium - Instruments [Member]", "documentation": "Chromium - Instruments [Member]" } } , "auth_ref": "r741" } } , "normalizedStringItemType": { "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": { "http://www.10xgenomics.com/role/CoverPage": { "lang": "en-us", "role": "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } , "auth_ref": "r742" } } , "txg_ClassBCommonStocksConvertedToClassACommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.10xgenomics.com/20240630", "localname": "ClassBCommonStocksConvertedToClassACommonStockMember", "presentation": { "http://www.10xgenomics.com/role/CapitalStockScheduleofCommonStockIssuedandOutstandingDetails": { "lang": "en-us", "role": "terseLabel": "Class B common stock converted to Class A common stock", "label": "Class B Common Stocks Converted to Class A Common Stock [Member]", "documentation": "Class B Common Stocks Converted to Class A Common Stock [Member]" } } , "auth_ref": "r743" } } , "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDomain", "presentation": { "http://www.10xgenomics.com/role/CapitalStockAdditionalInformationDetail": { "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsOfStockholdersEquity": "http://www.10xgenomics.com/role/CoverPage", "http://www.10xgenomics.com/role/EquityIncentivePlansAdditionalInformationDetails": { "lang": "en-us", "role": "terseLabel": "Class of Stock [Domain]", "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } , "auth_ref": "r114", "r124", "r125", "r126", "r153", "r171", "r172", "r174", "r176", "r184", "r185", "r235", "r265", "r267", "r268", "r269", "r272", "r273", "r277", "r278", "r281", "r284", "r291", "r394", "r522", "r523", "r524", "r525", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r552", "r573", "r591", "r605", "r606", "r607", "r608", "r609", "r779", "r798", "r804" } } , "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockLineItems", "presentation": { "http://www.10xgenomics.com/role/CapitalStockAdditionalInformationDetail": { "lang": "en-us", "role": "terseLabel": "Class of Stock Line Items", "label": "Class of Stock Line Items", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } , "auth_ref": "r124", "r125", "r126", "r184", "r277", "r278", "r281", "r291", "r394", "r522", "r523", "r524", "r525", "r527", "r528", "r529" } } , "CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": "en-us", "role": "terseLabel": "Company Selected Measure Amount", "label": "Company Selected Measure Amount", "documentation": "The entire disclosure for commitments and contingencies." } } , "auth_ref": "r899", "r253", "r254", "r613", "r835", "r837" } } , "us-gaap_CommonClassAMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonClassAMember", "presentation": { "http://www.10xgenomics.com/role/CapitalStockAdditionalInformationDetail": { "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsOfStockholdersEquity": "http://www.10xgenomics.com/role/CoverPage", "http://www.10xgenomics.com/role/EquityIncentivePlansAdditionalInformationDetails": { "lang": "en-us", "role": "terseLabel": "Common Class A", "label": "Common Class A [Member]", "documentation": "Classification of common stock representing ownership interest in a corporation." } } , "auth_ref": "r931" } } , "us-gaap_CommonClassBMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonClassBMember", "presentation": { "http://www.10xgenomics.com/role/CapitalStockAdditionalInformationDetail": { "http://www.10xgenomics.com/role/CoverPage": { "lang": "en-us", "role": "terseLabel": "Common Class B", "label": "Common Class B [Member]", "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation." } } , "auth_ref": "r931" } } , "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "presentation": { "http://www.10xgenomics.com/role/EquityIncentivePlansAdditionalInformationDetails": { "lang": "en-us", "role": "terseLabel": "Common stock reserved for issuance (in shares)", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "documentation": "Aggregate number of common shares reserved for future issuance." } } , "auth_ref": "r61" } } , "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": { "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsOfStockholdersEquity": { "lang": "en-us", "role": "verboseLabel": "Common Stock", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } , "auth_ref": "r693", "r684", "r685", "r687", "r688", "r689" } } , "r800", "r801", "r803", "r879", "r930", "r931" } } , "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": { "http://www.10xgenomics.com/role/CapitalStockAdditionalInformationDetail": { "lang": "en-us", "role": "verboseLabel": "Common stock shares issued (in shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } , "auth_ref": "r61" } } , "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": { "http://www.10xgenomics.com/role/CapitalStockAdditionalInformationDetail": { "lang": "en-us", "role": "verboseLabel": "Common stock shares outstanding (in shares)", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } , "auth_ref": "r11", "r61", "r52", "r570", "r931", "r932" } } , "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.10xgenomics.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } } , "presentation": { "http://www.10xgenomics.com/role/CondensedConsolidatedBalanceSheets": { "lang": "en-us", "role": "terseLabel": "Common stock", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } , "auth_ref": "r61", "r499", "r666" } } , "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": "en-us", "role": "terseLabel": "Compensation Actually Paid vs. Company Selected Measure", "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "documentation": "Compensation Actually Paid vs. Company Selected Measure [Text Block]" } } , "auth_ref": "r746" } } , "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": "en-us", "role": "terseLabel": "Compensation Actually Paid vs. Net Income", "label": "Compensation Actually Paid vs. Net Income [Text Block]", "documentation": "Compensation Actually Paid vs. Net Income [Text Block]" } } , "auth_ref": "r745" } } , "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": "en-us", "role": "terseLabel": "Compensation Actually Paid vs. Other Measure", "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "documentation": "Compensation Actually Paid vs. Other Measure [Text Block]" } } , "auth_ref": "r747" } } , "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": "en-us", "role": "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return", "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "documentation": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]" } } , "auth_ref": "r744" } } ,

gaap_DebtSecuritiesAvailableForSaleRealizedLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleRealizedLoss", "crdr": "debit", "presentation": { "http://www.10xgenomics.com/role/OtherFinancialStatementInformationAdditionalInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Debt securities, available for sale, realized loss", "label": "Debt Securities, Available for Sale, Realized Loss", "documentation": "Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": { "r233" } }, "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleTableTextBlock", "presentation": { "http://www.10xgenomics.com/role/OtherFinancialStatementInformationTables": { "lang": { "en-us": { "role": { "terseLabel": "Schedule of Debt Securities, Available for Sale", "label": "Debt Securities, Available for Sale [Table Text Block]", "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": { "r813", "r814", "r815", "r816", "r817", "r818", "r819", "r820", "r821", "r822", "r823", "r826" } }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "calculation": { "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": { "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsOfCashFlows": { "lang": { "en-us": { "role": { "terseLabel": "Depreciation and amortization", "label": "Depreciation, Depletion and Amortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": { "r7", "r182", "r191", "r195", "r637", "r638" } }, "txg_DisclosureOfAdditionalInformationRelatedToOperatingLeasesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.10xgenomics.com/20240630", "localname": "DisclosureOfAdditionalInformationRelatedToOperatingLeasesTableTextBlock", "presentation": { "http://www.10xgenomics.com/role/CommitmentsandContingenciesTables": { "lang": { "en-us": { "role": { "terseLabel": "Schedule of Additional Information Related to Operating Leases", "label": "Disclosure of Additional Information Related To Operating Leases [Table Text Block]", "documentation": "Disclosure of additional information related to operating leases." } } }, "auth_ref": { } }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": { "http://www.10xgenomics.com/role/EquityIncentivePlans": { "lang": { "en-us": { "role": { "terseLabel": "Equity Incentive Plans", "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": { "r315", "r319", "r347", "r348", "r349", "r651" } }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Share-based Payment Arrangement [Abstract]", "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": { } }, "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "presentation": { "http://www.10xgenomics.com/role/EquityIncentivePlansTables": { "lang": { "en-us": { "role": { "terseLabel": "Schedule of Recorded Stock-based Compensation Expense in the Condensed Consolidated Statement of Operations", "label": "Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]", "documentation": "Tabular disclosure of share-based payment arrangement." } } }, "auth_ref": { "r9", "r45" } }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": { "http://www.10xgenomics.com/role/CoverPage": { "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QF statements have focus Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": { } }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": { "http://www.10xgenomics.com/role/CoverPage": { "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": { } }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationTable", "presentation": { "http://www.10xgenomics.com/role/CoverPage": { "lang": { "en-us": { "role": { "terseLabel": "Document Information [Table]", "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": { } }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": { "http://www.10xgenomics.com/role/CoverPage": { "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K, the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A, the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": { } }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": { "http://www.10xgenomics.com/role/CoverPage": { "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as a quarterly report." } } }, "auth_ref": { "r696" } }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": { "http://www.10xgenomics.com/role/CoverPage": { "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": { "r728" } }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": { "http://www.10xgenomics.com/role/CoverPage": { "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": { } }, "ecd_DvdsOrOthrErngsPdOnEqtyAwrdsNtOthrsRflctdInThCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "DvdsOrOthrErngsPdOnEqtyAwrdsNtOthrsRflctdInThCompForCvrdYrMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year", "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]" } } }, "auth_ref": { "r739" } }, "us-gaap_EMEAMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EMEA Member", "presentation": { "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofRevenuebyGeographicRegionDetails": { "lang": { "en-us": { "role": { "terseLabel": "Europe, Middle East and Africa", "label": "EMEA [Member]", "documentation": "Regions of Europe, Middle East and Africa." } } }, "auth_ref": { "r933", "r934", "r935", "r936" } }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "terseLabel": "Earnings Per Share [Abstract]", "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": { } }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": { "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsOfOperations": { "lang": { "en-us": { "role": { "terseLabel": "Net loss per share, basic (in dollars per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": { "r42", "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r166", "r167", "r168", "r169", "r171", "r174", "r175", "r176", "r181", "r362", "r365", "r379", "r380", "r480", "r501", "r634" } }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": { "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsOfOperations": { "lang": { "en-us": { "role": { "terseLabel": "Net loss per share, diluted (in dollars per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": { "r142", "r159", "r160", "r161", "r162", "r163", "r164", "r171", "r174", "r175", "r176", "r181", "r362", "r365", "r379", "r380", "r480", "r501", "r634" } }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerSharePolicyTextBlock", "presentation": { "http://www.10xgenomics.com/role/SummaryofSignificantAccountingPolicies": { "lang": { "en-us": { "role": { "terseLabel": "Net Loss Per Share", "label": "Earnings Per Share, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": { "r28", "r29", "r178" } }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": { "http://www.10xgenomics.com/role/NetLossPerShare": { "lang": { "en-us": { "role": { "terseLabel": "Net Loss Per Share", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": { "r168", "r177", "r179", "r180" } }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 4.0 } }, "presentation": { "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsOfCashFlows": { "lang": { "en-us": { "role": { "terseLabel": "Effect of exchange rate changes on cash, cash equivalents, and restricted cash", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": { "r395" } }, "us-gaap_EmployeeBenefitsAndShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeBenefitsAndShareBasedCompensation", "crdr": "debit", "presentation": { "http://www.10xgenomics.com/role/EquityIncentivePlansAdditionalInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Share based payment arrangement recognized", "label": "Employee Benefits and Share-Based Compensation", "documentation": "Amount of expense for employee benefit and equity-based compensation." } } }, "auth_ref": { } }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.10xgenomics.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleofAccruedCompensationandRelatedBenefitsDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "presentation": { "http://www.10xgenomics.com/role/CondensedConsolidatedBalanceSheets": { "lang": { "en-us": { "role": { "terseLabel": "Accrued compensation and related benefits", "label": "Employee-related Liabilities, Current", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": { "r54" } }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "presentation": { "http://www.10xgenomics.com/role/EquityIncentivePlansScheduleofRecordedStockBasedCompensationExpenseintheCondensedConsolidatedStatementofOperationsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Share-based Payment Arrangement, Expensed [Line Items]", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { } }, "us-gaap_EmployeeStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockMember", "presentation": { "http://www.10xgenomics.com/role/EquityIncentivePlansAdditionalInformationDetails": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Employee Stock", "label": "Employee Stock [Member]", "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock." } } }, "auth_ref": { } }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri":

"http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": -/

"http://www.10xgenomics.com/role/NetLossPerShareSharesOfCommonStockEquivalentsWereExcludedFromTheComputationOfDilutedNetLossPerShareDetails",

"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": -/ "en-us", "role": -/ "terseLabel": "Stock options to purchase common stock", "label": "Share-Based Payment Arrangement, Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "auth_ref": -/ "dei_EntityAddressAddressLine1": -/ "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": -/ "http://www.10xgenomics.com/role/CoverPage", "lang": -/ "en-us", "role": -/ "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "auth_ref": -/ "dei_EntityAddressCityOrTown": -/ "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": -/ "http://www.10xgenomics.com/role/CoverPage", "lang": -/ "en-us", "role": -/ "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town", "auth_ref": -/ "dei_EntityAddressPostalZipCode": -/ "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": -/ "http://www.10xgenomics.com/role/CoverPage", "lang": -/ "en-us", "role": -/ "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code", "auth_ref": -/ "dei_EntityAddressStateOrProvince": -/ "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": -/ "http://www.10xgenomics.com/role/CoverPage", "lang": -/ "en-us", "role": -/ "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province", "auth_ref": -/ "dei_EntityCentralIndexKey": -/ "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": -/ "http://www.10xgenomics.com/role/CoverPage", "lang": -/ "en-us", "role": -/ "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK", "auth_ref": -/ "r694", "dei_EntityCommonStockSharesOutstanding": -/ "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": -/ "http://www.10xgenomics.com/role/CoverPage", "lang": -/ "en-us", "role": -/ "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument", "auth_ref": -/ "dei_EntityCurrentReportingStatus": -/ "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": -/ "http://www.10xgenomics.com/role/CoverPage", "lang": -/ "en-us", "role": -/ "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure", "auth_ref": -/ "dei_EntityEmergingGrowthCompany": -/ "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": -/ "http://www.10xgenomics.com/role/CoverPage", "lang": -/ "en-us", "role": -/ "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria", "auth_ref": -/ "r694", "dei_EntityFileNumber": -/ "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": -/ "http://www.10xgenomics.com/role/CoverPage", "lang": -/ "en-us", "role": -/ "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen", "auth_ref": -/ "dei_EntityFilerCategory": -/ "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": -/ "http://www.10xgenomics.com/role/CoverPage", "lang": -/ "en-us", "role": -/ "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure", "auth_ref": -/ "r694", "dei_EntityIncorporationStateCountryCode": -/ "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": -/ "http://www.10xgenomics.com/role/CoverPage", "lang": -/ "en-us", "role": -/ "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation", "auth_ref": -/ "dei_EntityInformationLineItems": -/ "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInformationLineItems", "presentation": -/ "http://www.10xgenomics.com/role/CoverPage", "lang": -/ "en-us", "role": -/ "terseLabel": "Entity Information [Line Items]", "label": "Entity Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table", "auth_ref": -/ "dei_EntityInteractiveDataCurrent": -/ "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": -/ "http://www.10xgenomics.com/role/CoverPage", "lang": -/ "en-us", "role": -/ "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)", "auth_ref": -/ "r779", "dei_EntityRegistrantName": -/ "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": -/ "http://www.10xgenomics.com/role/CoverPage", "lang": -/ "en-us", "role": -/ "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC", "auth_ref": -/ "r694", "dei_EntityShellCompany": -/ "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": -/ "http://www.10xgenomics.com/role/CoverPage", "lang": -/ "en-us", "role": -/ "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act", "auth_ref": -/ "r694", "dei_EntitySmallBusiness": -/ "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": -/ "http://www.10xgenomics.com/role/CoverPage", "lang": -/ "en-us", "role": -/ "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)", "auth_ref": -/ "r694", "dei_EntityTaxIdentificationNumber": -/ "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": -/ "http://www.10xgenomics.com/role/CoverPage", "lang": -/ "en-us", "role": -/ "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS", "auth_ref": -/ "r694", "us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems": -/ "normalizedStringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EntityWideInformationRevenueFromExternalCustomerLineItems", "presentation": -/ "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleOfRevenueBySourceDetails", "lang": -/ "en-us", "role": -/ "terseLabel": "Revenue from External Customer [Line Items]", "label": "Revenue from External Customer [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table", "auth_ref": -/ "ecd_EqtyAwrdsAdjFnTextBlock": -/ "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": -/ "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": -/ "en-us", "role": -/ "terseLabel": "Equity Awards Adjustments, Footnote", "label": "Equity Awards Adjustments, Footnote", "documentation": "Equity Awards Adjustments, Footnote", "auth_ref": -/ "r733", "ecd_EqtyAwrdsAdjExclgValRprtdInSummaryCompstnTblMember": -/ "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjExclgValRprtdInSummaryCompstnTblMember", "presentation": -/ "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": -/ "en-us", "role": -/ "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table", "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]", "auth_ref": -/ "r774", "ecd_EqtyAwrdsAdjMember": -/ "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjMember", "presentation": -/ "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": -/ "en-us", "role": -/ "terseLabel": "Equity Awards Adjustments [Member]", "label": "Equity Awards Adjustments [Member]", "documentation": "Equity Awards Adjustments [Member]", "auth_ref": -/ "r774", "ecd_EqtyAwrdsInSummaryCompstnTblForApplByMember": -/ "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsInSummaryCompstnTblForApplByMember", "presentation": -/ "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": -/ "en-us", "role": -/ "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table", "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]", "auth_ref": -/ "r774", "us-gaap_EquityAbstract": -/ "normalizedStringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityAbstract", "lang": -/ "en-us", "role": -/ "terseLabel": "Equity [Abstract]", "label": "Equity [Abstract]", "documentation": "Equity [Abstract]", "auth_ref": -/ "us-gaap_EquityComponentDomain": -/ "normalizedStringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": -/ "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsOfStockholdersEquity", "lang": -/ "en-us", "role": -/ "terseLabel": "Equity Component [Domain]", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "auth_ref": -/ "r11", "r115", "r138", "r139", "r140", "r154", "r155", "r156", "r158", "r163", "r165", "r167", "r183", "r236", "r237", "r249", "r292", "r356", "r357", "r359", "r360", "r361", "r363", "r364", "r365", "r370", "r371", "r372", "r373", "r374", "r375", "r378", "r396", "r397", "r399", "r400", "r401", "r402", "r403", "r413", "r497", "r514", "r515", "r516", "r527", "r591", "ecd_EquityValuationAssumptionDifferenceFnTextBlock": -/ "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": -/ "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": -/ "en-us", "role": -/ "terseLabel": "Equity Valuation Assumption Difference, Footnote", "label": "Equity Valuation Assumption Difference, Footnote [Text Block]", "auth_ref": -/ "r743", "ecd_ErrCompAnalysisTextBlock": -/ "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": -/ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "lang": -/ "en-us", "role": -/ "terseLabel": "Erroneous Compensation Analysis [Text Block]", "label": "Erroneous Compensation Analysis [Text Block]", "documentation": "Erroneous Compensation Analysis", "auth_ref": -/ "r701", "r711", "r721", "r753", "ecd_ErrCompRecoveryTable": -/ "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": -/ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "lang": -/ "en-us", "role": -/ "terseLabel": "Erroneously Awarded Compensation Recovery", "label": "Erroneously Awarded Compensation Recovery [Table]", "auth_ref": -/ "r698", "r708", "r718", "r750", "ecd_ExecutiveCategoryAxis": -/ "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": -/ "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": -/ "en-us", "role": -/ "terseLabel": "Executive Category", "label": "Executive Category [Axis]", "documentation": "Executive Category [Axis]", "auth_ref": -/ "r749", "us-gaap_FairValueByFairValueHierarchyLevelAxis": -/ "normalizedStringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": -/ "http://www.10xgenomics.com/role/OtherFinancialStatementInformationAvailableForSaleSecuritiesDetails", "lang": -/ "en-us", "role": -/ "terseLabel": "Fair Value Hierarchy and NAV [Axis]", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient", "auth_ref": -/ "r274", "r300", "r309", "r310", "r311", "r312", "r313", "r381", "r382", "r384", "r385", "r386", "r389", "r390", "r392", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r750", "r751", "r752", "r753", "r754", "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r778", "r779", "r780", "r781", "r782", "r783", "r784", "r785", "r786", "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r808", "r809", "r810", "r811", "r812", "r813", "r814", "r815", "r816", "r817", "r818", "r819", "r820", "r821", "r822", "r823", "r824", "r825", "r826", "r827", "r828", "r829", "r830", "r831", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850", "r851", "r852", "r853", "r854", "r855", "r856", "r857", "r858", "r859", "r860", "r861", "r862", "r863", "r864", "r865", "r866", "r867", "r868", "r869", "r870", "r871", "r872", "r873", "r874", "r875", "r876", "r877", "r878", "r879", "r880", "r881", "r882", "r883", "r884", "r885", "r886", "r887", "r888", "r889", "r890", "r891", "r892", "r893", "r894", "r895", "r896", "r897", "r898", "r899", "r900", "r901", "r902", "r903", "r904", "r905", "r906", "r907", "r908", "r909", "r910", "r911", "r912", "r913", "r914", "r915", "r916", "r917", "r918", "r919", "r920", "r921", "r922", "r923", "r924", "r925", "r926", "r927", "r928", "r929", "r930", "r931", "r932", "r933", "r934", "r935", "r936", "r937", "r938", "r939", "r940", "r941", "r942", "r943", "r944", "r945", "r946", "r947", "r948", "r949", "r950", "r951", "r952", "r953", "r954", "r955", "r956", "r957", "r958", "r959", "r960", "r961", "r962", "r963", "r964", "r965", "r966", "r967", "r968", "r969", "r970", "r971", "r972", "r973", "r974", "r975", "r976", "r977", "r978", "r979", "r980", "r981", "r982", "r983", "r984", "r985", "r986", "r987", "r988", "r989", "r990", "r991", "r992", "r993", "r994", "r995", "r996", "r997", "r998", "r999", "r1000", "us-gaap_FairValueInputsLevel1Member": -/ "normalizedStringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": -/ "http://www.10xgenomics.com/role/OtherFinancialStatementInformationAvailableForSaleSecuritiesDetails", "lang": -/ "en-us", "role": -/ "terseLabel": "Level 1", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date", "auth_ref": -/ "r274", "r308", "r313", "r383", "r390", "r417", "r648", "r649", "r653", "us-gaap_FairValueInputsLevel2Member": -/ "normalizedStringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member", "presentation": -/ "http://www.10xgenomics.com/role/OtherFinancialStatementInformationAvailableForSaleSecuritiesDetails", "lang": -/ "en-us", "role": -/ "terseLabel": "Level 2", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets", "auth_ref": -/ "r274", "r308", "r313", "r383", "r384", "r390", "r418", "r642", "r643", "r647", "r648", "r649", "r653", "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": -/ "normalizedStringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": -/ "http://www.10xgenomics.com/role/OtherFinancialStatementInformationAvailableForSaleSecuritiesDetails", "lang": -/ "en-us", "role": -/ "terseLabel": "Fair Value Hierarchy and NAV [Domain]", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value", "auth_ref": -/ "r274", "r308", "r309", "r310", "r311", "r312", "r313", "r381", "r383", "r384", "r385", "r386", "r389", "r390", "r392", "r417", "r418", "r419", "r642", "r643", "r647", "r648", "r649", "r653", "r658", "us-gaap_FinanceLeaseRightOfUseAssetAmortization": -/ "normalizedStringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseRightOfUseAssetAmortization", "presentation": -/ "http://www.10xgenomics.com/role/OtherFinancialStatementInformationAvailableForSaleSecuritiesDetails", "lang": -/ "en-us", "role": -/ "terseLabel": "Finance Lease Right of Use Asset Amortization", "label": "Finance Lease Right of Use Asset Amortization", "documentation": "Finance Lease Right of Use Asset Amortization", "auth_ref": -/ "r749", "us-gaap_MonetaryItem": -/ "normalizedStringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MonetaryItem", "presentation": -/ "http://www.10xgenomics.com/role/OtherFinancialStatementInformationAvailableForSaleSecuritiesDetails", "lang": -/ "en-us", "role": -/ "terseLabel": "Monetary Item", "label": "Monetary Item", "documentation": "Monetary Item", "auth_ref": -/ "r749", "us-gaap_MonetaryItem": -/ "normalizedStringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MonetaryItem", "presentation": -/ "http://www.10xgenomics.com/role/OtherFinancialStatementInformationAvailableForSaleSecuritiesDetails", "lang": -/ "en-us", "role": -/ "terseLabel": "Monetary Item", "label": "Monetary Item", "documentation": "Monetary Item", "auth_ref": -/ "r749", "us-gaap_MonetaryItem": -/ "normalizedStringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MonetaryItem", "presentation": -/ "http://www.10xgenomics.com/role/OtherFinancialStatementInformationAvailableForSaleSecuritiesDetails", "lang": -/ "en-us", "role": -/ "terseLabel": "Monetary Item", "label": "Monetary Item", "documentation": "Monetary Item", "auth_ref": -/ "r749", "us-gaap_MonetaryItem": -/ "normalizedStringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MonetaryItem", "presentation": -/ "http://www.10xgenomics.com/role/OtherFinancialStatementInformationAvailableForSaleSecuritiesDetails", "lang": -/ "en-us", "role": -/ "terseLabel": "Monetary Item", "label": "Monetary Item", "documentation": "Monetary Item", "auth_ref": -/ "r749", "us-gaap_MonetaryItem": -/ "normalizedStringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MonetaryItem", "presentation": -/ "http://www.10xgenomics.com/role/OtherFinancialStatementInformationAvailableForSaleSecuritiesDetails", "lang": -/ "en-us", "role": -/ "terseLabel": "Monetary Item", "label": "Monetary Item", "documentation": "Monetary Item", "auth_ref": -/ "r749", "us-gaap_MonetaryItem": -/ "normalizedStringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MonetaryItem", "presentation": -/ "http://www.10xgenomics.com/role/OtherFinancialStatementInformationAvailableForSaleSecuritiesDetails", "lang": -/ "en-us", "role": -/ "terseLabel": "Monetary Item", "label": "Monetary Item", "documentation": "Monetary Item", "auth_ref": -/ "r749", "us-gaap_MonetaryItem": -/ "normalizedStringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MonetaryItem", "presentation": -/ "http://www.10xgenomics.com/role/OtherFinancialStatementInformationAvailableForSaleSecuritiesDetails", "lang": -/ "en-us", "role": -/ "terseLabel": "Monetary Item", "label": "Monetary Item", "documentation": "Monetary Item", "auth_ref": -/ "r749", "us-gaap_MonetaryItem": -/ "normalizedStringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MonetaryItem", "presentation": -/ "http://www.10xgenomics.com/role/OtherFinancialStatementInformationAvailableForSaleSecuritiesDetails", "lang": -/ "en-us", "role": -/ "terseLabel": "Monetary Item", "label": "Monetary Item", "documentation": "Monetary Item", "auth_ref": -/ "r749", "us-gaap_MonetaryItem": -/ "normalizedStringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MonetaryItem", "presentation": -/ "http://www.10xgenomics.com/role/OtherFinancialStatementInformationAvailableForSaleSecuritiesDetails", "lang": -/ "en-us", "role": -/ "terseLabel": "Monetary Item", "label": "Monetary Item", "documentation": "Monetary Item", "auth_ref": -/ "r749", "us-gaap_MonetaryItem": -/ "normalizedStringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MonetaryItem", "presentation": -/ "http://www.10xgenomics.com/role/OtherFinancialStatementInformationAvailableForSaleSecuritiesDetails", "lang": -/ "en-us", "role": -/ "terseLabel": "Monetary Item", "label": "Monetary Item", "documentation": "Monetary Item", "auth_ref": -/ "r749", "us-gaap_MonetaryItem": -/ "normalizedStringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MonetaryItem", "presentation": -/ "http://www.10xgenomics.com/role/OtherFinancialStatementInformationAvailableForSaleSecuritiesDetails", "lang": -/ "en-us", "role": -/ "terseLabel": "Monetary Item", "label": "Monetary Item", "documentation": "Monetary Item", "auth_ref": -/ "r749", "us-gaap_MonetaryItem": -/ "normalizedStringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MonetaryItem", "presentation": -/ "http://www.10xgenomics.com/role/OtherFinancialStatementInformationAvailableForSaleSecuritiesDetails", "lang": -/ "en-us", "role": -/ "terseLabel": "Monetary Item", "label": "Monetary Item", "documentation": "Monetary Item", "auth_ref": -/ "r749", "us-gaap_MonetaryItem": -/ "normalizedStringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MonetaryItem", "presentation": -/ "http://www.10xgenomics.com/role/OtherFinancialStatementInformationAvailableForSaleSecuritiesDetails", "lang": -/ "en-us", "role": -/ "terseLabel": "Monetary Item", "label": "Monetary Item", "documentation": "Monetary Item", "auth_ref": -/ "r749", "us-gaap_MonetaryItem": -/ "normalizedStringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MonetaryItem", "presentation": -/ "http://www.10xgenomics.com/role/OtherFinancialStatementInformationAvailableForSaleSecuritiesDetails", "lang": -/ "en-us", "role": -/ "terseLabel": "Monetary Item", "label": "Monetary Item", "documentation": "Monetary Item", "auth_ref": -/ "r749", "us-gaap_MonetaryItem": -/ "normalizedStringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MonetaryItem", "presentation": -/ "http://www.10xgenomics.com/role/OtherFinancialStatementInformationAvailableForSaleSecuritiesDetails", "lang": -/ "en-us", "role": -/ "terseLabel": "Monetary Item", "label": "Monetary Item", "documentation": "Monetary Item", "auth_ref": -/ "r749", "us-gaap_MonetaryItem": -/ "normalizedStringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MonetaryItem", "presentation": -/ "http://www.10xgenomics.com/role/OtherFinancialStatementInformationAvailableForSaleSecuritiesDetails", "lang": -/ "en-us", "role": -/ "terseLabel": "Monetary Item", "label": "Monetary Item", "documentation": "Monetary Item", "auth_ref": -/ "r749", "us-gaap_MonetaryItem": -/ "normalizedStringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MonetaryItem", "presentation": -/ "http://www.10xgenomics.com/role/OtherFinancialStatementInformationAvailableForSaleSecuritiesDetails", "lang": -/ "en-us", "role": -/ "terseLabel": "Monetary Item", "label": "Monetary Item", "documentation": "Monetary Item", "auth_ref": -/ "r749", "us-gaap_MonetaryItem": -/ "normalizedStringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MonetaryItem", "presentation": -/ "http://www.10xgenomics.com/role/OtherFinancialStatementInformationAvailableForSaleSecuritiesDetails", "lang": -/ "en-us", "role": -/ "terseLabel": "Monetary Item", "label": "Monetary Item", "documentation": "Monetary Item", "auth_ref": -/ "r749", "us-gaap_MonetaryItem": -/ "normalizedStringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MonetaryItem", "presentation": -/ "http://www.10xgenomics.com/role/OtherFinancialStatementInformationAvailableForSaleSecuritiesDetails", "lang": -/ "en-us", "role": -/ "terseLabel": "Monetary Item", "label": "Monetary Item", "documentation": "Monetary Item", "auth_ref": -/ "r749", "us-gaap_MonetaryItem": -/ "normalizedStringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MonetaryItem", "presentation": -/ "http://www.10xgenomics.com/role/OtherFinancialStatementInformationAvailableForSaleSecuritiesDetails", "lang": -/ "en-us", "role": -/ "terseLabel": "Monetary Item", "label": "Monetary Item", "documentation": "Monetary Item", "auth_ref": -/ "r749", "us-gaap_MonetaryItem": -/ "normalizedStringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MonetaryItem", "presentation": -/ "http://www.10xgenomics.com/role/OtherFinancialStatementInformationAvailableForSaleSecuritiesDetails", "lang": -/ "en-us", "role": -/ "terseLabel": "Monetary Item", "label": "Monetary Item", "documentation": "Monetary Item", "auth_ref": -/ "r749", "us-gaap_MonetaryItem": -/ "normalizedStringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MonetaryItem", "presentation": -/ "http://www.10xgenomics.com/role/OtherFinancialStatementInformationAvailableForSaleSecuritiesDetails", "lang": -/ "en-us", "role": -/ "terseLabel": "Monetary Item", "label": "Monetary Item", "documentation": "Monetary Item", "auth_ref": -/ "r749", "us-gaap_MonetaryItem": -/ "normalizedStringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MonetaryItem", "presentation": -/ "http://www.10xgenomics.com/role/OtherFinancialStatementInformationAvailableForSaleSecuritiesDetails", "lang": -/ "en-us", "role": -/ "terseLabel": "Monetary Item", "label": "Monetary Item", "documentation": "Monetary Item", "auth_ref": -/ "r749", "us-gaap_MonetaryItem": -/ "normalizedStringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MonetaryItem", "presentation": -/ "http://www.10xgenomics.com/role/OtherFinancialStatementInformationAvailableForSaleSecuritiesDetails", "lang": -/ "en-us", "role": -/ "terseLabel": "Monetary Item", "label": "Monetary Item", "documentation": "Monetary Item", "auth_ref": -/ "r749", "us-gaap_MonetaryItem": -/ "normalizedStringItemType", "nsuri

"MtrTermsOfTrdArrTextBlock": {"presentation": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": "en-us", "role": "terseLabel", "Material Terms of Trading Arrangement": {"label": "Material Terms of Trading Arrangement [Text Block]", "auth_ref": "r768", "ecd_NamedExecutiveOfficersFnTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": "en-us", "role": "terseLabel", "Named Executive Officers Footnote": {"label": "Named Executive Officers Footnote [Text Block]", "auth_ref": "r742", "us-gaap_NetCashProvidedByUsedInFinancingActivities": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsOfCashFlows", "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0, "presentation": "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsOfCashFlows", "lang": "en-us", "role": "totalLabel", "Net cash provided by financing activities": {"label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "auth_ref": "r146", "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsOfCashFlows", "lang": "en-us", "role": "terseLabel", "Investing activities": {"label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "auth_ref": "r146", "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsOfCashFlows", "lang": "en-us", "role": "terseLabel", "Operating activities": {"label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "auth_ref": "r79", "r80", "r81", "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsOfCashFlows", "lang": "en-us", "role": "totalLabel", "Net cash used in operating activities": {"label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "auth_ref": "r79", "r80", "r81", "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss", "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 2.0, "presentation": "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss", "lang": "en-us", "role": "totalLabel", "Net loss": {"label": "Net loss", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "auth_ref": "r74", "r81", "r104", "r116", "r133", "r136", "r140", "r153", "r157", "r159", "r160", "r161", "r162", "r163", "r166", "r167", "r173", "r235", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r362", "r365", "r380", "r394", "r496", "r572", "r589", "r590", "r691", "r845", "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": "http://www.10xgenomics.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "lang": "en-us", "role": "terseLabel", "Recently Issued Accounting Pronouncement and Disclosure Rules": {"label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "auth_ref": "r74", "ecd_NonGaapMeasureDescriptionTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": "en-us", "role": "terseLabel", "Non-GAAP Measure Description": {"label": "Non-GAAP Measure Description [Text Block]", "auth_ref": "r741", "ecd_NonNeosMember": {"xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "lang": "en-us", "role": "terseLabel", "Non-NEOs": {"label": "Non-NEOs [Member]", "auth_ref": "r705", "r715", "r725", "r749", "r757", "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {"xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": "en-us", "role": "terseLabel", "Non-PEO-NEO Average Compensation Actually Paid Amount": {"label": "Non-PEO-NEO Average Compensation Actually Paid Amount", "auth_ref": "r732", "ecd_NonPeoNeoAvgTotalCompAmt": {"xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": "en-us", "role": "terseLabel", "Non-PEO-NEO Average Total Compensation Amount": {"label": "Non-PEO-NEO Average Total Compensation Amount", "auth_ref": "r731", "ecd_NonPeoNeoMember": {"xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": "en-us", "role": "terseLabel", "Non-PEO-NEO [Member]", "auth_ref": "r749", "ecd_NonRule10b51ArrAdoptedFlag": {"xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": "en-us", "role": "terseLabel", "Non-Rule 10b5-1 Arrangement Adopted": {"label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "auth_ref": "r768", "ecd_NonRule10b51ArrTrmtdFlag": {"xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmtdFlag", "presentation": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": "en-us", "role": "terseLabel", "Non-Rule 10b5-1 Arrangement Terminated": {"label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "auth_ref": "r768", "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncashInvestingAndFinancingItemsAbstract", "presentation": "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsOfCashFlows", "lang": "en-us", "role": "terseLabel", "Noncash investing and financing activities": {"label": "Noncash Investing and Financing Items [Abstract]", "auth_ref": "r768", "us-gaap_NonoperatingIncomeExpense": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsOfOperations", "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0, "presentation": "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsOfOperations", "lang": "en-us", "role": "totalLabel", "Total other income": {"label": "Nonoperating Income (Expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "auth_ref": "r76", "us-gaap_NonoperatingIncomeExpenseAbstract": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsOfOperations", "lang": "en-us", "role": "terseLabel", "Other income (expense)": {"label": "Nonoperating Income (Expense) [Abstract]", "auth_ref": "r76", "us-gaap_OperatingExpenses": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "calculation": "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsOfOperations", "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 2.0, "presentation": "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsOfOperations", "lang": "en-us", "role": "totalLabel", "Total operating expenses": {"label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "auth_ref": "r76", "us-gaap_OperatingExpensesAbstract": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsOfOperations", "lang": "en-us", "role": "terseLabel", "Operating expenses": {"label": "Operating Expenses [Abstract]", "auth_ref": "r76", "us-gaap_OperatingIncomeLoss": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsOfOperations", "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0, "presentation": "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsOfOperations", "lang": "en-us", "role": "totalLabel", "Loss from operations": {"label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "auth_ref": "r107", "r636", "r805", "r806", "r807", "r808", "r809", "us-gaap_OperatingLeaseImpairmentLoss": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseImpairmentLoss", "crdr": "debit", "calculation": "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsOfCashFlows", "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 17.0, "presentation": "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsOfCashFlows", "lang": "en-us", "role": "terseLabel", "Lease and asset impairment charges": {"label": "Operating Lease, Impairment Loss", "documentation": "Amount of loss from impairment of right-of-use asset from operating lease.", "auth_ref": "r887", "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "presentation": "http://www.10xgenomics.com/role/CommitmentsandContingenciesScheduleofCompanysOperatingLeaseLiabilitiesDetail", "lang": "en-us", "role": "terseLabel": "Operating lease liabilities, current": {"label": "Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]", "auth_ref": "r405", "us-gaap_OperatingLeaseLiability": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiability", "crdr": "credit", "calculation": "http://www.10xgenomics.com/role/CommitmentsandContingenciesScheduleofCompanysOperatingLeaseLiabilitiesDetail", "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0, "presentation": "http://www.10xgenomics.com/role/CommitmentsandContingenciesScheduleofCompanysOperatingLeaseLiabilitiesDetail", "lang": "en-us", "role": "totalLabel", "Present value of operating lease liabilities": {"label": "Operating Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "auth_ref": "r405", "us-gaap_OperatingLeaseLiabilityCurrent": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": "http://www.10xgenomics.com/role/CondensedConsolidatedBalanceSheets", "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0, "presentation": "http://www.10xgenomics.com/role/CommitmentsandContingenciesScheduleofCompanysOperatingLeaseLiabilitiesDetail", "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 2.0, "presentation": "http://www.10xgenomics.com/role/CommitmentsandContingenciesScheduleofCompanysOperatingLeaseLiabilitiesDetail", "lang": "en-us", "role": "totalLabel", "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current": {"label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "auth_ref": "r405", "us-gaap_OperatingLeaseLiabilityNoncurrent": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": "http://www.10xgenomics.com/role/CommitmentsandContingenciesScheduleofCompanysOperatingLeaseLiabilitiesDetail", "parentTag": "us-gaap_OperatingLeaseLiability",

"order": 4.0 } } , "presentation": { "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsOfCashFlows" } , "lang": { "en-us" } , "role": { "negatedLabel" } , "Purchases of property and equipment": { "label": "Payments to Acquire Property, Plant, and Equipment" , "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale, includes cash outflows to pay for construction of self-constructed assets. } } } , "auth_ref": { "r78" } } , "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType" , "nsuri": "http://xbrl.sec.gov/ecd/2024" , "localname": "PeerGroupIssuersFnTextBlock" , "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" } , "lang": { "en-us" } , "role": { "terseLabel" } , "Peer Group Issuers, Footnote": { "label": "Peer Group Issuers, Footnote [Text Block]" } } } , "auth_ref": { "r740" } } , "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType" , "nsuri": "http://xbrl.sec.gov/ecd/2024" , "localname": "PeerGroupTotalShareholderRtnAmt" , "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" } , "lang": { "en-us" } , "role": { "terseLabel" } , "Peer Group Total Shareholder Return Amount": { "label": "Peer Group Total Shareholder Return Amount" } } } , "auth_ref": { "r740" } } , "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType" , "nsuri": "http://xbrl.sec.gov/ecd/2024" , "localname": "PeoActuallyPaidCompAmt" , "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" } , "lang": { "en-us" } , "role": { "terseLabel" } , "PEO Actually Paid Compensation Amount": { "label": "PEO Actually Paid Compensation Amount" } } } , "auth_ref": { "r732" } } , "ecd_PeoMember": { "xbrltype": "domainItemType" , "nsuri": "http://xbrl.sec.gov/ecd/2024" , "localname": "PeoMember" , "presentation": { "http://xbrl.sec.gov/ecd/2024" , "localname": "PeoMember" , "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" } , "lang": { "en-us" } , "role": { "terseLabel" } , "PEO Member": { "label": "PEO [Member]" } } } , "auth_ref": { "r749" } } , "ecd_PeoName": { "xbrltype": "normalizedStringItemType" , "nsuri": "http://xbrl.sec.gov/ecd/2024" , "localname": "PeoName" , "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" } , "lang": { "en-us" } , "role": { "terseLabel" } , "PEO Name": { "label": "PEO Name" } } } , "auth_ref": { "r742" } } , "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType" , "nsuri": "http://xbrl.sec.gov/ecd/2024" , "localname": "PeoTotalCompAmt" , "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" } , "lang": { "en-us" } , "role": { "terseLabel" } , "PEO Total Compensation Amount": { "label": "PEO Total Compensation Amount" } } } , "auth_ref": { "r731" } } , "us-gaap_PerformanceSharesMember": { "xbrltype": "domainItemType" , "nsuri": "http://fasb.org/us-gaap/2024" , "localname": "PerformanceSharesMember" , "presentation": { "http://www.10xgenomics.com/role/EquityIncentivePlansAdditionalInformationDetails" } , "lang": { "en-us" } , "role": { "terseLabel" } , "Performance Shares [Member]" , "documentation": "Share-based payment arrangement awarded for meeting performance target. } } } , "auth_ref": { "r731" } } , "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType" , "nsuri": "http://fasb.org/us-gaap/2024" , "localname": "PlanNameAxis" , "presentation": { "http://www.10xgenomics.com/role/EquityIncentivePlansAdditionalInformationDetails" } , "lang": { "en-us" } , "role": { "terseLabel" } , "Plan Name [Axis]" , "label": "Plan Name [Axis]" , "documentation": "Information by plan name for share-based payment arrangement. } } } , "auth_ref": { "r852" , "r853" , "r854" , "r855" , "r856" , "r857" , "r858" , "r859" , "r860" , "r861" , "r862" , "r863" , "r864" , "r865" , "r866" , "r867" , "r868" , "r869" , "r870" , "r871" , "r872" , "r873" , "r874" , "r875" , "r876" , "r877" } } , "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType" , "nsuri": "http://fasb.org/us-gaap/2024" , "localname": "PlanNameDomain" , "presentation": { "http://www.10xgenomics.com/role/EquityIncentivePlansAdditionalInformationDetails" } , "lang": { "en-us" } , "role": { "terseLabel" } , "Plan Name [Domain]" , "label": "Plan Name [Domain]" , "documentation": "Plan name for share-based payment arrangement. } } } , "auth_ref": { "r852" , "r853" , "r854" , "r855" , "r856" , "r857" , "r858" , "r859" , "r860" , "r861" , "r862" , "r863" , "r864" , "r865" , "r866" , "r867" , "r868" , "r869" , "r870" , "r871" , "r872" , "r873" , "r874" , "r875" , "r876" , "r877" } } , "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType" , "nsuri": "http://xbrl.sec.gov/ecd/2024" , "localname": "PnsnAdjsPrrSvcCstMember" , "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" } , "lang": { "en-us" } , "role": { "terseLabel" } , "Pension Adjustments Prior Service Cost" , "label": "Pension Adjustments Prior Service Cost [Member]" } } } , "auth_ref": { "r733" } } , "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType" , "nsuri": "http://xbrl.sec.gov/ecd/2024" , "localname": "PnsnAdjsSvcCstMember" , "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" } , "lang": { "en-us" } , "role": { "terseLabel" } , "Pension Adjustments Service Cost" , "label": "Pension Adjustments Service Cost [Member]" } } } , "auth_ref": { "r777" } } , "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType" , "nsuri": "http://xbrl.sec.gov/ecd/2024" , "localname": "PnsnBnftsAdjFnTextBlock" , "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" } , "lang": { "en-us" } , "role": { "terseLabel" } , "Pension Benefits Adjustments, Footnote": { "label": "Pension Benefits Adjustments, Footnote [Text Block]" } } } , "auth_ref": { "r732" } } , "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType" , "nsuri": "http://fasb.org/us-gaap/2024" , "localname": "PreferredStockValue" , "crdr": "credit" , "calculation": { "http://www.10xgenomics.com/role/CondensedConsolidatedBalanceSheets" } , "parentTag": "us-gaap_StockholdersEquity" , "weight": 1.0 , "order": 5.0 } } , "presentation": { "http://www.10xgenomics.com/role/CondensedConsolidatedBalanceSheets" } , "lang": { "en-us" } , "role": { "terseLabel" } , "Preferred Stock, Value, Issued" , "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity. } } } , "auth_ref": { "r60" , "r488" , "r666" } } , "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType" , "nsuri": "http://fasb.org/us-gaap/2024" , "localname": "PrepaidExpenseAndOtherAssetsCurrent" , "crdr": "debit" , "calculation": { "http://www.10xgenomics.com/role/CondensedConsolidatedBalanceSheets" } , "parentTag": "us-gaap_AssetsCurrent" , "weight": 1.0 , "order": 3.0 } } , "presentation": { "http://www.10xgenomics.com/role/CondensedConsolidatedBalanceSheets" } , "lang": { "en-us" } , "role": { "terseLabel" } , "Prepaid expenses and other current assets" , "label": "Prepaid Expense and Other Assets, Current" , "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. } } } , "auth_ref": { "r791" } } , "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": { "xbrltype": "monetaryItemType" , "nsuri": "http://fasb.org/us-gaap/2024" , "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" , "crdr": "debit" , "calculation": { "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsOfCashFlows" } , "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities" , "weight": 1.0 , "order": 2.0 } } , "presentation": { "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsOfCashFlows" } , "lang": { "en-us" } , "role": { "terseLabel" } , "Issuance of common stock from exercise of stock options and employee stock purchase plan purchases" , "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised" , "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised. } } } , "auth_ref": { "r2" , "r14" } } , "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": { "xbrltype": "monetaryItemType" , "nsuri": "http://fasb.org/us-gaap/2024" , "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" , "crdr": "debit" , "calculation": { "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsOfCashFlows" } , "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities" , "weight": 1.0 , "order": 2.0 } } , "presentation": { "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsOfCashFlows" } , "lang": { "en-us" } , "role": { "terseLabel" } , "Proceeds from maturities of marketable securities" , "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available for Sale" , "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale). } } } , "auth_ref": { "r143" , "r144" , "r812" } } , "us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities": { "xbrltype": "monetaryItemType" , "nsuri": "http://fasb.org/us-gaap/2024" , "localname": "ProceedsFromSaleOfHeldToMaturitySecurities" , "crdr": "debit" , "calculation": { "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsOfCashFlows" } , "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities" , "weight": 1.0 , "order": 3.0 } } , "presentation": { "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsOfCashFlows" } , "lang": { "en-us" } , "role": { "terseLabel" } , "Proceeds from sales of marketable securities" , "label": "Proceeds from Sale of Held-to-Maturity Securities" , "documentation": "The cash inflow associated with the sale of securities that had been designated as held-to-maturity. Excludes proceeds from maturities, prepayments and calls by the issuer. } } } , "auth_ref": { "r21" , "r201" } } , "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType" , "nsuri": "http://fasb.org/srt/2024" , "localname": "ProductOrServiceAxis" , "presentation": { "http://www.10xgenomics.com/role/OtherFinancialStatementInformationAdditionalInformationDetails" } , "lang": { "en-us" } , "role": { "terseLabel" } , "Product and Service [Axis]" , "label": "Product and Service [Axis]" } } } , "auth_ref": { "r196" , "r446" , "r503" , "r504" , "r505" , "r506" , "r507" , "r508" , "r509" , "r628" , "r645" , "r676" , "r677" , "r678" , "r680" , "r682" , "r841" , "r842" , "r849" , "r899" , "r901" , "r902" , "r903" , "r904" , "r905" , "r906" , "r907" , "r908" , "r909" , "r910" , "r911" , "r912" , "r913" , "r914" , "r915" , "r916" , "r917" , "r918" , "r919" , "r920" , "r921" , "r922" , "r923" , "r924" , "r925" , "r926" , "r928" , "r929" } } , "us-gaap_ProductWarrantyAccrual": { "xbrltype": "monetaryItemType" , "nsuri": "http://fasb.org/us-gaap/2024" , "localname": "ProductWarrantyAccrual" , "crdr": "credit" , "presentation": { "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleOfChangesInTheReserveForProductWarrantiesDetails" } , "lang": { "en-us" } , "role": { "periodStartLabel": "Beginning of period" , "periodEndLabel": "End of period" , "label": "Standard and Extended Product Warranty Accrual" , "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers. } } } , "auth_ref": { "r100" , "r259" , "r261" , "r264" } } , "us-gaap_ProductWarrantyAccrualClassifiedCurrent": { "xbrltype": "monetaryItemType" , "nsuri": "http://fasb.org/us-gaap/2024" , "localname": "ProductWarrantyAccrualClassifiedCurrent" , "crdr": "credit" , "calculation": { "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleOfAccruedExpenseAndOtherCurrentLiabilitiesDetails" } , "parentTag": "txg_AccruedExpensesAndOtherLiabilitiesCurrent" , "weight": 1.0 , "order": 5.0 } } , "presentation": { "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleOfAccruedExpenseAndOtherCurrentLiabilitiesDetails" } , "lang": { "en-us" } , "role": { "terseLabel": "Product warranties" , "label": "Product Warranty Accrual, Current" , "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers. For classified balance sheets, represents the current portion of the liabilities (due within one year or within the normal operating cycle if longer). } } } , "auth_ref": { "r54" , "r843" , "r844" } } , "us-gaap_ProductWarrantyAccrualPayments": { "xbrltype": "monetaryItemType" , "nsuri": "http://fasb.org/us-gaap/2024" , "localname": "ProductWarrantyAccrualPayments" , "crdr": "debit" , "presentation": { "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleOfChangesInTheReserveForProductWarrantiesDetails" } , "lang": { "en-us" } , "role": { "negatedLabel": "Repairs and replacements" , "label": "Standard and Extended Product Warranty Accrual, Decrease for Payments" , "documentation": "Amount of decrease in the standard and extended product warranty accrual from payments made in cash or in-kind to satisfy claims under the terms of the standard and extended product warranty. } } } , "auth_ref": { "r262" } } , "us-gaap_ProductWarrantyAccrualWarrantiesIssued": { "xbrltype": "monetaryItemType" , "nsuri": "http://fasb.org/us-gaap/2024" , "localname": "ProductWarrantyAccrualWarrantiesIssued" , "crdr": "credit" , "presentation": { "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleOfChangesInTheReserveForProductWarrantiesDetails" } , "lang": { "en-us" } , "role": { "terseLabel": "Amounts charged to cost of revenue" , "label": "Standard and Extended Product Warranty Accrual, Increase for Warranties Issued" , "documentation": "Amount of increase in the standard and extended product warranty accrual from warranties issued. } } } , "auth_ref": { "r263" } } , "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType" , "nsuri": "http://fasb.org/srt/2024" , "localname": "ProductsAndServicesDomain" , "presentation": { "http://www.10xgenomics.com/role/OtherFinancialStatementInformationAdditionalInformationDetails" } , "lang": { "en-us" } , "role": { "terseLabel": "Product and Service [Domain]" , "label": "Product and Service [Domain]" } } } , "auth_ref": { "r196" , "r446" , "r503" , "r504" , "r505" , "r506" , "r507" , "r508" , "r509" , "r628" , "r645" , "r676" , "r677" , "r678" , "r680" , "r841" , "r842" , "r849" , "r899" , "r901" , "r902" , "r903" , "r904" , "r905" , "r906" , "r907" , "r908" , "r909" , "r910" , "r911" , "r912" , "r913" , "r914" , "r915" , "r916" , "r917" , "r918" , "r919" , "r920" , "r921" , "r922" , "r923" , "r924" , "r925" , "r926" , "r928" , "r929" } } , "txg_ProductsAndServicesExcludingGrantRevenueMember": { "xbrltype": "domainItemType" , "nsuri": "http://www.10xgenomics.com/20240630" , "localname": "ProductsAndServicesExcludingGrantRevenueMember" , "presentation": { "http://www.10xgenomics.com/role/OtherFinancialStatementInformationAdditionalInformationDetails" } , "lang": { "en-us" } , "role": { "terseLabel": "Products and Services, Excluding Grant Revenue" , "label": "Products And Services, Excluding Grant Revenue [Member]" , "documentation": "Products And Services, Excluding Grant Revenue" } } } , "auth_ref": { "r8" } } , "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType" , "nsuri": "http://fasb.org/us-gaap/2024" , "localname": "PropertyPlantAndEquipmentByTypeAxis" , "presentation": { "http://www.10xgenomics.com/role/OtherFinancialStatementInformationAdditionalInformationDetails" } , "lang": { "en-us" } , "role": { "terseLabel": "Long-Lived Tangible Asset [Axis]" , "label": "Long-Lived Tangible Asset [Axis]" , "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale. } } } , "auth_ref": { "r8" , "r412" } } , "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType" , "nsuri": "http://fasb.org/us-gaap/2024" , "localname": "PropertyPlantAndEquipmentGross" , "crdr": "debit" , "calculation": { "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleOfPropertyPlantAndEquipmentDetail" } , "parentTag": "us-gaap_PropertyPlantAndEquipmentNet" , "weight": 1.0 , "order": 1.0 } } , "presentation": { "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleOfPropertyPlantAndEquipmentDetail" } , "lang": { "en-us" } , "role": { "verboseLabel": "Total property and equipment" , "label": "Property, Plant and Equipment, Gross" , "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. } } } , "auth_ref": { "r87" , "r119" , "r494" } } , "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType" , "nsuri": "http://fasb.org/us-gaap/2024" , "localname": "PropertyPlantAndEquipmentLineItems" , "presentation": { "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleOfPropertyPlantAndEquipmentDetail" } , "lang": { "en-us" } , "role": { "terseLabel": "Property,

Plant and Equipment [Line Items], "label": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. } }", "auth_ref": "r412", "us-gaap_PropertyPlantAndEquipmentNet", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": "http://www.10xgenomics.com/role/CondensedConsolidatedBalanceSheets", "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0, "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleOfPropertyPlantAndEquipmentDetail": "parentTag": null, "weight": null, "order": null, "root": true, "presentation": "http://www.10xgenomics.com/role/CondensedConsolidatedBalanceSheets", "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleOfPropertyPlantAndEquipmentDetail": "lang": "en-us", "role": "verboseLabel", "Property and equipment, net", "totalLabel": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "auth_ref": "r8", "r412", "r484", "r494", "r666", "us-gaap_PropertyPlantAndEquipmentTextBlock": "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": "http://www.10xgenomics.com/role/OtherFinancialStatementInformationTables", "lang": "en-us", "role": "terseLabel", "Schedule of Property and Equipment, Net", "label": "Property, Plant and Equipment [Table Text Block]", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated depreciation.", "auth_ref": "r8", "us-gaap_PropertyPlantAndEquipmentTypeDomain": "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": "http://www.10xgenomics.com/role/OtherFinancialStatementInformationAdditionalInformationDetails", "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleOfPropertyPlantAndEquipmentDetail": "lang": "en-us", "role": "terseLabel", "Long-Lived Tangible Asset [Domain]", "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "auth_ref": "r87", "r412", "ecd_PvpTable": "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": "en-us", "role": "terseLabel", "Pay vs Performance Disclosure", "label": "Pay vs Performance Disclosure [Table]", "auth_ref": "r730", "ecd_PvpTableTextBlock": "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": "en-us", "role": "terseLabel", "Pay vs Performance Disclosure, Table", "label": "Pay vs Performance [Table Text Block]", "auth_ref": "r730", "srt_RangeAxis": "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": "http://www.10xgenomics.com/role/EquityIncentivePlansAdditionalInformationDetails", "lang": "en-us", "role": "terseLabel", "Statistical Measurement [Axis]", "label": "Statistical Measurement [Axis]", "auth_ref": "r255", "r256", "r257", "r258", "r307", "r314", "r342", "r343", "r344", "r351", "r386", "r420", "r429", "r445", "r510", "r512", "r520", "r542", "r543", "r596", "r598", "r600", "r601", "r603", "r623", "r624", "r639", "r644", "r650", "r658", "r659", "r663", "r664", "r677", "r685", "r836", "r847", "r882", "r892", "r893", "r894", "r895", "r896", "srt_RangeMember": "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": "http://www.10xgenomics.com/role/EquityIncentivePlansAdditionalInformationDetails", "lang": "en-us", "role": "terseLabel", "Statistical Measurement [Domain]", "label": "Statistical Measurement [Domain]", "auth_ref": "r255", "r256", "r257", "r258", "r307", "r314", "r342", "r343", "r344", "r351", "r386", "r420", "r429", "r445", "r510", "r512", "r520", "r542", "r543", "r596", "r598", "r600", "r601", "r603", "r623", "r624", "r639", "r644", "r650", "r658", "r659", "r663", "r664", "r677", "r685", "r836", "r847", "r882", "r892", "r893", "r894", "r895", "r896", "ecd_RecoveryOfErrCompDisclosureLineItems": "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": "en-us", "role": "label", "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]", "auth_ref": "r698", "r708", "r718", "r750", "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost", "crdr": "debit", "calculation": "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsOfOperations", "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0, "presentation": "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsOfOperations", "lang": "en-us", "role": "terseLabel", "Research and development", "label": "Research and Development Expense (Excluding Acquired in Process Cost)", "documentation": "Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.", "auth_ref": "r878", "us-gaap_ResearchAndDevelopmentExpenseMember": "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": "http://www.10xgenomics.com/role/EquityIncentivePlansScheduleOfRecordedStockBasedCompensationExpenseintheCondensedConsolidatedStatementofOperationsDetails", "http://www.10xgenomics.com/role/OtherFinancialStatementInformationAdditionalInformationDetails": "lang": "en-us", "role": "verboseLabel", "Research and development", "terseLabel": "Research and development", "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "auth_ref": "r", "ecd_RestatementDateAxis": "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": "http://xbrl.sec.gov/ecd/role/FrrCompDisclosure", "lang": "en-us", "role": "terseLabel", "Restatement Determination Date", "label": "Restatement Determination Date [Axis]", "auth_ref": "r699", "r709", "r719", "r751", "ecd_RestatementDeterminationDate": "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "lang": "en-us", "role": "terseLabel", "Restatement Determination Date", "label": "Restatement Determination Date", "auth_ref": "r700", "r710", "r720", "r752", "ecd_RestatementDoesNotRequireRecoveryTextBlock": "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": "http://xbrl.sec.gov/ecd/role/FrrCompDisclosure", "lang": "en-us", "role": "terseLabel", "Restatement does not require recovery", "label": "Restatement Does Not Require Recovery [Text Block]", "auth_ref": "r707", "r717", "r727", "r759", "us-gaap_RestrictedStockUnitsRSUMember": "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockUnitsRSUMember", "presentation": "http://www.10xgenomics.com/role/NetLossPerShareSharesofCommonStockEquivalentsWereExcludedFromTheComputationofDilutedNetLossPerShareDetails", "lang": "en-us", "role": "terseLabel", "Restricted stock units", "label": "Restricted Stock Units [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "auth_ref": "r", "us-gaap_RetainedEarningsAccumulatedDeficit": "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": "http://www.10xgenomics.com/role/CondensedConsolidatedBalanceSheets", "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0, "presentation": "http://www.10xgenomics.com/role/CondensedConsolidatedBalanceSheets", "lang": "en-us", "role": "verboseLabel", "Accumulated deficit", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit).", "auth_ref": "r63", "r94", "r491", "r517", "r519", "r526", "r553", "r666", "us-gaap_RetainedEarningsMember": "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsOfStockholdersEquity", "lang": "en-us", "role": "verboseLabel", "Accumulated Deficit", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit).", "auth_ref": "r115", "r154", "r155", "r156", "r158", "r163", "r165", "r167", "r236", "r237", "r249", "r356", "r357", "r359", "r360", "r361", "r363", "r364", "r365", "r370", "r372", "r373", "r375", "r378", "r402", "r403", "r430", "r514", "r516", "r931", "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsOfOperations", "parentTag": "us-gaap_GrossProfit", "weight": 1.0, "order": 1.0, "presentation": "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsOfOperations", "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleOfRevenueByGeographicRegionDetails": "lang": "en-us", "role": "terseLabel", "Revenue", "verboseLabel": "Total revenue", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "auth_ref": "r105", "r106", "r182", "r187", "r188", "r193", "r195", "r196", "r197", "r199", "r303", "r304", "r446", "tqg_RevenueFromContractWithCustomerPaymentPeriod": "xbrltype": "durationItemType", "nsuri": "http://www.10xgenomics.com/20240630", "localname": "RevenueFromContractWithCustomerPaymentPeriod", "presentation": "http://www.10xgenomics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail": "lang": "en-us", "role": "terseLabel", "Revenue recognition payment due period", "label": "Revenue From Contract With Customer, Payment Period", "documentation": "Revenue From Contract With Customer, Payment Period", "auth_ref": "r", "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "presentation": "http://www.10xgenomics.com/role/SummaryofSignificantAccountingPoliciesPolicies", "lang": "en-us", "role": "terseLabel", "Revenue Recognition", "label": "Revenue from Contract with Customer [Policy Text Block]", "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "auth_ref": "r113", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r627", "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "presentation": "http://www.10xgenomics.com/role/OtherFinancialStatementInformationTables", "lang": "en-us", "role": "verboseLabel", "Schedule of Revenue by Geographic Location", "label": "Revenue from External Customers by Geographic Areas [Table Text Block]", "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.", "auth_ref": "r84", "us-gaap_RevenueRemainingPerformanceObligation": "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueRemainingPerformanceObligation", "crdr": "credit", "presentation": "http://www.10xgenomics.com/role/OtherFinancialStatementInformationAdditionalInformationDetails", "lang": "en-us", "role": "verboseLabel", "Transaction price allocated to remaining performance obligations", "label": "Revenue, Remaining Performance Obligation, Amount", "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.", "auth_ref": "r110", "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod": "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1", "presentation": "http://www.10xgenomics.com/role/OtherFinancialStatementInformationAdditionalInformationDetails", "lang": "en-us", "role": "terseLabel", "Expected period of revenue recognition", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period", "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in PnYnMnDnFnMnS format, for example, P1Y5M13D represents reported fact of one year, five months, and thirteen days.", "auth_ref": "r111", "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis", "presentation": "http://www.10xgenomics.com/role/OtherFinancialStatementInformationAdditionalInformationDetails", "lang": "en-us", "role": "terseLabel", "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]", "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in YYYY-MM-DD format.", "auth_ref": "r111", "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems", "presentation": "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleOfRevenueByGeographicRegionDetails", "lang": "en-us", "role": "terseLabel", "Revenues from External Customers and Long-Lived Assets [Line Items]", "label": "Revenues from External Customers and Long-Lived Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "auth_ref": "r", "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": "http://www.10xgenomics.com/role/CondensedConsolidatedStatementsOfCashFlows", "lang": "en-us", "role": "verboseLabel", "Right-of-use assets obtained in exchange for new operating lease liabilities", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "auth_ref": "r408", "r665", "ecd_Lease10b51ArrAdoptedFlag": "xbrltype": "booleanItemType", "nsuri":

"http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": "en-us", "role": "terseLabel", "Rule 10b5-1 Arrangement Adopted", "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "auth_ref": "r768", "ecd_Rule10b51ArrTrmndtFlag": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmndtFlag", "presentation": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": "en-us", "role": "terseLabel", "Rule 10b5-1 Arrangement Terminated", "label": "Rule 10b5-1 Arrangement Terminated [Flag]", "auth_ref": "r768", "txg_ScheduleOfAccruedCompensationandRelatedBenefitsTableTextBlock": "textBlockItemType", "nsuri": "http://www.10xgenomics.com/20240630", "localname": "ScheduleOfAccruedCompensationandRelatedBenefitsTableTextBlock", "presentation": "http://www.10xgenomics.com/role/OtherFinancialStatementInformationTables", "lang": "en-us", "role": "terseLabel", "Schedule of Accrued Compensation and Related Benefits", "label": "Schedule of Accrued Compensation and Related Benefits [Table Text Block]", "documentation": "Schedule of accrued compensation and related benefits", "auth_ref": "txg_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock": "textBlockItemType", "nsuri": "http://www.10xgenomics.com/20240630", "localname": "ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock", "presentation": "http://www.10xgenomics.com/role/OtherFinancialStatementInformationTables", "lang": "en-us", "role": "verboseLabel", "Schedule of Accrued Expense and Other Current Liabilities", "label": "Schedule of Accrued Liabilities and Other Current Liabilities [Table Text Block]", "documentation": "Schedule of accrued liabilities and other current liabilities", "auth_ref": "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": "http://www.10xgenomics.com/role/NetLossPerShareSharesofCommonStockEquivalentsWereExcludedFromTheComputationofDilutedNetLossPerShareDetails", "lang": "en-us", "role": "terseLabel", "Antidilutive Security, Excluded EPS Calculation", "label": "Antidilutive Security, Excluded EPS Calculation [Table]", "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS", "auth_ref": "r28", "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": "http://www.10xgenomics.com/role/NetLossPerShareTables", "lang": "en-us", "role": "terseLabel", "Schedule of Shares of Common Stock Equivalents Excluded from Computation of Diluted Net Loss Per Share", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities", "auth_ref": "r28", "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "presentation": "http://www.10xgenomics.com/role/EquityIncentivePlansScheduleOfRecordedStockBasedCompensationExpenseintheCondensedConsolidatedStatementofOperationsDetails", "lang": "en-us", "role": "terseLabel", "Share-based Payment Arrangement, Expensed and Capitalized, Amount", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements", "auth_ref": "r47", "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable", "presentation": "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleOfRevenueSourceDetails", "lang": "en-us", "role": "terseLabel", "Revenue from External Customers by Products and Services", "label": "Segment Reporting, Revenue from External Customer, Product and Service [Table]", "documentation": "Disclosure of information about revenue from external customer by product and service when not provided as part of reportable operating segment information", "auth_ref": "r34", "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable", "presentation": "http://www.10xgenomics.com/role/OtherFinancialStatementInformationTables", "lang": "en-us", "role": "verboseLabel", "Schedule of Revenue by Source", "label": "Revenue from External Customers by Products and Services [Table Text Block]", "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information", "auth_ref": "r34", "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": "http://www.10xgenomics.com/role/OtherFinancialStatementInformationTables", "lang": "en-us", "role": "terseLabel", "Schedule of Inventory", "label": "Schedule of Inventory, Current [Table Text Block]", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process", "auth_ref": "r17, r67, r68, r69", "us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfProductWarrantyLiabilityTableTextBlock", "presentation": "http://www.10xgenomics.com/role/OtherFinancialStatementInformationTables", "lang": "en-us", "role": "terseLabel", "Schedule of Changes in the Reserve for Product Warranties", "label": "Schedule of Product Warranty Liability [Table Text Block]", "documentation": "Tabular disclosure of the changes in the guarantor's aggregate product warranty liability, including the beginning balance of the aggregate product warranty liability, the aggregate reductions in that liability for payments made (in cash or in kind) under the warranty, the aggregate changes in the liability for accruals related to product warranties issued during the reporting period, the aggregate changes in the liability for accruals related to preexisting warranties (including adjustments related to changes in estimates), and the ending balance of the aggregate product warranty liability", "auth_ref": "r260", "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleOfPropertyPlantAndEquipmentDetail", "lang": "en-us", "role": "terseLabel", "Property, Plant and Equipment", "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated depreciation", "auth_ref": "r8, r412", "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable", "presentation": "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleOfRevenuebyGeographicRegionDetails", "lang": "en-us", "role": "terseLabel", "Schedule of Revenues from External Customers and Long-Lived Assets", "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]", "documentation": "Disclosure of information about revenue from external customer and long-lived asset by geographical area. Long-lived asset excludes financial instrument, customer relationship with financial institution, mortgage and other servicing right, deferred policy acquisition cost, and deferred tax asset", "auth_ref": "r35, r71", "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": "http://www.10xgenomics.com/role/EquityIncentivePlansAdditionalInformationDetails", "http://www.10xgenomics.com/role/EquityIncentivePlansFairValuesOfSharesUnderthePerformanceStockOptionsDetails", "lang": "en-us", "role": "terseLabel", "Schedule of Share-based Compensation Arrangements by Share-based Payment Award", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement", "auth_ref": "r316, r318, r320, r321, r322, r323, r324, r325, r326, r327, r328, r329, r330, r331, r332, r333, r334, r335, r336, r337, r338, r339, r340, r341, r342, r343, r344, r345", "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "presentation": "http://www.10xgenomics.com/role/EquityIncentivePlansTables", "lang": "en-us", "role": "verboseLabel", "Schedule of RSU Activity", "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]", "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year", "auth_ref": "r95", "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": "http://www.10xgenomics.com/role/EquityIncentivePlansTables", "lang": "en-us", "role": "terseLabel", "Schedule of the Company's Stock Option Activity", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value", "auth_ref": "r12, r13, r95", "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": "http://www.10xgenomics.com/role/EquityIncentivePlansTables", "lang": "en-us", "role": "terseLabel", "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions", "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions", "auth_ref": "r96", "us-gaap_ScheduleOfStockByClassTable": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockByClassTable", "presentation": "http://www.10xgenomics.com/role/CapitalStockAdditionalInformationDetail", "lang": "en-us", "role": "terseLabel", "Schedule of Stock by Class", "label": "Stock, Class of Stock [Table]", "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks", "auth_ref": "r39, r40, r41, r42, r43, r44, r90, r92, r93, r94, r124, r125, r126, r184, r277, r278, r279, r281, r284, r289, r291, r522, r523, r524, r525, r644, r779, r798", "us-gaap_ScheduleOfStockByClassTableTextBlock": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockByClassTableTextBlock", "presentation": "http://www.10xgenomics.com/role/CapitalStockTables", "lang": "en-us", "role": "terseLabel", "Schedule of Common Stock Issued and Outstanding", "label": "Schedule of Stock by Class [Table Text Block]", "documentation": "Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid-in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount, dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable therefrom, number of shares authorized, issued, and outstanding", "auth_ref": "r16, r38, r39, r40, r41, r42, r43, r44, r60, r61, r92, r93, r94", "dei_Security12bTitle": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": "http://www.10xgenomics.com/role/CoverPage", "lang": "en-us", "role": "terseLabel", "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security", "auth_ref": "r63", "us-gaap_SecurityDeposit": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SecurityDeposit", "crd": "debit", "presentation": "http://www.10xgenomics.com/role/CommitmentsandContingenciesAdditionalInformationDetail", "lang": "en-us", "role": "terseLabel", "Security deposit", "label": "Security Deposit", "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease", "auth_ref": "r789", "dei_SecurityExchangeName": "securityExchangeNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": "http://www.10xgenomics.com/role/CoverPage", "lang": "en-us", "role": "terseLabel", "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered", "auth_ref": "r695", "srt_SegmentGeographicalDomain": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "SegmentGeographicalDomain", "presentation": "http://www.10xgenomics.com/role/OtherFinancialStatementInformationScheduleOfRevenuebyGeographicRegionDetails", "lang": "en-us", "role": "terseLabel", "Geographical Domain", "label": "Geographical Domain", "auth_ref": "r19, r198, r447, r448, r449, r450, r451, r452, r453, r454, r455, r456, r457, r458, r459, r460, r461, r462, r463, r464, r465, r466, r467, r468, r469, r470, r471, r472, r473, r474, r475, r476, r539, r540, r541, r597, r599, r602, r604, r611, r614, r615, r616, r617, r618, r619, r620, r621, r622, r629, r646, r668, r669, r670, r671, r672,

F&MUPIC59+2FX3RUI>v54@LJQKPSMB.MDY.(005UJE<<MPOH(0))VGWDEEFFE!CS+IS7PZ>U3=I2*FF!Q7-V=X1+Y)UOIQ(ZU.=
M%HL-1FZ.O4SFG6QLP8R6.KRIDE7FA2:R9L///WUKU+LPP48Z(7_M6_G0)71R2%90D)=-&P%>ZM5<-%>W\$7L7M\$SWD_I.O.QYY"KT224S6A.MOEG_X4?>I2
ZL'REIP17U1VU7Y35W1@WB9<v@1%3Z0>ZK<vY!AIGB5Z.MCZ7TEGE45F57%>18Y5%>ZATY752B7Z.M5Y\$B\$ZU?FEMH6-%>Y:LLIC#G(=I_#H-S1B
MX#>9R<>2VERHOG.MO%Q@.5UJ8?B5-ZMYB9VYG\$.@Q(E)R>DX+T20_I9Z?(RI&VIRH0H1.M8E5&#KXDRWHL(8W%)6LFG/AS62GZO.Q0DRB#(L91_8?T(U)O:5K5M<=<
MA6B%+4IK8G1M/PUL.B>PJX5UVZ8HDV7V&LQO>3FE'6>PV=I#7'350 JK_MLTXIH8R%K22#LR_4A)ETIM6-YV*OJZWY1H,ISBPP2X\$XP4X&.#RYI/W%IG_M_%FP-VIANIYEI&
Z13=27Y2G561_6I(C66MGY2_P6=I2VJEM.L1HXL1X7Y).W5K<6%O.MI4RBPM>BD\$S#KNJ04K3U1P8?WCKL1G_U.ME=I'7Z)@=>#Z1#2.E1L253#AKH13C(24)OYV?
9L#0R-B1-KW7#XF#H#9#2_M#8RELO=>.TZ&M/YOXN<>GS2LXKYNF-TVKSM<>SL>TP_ML#Q<022.76<=I_P>.%M#3/U#M#9Y000(=>#XMD+2#L2+4CAO3Z(=)EVE?
M9?>F6W3AE7.W.N%>.G0G85<36W#183.OYD)I&HE@&K'WV113Z9B.9.6<MS_UV@Q403(GM_19H_M)=J5X9>D-D9(N1R<80SXOXW/CX1L#M%#BO-19
M\$5H_16=>.vY+DM(XZM_9V>E\$D18MOP)EIXHO@&&K'WV1P(4Y.A4PQI<=>CU.MI6(GI7Z-EH).M1_>Y.R0G_ND).2=GUH1%#_6.S_4L#X5<O(KAS7I'P>=>05A5<@>0@KL8M/
M*K'S1:UFQDXV/8N1!@9R6U4YP=86-9LD>MGN18U0/1=)O40G<=9%>#0J6_M/2L#08R;LZ=46YVVF<#HS9R@WVFP1<QV&L_I#N1/B.\$227E;&#H1.XWK-PL?
5JG_2@>OQD17<0>S.W9.Y7&_0M'>MN<8%>N1H!@HO#GBHWF'XGP#DIS_2'V7\$3_1-Y12)ZAGC.3E#N'K1'M60 MQ<1A<1=DI54C<8HHWOTN1H#_2NRHN?
(S36<K_XO45=I2?G5Y7X9HO.MU7NSTK1+Z13D2>S&IOHXOB<1+MMVY4A3OPTP2)EAGL_5%4X#IT*RC9YR=C)7AFWC6LPM@R%FLOCHZC MPR9_&
(494+71#>DFZWKZ+65ZV>A4H(9'>1.3%>8DU#11_G5INE\$S<_5'M7.FK8&GH:R_5100F@LZ8Z)KOU71-IYN#IO1#_B2L5_7N#(ID_>M30%NF_M57QX16%Z?P_LB#5U-1)&TQ!
L1B10M(ZLZAMREI(5PM+AKHE=CX579Z32B8_M#>V1QK_M#_+17+P.F4L_7%&#>VFSO=F3L5102?XMR50N1VIE_#N(TM_MX0%O)1=42.ETI00ZLHO7YHMY.
(GDRXHP:FLLE1-ZB@1H-2:54AP_MK6BC)Q"U_UE.%!\$0#_7?RTN6E.M<8\$>QW6Z!\$K)7>_LMLG71Q/L5,F15?3UQG@#>1NMRB_G.L2#B#00J R
M0JHD?>VY#07W+&YSKU_UMB6=>UZ'L5>V5G+&CIZO_<+>+Y0>8A8NOL_MWB\$5_T52'>#8:8B1YB4EE_4W#K1R34_F4_93L13#4Z71M28R!>D67<
MJBZ90U?P#>MT-L_P'Q75H18;HJLME20'5(I#TEBL<IWD2D_G=5<=2>MSHM6G-I.FE'4%>AM_XAM\$M51_6&2I&_NGB.50HQLW+JF1'1%>G)W?>#K'MRP#8M.K=P-
/4:0UV15:6H#5-BBK#MHEA61P1W2_#(HW2K)1M1DC-H#N-W.%FD=8:51@Q245VE_>O1Y2XW_MP>#H(FIAKXA_7?>11HP?JA'N9">#>#P=6V&VU_S3'B875FB20<HRFI
M#BL>#N(6)K(R7ODA_4H1912B<_JD'Y7&Q&#%U1X1L2V1/CB7ER_M7L1M+1Y!A!F7@YH52&SON>RAYM(CMLN52Z>LJA13ZL&H+I&B.D3<C(MJH_PJ#B%G7<?>
UAP)S<8U?>LSA&J:6D17V>JEE'AO:UO&L_PJ5B6..M6.747C<1318<3>Z19ZG:POJ2.G+5:8E\$5'6'U#NCZ9>8IC7Y7Z19KU^N:L_M>IE'DEO16D9R_HJR?
#E.F4VUVEZ@EIOALR_I9X<2E'NJDH4+1KR810_M=E_P>O5%4%>47?>D519RANJP1'>8K1P'09&&_>JZO+1H1'U1J#N<#>QUAZRR<4WIE9I_58N1U?>
+X#F4VU+X#EAGIAGW3M.8'>2@>5ZXTZ5D5_M8_!#82801CIX10U<=2?>#*K7Z0M(O)9D<-19%>CKH6/HROM?IBDFF/#M_MR3>Q<_L_8.5H#1+XUK6&SXN5<1-1-
24&G5%?>F05_4K1SIBMHJ.LB_K6_M4Z1P1&F5?7KR/L1+IN_3LKM5_?>.Z(O.GB.1904W2_UG6Y?G5&V#PM2E\$4'L.MW1_IB@f5_0_MH15EOMT_0_3SW_93&.DZ1-
V+OFAL_HDN'U+M#81L'>N961541P?>MENOS?N3U_7J6G558.7?+1V595+&F1MY_MN080A11=4XFE_1_#E(FM1'1'>M2PWSN/EUT?P4I@9'>G1U(019'71=0Q%'%&
*_FM9#%F/L>f)2:IS_MAS64H^+6PH;G=9@P'U<_!PSVQC-9GHHG?56T5PX8#>#>MYJ?>D1D+31DCXFE)P.M)OXZ.CYLGPF#9#ILZ.V6\$NG..<1?SF<W0+
L31>=>BJZMO_2TU+6_!YJ5HK;MRO1/FUZU'>_YN=O4J07?_I08Z+1FN57L@Y.V7.UL1UD6HX3A33W>E0XGNP_MM#3ZIO=>?_D2+G)>
EJ1+72H1'OR#MNCZDBB56_MHYKPD@4P?5A1LWY31%M_>A_R1W179RG030KZ35E'3+G1=C_KZ6_6GVRTBUKSI7_VFH=YA_25*Q
MW=>313&2/GON#>VON<3'>6%>.IDRTI59<=>7195?WFO@1K17_M48086I_81DH?2V0GHV5_?>Q>G1B?_20HXEG64.U=#\$1#B#MJSF4Q(FQ%>
M(4<3SR\$&_#&#%&#(O#1=6J_#6GT'3KPO59_XM3=U2(>S0H1_H5+G_S3E_N.MIWE1#22V0A4Q'LF#_R#>TY_U2@04TD.D#>K&W_U0K1P.FE(G_IG%0T1_DAI
MRUIAYWISGF<0D'0\$H?D-OB'..!>XN#GJRJE1HBL9HD_IY_C60'+>H0513\$UD_M->YZ8IC5Y(O.U'IRBKD<0?>UC>#XP&MW1CV5+G-Y:6QJP#_40M5C@>T#KBI
MNHW.KG5D1M.MW&I9#613_U6F1&M2?>RVI_12C<#1Q30_JDNW1?4_MAA_09>?>F.8406#>C3LRY3A'X1+&&\$Z'95_?2_NEXBTH7.FEP@>21_JI_#M5<EX7+7%>(S10G
9M1N7-VH1_M3%#J@U'U1C\$S<4A4_5.MJL_?>G.HJSH@LH2_VML9M5D.#CMNEN+>6WZ54AMUC'9>B6#M#/MCCSHY'X(L2P?B2439561SR)<C#F?E2D_M0.MB1@f
=AM1=SSP?TY5%>D7P1N6RM.LK@K+&W/JR1P(5_59;U=DIEY)N2_71RHG_6GR7Y192R&#S7H1_ZICKS@M0U1_H1S80Y51?@_A#P_>B_M4HJPLQ-QP1A9(Q3<9E_HSI>R_P5?I
V5PL4'>#<(>K-R\$7JH.GG9>R14_M3K&2/JR1J9M1=Q)U_EB5U1'>215+BUH0A2Z%>25%Q101.68J<_XJ31_MCKMPE1[BD?>129C9Y?T<_>D48L#G1X87H6IDIN_A.B5580_AG2
M%#H>_JK=>9:VYDOL4RMPGJH.AOGDM\$0+>8\$PU_/>Q19CZ+H1_GET<1X'VEB.YZN_3GV04ORZYDN_?M6_ML=>B+O1M)D+6AJ_Y>#A+TG<X\$YQ)YTBIBDZ?>
<=>D.S1XQG_IWV'>MGZ_26ᤌY%#FM3?>6?>13V_CWHUA0JHU3(765.9%>P_M2Z#V<2%>2H(P_5FXFR06HD<17H1HDTZ9M;X1=IM#>=43&.00U0+HO1.MD(HK#8-N46\$
I9U>>#>E_D1P'W(MQ<4X2&#JY2KW8J1B2#_M2.C_2&Z_M-N_VU\$1U7(KIAB1_>A=IEM55&@SMT5.H=2&*_@<1B45D&#>R-MV&G&1F6'37S;
'HJ&JBRWZ@:U.Y1K60M2HFFZ)X#9'3UWR#*#_WAK'_M_O1>SZ66Q'_B_U'P>WADI+17RWMM'_YQ<2R6&#UM+1102_ZB_D_T\$<1'_M1+CH'N6'2A1I
(9A5\$SRU_1_H1JYX#2P88&@KEFFI(9A'_L@FA'>MY4_3P2R8'_8K1'>#>KEFL1P2R?R'JRN1#80RW'YSIPULY76S%U1D_2H_D#>M1H1'>F&FIE_M1@2H_D<J
IE.Q%7HTUE9>2E#U/>+JW_ZHMFUF\$FPQ?&?@_@_+>#BE.7_MJ&Q'F#0'6VLE8&G7F1F516%>GI=N51?P7C(=V1OXX41UG1#_U#>#*U'T_M7M<#3C.PD23I
OHRVVEW>#:#Y_#1+M52D7Y.ZK1_C1HJH?>F-R_YN_MPK3HPT96&70BA/02C61_M.L15@_M2H5TM_..9%<#7C<#0&L_>B94_M10&(8&R1LY9R&K#W@/D0&4'_=
IC1C2C@!AMG1A_H4<=>TP'44<1.W/L_M1:150C^1/81N.WY1012.OX0.T.S&F'>A'X'PQ1MCM2W1L101L8'>=HMZ<HW<&_&WR1'>?>09G1H'>'F4_62.45PC_BA'Y-E'
MP'_1-1_#S_9032923P<#&#B&0&#>H1D<N<1_UF=>1&8'>#>CD28'_M_>#>5)D(=>VH90B0<_>9F_M_>9ER1=SW72LUDYWYK1.N9'M3Q<_>ATUHTY_UGE?>
M'_#60'44NGA_!>#>G#U_M#A?>GVY_R<=>GIV_PPMK_08Z1(5>8?>NMD(E=0&4_Y%<#>K_0H0B=M_HBM>30I3?B4B?GE_2_TB6
>3>83J5E5>V1H7T_YPP33F?>=>5>O_MK4&WB+8&#>F4+L2%>DY_0VZ1;0U\$%(F1RCB?7UJ1.1%L#(65'RCB:_IM
M#_1%#M#40A14?>7UL18%>4Z3Q51P29>8LZ3Q6V2VWBKRFYKOCG_U_H7<=>3V_MZ?>4A0\$'_518CF'>#10I#1+OM6)1JBN1@2H1Q1_E_FH\$7168(D^W_OW_M<69196D)H
(#V1U61E^>_!>VA#K1W#=>G/12305MJLXGZ1?>2PPB18XMM_M41<=>D;=2UEPDI_1A42INYO0V6'ON?P?T^>P_L/D3J_0KRCZ1FWP#_K
M14)HW.D5H1R#_#U1_D1=OUV@Y0+ZFH1SH1+3P<CZ>X%_PK=>#_M_BG_W0#>H1'W7&65Y1#1<#>XPZ?>VF1(G_>GU@>H1'Y89L<F_!L_PBRUW.M3P<XIT'>CZZ
>2>I_VB@P5T7?616F3B_M_?>C_082D)E=>A#H110G'25Q1KVS_02#779C'K#RR1#>#>2@2&#P4L?Z8J3_MY^LH5H8?7H1GQ_P&G_08-2B6T58R<+>YR9?GWPU1?0P1_NX3AP4
M.O@>47W>#14P91XX_F#H_548)I^KT(HR1^>K.O-B_ZK?Y_!>GL+%YN5M2_MCBW_V_OUGU_VEM54X5L_23_048E15M4V_F2EZ_VS13TBRDN=AM
MV\$5'>V156'4MRF'_0H1_>1K1815#2X6S2_M104H7M=3C'_MDPKR&3#3Y&S(17767G1_1%>ZKV<1%>#GOV.RCGMWH+Z3E1F1+1N_<
MOER3K00V6&LZ82_UO_DSL1YDYK\$?_I9FA01_4&X1C@>_72Y&4<4_T'E_M6L_W_IPN9;JTTZ4<=>O1?JX?Q3J+E=3'<=>1+MSP?70HJ<=>K9IR<1U3S<6-K
M<CHVH1.B13G(6051ZD.OK+AL'>XV>V(O4UE9HD_TALXAA4BP'>(D#>#1'_ME715E681'N701_NN4K#W1W1O@>L<D5B:00GU<AN1.0'1'>2BZ_5@>8=6>^N_MIE1
=29M55<3WU1L'K'PUD_P.O5_VF?>SKUJWFEM=O#(4_'1DZ51E2?>Q'_ME'&#>I^>KR8K6D;PN#W+N&A'0)2>-HXMD15W8M/6Y65MEX#M#_4\$H#>
<>7H(4H08_861#R_>G&S\$50+191\$BMRI84N)JEG)Y(C_LG7+L8_MHHWEOCE&5=69\$3F<_!>F<=>N4>Y9?B4L7+&CGL1+>F0=28IA5.G#1_M0HJ071_Y1-
F<9>_P1X<V9)N1VW08?>7<_>B1W2+H9->9DJJGOM)(&O_M'PZ'8IG<_>GDW>16ZK1Z_6M=MX1_2_D1H)1N1A_X1V1W6#(2_S1R)_M_A\$N1+1'(P'>M2Y1K-
>90W?>P5PE1'5#>v08M1'>M6'2X7X>I&7D3H7V9.F.H=V5U97+>2'>vY12B(C)@CV'81V?>'>R2LZ1Y_V_M#>=>_0P7V1+L\$>PH1L\$>OKVYEX1WQSF35.4QE_KH<10112B-
HU<#>MHE@>#4ZP+182>+>1+V5Y76N&9S&K#K_>EHRH1\$1%>05HTY'461'>YMB_M4+9\$T\$S_0_>M=M:03/70HY@>81L5_02_G4=2_MYYHR/141H1
M'_#E_>G4&#>18'E@>3&68L_L1_#>E61B40_40_>J3F_SHM(Y)Z9=>BUT1_M@CV'4706U_VT1&H1U3U<90HOM05\$E0'>0EL(C@V)1_>+>R6BVI_6<MZ?>36<_>U<0'00X?
PH1L\$>6K(G6S5>KOCIG0Y?%>?<=>WH1PL'E_M\$C(=>Z79D1T<5X'>@XAWFQ_0H5UB75-3'S&L\$R&(E@CV'81(CV'5RS_MX1Z1V_9?
OJFPJPTQAJONK)1B'>Z6MZY?P%>7(RR<PJK_1XBNS%TAND4M6NEYFL1D5V_81V^>HJ=>7TD1R'>P'>17R&BORN)/>T>+>40K'MTCA7'>XIN>D/MD/MH04EJH2FMBZB-
FM1\$>SMHU2GOOXLDJRMAN181?>(4FCB#>1K1XBKMA_MW.M4&E.XCA&3HWAEE&M9Q5B1H_P9<=>9\$M5ONSW17>H>#>OBOK'R<=>MMSL70LHD1Z.LY7502?
L1R)0D2JDC1LFEUYOXB2/BEYVJ5C_M.3C<CZ_MU_V=(M3<=>6X14BE_14MSRZ7XGZARH/00'>0)HAH'Y7BG67_11220_7W1HCW_MB79D=>=>1'27W2)5_>U<0_01)PHEB&
>2>H1HGM611.OM010X>R4S.'A.O.L.ME9U<3FD5Z73N1LZ97H1U0B8\$'_#>5B5M65&SX5V1>15H?1U32VL_MBE5(6=EX&#U7V7_KG\$>A_D1J12\$91'PE?>=>A3Y
HE..8\$>_M1561_YZ.F1N1DM'6.FOOPK@BLA_H1(CU'7'>K'38C30_L1'N.X1WHU3KQ4<=>P18F_LD530'0EL(C@CV<Z>_M3_12Z_EH2YSIDR/X70%\$Y1YNRD=DY
H1L>>YK0D2#>NV531'_J3_M.S>>47NMP<_>1RD)1.LL>>K?_2_3F?2'X?D>136)DH<S>TPW1L_Y1\$>P
M1H1L>>PA<MDP'>7.WH1<K'>K'_D_M.5>#V1&Y97>Z&V#K106V4A76.ZM_XHCOBH1'Z'>M19-9PRB1VVKU#MOS2^IARI'NK5W6VIG;H3B605R1/11_9UX1'3J'F5C7U?>
15MNLX9_2'W=>1PY'2W@>KZCRZ9M71GP_M'P'>4V516W1'1'273W+>B7'>OIN'K#>#>4GX<=>_>6&T<'X'4'>JEPMNF_MXGQPT1'>4R.K<=>7=>59V.M5+>3Z?
#>ANV@1G#N<VGE_H1M1H1HUP60_1M'L1X'Q1<4BVE?>690(MFP5_0&IG>#>R1FBBDK2P2.FA9H1+14LY9V_MF2\$EM7A(UB_E_A&L.VYBM.RY2P.MWC&3M15924?
N:6U.VKP).IM(=>CV_#_M12C<=>+>N1SH1MKG_Z91RO'Z>J1_M\$N'AN'>Z>P1L'F?>5Z'>MOM&#U#H3UH#>N+W%9?78/1X)G_YFVG9+>O_M7<NS'>7>84?>H1B31'5%_Q
7>1+1L>#>PH1L\$>G1/G2U9X'0'E_I_M1_40F1B'G+LDT'3\$>84#>#>G'C'4RGT#_ON?>7WT'2KJ2H_Z1L76D&RG=>=>M26_G_@132J3'>#>A_LH?NMD)11=>#>SU9W2YK<?>
>N>#>@>1FO'59&4&5N7O1+>M&X.W.9.2M>19W0T1U@UDN'T'6L8(112_0RELF15B=>#P'P'=>#4#0R6G_M.N16B'X0B31+J8U1'>Q=1'>FNJ-P10N3V_U5'YMY4K(KY?>
(=>E1X&#>1W_M541C#>@>FZ>YD0L'60H'>Q'>U'>LYL1D=P'>N_X1<21KBE1QKUGL3JN2P3_3(M.PP2_30NP_230&F_R_L&VU1_R1L_V_Z021PYK6@_#>1'4>?>6PR'>1'>G_9M1
G'_S#A77L6G-X3<N1OG'TSS'>2'>9U1'>835D10D8P@#8_M_@1V?J1'0_I\$C_B_M_@>2-3(G1Z'_#>MD1T_29&G_SW'>L'6_MU4R1+19C_H0YABXCU21G_9L1)1LX<
>3_3H1D/2\$>XOJ371H.OP>C.M2B0C)G5)AUN_V_G3<=>#>Z2&#>1&3@P5LR_71H91#18ZK.F#19B5E6>1'>4<=>6XAGQ95FX7>5T_U=>MCG#7\$G7B?>?
1YV<#>7WFY<1)G4Y_0%>2_610W1#>_0J1'>2'>+>H=1'>F_M@_71818VF'GT/G+>1'>6PH1_GOH?>RNV'>@P7F1'0NP15'>U1_66J3G5V1+>MOQO'>L'E=Z_N1_26VE?
1Y7E_ZW_1715;6519+P&W9RHMU@1H1#>Z_>=>E'>H57JH'E'>0Y&4'>J1'>GUFJ9_CV_HSV1XK&#S0HN#>5_M1X<1_RU)Y0A_V_>U5U1HRZT?E(G_6D<#>AN\$KUNBGRO#>+>
>XN_M#_7R_9#>C1581R1@>PW;@LG55P0A'>XN1_3%>E'>P'DMV@V1O)ZM_P_MDKQ1W1'>G_C_4HW=>N7Z1'27_>#>+>MNYD866'>VJN4OC'>#>E_M1(0V?>Z#8&K#>L1N3?
H<8'A_LQ_33L)SH#YV16141XID2FV_WACH1<#>1_VN1.P48_@>A=E_U'>5(GOG_E_MME;4_@>#>NLAN1_0531'=>(U5P27VD.V1'>MFK2\$>OYN1N&U104?>=>O1321UE1H6H18<=>
MR#%>DK6=>8L#_>BD@>AS3W>3P>2ALNR10?5T79D_FE_TK0=QK#>6YW_UYEZ_C_GZ_VF?>38AS1Z1T+\$_4B_M<PDI_G13C_H7#1X7-07=PX5BN:2F5M_6'>C\$>E1_M1H1UW>
G/G>@>6XQO_62NZF<0_83-NW#>V7FOK'KBO1N'OBX(MWZ#_M1+M4:5V61_M1K_L1'>4TN1@T93Q15&G4_YOS<=>PP#K_4H1_U'>ET@>8R_S4_MRY5<=>ICFZ+1?
Z'>1L_1Z8BEASZ<0_WGD2=1_10_W6#>V179+1_K_H'>RGK1X:5<21BY1USY_M1+Y_>E'>Z'>H05:06Y<4'>HSPY4_N16Z15R9RR1T1_>E0_W#>K<=>3F>V_T\$1
M342MXXM_Z_RRI#>+>WG0?>VY05?>J_K_Z6T_M6%2VH'J&K&1'>Q10WB40_L1_M#>=4C'>1?>K'>G'>UO(M)FEHD_L1)O_M#>E840S1'>OO'>=>#>EMZ5>D(4Z_>M2R<@>192V41_%>
'>SU_7WUX.F?>=>1\$1Y4_E2SD5\$>CR_50H'>U576<VX_M1QW1L16@_T1'>F#>K'>HWANU'>E&R'>W61'>L'>S'>IRB)SIZCV11H6&#KMW'>N_1HNV1K1'>#>M?>Z1=K#>M1W1U
'>B0XASK5_C<6_#>2X1%>69X?>70Z&RS38K<3M'>YMB<Y_U.FUL_3E.N%>0(C'11_MB7CRAIS<=>J&#>H&5L_UB2HWP0D1>L_>X\$>X'>Y9E'>K1H3P'>X&_A18_VW&C_M9-S>=>
ALRZ01VYPP_0T2_>8@K_L(D3G'G'OF94+DS_JZ'>#>W'>F'>5'>T_M24T_M#>D<=>#>H_61'>K'>#>M6CK8<=>+>B+W%0825+LEB1_51-B'>B'>H'>H'>KCC+0_3'
MX#P5)>75N1M(6@5+0S1Y1=IS>P\$>=>#>K%>E&X+DP-M_70X1E70_3_M_04XKX&Z51MBJG&8A1'S2'>O<5VN=>=>X?S2_0G14L\$>S9FTC1@>D@>1_M'OOQY>A@>L(513&R1
ML1K'241'>O'D'>6:QLL_4M'HEC@>(L'>PV'>L2%>N1587<=>#>09K4L_D#>1HJ0@>H.O.P'>X1L_N#>M1G1_1<75)
M#>B18'>LGH?>YXS@>OHUUG&NOW_9#>H1E1W8'>N'>D'>L'>N'>W'>=>NBYO1J'>MISE'>XNBT61D_1#>=>1V?61'>14Y2_V1L1H1H8D8.F'6'>#>D70AWAP_N9<M#>71_Z1'>3N>#>SW1M?>
Y#D.MUE<=>L_>IMSUY%>#>Q2DYC_QL<_>GYN<X3A&L14\$>GMF'>OX&6%>5%>6%>#>P>MP>P%>FHB7AHL'GP%>4BA48_22L1P?>=>1'>TQ2'>6168H1'12V14B&M'>61R_XM2#>5JAH5
>6Z(SO'>FNK'>T_>GL1+4)8K'8?>T1_0V1'>N@1621_ML1H7M7MRP%112U7F4VR+OTF+1'>BES02_?EPIZ<@>BFGSI&#>Z0_YZ'>F1U'>55<=>M7&AL'12V14B&M'>61R_XM2#>5JAH5
>#>8)D5_D'>1'>XHY71R;JPL_M12<01PV_1ME=5RM=90Y+>@>9S_E2@365(MWH=>2BO_G_OOK;J1-D.9&#>M@03LMMCEM19&<=>25_WH120H;1Z)08K(NB.YTG@>G9
I_ZR6K615XW17Y_M1IM<11X@>@>#>Y&L_FQ040>#>5%>AV14R5%>#>Y6#K_080Y%>#>1QH1+17L2ZU_M8C8L'>@>K1'>@>9C%>7D_2BG5V_M1Z1'>?>=>_Z1WB:V1YQX_U.M@%118_U.LZ1
M4ALE5=>@>1_RML_10'GE3'>2X71G'>7#>M1'S(RV1Y_0R&H_HK&#>8YU'0'_M#>N#>B&K&#>E&D77_X1W38K&L.GW_2'82\$>#>1'>Z'>P18A@P1<=>Z>=03\$
M6TEN0\$>C.OHAG619W36@>PYLDB7R)J'>Q.E.95=>=>#>3\$>OKO1_U(6&X'>M_C1V46179GTJX<#>#>M1H4661Y1M1X<5=Z1AE0C&#>X_1K69N@GWH1
M1B@>#>SLO_>71@>=>#>H#>S+>8TV5'>#>+>BC_DV4?>21CX&#>8L49F'_M1_WH1(KK&#>=73E'_>G-U<C@>17E'>ZVX_EH'L491=>F'>C'>M'>MP81'>5XUUR1VC0N2'_8W5?
'>A_SBL>D_#>7H?><<>>931_M1H03'>Y'>C_DN4?>1M\$>T'>P_U'>V'>T'>Q'>Y'D&PDS'A'>#>8&#>YSO_@>#>42_M3'>7C7E(GE.91KXF1_VV05_0EBV#R3G
HT&VOYAAALE&L_VL_CQF1C4R<_M_595G100A'>#>GEN+>D\$32FX69ER%_9WHL<=>62?>2_MWNW1GZA0>L_KTW_NF1'>@>G7X1Q>Y%>68R'>H1U_1O&KX4U8N_M@_A)^(=98
1)02IE7HX@>G7V1Y1G#_#>7H1_00BZ7P0A'_M'BK'L'>#>1_M6G1'>1'>#>=>S2G(OUK'>SVIHE1_1_HFRG@>LZ_7_M1_0C'>P1Q1'>G1N'>G'>H5_M0410P'>#>2.6E<=>7D?>#>J6?>
RLL_HAD6V_23K0%>0_U#>34F#

M^N9%SQGN6MK-UJ3P^&JVA4F5/VERH8H5%7%/MV2IV7%<XZE5GG9GF8-KY^KMX;^%A2IN,Y>PM-6G7 M4S=>P(QO=L&5J;AAM.Z06DZ&M^JVO19;DN&IG60FM-
^DY7X<6M M4=-0WSIQI/1BJV^>MB;C2V-4B13C2527%99HA;F6K#21>VVA+O1/1MCOO:IG657%K=9-2^E-0^TVD-LJ.8Z5&F8VX3H3GM9=>^@SG;MSCR14D&M=0H.0\$YQ:
2=H M7L3H+?1H0Y5N2PX%<=>F1Z2N5;J.W.DJ3Y<5GG6O0>4A^GHUNIF<6>17XQ0.7+1^#ST&S0QHK&A MPWA+&90 JV4-
4+VY2P>1.AWO.VW+>D<4=>Y=>F1Z2N5;J.W.DJ3Y<5GG6O0>4A^GHUNIF<6>17XQ0.7+1^#ST&S0QHK&A MPWA+&90 JV4-
JE5M&BJC+6JZ+>YINM%>.\$VX^MX^&D\$S^"B2",B^6KY73 MYGA6GI0C+%EEHKGM5517F04=JE.NJ.C%7IAR5JBL^O6JIB(P8M9\$>OKB1
M^J)>SH96/S30^HAP=AINN.F@HQU&L.C.M^V4W#4E1W=FZK9 W3F M6#(D<1^>D^HOKM^7QZ>P^YSZ P L%5IZL@PPU8-6I@P M^MX TLU+H;JHM+M(EE@Z5I
1MW75M64B9^GA5 J2P61J5A5Y08 L^LKI M6)OPVJ.BGQ4SD.1J25B6=5IPO^YR^DHBKMBRO(4 ED)=@D2CM692EWL.PfZ%>MXY>+H16=>+1RX2IZE^7KBKIZ R6^@K008?
LEB2L^AWIZUNSI>?>P@VY^ML@S.MWZ:BC#7L54Z80V%WKW%ISE^ISA^+WYGPPEM&6TR@<3T J^3YXO M&S2.01J3^JNYG0U=>B=OG+L25 (BL^I16#D:Y7UE1
Y9B0%=>W&K1Q395>MPX^S18>@<I<8 J.VY:1YH1N^TRO+&B LK51PTX^R^S^N1N9E^&293?> MDAE^XK Y^X^4#17-5R15Z1NL%5+<3WV/HDVY13+ZW^U9GL>.EV T
M12UGVY42HD^<9N7J.75>1>UP1.5:SS9EU5-%2J...14UQ+L^46T6Y3.MS1^S#1U^5Z5AB%COU0DR<68U=NNY5YMDI^KGDRDK5T.U M1BF^G^9:

"E"(MDX0S)& <^<^/T7ZD?&8-ZO2VIC=P9(f.5.[OS>1.7\$10P04

E T>=M2^*YDK0^RVFO^I5=(JM)A3O?@SMD/PIDX#M:IP+?@)EN^8Z4<5.U5HOG(C^K.5^WZS.JSFAG>7YV^14D6G^FA8I%>M@^\$B^T&0182)H^W^#KRONMLL\$+11
BB^5WH54X<^5G-1%ZNYV^71T&M.YXKH 04W="M^1-9531UJHOZ54EEP-^K^TVG18L"3(54.HVPC^C^BO M9MW^U=I^IBH.LZSHU>^<SBNWO^T^YZA-Z^BEQQ^5%
(B0DC X^B.51ECC M1.71\$E(OI^I^WEP35&JZ8.W6^C^YI/L9<8^PX3 JZY040W7HOR&VILV- M^Y50^>@RH:12V9G^HINLA.RP6%552Y^11<S&L 0^
M^M^&@A^1.TZT.575.%A6E720R+3L:HH5PME9T8Z=>+IFE8N2D^?JW3Z& MWM W45Y.HHX3J>K+J.5+2PF?&P2^G^T^I^*1.ZI.F6^K:1AFZC2H
M=M..2R=VJW^11^>^#QJPHC7715>+>FUI.6:1^YB6CB%U^G^>.*3 M^E%&U:U5HUZL5(67Z6CCF7H5103C^>0@.1H6G1>U76FE^4CVQ027Z
M1PU^U^>A7ED)4L4H^%ZYR YI^<J>5V>A\$N8<3^?FY 00K7J.R M.IGBI&AS^N3Z=JWJ^C15=">CJ^9-1-16^<4^<V^<U(UD)0EQ^?19V7QH M3SIN?
J I(T3.6^21G+M1E)1MGLF^3^X5^161+V.E.6W.^3^YX^G.&ZV5D+E.TG.M10L\$Z4Z^4.1L:1/1%2160?1.7N8JH^<=>NMX8T.0BR066JH0F=1D+M5.T+V2PB06X&=5-
F(T75M&5.9FN3BHLZBZD.8YD8165GZV:(C1J MIB^T^L=>U\$KTFD(K34 9I^G<+RU N6&^0Y^FP90Z7G190^S=6^W)C M2^@8433UHY2Z^Z%>H.THKK6:3 W@BI=Z@55;1#*81?
M^A1<^#HUMQ03MZL^>X>TORA.NOG^<O>9^R^HJIMX^<F.H^I^P^F^@T7J.H.MI^<F^Y266EAWK?R&=>@3Y633WVU7+2MDK8U^0^6I&ATBE.L^FZ1^U^00
M^TXL4Y=1PO^9\$W0^0^N5^3P2I6@L4G_X1H^H^M1^MXYA^XIS^RWP^0>IHX<I^Q>PPR?P^44)JL^P1S6^X(LHCBBN?L.L.M^=VL MWHQIZC5I^C^+A^+L\$D7@.JOYZ
9#LH^T6050^1YX-LS6>O9S.5ZY>L M3^&9.S.T<8L1.LO.A0A^&H-1J3.HH4A<I^>17:1XOP5W5&S^7.LMU^MG.5AC.FM^UO.G1^E^Z.O+^A^<S^X-IG^X9XH^1)@5^Y8A:7
^XH<6H(0VE M8Z).E.L.Z^G^<^>.G15M8T^CRM M MXI7U>P^#K(P<^%65KU 2LD59LITOM5C ZB^BHH(Q-QC^*16131>1>1^<X MNY=%4OUST3LVIG^%H0F?
T(G0F1GL440V(=+>)>XGB7.1\$7B0+M1550L M2^?RYUJ/L=>U\$KTFD(K34 9I^G<+RU N6&^0Y^FP90Z7G190^S=6^W)C M2^@8433UHY2Z^Z%>H.THKK6:3 W@BI=Z@55;1#*81?
ZTQX01H4@C27W@BHM^M+P&F&J.NM\$E=(HEI.EZ&IYE10=ONABI9^2M^X1P.9YL3Q>NGZ4O=>F^M8P2>7YVDI+U(B@96W115<L^S&&K^<K^%L7G14E5^E18^J)=VHHHJ^4726J
M^>HDX&C8I1;SXMCBJKA-50033#^N7C-6&A.1#4=28R@%#>OJ^1^%CM^MW=WI31.R52&#&@PO3N.T.T&ZILGT/4HH^I4CPE&S10UJZO-VNY8V1V
M^1=N+MS="W.2W1UUKD>L>PE.F.L^>O^&N^G^I^FDJ^MOC^9^>1^>JENE>DHU<1>?>J3#^CPO^?>9W^1JH5P88^%NR&@>10166U
MVN<8Z^YAAU^U01^%HOA5+000H^<CIZGAI^2^R8K6CMXIV1V5W^VOT3O MM^M^<C^UETFKGG^<C^YLN^P^=">9XNK^G0>2VUBCZUW8HWU^LMGN^CF^?2 M^2)NS@U7
U^0C8HUR&F^C0975510^02B^1S.G<L^7#S H^Y^0@OR^?>(<8 ME7X^P^T^O>=>D^WZ1^TEL(720^R^A.U.W^S)SUG^M25M(UHV1=39N;GJHN.M9R.W^X(Y>F^3
^R4R^1+9Z0)7XIR^1A2D.O^<SME9OQLR.M^WKO?Z0EWWK3;D0\$#PU)76HJP.(9J;O6<Z^R^W)5J+5I<^26W&2^0Z M^M^M400.O.DUK&M^?>
W\$QV^C^QVW^M.ZIS=6X8AJJ.Y5L^91H<RDM1^M^9@>J7T3E0722+XTFD(1=9LWR&>=JUN-5H G=1=L^N.29;1^%FN^<N^=759\$=>S5R^>6E.P-A^VN+&B76)DQ5+
MFBH8QVJW^>Z02IUB>?DKIF39&>L9L^1^<H8V0.ZOX(MUF M(HTR47KBAE)E&BJSRLJ=JW^N^H%>FZ^N&Y^=>00Y0<2.B^3U2GA6^>MNX2LN^202IPFB85\$1@S/?
N9Y>7-8IKFM(E^>5-1>R^%>W^D^1.2CW^T=1018^R50@P7.M6)KIKH2)WAK9XP>3R13(G^O)3PE1J^U^>UDT^O&8P^>7^P@14HBYG^C^>W^1.6^U7@/MH1
M1W6.D=>51H.L.6J&Z(BG^?/1>R^>7@>D>H>YSYP7E^&F^RYO.N^<FR>1D^?>2.KV5 MVF770=6-14+>R^2D1UUC7WR^1E)51%15/>^O1Q 1^>F^#1^#862 M^<6^&C1XR
1^>1^>E.2^>#1C1)G11)9^H^V^W^D^M^H^L^G^I^>4AX^KD^S^F^D^1)J^I^Y^L^&F^R^G^P^Q^Y^K^<Q.A^+A^8.%EX<S^<+M^QJMF^H^X^%IKAC^>
(2^?E.2^>#1P2=>#1C1)G11)9^H^V^W^D^M^H^L^G^I^>4AX^KD^S^F^D^1)J^I^Y^L^&F^R^G^P^Q^Y^K^<Q.A^+A^8.%EX<S^<+M^QJMF^H^X^%IKAC^>
M^>HDX&C8I1;SXMCBJKA-50033#^N7C-6&A.1#4=28R@%#>OJ^1^%CM^MW=WI31.R52&#&@PO3N.T.T&ZILGT/4HH^I4CPE&S10UJZO-VNY8V1V
M^1=N+MS="W.2W1UUKD>L>PE.F.L^>O^&N^G^I^FDJ^MOC^9^>1^>JENE>DHU<1>?>J3#^CPO^?>9W^1JH5P88^%NR&@>10166U
MVN<8Z^YAAU^U01^%HOA5+000H^<CIZGAI^2^R8K6CMXIV1V5W^VOT3O MM^M^<C^UETFKGG^<C^YLN^P^=">9XNK^G0>2VUBCZUW8HWU^LMGN^CF^?2 M^2)NS@U7
U^0C8HUR&F^C0975510^02B^1S.G<L^7#S H^Y^0@OR^?>(<8 ME7X^P^T^O>=>D^WZ1^TEL(720^R^A.U.W^S)SUG^M25M(UHV1=39N;GJHN.M9R.W^X(Y>F^3
^R4R^1+9Z0)7XIR^1A2D.O^<SME9OQLR.M^WKO?Z0EWWK3;D0\$#PU)76HJP.(9J;O6<Z^R^W)5J+5I<^26W&2^0Z M^M^M400.O.DUK&M^?>
W\$QV^C^QVW^M.ZIS=6X8AJJ.Y5L^91H<RDM1^M^9@>J7T3E0722+XTFD(1=9LWR&>=JUN-5H G=1=L^N.29;1^%FN^<N^=759\$=>S5R^>6E.P-A^VN+&B76)DQ5+
MFBH8QVJW^>Z02IUB>?DKIF39&>L9L^1^<H8V0.ZOX(MUF M(HTR47KBAE)E&BJSRLJ=JW^N^H%>FZ^N&Y^=>00Y0<2.B^3U2GA6^>MNX2LN^202IPFB85\$1@S/?
N9Y>7-8IKFM(E^>5-1>R^%>W^D^1.2CW^T=1018^R50@P7.M6)KIKH2)WAK9XP>3R13(G^O)3PE1J^U^>UDT^O&8P^>7^P@14HBYG^C^>W^1.6^U7@/MH1
M1W6.D=>51H.L.6J&Z(BG^?/1>R^>7@>D>H>YSYP7E^&F^RYO.N^<FR>1D^?>2.KV5 MVF770=6-14+>R^2D1UUC7WR^1E)51%15/>^O1Q 1^>F^#1^#862 M^<6^&C1XR
1^>1^>E.2^>#1C1)G11)9^H^V^W^D^M^H^L^G^I^>4AX^KD^S^F^D^1)J^I^Y^L^&F^R^G^P^Q^Y^K^<Q.A^+A^8.%EX<S^<+M^QJMF^H^X^%IKAC^>
(2^?E.2^>#1P2=>#1C1)G11)9^H^V^W^D^M^H^L^G^I^>4AX^KD^S^F^D^1)J^I^Y^L^&F^R^G^P^Q^Y^K^<Q.A^+A^8.%EX<S^<+M^QJMF^H^X^%IKAC^>

(IG5+4HL)WIA2&(W0R5K(38N^#4BR@+LB M.54810V^ADY.V22G7OPN^P.U0IBFHY.OC03Q^J.&1.FGHG-/P;<\$^>RB MXN/0.X)>_XIS.(G:P9169U?+>WXAS^*8RR0?
FX6.ZD&).Y#V@?..M51/597CF=>@G+1@RY.IPZPM410+52@..70^F&:UYP7TCMV1>WB9R95&S ME2MS.BIUVS.<YVW0.N^70B.T>TVB6A&KDS^BFC MM0L4IV3<1
<=>I531VW2CUW^YX@IG69J^<=>2^FV0.(02DNR).E1GB M^C^G^HMBABE1D.VL193<L^>2U M^CZ7^<UMXW7.7#>G71V.976X2^ORR1E2395MXLOKUBJ^&7%U>N
I%<G^#AB M^>X^Y21J(HVMV^#PK8^NB^>I^F^GX^Z^>M^X^Y^>YX^C4^21% M2^<=>57CLB^#LH1B.UJ1VHVN.U^<OYVWVW^>NRH44TIVZL@OU<M+>OU79)N#IWK3.G
M^ZPU.G@U0GPH48^+61@L.L.QXFEM.G&S^<U^P^H^L^X^L^>(<9^01269.M^NU^&S^>49X&S^P0^P&S^>NWV5>GID 1Q1Q5=0>+S0S94GL@IA^MVL1+9T^7
M2OU.S@7T.H.U^H5-398N6.PIX9Z19=1T<S(OO.U^<O^L3^>2^>N^N4^#M^S^<O^>10DY^>PHW80^2T+6V7F7)=@U.W5VN;818YTL^HFEF7?>66W>14L(V^M+0 R.R6NR6
M^ME-IC^<X23B2AL^H M9.18L^#80^H^S^IN^>OMOO^<NK^<@^>151>7NWJ=JL^L^L^4 MC5^4^L^L^6HGX1.16%&S.2B6H1V4ZVXGD^M^K&X^P^>4WJF6^>O M1L^<^>BGLF
FD726JH(O)ZL^2L0GS@1516TK3^?9E2T(62.F.A^T^R^<J^>M^F^X^W^7E^G^V^C^L^>.>93X<WGPL^3#D1@ZV9Z1AOV^C^L^Z^T^U3Y)Z&S^<M^>U^<X^Z^L^U^>P^M^X^>3S^>6FFHM^>
<@>DQ^<S^>=>7H^<N^>=>V^<H^M^#NEZ.M^KMH((J^>M^F^Z^>1>=>57.8R^9L^H^HAHL^R^P^A^>S^>I^M^O^>PV61^>AZP^>X^>)<M^>(M^H^E^L^>Y^>S^>O^>B^>A^>
9GL@T^WYVBDIGS<42^E^F193219Z2=>T M2^A1<538H(9)9UW^Z^X^Y^N3^?>W1^L^C^I^>E^X^>9E^R^J^UAC HENTEZL M^<FIB+I\$>BZ\$)Q>>#4Q^#&9DBQS;RR^P2-
3^>E0^E^>BZ^>+T^Z^5^I^R^W^L^M^K36&G?>N^>L^>176>2.5(KH=B=2/P^>2^>S^>+>#14L(PA^>R^I^>#>=>9M^M^>1^>L6@13CE
G1Y^>FN^>010P^>@HP0EL^6847PG^>OJ^>5^>1^>P^>6C^>5Y26E.MDH^<I^>F9?>H^>0%>=>#14L(PA^>R^I^>#>=>9M^M^>1^>L6@13CE
BA7^>M^>#27MA^>@NZS1&142KH5>U3TR1/1>1^>2M^>ZM^>O.M^>A^>V^>L^>3^>M^>S^>M^>K^>I^>P^>E^>2^>#A^>A^>F^>V^>X^>O^>A^>2^>N^>A^>C^>N^>S1U9L^>M6^>1^>DH<3>G^>HHI^>D=>A>7^>1^>#>N4PR.Y
OQ/1H^>#52AUL(OH^>M^>F^>#2R5>WYX38PFE^>ZD^>=2^>7^>BL<=>5P15.83%G ERY(F^>4\$W).A3I&MGT^>R^>+>1^>L^>7L0.M^<?>510V45+Z6+1^>#N^>#1H\$G^>ZM^>H^>E.M.O.(E\$^>G^>IT3Z
72444Q^>SP)1&F0GPP^>XUAB6<=>D^>H^>U^>N^>J^>B^>F^>003 M^>H^>M^>C^>M^>O.#>H^>L^>T^>4Q<=>7^>HEN^>N^>O^>Q^>@>N^>N^>V^>N^>=>(9^>V^>)>K^>C^>3B0ZRU1 MRR+>S^>C^>(I&R=B^>D^>
B4R1E9D0X4&00%64W&W^>#>AOC3P^>T^>U3M.J0^>#1^>PM M2.BX^>#0.92ZV1%GOJ<

(IG5+4HL)WIA2&(W0R5K(38N^#4BR@+LB M.54810V^ADY.V22G7OPN^P.U0IBFHY.OC03Q^J.&1.FGHG-/P;<\$^>RB MXN/0.X)>_XIS.(G:P9169U?+>WXAS^*8RR0?
FX6.ZD&).Y#V@?..M51/597CF=>@G+1@RY.IPZPM410+52@..70^F&:UYP7TCMV1>WB9R95&S ME2MS.BIUVS.<YVW0.N^70B.T>TVB6A&KDS^BFC MM0L4IV3<1
<=>I531VW2CUW^YX@IG69J^<=>2^FV0.(02DNR).E1GB M^C^G^HMBABE1D.VL193<L^>2U M^CZ7^<UMXW7.7#>G71V.976X2^ORR1E2395MXLOKUBJ^&7%U>N
I%<G^#AB M^>X^Y21J(HVMV^#PK8^NB^>I^F^GX^Z^>M^X^Y^>YX^C4^21% M2^<=>57CLB^#LH1B.UJ1VHVN.U^<OYVWVW^>NRH44TIVZL@OU<M+>OU79)N#IWK3.G
M^ZPU.G@U0GPH48^+61@L.L.QXFEM.G&S^<U^P^H^L^X^L^>(<9^01269.M^NU^&S^>49X&S^P0^P&S^>NWV5>GID 1Q1Q5=0>+S0S94GL@IA^MVL1+9T^7
M2OU.S@7T.H.U^H5-398N6.PIX9Z19=1T<S(OO.U^<O^L3^>2^>N^>N^>4^#M^>S^>O^>10DY^>PHW80^2T+6V7F7)=@U.W5VN;818YTL^HFEF7?>66W>14L(V^M+0 R.R6NR6
M^ME-IC^<X23B2AL^H M9.18L^#80^H^S^IN^>OMOO^<NK^<@^>151>7NWJ=JL^L^L^4 MC5^4^L^L^6HGX1.16%&S.2B6H1V4ZVXGD^M^K&X^P^>4WJF6^>O M1L^<^>BGLF
FD726JH(O)ZL^2L0GS@1516TK3^?9E2T(62.F.A^T^R^<J^>M^F^X^W^7E^G^V^C^L^>.>93X<WGPL^3#D1@ZV9Z1AOV^C^L^Z^T^U3Y)Z&S^<M^>U^<X^Z^L^U^>P^M^X^>3S^>6FFHM^>
<@>DQ^<S^>=>7H^<N^>=>V^<H^M^#NEZ.M^KMH((J^>M^F^Z^>1>=>57.8R^9L^H^HAHL^R^P^A^>S^>I^M^O^>PV61^>AZP^>X^>)<M^>(M^H^E^L^>Y^>S^>O^>B^>A^>
9GL@T^WYVBDIGS<42^E^F193219Z2=>T M2^A1<538H(9)9UW^Z^X^Y^N3^?>W1^L^C^I^>E^X^>9E^R^J^UAC HENTEZL M^<FIB+I\$>BZ\$)Q>>#4Q^#&9DBQS;RR^P2-
3^>E0^E^>BZ^>+T^Z^5^I^R^W^L^M^K36&G?>N^>L^>176>2.5(KH=B=2/P^>2^>S^>+>#14L(PA^>R^I^>#^>=>9M^M^>1^>L6@13CE
G1Y^>FN^>010P^>@HP0EL^6847PG^>OJ^>5^>1^>P^>6C^>5Y26E.MDH^<I^>F9?>H^>0%>=>#14L(PA^>R^I^>#^>=>9M^M^>1^>L6@13CE
BA7^>M^>#27MA^>@NZS1&142KH5>U3TR1/1>1^>2M^>ZM^>O.M^>A^>V^>L^>3^>M^>S^>M^>K^>I^>P^>E^>2^>#A^>A^>F^>V^>X^>O^>A^>2^>N^>A^>C^>N^>S1U9L^>M6^>1^>DH<3>G^>HHI^>D=>A>7^>1^>#>N4PR.Y
OQ/1H^>#52AUL(OH^>M^>F^>#2R5>WYX38PFE^>ZD^>=2^>7^>BL<=>5P15.83%G ERY(F^>4\$W).A3I&MGT^>R^>+>1^>L^>7L0.M^<?>510V45+Z6+1^>#N^>#1H\$G^>ZM^>H^>E.M.O.(E\$^>G^>IT3Z
72444Q^>SP)1&F0GPP^>XUAB6<=>D^>H^>U^>N^>J^>B^>F^>003 M^>H^>M^>C^>M^>O.#>H^>L^>T^>4Q<=>7^>HEN^>N^>O^>Q^>@>N^>N^>V^>N^>=>(9^>V^>)>K^>C^>3B0ZRU1 MRR+>S^>C^>(I&R=B^>D^>

M2X5(KWFJ5...>+H8'E/MJ=\$EYH4PN*AB*UCDMFH:LZK6K J)WVC H, M''O=L'C)V0'POLGGTX>/5>CT:8K\$A<OE#09C\$SKU O<("=D); SAY2?GS3 M&@<(J7FS20W? Q=...>

AX?>4ITM)9VA3-Z#Q<N)JTRFM;#KP<RS MLCI*#3-70)2P0R<@%9%A7*#8,693GE(PDAW:8=4ECVR [G+ S2O17;MB>ILO &\$*(X9@5SBDFFD3Y@I
HA)~(62H5)@4)P)R)H BW-ZN M3~SP2G(Z8-5=O.YW>B&IJOISO)S8OIL Z%~UE514XV53T7J5HUAJAMCIG3 M.KG.MXG.~6IUS\$CV.U.G.2_K.NL(D)C0,14)H BM)(&G&F
H@~#1R)M.8547F)047K)H.8R-U*W2W5-3YK3H&S~#6466P%G\$C>0>>&KUH H_9ED WE 5=&C<IYD Y.MI-MZ~""Z3P10%>2=ET-OP19N.MIG<W\$S
NM5I4SEU4K;#64YV>56? MUZMUW_U+L?7P2R_>#GD4.WELL_A@.D00_1\$SD4A.&K9E9Q><-2WI?>TLZM.MB.XF84.PDG?T)FKNY5.G5:HENT?>K5IHL?>7(O)HFM48;(G7-
U/F(9 M%N+<=0.7_E*KK=472/8?>#57&6*MOJ?Z?#!\$>0S M\$O?>.<T^YFCO#4(@>FKA\$><0F5F+3]JM#9 MYZ\$S#@<C)T9^NXJH!&=-YB,1,1,7LTY8#RZH7?>
HWXGEYK7FWH^Z M7YELUYI5CX^X[50]U?<L-NFZA>@:1RAE\$4 HD^E00\$)(FP)Z?_M@H2D)N.W.F9.9QWYQ+ MCZ.X2T LP P(L(4 10D&)&@8B0+2&
C(O.0%Y3Q0FV191Y5B^>FYOIHL^E.ZPYS5MFOU)=-(LWZ)>K86YG^F\$UWU.(Q)OQB8(1UR-J^&L)TBP.JO.HHJ9%9 MX-00.1=M*J8(IA09920)<8
H)92AFV.L7I.F86.20^YIYX6.29%JHDW=M<49F05G>>6L+<FTRUAU?7C3T.FFHX?2.23XAG.&?SE^PJ18-TLD M\$B^YV)~#J2+>4DQ VGB9PG%8?76.F.4.
M\$CU=DM.P7N3)N33)YH0SN<?H LLD0I0GIESZD?5OJW.L1.W.Y.MJKK?2.7TRV.RX.X24MKMSPN7W0%P52B(8*5)&J1.FI8%>4WR VEBW%>9%MSM@NBK1.B;#D
(9%FHN9FXSK1? MD^S.IL\$C\$-8?AYVS8G19960I^O/TN=7%EZIW27?45YN6+OUZOJ+H MP^+DE?E^WS^KRI^7RX(SUE4P^4 UY)Y?TX7D2@#2.&%I@)D9)L&9G8
MO^H>>H-2OQCW\$S.D.K>.U75#H(L7H?2YH#9S#1.B.M.Y_X\$X^65.229D1C9P^UF1D3?7LXO4K^JKE.52^NI^L^L^XPT0S^Z^MJO^H^FNW%IS>4U^A^KJ09T8&E^<
M^#DJ36(884(C^H^WZ>10FD)E M\$EGB<3YH>SEUC=8PVBMCU5T1U.F9\$&^&FU4A.F^GL#6I&65(I01A9.9.M)~&LZLNOKJN)KW@08S
(D6NUS>O)KM^E.M^H_RNB?7+793>8512 M3)J^URKDKNY=^M&522.M50M7.C7R)GJPI^JHWV^&A&63Y4A<^CNJH.K.M.&I%U?26G^V6.T2H?AWZV^<
F.L=XOGG3MR.RTN^E^T^R9R+LAZ.5 M0RP.PZD.W05@+L.FP^*#515F12(01).CZS65YBDS7DU:3RN.IK6.M2V>2VFVE=#&@>EUI
BRLWBBC LE\$X556444MP3IEU^08?>17^ZWV=U7.MXXK?KHM>Z6@N14.K3.U*6&YLT+V17WP\$-IC?IEW).NB)GQ#>ZG(Y\$M%CBX&S(HYX_10H)P(3^V+V5.D09IV
M2R10C@<=1H.W7P.3S^E1\$&T^C66Z?<8.7#HJRE M23WE^DY.GZ^U93G7ZHEV^FHU.Q=E5^7F2L2I2ON)4&#* S.U3U3UW
MO(XVO.L\$W5.X78LVDI90>=>#PDS^44^C.PY2D0/(U5KAN7.L.M.M.T@6GBL>J8B9)PIKT3578^B8^YF60BNOU&3KEE^K83T^>L(1#)SX^TTW5^JH(=^>O92\$<
H\$O9NJ^6WNZD.M^MG^C(L^L^W5.9L.)<KU>E.OI@K(H.MRTVLFVDVIRX.WF>=>8J5IWOV^V7HJ2N.J.@>#9JKI^T\$FLHFN94JZ1^O.M3.A>ZKNNE^9XYE(T2>T.
(ZK+ESN)B/L^+Z2E^K9L0(400=H0A3X^M.YX2+D.AB8)O.F.2@<#ZIS.T.DPYL+87^SHUS8VZ&IKV45I^Y.L3.MSIH?>#D0?#H9.F.=4HE=26.UOX0.5RS??
R/0#1#XLW)++L.V77B(-8 MO@QGX1^FL6ZHV<LLRLM57L OTJ&LJIG72VB(SD2-0.7A&C(L8<9##.M0^00QM6)NB@RZUNRH^10YO/L^T>%W.PIA%N>7EO#.6HUJWH
I>#A#>G.U5>66H>?D.FK^3NK^&C^R5^R^4A>JFWHGER>GCYVO MXI8(C7H1#FAA2.VNX)J^Y9.GRO 1#F(L0P^>+NJOXU^>UKS^T^M^K^P<I>=IN.FI^P45F^0<8
M4.L.DW.L15)1)3#&S.ZO1K^H1A5)1.L2.MMG4)K^I^YV<+M4IR.YV.^*H0=>DL3.D.@3.IAFI.Z4^B-K &A\$4@.GS(O)SRVY41)MM?P>O^W^NV^E)4HDW
I1&H&8JDS6^?4(Q^&A^#S.H8XK8)K8MO^H^K^R06>6YI.MZ5GCO.LK^92PIA9YEV.PUJMDI^PVOYGH9YD.V8.#6I.1X9.B-IV<#>W.W.MAIFM-I<^4J^C\$^0DA2I^5
90&E@H@ZOM<1B.F^MAD.K&N^K.HJPI@N?>M^2V9Y.Q1.KWY2NHOJ5EY.E00^89^1.MG(C\$>Z1G^K\$<D^1.4U@0GP21HDB9G43I6R2^PRLR4=84U@NA>@WAW;#S
M\$T^INB0B1)H0E3M^Y&8L4B5CF8J^HC^#GIG@UCSI-MS.2.15%2DNZOGH0+7&SK1W.2DIOW^E.*0P&OZ.C56^M>JZU>58T^90=30C^H8.2#O4>.@3
M=HKI^Y7.AC92I^L^R^H7^7F5^M0I5X2WKL^Y^T^L^A\$8)01D&5^M^Z15E^X^X^1E^D8E.U@=6KW0.(FE+4K<?3BK5JOV^M^KG^H26X^I0697^7U^L^ME^SB?
L.H\$@Y^D.52^Z1S&4&H^W^D^OPQSO^8NB^4#Y.WO1T0^R^G\$S@S^# MELX9<2^F2+01J3G2J^B<=UT^HCG2KAFN(C^RO=3YB?2>UGY\$Z\$>LQ.M7U5N^%2FL7HZ
J1)G&H&8JDS6^?4(Q^&A^#S.H8XK8)K8MO^H^K^R06>6YI.MZ5GCO.LK^92PIA9YEV.PUJMDI^PVOYGH9YD.V8.#6I.1X9.B-IV<#>W.W.MAIFM-I<^4J^C\$^0DA2I^5
90&E@H@ZOM<1B.F^MAD.K&N^K.HJPI@N?>M^2V9Y.Q1.KWY2NHOJ5EY.E00^89^1.MG(C\$>Z1G^K\$<D^1.4U@0GP21HDB9G43I6R2^PRLR4=84U@NA>@WAW;#S
M\$T^INB0B1)H0E3M^Y&8L4B5CF8J^HC^#GIG@UCSI-MS.2.15%2DNZOGH0+7&SK1W.2DIOW^E.*0P&OZ.C56^M>JZU>58T^90=30C^H8.2#O4>.@3
M=HKI^Y7.AC92I^L^R^H7^7F5^M0I5X2WKL^Y^T^L^A\$8)01D&5^M^Z15E^X^X^1E^D8E.U@=6KW0.(FE+4K<?3BK5JOV^M^KG^H26X^I06

RYI<#5WG+I75:SH"1@W?2ZWI9OWZJ=HK52WUOV8+61 MJSO:SH#0,1*8VL 08 DIO7MI 800EZ WK*702!\$#S-2BI*PYO>N397CJN MBTJYKA~W9,4S;
HN<-7IG VSSKZ0>TUC*9ESRMZ>DG2<2>OJ1+69F0Z4J6&YMA-WM(=NT7ZRXLEFEG-9L PZA3<IHP /H+4M@/IEIS&+3 3K L8G=R*E7G*2+
M0791?5 7FIU7+0O=ZUWVNI)THK&E7>B6(4+X)+7KX1527ZS5I4LH MPSS.4*J87<T/SJPG&XSBBG510N #MB G.PLV I1.1<#>HF+D<>MNVPY<
MNZJ.ME#H8&8.M.U. RY73.HL.0J>W.G0Z(0L;E)D9J+I<Z.F0<I>(9>B=&SXF&G43167A<MBG523IA;SK5G0;FGY132<ORYOGLD+<I5G77+VZ07ZS?7OY
M*;JL<&IEE3<H)NSEIT+<W+PWPMM890HUJ&VU;<2W+V79#>D1SV"@NK8?7V-M'D0;@<RJI&MWJ3I-7I05C(I(151=U)Q)(>?>OUTI/FS6KMY<B_*<JRD6S?G.M.DJ7<EQ=1R
/5&H174N3.IW077I<H5=EV(I1)<6L0N144S:@&A+WM.M0M.1%>L>@<G<7<K F5)N+99C1K*53NYB,6IEM5Z71..R%>X2FOU+<Z1S+M7.1 2 Z;Q8/QE<~<Z/0>
/6)YPP0120>ROM8>#M=8*872M_*24ZAD26YSLZTFC J9U+LZP.ZG@H(SB_*XIEHTQ=8.H.B;H+I+MUOIE5C7I6E5PL7494R.3F&6IEH.2V1K7X7U2W<@35&I@.G<
+<WGIN(FEAIKPCM2L9.5<XCDQ:5/E.V_*Y0H71XID&8 MN15M1.1%>G.D-X 0(10Q%)<?>CYS.&TUS<DQAGRS12/135R-I?>T?>D7 MV9:8GD<2#ZN29?>UP
6SH6ASGVH12E63YWDW.8J.5@<(KIRH7I.24>M6+C1L15W659(CVIEO*4OK)M<VSG.9EVIWDFW9X5E 5I&X.102<GJ(HQO>
MU/52N3'DU(T%23?)%VEAK,SS/K<575>=E07ZBL+<F#9.7/3(9I7:R7K"1 M(HJ)(\$V13W%>UD<#>H*W92YK6G37>I*Y,YW8YA
@.HHTK5>1J<#>N<1<=C@W36#PHZ?Y3KP>W9310KPF>W913 MHJ94.QO>I29CEEM.LZ-H/9?>#G=0556%>KS<7>V7R9A>HBE)2KKI+R:7G.(
MVORSY.6I2R1>VJ(9S&JN)OUVU1?>SH23-UN19.V.8U9VD.L=74.PIQIO MW.0>?>OCXYI@>ZIEHTI1C.A0NUSC7?>OHZ<S2L8FD.NW016 A.O<M> MXI>KHHT.IB.BN&M%?>
1/12KWE=UGT7HFN?LX123W90(LUFTIO&L.O&MB@)128A0B)9749B&8<DAYAK<L+L/GG1>=<42?>L7HBVK&CDT+IYNI.MJ<+31 C6GZYH1O<U+Y6YVU<#>X1P<D4
9K<L5L1:18&1A1XO.(B8 581B&102I.7DXZ9D#M?HJ.UJ?512CRS6&G<Z DVOVIAJ)XN7YU>S7?OIQO?>B(FRS8I9Q179.MXNG=(P&N?>W<~>#9W7548D2H/NXZ?N1#
FPAIV&C<VWJR<O>+IL(C.F.HM)M<@B2I B55&I-TMA&255D RI&#NEV35%U/AP6-YA*NMTSQO??">M7IDS(AS?422)CORV(?>O9BOKW4>P.8M1YQPA.2IQ<I
J5A7?%XIQ<=N.M<62D9Y01H1(L5+5M2XOMK&L=P124#7.1)M.08N1+1.0WZ.NY+I+67Z MST4I6M(W8Q)1+1U+21.9VE?>T1WU1.HAZ?>4VT&9YAAO<6>UV13<6<
MNRMO0<I2 I?H1AV52?15XK?H1MLLZND?XMK?1MLN?Y45<I&Z9?>SAT)I.M7.ZB&382P244YIN.L16G.0S.OI@HVG(IEEAK30@TB91#M.NH+L5.12. M9IN
38IHE2U9U(L2VG1&J7H1-HE7X.N2I.Y1VZ.IYU.I1>I?>O>8H.MO2.C@D11D1&4TACA08B+0%F(C>4V 09X2132P*RO="BN98MFV&H&KSSGO
M.MEFT>GSF.UJ.WTIG.HG.#0&G.AJ1C6D%>+>#7WITN(OUFENQ)1)Y.M.7P26GZVGHEN)ZVYV+QLEF7+I(MS)I614VH35#ZEFU#KXYH7&4I7ZEM5
M%.6>6)T3BYO).OMN*+UL (\$O214+22.Y7@00160F<4G<1<@30B-H>7%I M&G<U?>2.5. ^S 2XD#8.7S6N<#>OAD".IUT3'D&SFH&SK1W%0-Q<2%>C<F>SMK5:UF*YI+X9
L0)AKR7L7M4+H#>M1<4>B&N&L7Q?IKXIBFH.AWU>IP1Z0<4R7&M&I&X6>.>@JSDL=M2.0.2)HJ?>20*XW+IR>=>D/>J&XZNU<0+<I+H&X.IJH?>29>V7F9.E.MDFX?
2S.N1<E>#HIBU?19Q@WRM(LCL&P2N1) W&XJ.P5?PT6N1.P5?R713?Q57R+8I&X.A?<X0SL0.O.HC%>I&F&YB.9.MI<@<HVF5H7HJ..S1<SN<YHROVU>=<I#H 62LTF@<
A1S9+1<6<I&K3*G<N.M.S5W7M?><>>GROP.MOY<-->PTRX90P96%QO&S.L=<40%>A4%<2H MXPCLLECO&LNUP&CSWZ>MLR'L.L@6IGCV#W<#>J.D.E.5.65&5IWX.N.OP
MXG7E2U9U(L2VG1&J7H1-HE7X.N2I.Y1VZ.IYU.I1>I?>O>8H.MO2.C@D11D1&4TACA08B+0%F(C>4V 09X2132P*RO="BN98MFV&H&KSSGO
M.MEFT>GSF.UJ.WTIG.HG.#0&G.AJ1C6D%>+>#7WITN(OUFENQ)1)Y.M.7P26GZVGHEN)ZVYV+QLEF7+I(MS)I614VH35#ZEFU#KXYH7&4I7ZEM5
M%.6>6)T3BYO).OMN*+UL (\$O214+22.Y7@00160F<4G<1<@30B-H>7%I M&G<U?>2.5. ^S 2XD#8.7S6N<#>OAD".IUT3'D&SFH&SK1W%0-Q<2%>C<F>SMK5:UF*YI+X9
L0)AKR7L7M4+H#>M1<4>B&N&L7Q?IKXIBFH.AWU>IP1Z0<4R7&M&I&X6>.>@JSDL=M2.0.2)HJ?>20*XW+IR>=>D/>J&XZNU<0+<I+H&X.IJH?>29>V7F9.E.MDFX?
2S.N1<E>#HIBU?19Q@WRM(LCL&P2N1) W&XJ.P5?PT6N1.P5?R713?Q57R+8I&X.A?<X0SL0.O.HC%>I&F&YB.9.MI<@<HVF5H7HJ..S1<SN<YHROVU>=<I#H 62LTF@<
A1S9+1<6<I&K3*G<N.M.S5W7M?><>>GROP.MOY<-->PTRX90P96%QO&S.L=<40%>A4%<2H MXPCLLECO&LNUP&CSWZ>MLR'L.L@6IGCV#W<#>J.D.E.5.65&5IWX.N.OP
MXG7E2U9U(L2VG1&J7H1-HE7X.N2I.Y1VZ.IYU.I1>I?>O>8H.MO2.C@D11D1&4TACA08B+0%F(C>4V 09X2132P*RO="BN98MFV&H&KSSGO
M.MEFT>GSF.UJ.WTIG.HG.#0&G.AJ1C6D%>+>#7WITN(OUFENQ)1)Y.M.7P26GZVGHEN)ZVYV+QLEF7+I(MS)I614VH35#ZEFU#KXYH7&4I7ZEM5
M%.6>6)T3BYO).OMN*+UL (\$O214+22.Y7@00160F<4G<1<@30B-H>7%I M&G<U?>2.5. ^S 2XD#8.7S6N<#>OAD".IUT3'D&SFH&SK1W%0-Q<2%>C<F>SMK5:UF*YI+X9
L0)AKR7L7M4+H#>M1<4>B&N&L7Q?IKXIBFH.AWU>IP1Z0<4R7&M&I&X6>.>@JSDL=M2.0.2)HJ?>20*XW+IR>=>D/>J&XZNU<0+<I+H&X.IJH?>29>V7F9.E.MDFX?
2S.N1<E>#HIBU?19Q@WRM(LCL&P2N1) W&XJ.P5?PT6N1.P5?R713?Q57R+8I&X.A?<X0SL0.O.HC%>I&F&YB.9.MI<@<HVF5H7HJ..S1<SN<YHROVU>=<I#H 62LTF@<
A1S9+1<6<I&K3*G<N.M.S5W7M?><>>GROP.MOY<-->PTRX90P96%QO&S.L=<40%>A4%<2H MXPCLLECO&LNUP&CSWZ>MLR'L.L@6IGCV#W<#>J.D.E.5.65&5IWX.N.OP
MXG7E2U9U(L2VG1&J7H1-HE7X.N2I.Y1VZ.IYU.I1>I?>O>8H.MO2.C@D11D1&4TACA08B+0%F(C>4V 09X2132P*RO="BN98MFV&H&KSSGO
M.MEFT>GSF.UJ.WTIG.HG.#0&G.AJ1C6D%>+>#7WITN(OUFENQ)1)Y.M.7P26GZVGHEN)ZVYV+QLEF7+I(MS)I614VH35#ZEFU#KXYH7&4I7ZEM5
M%.6>6)T3BYO).OMN*+UL (\$O214+22.Y7@00160F<4G<1<@30B-H>7%I M&G<U?>2.5. ^S 2XD#8.7S6N<#>OAD".IUT3'D&SFH&SK1W%0-Q<2%>C<F>SMK5:UF*YI+X9
L0)AKR7L7M4+H#>M1<4>B&N&L7Q?IKXIBFH.AWU>IP1Z0<4R7&M&I&X6>.>@JSDL=M2.0.2)HJ?>20*XW+IR>=>D/>J&XZNU<0+<I+H&X.IJH?>29>V7F9.E.MDFX?
2S.N1<E>#HIBU?19Q@WRM(LCL&P2N1) W&XJ.P5?PT6N1.P5?R713?Q57R+8I&X.A?<X0SL0.O.HC%>I&F&YB.9.MI<@<HVF5H7HJ..S1<SN<YHROVU>=<I#H 62LTF@<
A1S9+1<6<I&K3*G<N.M.S5W7M?><>>GROP.MOY<-->PTRX90P96%QO&S.L=<40%>A4%<2H MXPCLLECO&LNUP&CSWZ>MLR'L.L@6IGCV#W<#>J.D.E.5.65&5IWX.N.OP
MXG7E2U9U(L2VG1&J7H1-HE7X.N2I.Y1VZ.IYU.I1>I?>O>8H.MO2.C@D11D1&4TACA08B+0%F(C>4V 09X2132P*RO="BN98MFV&H&KSSGO
M.MEFT>GSF.UJ.WTIG.HG.#0&G.AJ1C6D%>+>#7WITN(OUFENQ)1)Y.M.7P26GZVGHEN)ZVYV+QLEF7+I(MS)I614VH35#ZEFU#KXYH7&4I7ZEM5
M%.6>6)T3BYO).OMN*+UL (\$O214+22.Y7@00160F<4G<1<@30B-H>7%I M&G<U?>2.5. ^S 2XD#8.7S6N<#>OAD".IUT3'D&SFH&SK1W%0-Q<2%>C<F>SMK5:UF*YI+X9
L0)AKR7L7M4+H#>M1<4>B&N&L7Q?IKXIBFH.AWU>IP1Z0<4R7&M&I&X6>.>@JSDL=M2.0.2)HJ?>20*XW+IR>=>D/>J&XZNU<0+<I+H&X.IJH?>29>V7F9.E.MDFX?
2S.N1<E>#HIBU?19Q@WRM(LCL&P2N1) W&XJ.P5?PT6N1.P5?R713?Q57R+8I&X.A?<X0SL0.O.HC%>I&F&YB.9.MI<@<HVF5H7HJ..S1<SN<YHROVU>=<I#H 62LTF@<
A1S9+1<6<I&K3*G<N.M.S5W7M?><>>GROP.MOY<-->PTRX90P96%QO&S.L=<40%>A4%<2H MXPCLLECO&LNUP&CSWZ>MLR'L.L@6IGCV#W<#>J.D.E.5.65&5IWX.N.OP
MXG7E2U9U(L2VG1&J7H1-HE7X.N2I.Y1VZ.IYU.I1>I?>O>8H.MO2.C@D11D1&4TACA08B+0%F(C>4V 09X2132P*RO="BN98MFV&H&KSSGO
M.MEFT>GSF.UJ.WTIG.HG.#0&G.AJ1C6D%>+>#7WITN(OUFENQ)1)Y.M.7P26GZVGHEN)ZVYV+QLEF7+I(MS)I614VH35#ZEFU#KXYH7&4I7ZEM5
M%.6>6)T3BYO).OMN*+UL (\$O214+22.Y7@00160F<4G<1<@30B-H>7%I M&G<U?>2.5. ^S 2XD#8.7S6N<#>OAD".IUT3'D&SFH&SK1W%0-Q<2%>C<F>SMK5:UF*YI+X9
L0)AKR7L7M4+H#>M1<4>B&N&L7Q?IKXIBFH.AWU>IP1Z0<4R7&M&I&X6>.>@JSDL=M2.0.2)HJ?>20*XW+IR>=>D/>J&XZNU<0+<I+H&X.IJH?>29>V7F9.E.MDFX?
2S.N1<E>#HIBU?19Q@WRM(LCL&P2N1) W&XJ.P5?PT6N1.P5?R713?Q57R+8I&X.A?<X0SL0.O.HC%>I&F&YB.9.MI<@<HVF5H7HJ..S1<SN<YHROVU>=<I#H 62LTF@<
A1S9+1<6<I&K3*G<N.M.S5W7M?><>>GROP.MOY<-->PTRX90P96%QO&S.L=<40%>A4%<2H MXPCLLECO&LNUP&CSWZ>MLR'L.L@6IGCV#W<#>J.D.E.5.65&5IWX.N.OP
MXG7E2U9U(L2VG1&J7H1-HE7X.N2I.Y1VZ.IYU.I1>I?>O>8H.MO2.C@D11D1&4TACA08B+0%F(C>4V 09X2132P*RO="BN98MFV&H&KSSGO
M.MEFT>GSF.UJ.WTIG.HG.#0&G.AJ1C6D%>+>#7WITN(OUFENQ)1)Y.M.7P26GZVGHEN)ZVYV+QLEF7+I(MS)I614VH35#ZEFU#KXYH7&4I7ZEM5
M%.6>6)T3BYO).OMN*+UL (\$O214+22.Y7@00160F<4G<1<@30B-H>7%I M&G<U?>2.5. ^S 2XD#8.7S6N<#>OAD".IUT3'D&SFH&SK1W%0-Q<2%>C<F>SMK5:UF*YI+X9
L0)AKR7L7M4+H#>M1<4>B&N&L7Q?IKXIBFH.AWU>IP1Z0<4R7&M&I&X6>.>@JSDL=M2.0.2)HJ?>20*XW+IR>=>D/>J&XZNU<0+<I+H&X.IJH?>29>V7F9.E.MDFX?
2S.N1<E>#HIBU?19Q@WRM(LCL&P2N1) W&XJ.P5?PT6N1.P5?R713?Q57R+8I&X.A?<X0SL0.O.HC%>I&F&YB.9.MI<@<HVF5H7HJ..S1<SN<YHROVU>=<I#H 62LTF@<
A1S9+1<6<I&K3*G<N.M.S5W7M?><>>GROP.MOY<-->PTRX90P96%QO&S.L=<40%>A4%<2H MXPCLLECO&LNUP&CSWZ>MLR'L.L@6IGCV#W<#>J.D.E.5.65&5IWX.N.OP
MXG7E2U9U(L2VG1&J7H1-HE7X.N2I.Y1VZ.IYU.I1>I?>O>8H.MO2.C@D11D1&4TACA08B+0%F(C>4V 09X2132P*RO="BN98MFV&H&KSSGO
M.MEFT>GSF.UJ.WTIG.HG.#0&G.AJ1C6D%>+>#7WITN(OUFENQ)1)Y.M.7P26GZVGHEN)ZVYV+QLEF7+I(MS)I614VH35#ZEFU#KXYH7&4I7ZEM5
M%.6>6)T3BYO).OMN*+UL (\$O214+22.Y7@00160F<4G<1<@30B-H>7%I M&G<U?>2.5. ^S 2XD#8.7S6N<#>OAD".IUT3'D&SFH&SK1W%0-Q<2%>C<F>SMK5:UF*YI+X9
L0)AKR7L7M4+H#>M1<4>B&N&L7Q?IKXIBFH.AWU>IP1Z0<4R7&M&I&X6>.>@JSDL=M2.0.2)HJ?>20*XW+IR>=>D/>J&XZNU<0+<I+H&X.IJH?>29>V7F9.E.MDFX?
2S.N1<E>#HIBU?19Q@WRM(LCL&P2N1) W&XJ.P5?PT6N1.P5?R713?Q57R+8I&X.A?<X0SL0.O.HC%>I&F&YB.9.MI<@<HVF5H7HJ..S1<SN<YHROVU>=<I#H 62LTF@<
A1S9+1<6<I&K3*G<N.M.S5W7M?><>>GROP.MOY<-->PTRX90P96%QO&S.L=<40%>A4%<2H MXPCLLECO&LNUP&CSWZ>MLR'L.L@6IGCV#W<#>J.D.E.5.65&5IWX.N.OP
MXG7E2U9U(L2VG1&J7H1-HE7X.N2I.Y1VZ.IYU.I1>I?>O>8H.MO2.C@D11D1&4TACA08B+0%F(C>4V 09X2132P*RO="BN98MFV&H&KSSGO
M.MEFT>GSF.UJ.WTIG.HG.#0&G.AJ1C6D%>+>#7WITN(OUFENQ)1)Y.M.7P26GZVGHEN)ZVYV+QLEF7+I(MS)I614VH35#ZEFU#KXYH7&4I7ZEM5
M%.6>6)T3BYO).OMN*+UL (\$O214+22.Y7@00160F<4G<1<@30B-H>7%I M&G<U?>2.5. ^S 2XD#8.7S6N<#>OAD".IUT3'D&SFH&SK1W%0-Q<2%>C<F>SMK5:UF*YI+X9
L0)AKR7L7M4+H#>M1<4>B&N&L7Q?IKXIBFH.AWU>IP1Z0<4R7&M&I&X6>.>@JSDL=M2.0.2)HJ?>20*XW+IR>=>D/>J&XZNU<0+<I+H&X.IJH?>29>V7F9.E.MDFX?
2S.N1<E>#HIBU?19Q@WRM(LCL&P2N1) W&XJ.P5?PT6N1.P5?R713?Q57R+8I&X.A?<X0SL0.O.HC%>I&F&YB.9.MI<@<HVF5H7HJ..S1<SN<YHROVU>=<I#H 62LTF@<
A1S9+1<6<I&K3*G<N.M.S5W7M?><>>GROP.MOY<-->PTRX90P96%QO&S.L=<40%>A4%<2H MXPCLLECO&LNUP&CSWZ>MLR'L.L@6IGCV#W<#>J.D.E.5.65&5IWX.N.OP
MXG7E2U9U(L2VG1&J7H1-HE7X.N2I.Y1VZ.IYU.I1>I?>O>8H.MO2.C@D11D1&4TACA08B+0%F(C>4V 09X2132P*RO="BN98MFV&H&KSSGO
M.MEFT>GSF.UJ.WTIG.HG.#0&G.AJ1C6D%>+>#7WITN(OUFENQ)1)Y.M.7P26GZVGHEN)ZVYV+QLEF7+I(MS)I614VH35#ZEFU#KXYH7&4I7ZEM5
M%.6>6)T3BYO).OMN*+UL (\$O214+22.Y7@00160F<4G<1<@30B-H>7%I M&G<U?>2.5. ^S 2XD#8.7S6N<#>OAD".IUT3'D&SFH&SK1W%0-Q<2%>C<F>SMK5:UF*YI+X9
L0)AKR7L7M4+H#>M1<4>B&N&L7Q?IKXIBFH.AWU>IP1Z0<4R7&M&I&X6>.>@JSDL=M2.0.2)HJ?>20*XW+IR>=>D/>J&XZNU<0+<I+H&X.IJH?>29>V7F9.E.MDFX?
2S.N1<E>#HIBU?19Q@WRM(LCL&P2N1) W&XJ.P5?PT6N1.P5?R713?Q57R+8I&X.A?<X0SL0.O.HC%>I&F&YB.9.MI<@<HVF5H7HJ..S1<SN<YHROVU>=<I#H 62LTF@<
A1S9+1<6<I&K3*G<N.M.S5W7M?><>>GROP.MOY<-->PTRX90P96%QO&S.L=<40%>A4%<2H MXPCLLECO&LNUP&CSWZ>MLR'L.L@6IGCV#W<#>J.D.E.5.65&5IWX.N.OP
MXG7E2U9U(L2VG1&J7H1-HE7X.N2I.Y1VZ.IYU.I1>I?>O>8H.MO2.C@D11D1&4TACA08B+0%F(C>4V 09X2132P*RO="BN98MFV&H&KSSGO
M.MEFT>GSF.UJ.WTIG.HG.#0&G.AJ1C6D%>+>#7WITN(OUFENQ)1)Y.M.7P26GZVGHEN)ZVYV+QLEF7+I(MS)I614VH35#ZEFU#KXYH7&4I7ZEM5
M%.6>6)T3BYO).OMN*+UL (\$O214+22.Y7@00160F<4G<1<@30B-H>7%I M&G<U?>2.5. ^S 2XD#8.7S6N<#>OAD".IUT3'D&SFH&SK1W%0-Q<2%>C<F>SMK5:UF*YI+X9
L0)AKR7L7M4+H#>M1<4>B&N&L7Q?IKXIBFH.AWU>IP1Z0<4R7&M&I&X6>.>@JSDL=M2.0.2)HJ?>20*XW+IR>=>D/>J&XZNU<0+<I+H&X.IJH?>29>V7F9.E.MDFX?
2S.N1<E>#HIBU?19Q@WRM(LCL&P2N1) W&XJ.P5?PT6N1.P5?R713?Q57R+8I&X.A?<X0SL0.O.HC%>I&F&YB.9.MI<@<HVF5H7HJ..S1<SN<YHROVU>=<I#H 62LTF@<
A1S9+1<6<I&K3*G<N.M.S5W7M?><>>GROP.MOY<-->PTRX90P96%QO&S.L=<40%>A4%<2H MXPCLLECO&LNUP&CSWZ>MLR'L.L@6IGCV#W<#>J.D.E.5.65&5IWX.N.OP
MXG7E2U9U(L2VG1&J7H1-HE7X.N2I.Y1VZ.IYU.I1>I?>O>8H.MO2.C@D11D1&4TACA08B+0%F(C>4V 09X2132P*RO="BN98MFV&H&KSSGO
M.MEFT>GSF.UJ.WTIG.HG.#0&G.AJ1C6D%>+>#7WITN(OUFENQ)1)Y.M.7P26GZVGHEN)ZVYV+QLEF7+I(MS)I614VH35#ZEFU#KXYH7&4I7ZEM5
M%.6>6)T3BYO).OMN*+UL (\$O214+22.Y7@00160F<4G<1<@30B-H>7%I M&G<U?>2.5. ^S 2XD#8.7S6N<#>OAD".IUT3'D&SFH&SK1W%0-Q<2%>C<F>SMK5:UF*YI+X9
L0)AKR7L7M4+H#>M1<4>B&N&L7Q?IKXIBFH.AWU>IP1Z0<4R7&M&I&X6>.>@JSDL=M2.0.2)HJ?>20*XW+IR>=>D/>J&XZNU<0+<I+H&X.IJH?>29>V7F9.E.MDFX?
2S.N1<E>#HIBU?19Q@WRM(LCL&P2N1) W&XJ.P5?PT6N1.P5?R713?Q57R+8I&X.A?<X0SL0.O.HC%>I&F&YB.9.MI<@<HVF5H7HJ..S1<SN<YHROVU>=<I#H 62LTF@<
A1S9+1<6<I&K3*G<N.M.S5W7M?><>>GROP.MOY<-->PTRX90P96%QO&S.L=<40%>A4%<2H MXPCLLECO&LNUP&CSWZ>MLR'L.L@6IGCV#W<#>J.D.E.5.65&5IWX.N.OP
MXG7E2U9U(L2VG1&J7H1-HE7X.N2I.Y1VZ.IYU.I1>I?>O>8H.MO2.C@D11D1&4TACA08B+0%F(C>4V 09X2132P*RO="BN98MFV&H&KSSGO
M.MEFT>GSF.UJ.WTIG.HG.#0&G.AJ1C6D%>+>#7WITN(OUFENQ)1)Y.M.7P26GZVGHEN)ZVYV+QLEF7+I(MS)I614VH35#ZEFU#KXYH7&4I7ZEM5
M%.6>6)T3BYO).OMN*+UL (\$O214+22.Y7@00160F<4G<1<@30B-H>7%I M&G<U?>2.5. ^S 2XD#8.7S6N<#>OAD".IUT3'D&SFH&SK1W%0-Q<2%>C<F>SMK5:UF*YI+X9
L0)AKR7L7M4+H#>M1<4>B&N&L7Q?IKXIBFH.AWU>IP1Z0<4R7&M&I&X6>.>@JSDL=M2.0.2)HJ?>20*XW+IR>=>D/>J&XZNU<0+<I+H&X.IJH?>29>V7F9.E.MDFX?
2S.N1<E>#HIBU?19Q@WRM(LCL&P2N1) W&XJ.P5?PT6N1.P5?R713?Q57R+8I&X.A?<X0SL0.O.HC%>I&F&YB.9.MI<@<HVF5H7HJ..S1<SN<YHROVU>=<I#H 62LTF@<
A1S9+1<6<I&K3*G<N.M.S5W7M?><>>GROP.MOY<-->PTRX90P96%QO&S.L=<40%>A4%<2H MXPCLLECO&LNUP&CSWZ>MLR'L.L@6IGCV#W<#>J.D.E.5.65&5IWX.N.OP
MXG7E2U9U(L2VG1&J7H1-HE7X.N2I.Y1VZ.IYU.I1>I?>O>8H.MO2.C@D11D1&4TACA08B+0%F(C>4V 09X2132P*RO="BN98MFV&H&KSSGO
M.MEFT>GSF.UJ.WTIG.HG.#0&G.AJ1C6D%>+>#7WITN(OUFENQ)1)Y.M.7P26GZVGHEN)ZVYV+QLEF7+I(MS)I614VH35#ZEFU#KXYH7&4I7ZEM5
M%.6>6)T3BYO).OMN*+UL (\$O214+22.Y7@00160F<4G<1<@30B-H>7%I M&G<U?>2.5. ^S 2XD#8.7S6N<#>OAD".IUT3'D&SFH&SK1W%0-Q<2%>C<F>SMK5:UF*YI+X9
L0)AKR7L7M4+H#>M1<4>B&N&L7Q?IKXIBFH.AWU>IP1Z0<4R7&M&I&X6>.>@JSDL=M2.0.2)HJ?>20*XW+IR>=>D/>J&XZNU<0+<I+H&X.IJH?>29>V7F9.E.MDFX?
2S.N1<E>#HIBU?19Q@WRM(LCL&P2N1) W&XJ.P5?PT6N1.P5?R713?Q57R+8I&X.A?<X0SL0.O.HC%>I&F&YB.9.MI<@<HVF5H7HJ..S1<SN<YHROVU>=<I#H 62LTF@<
A1S9+1<6<I&K3*G<N.M.S5W7M?><>>GROP.MOY<-->PTRX90P96%QO&S.L=<40%>A4%<2H MXPCLLECO&LNUP&CSWZ>MLR'L.L@6IGCV#W<#>J.D.E.5.65&5IWX.N.OP
MXG7E2U9U(L2VG1&J7H1-HE7X.N2I.Y1VZ.IYU.I1>I?>O>8H.MO2.C@D11D1&4TACA08B+0%F(C>4V 09X2132P*RO="BN98MFV&H&KSSGO
M.MEFT>GSF.UJ.WTIG.HG.#0&G.AJ1C6D%>+>#7WITN(OUFENQ)1)Y.M.7P26GZVGHEN)ZVYV+QLEF7+I(MS)I614VH35#ZEFU#KXYH7&4I7ZEM5
M%.6>6)T3BYO).OMN*+UL (\$

financial statements have been condensed or omitted. The accompanying unaudited condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to state fairly the Company's financial position, results of operations, comprehensive loss and cash flows for the periods presented, but are not necessarily indicative of the results of operations to be anticipated for any future annual or interim period. All intercompany transactions and balances have been eliminated. The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosure of contingent assets and liabilities. Actual results could differ from those estimates.

Summary of Significant Accounting Policies

Revenue Recognition

The Company generates revenue from sales of products and services, and its products consist of instruments and consumables. Revenue from product sales is recognized when control of the product is transferred, which is generally upon shipment to the customer. Instrument service agreements, which relate to extended warranties, are typically entered into for one-year terms, following the expiration of the standard one-year warranty period. Revenue for extended warranties is recognized ratably over the term of the extended warranty period as a stand ready performance obligation. Revenue is recorded net of discounts, distributor commissions and sales taxes collected on behalf of governmental authorities. Customers are invoiced generally upon shipment, or upon order for services, and payment is typically due within 30 days. Cash received from customers in advance of product shipment or providing services is recorded as a contract liability. The Company's contracts with its customers generally do not include rights of return or a significant financing component.

Net Loss Per Share

Net loss per share is computed using the two-class method required for multiple classes of common stock and participating securities. The rights, including the liquidation and dividend rights and sharing of losses, of the Class A common stock and Class B common stock are identical, other than voting rights. As the liquidation and dividend rights and sharing of losses are identical, the undistributed earnings are allocated on a proportionate basis and the resulting net loss per share will, therefore, be the same for both Class A and Class B common stock on an individual or combined basis.

Basic net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period, adjusted for outstanding shares that are subject to repurchase.

Diluted net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period, adjusted for outstanding shares that are subject to repurchase. For periods in which the Company reports net losses, diluted net loss per share is the same as basic net loss per share because potentially dilutive shares of common stock are not assumed to have been issued if their effect is anti-dilutive.

Recently Issued Accounting Pronouncement and Disclosure Rules

In December 2023, the FASB issued ASU No. 2023-09, *Income Taxes*, which prescribes standardized categories and disaggregation of information in the reconciliation of provision for income taxes, requires disclosure of disaggregated income taxes paid, and modifies other income tax-related disclosure requirements. The updated standard is effective beginning with the Company's fiscal year 2025 annual reporting period. Early adoption is permitted. The Company is currently evaluating the impact that the updated standard will have on its related disclosures.

In March 2024, the Securities and Exchange Commission (SEC) issued Final Rule No. 33-11275, *The Enhancement and Standardization of Climate-Related Disclosures for Investors*. If effected as issued, the rule would require registrants to provide certain climate related disclosures in their annual reports. While in April 2024 the SEC stayed Final Rule No. 33-11275 in connection with legal challenges to the rule, the Company is in the process of analyzing the impact of the rule on its related disclosures.

Other Financial Statement Information

Available for sale securities

Available for sale securities consisted of the following (in thousands):

	December 31, 2023
U.S. Government securities	10.871%
U.S. Corporate securities	6.945%
U.S. Municipal securities	0.1%
Foreign securities	0.1%
Equity securities	0.374%
Other	0.1%
Total	19.471%

Amortized Cost

	June 30, 2024	December 31, 2023
U.S. Government securities	9.1%	10.871%
U.S. Corporate securities	6.802%	6.945%
U.S. Municipal securities	0.1%	0.1%
Foreign securities	0.1%	0.1%
Equity securities	0.374%	0.374%
Other	0.1%	0.1%
Total	16.557%	19.471%

Gross Unrealized Gains

	June 30, 2024	December 31, 2023
U.S. Government securities	0.1%	0.1%
U.S. Corporate securities	0.1%	0.1%
U.S. Municipal securities	0.1%	0.1%
Foreign securities	0.1%	0.1%
Equity securities	0.1%	0.1%
Other	0.1%	0.1%
Total	0.6%	0.6%

Gross Unrealized Losses

	June 30, 2024	December 31, 2023
U.S. Government securities	0.1%	0.1%
U.S. Corporate securities	0.1%	0.1%
U.S. Municipal securities	0.1%	0.1%
Foreign securities	0.1%	0.1%
Equity securities	0.1%	0.1%
Other	0.1%	0.1%
Total	0.6%	0.6%

Fair Value

	June 30, 2024	December 31, 2023
U.S. Government securities	9.1%	10.871%
U.S. Corporate securities	6.802%	6.945%
U.S. Municipal securities	0.1%	0.1%
Foreign securities	0.1%	0.1%
Equity securities	0.374%	0.374%
Other	0.1%	0.1%
Total	16.557%	19.471%

height:120%>On October 20, 2022, NanoString filed suit against the Company in the U.S. District Court for the District of Delaware alleging that the Company's Visium products infringe U.S. Patent No. 11,473,142 (the "142 patent"), a continuation of the 689 patent (the "NanoString Action"). NanoString seeks, among other relief, injunctive relief and unspecified damages (including attorneys' fees) in relation to the Company's making, using, selling, offering to sell, exporting and/or importing in the United States Visium products and associated instruments, reagents and services. On January 24, 2023, the Court severed NanoString's claims with respect to the 689 patent from the CosMx Action and consolidated those claims with this action. NanoString filed an amended complaint on January 27, 2023. The Company filed an answer to the NanoString Action on February 10, 2023. Discovery is in progress. A Markman hearing was held on January 10, 2024, and the Court issued its claim construction order on February 1, 2024. Bruker Spatial Biology, Inc. and Bruker Nano, Inc. were substituted as plaintiffs in the NanoString Action in June 2024. A trial date in the NanoString Action has not yet been set. The Company believes these claims in the NanoString Action are meritless and intends to vigorously defend itself.</div><div style="margin-top:12pt;text-align:justify;text-indent:27pt">On August 16 and September 25, 2023, the Company filed petitions for inter partes review ("IPR") of the 689 patent and the 142 patent, respectively. On February 1, 2024, IPR was instituted for the 689 patent. An institution decision for the IPR against the 142 patent is pending.</div><div style="margin-top:12pt;text-align:justify;text-indent:27pt">On January 30, 2024, NanoString filed a petition for IPR of U.S. Patent No. 11,542,554 (the "554 patent"), which is asserted by the Company against NanoString in the CosMx Action. An institution decision for the IPR against the 554 patent is pending.</div><div style="margin-top:12pt;text-align:justify;text-indent:27pt">On March 9, 2022, the Company filed suit in the Munich Regional Court in Germany alleging that NanoString's CosMx Spatial Molecular Imager and associated instruments, reagents and services infringe EP Patent No. 2794928B1 (the "EP928 patent") (the "Germany CosMx Action"). A hearing on infringement was held on March 23, 2023. On May 17, 2023, the Munich Regional Court found that the CosMx products infringe the EP928 patent and issued a permanent injunction requiring NanoString to stop selling and supplying CosMx instruments and reagents for RNA detection in Germany. The injunction took effect on June 1, 2023. On May 25, 2023, NanoString filed an appeal of the Germany CosMx Action in the Munich Higher Regional Court.</div><div style="margin-top:12pt;text-align:justify;text-indent:27pt">A hearing was held on March 23, 2023. On May 17, 2023, the Munich Regional Court found that the CosMx products infringe the EP928 patent and issued a permanent injunction requiring NanoString to stop selling and supplying CosMx instruments and reagents for RNA detection in Germany. The injunction took effect on June 1, 2023. On May 25, 2023, NanoString filed an appeal of the Germany CosMx Action in the Munich Higher Regional Court.</div><div style="margin-top:12pt;text-align:justify;text-indent:27pt">On July 29, 2022, NanoString filed a nullity action with the German Federal Patent Court challenging the validity of the EP928 patent.</div><div style="margin-top:12pt;text-align:justify;text-indent:27pt">On June 1, 2023, the Company filed requests for preliminary injunctions in the Munich Local Division of the Unified Patent Court ("UPC") alleging that NanoString's CosMx Spatial Molecular Imager and associated instruments, reagents and services for RNA detection infringe the EP928 patent and EP Patent No. 4108792 (the "EP792 patent"). Hearings were held for the EP792 and EP928 patents on September 5 and September 19, respectively.</div><div style="margin-top:12pt;text-align:justify;text-indent:27pt">On September 19, 2023, the UPC granted the Company's request with respect to the EP792 patent and issued a preliminary injunction requiring NanoString to stop selling and supplying CosMx instruments and reagents for RNA detection in all 17 UPC member states. On October 10, 2023, the UPC denied the Company's preliminary injunction request for the EP928 patent.</div><div style="margin-top:12pt;text-align:justify;text-indent:27pt">On October 2, 2023, NanoString filed an appeal of the preliminary injunction for the EP792 patent in the UPC Court of Appeals.</div><div style="margin-top:12pt;text-align:justify;text-indent:27pt">A hearing was held before the UPC Court of Appeals on December 18, 2023. The UPC Court of Appeals overturned the preliminary injunction on February 26, 2024.</div><div style="margin-top:12pt;text-align:justify;text-indent:27pt">On August 31 and September 18, 2023 the Company filed main requests in the Munich Local Division of the UPC alleging that NanoString's CosMx Spatial Molecular Imager and associated instruments, reagents and services for RNA detection infringe the EP792 and EP928 patents, respectively.</div><div style="margin-top:12pt;text-align:justify;text-indent:27pt">No hearings have yet been set for these main requests.</div><div style="margin-top:12pt;text-align:justify;text-indent:27pt">On July 18, 2023, NanoString filed an opposition in the European Patent Office challenging the validity of the EP792 patent. An oral hearing for this opposition is scheduled on March 18, 2025. On July 27, 2023, NanoString filed a revocation action in the Munich Central Division of the UPC challenging the validity of the EP928 patent. An oral hearing for this revocation action is scheduled for September 18, 2024.</div><div style="margin-top:12pt;text-align:justify;text-indent:27pt">On May 3, 2022, the Company filed suit against Vizgen, Inc. ("Vizgen") in the U.S. District Court for the District of Delaware alleging that Vizgen's MERSCOPE Platform and workflow and/or Vizgen's Lab Services program, including associated instruments and reagents, infringe U.S. Patent Nos. 11,021,737, 11,293,051, 11,293,052, 11,293,054 and 11,299,767. The Company seeks, among other relief, injunctive relief and unspecified damages (including attorneys' fees) in relation to Vizgen's making, using, selling, offering to sell, exporting and/or importing in the United States the MERSCOPE Platform and workflow and/or Vizgen's Lab Services program, including associated instruments and reagents. On July 25, 2022, Vizgen filed a motion to dismiss the Company's claims for willful and indirect infringement, which the Court denied on September 19, 2022. Discovery is in progress. A Markman hearing was held on January 10, 2024, and the Court issued its claim construction order on February 1, 2024.</div><div style="margin-top:12pt;text-align:justify;text-indent:27pt">On August 30, 2022, Vizgen filed its answer and counterclaims alleging that the Company's Xenium product infringes U.S. Patent No. 11,098,303 (the "303 patent"). Vizgen seeks, among other relief, injunctive relief and unspecified damages (including attorneys' fees) in relation to the Company's making, using, selling, offering to sell, exporting and/or importing in the United States Xenium products, including associated instruments and reagents. Vizgen also filed counterclaims alleging that the Company tortiously interfered with Vizgen's contractual and business relationship with Harvard and that the Company engaged in unfair practices under Massachusetts state law. On October 27, 2022, the Company filed a partial answer and motion to dismiss the infringement counterclaim and the tort counterclaims. On February 2, 2023, the Company's motion to dismiss was denied. The Company believes Vizgen's claims are meritless and intends to vigorously defend itself.</div><div style="margin-top:12pt;text-align:justify;text-indent:27pt">On March 15, 2023, the Company filed an amended complaint additionally alleging that the MERSCOPE Platform and workflow and Vizgen's Lab Services program infringe U.S. Patent Nos. 11,549,136 and withdrawing its claim of infringement of U.S. Patent No. 11,293,054. On April 17, 2023, Vizgen filed its answer adding amended counterclaims including antitrust, unfair competition, tort and contract counterclaims. Vizgen seeks, among other relief, injunctive relief (including that the Company grant Vizgen a license to the patents that the Company asserted against Vizgen) and unspecified damages (including attorneys' fees). On May 10, 2023, the Company filed a motion to dismiss Vizgen's amended counterclaims. On July 10, 2023, the Court granted the Company's motion to dismiss Vizgen's contract counterclaim but otherwise denied the Company's motion to dismiss. On April 29, 2024, Vizgen amended its counterclaims to add additional antitrust counterclaims based on alleged bundling and predatory pricing. The Company believes Vizgen's claims are meritless and intends to vigorously defend itself.</div><div style="margin-top:12pt;text-align:justify;text-indent:27pt">Trial on the Company's claims and on Vizgen's non-patent counterclaims is scheduled for February 2025. A trial date on Vizgen's counterclaim regarding the 303 patent is expected to be set for the second half of 2024.</div><div style="margin-top:12pt;text-align:justify;text-indent:27pt">On August 30, 2023, the Company filed a petition for IPR of the 303 patent. Institution was denied on March 7, 2024.</div><div style="margin-top:12pt;text-align:justify;text-indent:27pt">On June 1, 2023, the Company filed suit in the Hamburg Local Division of the UPC alleging that Vizgen's MERSCOPE products infringe the EP792 patent. The Company seeks, among other relief, injunctive relief and unspecified damages (including attorneys' fees) in relation to Vizgen's MERSCOPE products in all 17 UPC member states.</div><div style="margin-top:12pt;text-align:justify;text-indent:27pt">On August 24, 2022, the Company filed suit against Parse Biosciences, Inc. ("Parse") in the U.S. District Court for the District of Delaware alleging that Parse's Evercode Whole Transcriptomics products and ATAC-seq products infringe U.S. Patent Nos. 10,155,981 (the "981 patent"), 10,697,013 (the "013 patent"), 10,240,197 (the "197 patent"), 10,150,995, 10,619,207 and 10,738,357. The Company seeks, among other relief, injunctive relief and unspecified damages (including attorneys' fees) in relation to Parse's making, using, selling, offering to sell, exporting and/or importing in the United States Parse's Evercode Whole Transcriptomics products and ATAC-seq products. On October 17, 2022, Parse filed a motion to dismiss alleging that the asserted claims are directed to patent ineligible subject matter. The Court held a hearing on the motion to dismiss on November 22, 2022, and supplemental briefing was submitted on December 15, 2022. On September 14, 2023, the Court denied the motion. Parse filed its answer on October 6, 2023. A Markman hearing was held on February 21, 2024, and the Court issued its claim construction order on May 3, 2024. Trial is scheduled for December 2024.</div><div style="margin-top:12pt;text-align:justify;text-indent:27pt">Between April 20 and June 21, 2023, Parse filed petitions for IPR of all of the patents asserted. On October 13, 2023, IPR was instituted on the 981 patent. Oral argument for the 981 IPR took place on July 24, 2024. A final written decision on the 981 IPR is expected in October 2024. The PTAB denied institution of Parse's petitions for IPR on the other five asserted patents.</div><div style="margin-top:12pt;text-align:justify;text-indent:27pt">On January 2 and 5, 2024, Parse filed rehearing requests with the PTAB for the 197 and 013 patents, respectively. On February 5, 2024, the PTAB instituted IPRs for the 197 and 013 patents on Parse's requests for rehearing.</div><div style="margin-top:12pt;text-align:justify;text-indent:27pt">On November 6, 2023, Parse filed a motion to stay the Delaware action pending the IPRs. On December 21, 2023, the court denied Parse's motion to stay. On February 8, 2024, Parse filed a renewed motion to stay. On February 20, 2024, the court denied Parse's renewed motion to stay.</div><div style="margin-top:12pt;text-align:justify;text-indent:27pt">Curio filed a motion to stay the Delaware action pending the IPRs. On December 21, 2023, the court denied Parse's motion to stay. On February 8, 2024, Parse filed a renewed motion to stay. On February 20, 2024, the court denied Parse's renewed motion to stay.</div><div style="margin-top:12pt;text-align:justify;text-indent:27pt">On December 1, 2023, the Company filed suit against Curio Bioscience, Inc. ("Curio") in the U.S. District Court for the District of Delaware alleging that the Curio Seeker Spatial Mapping Kit and associated products and services infringe U.S. Patent Nos. 10,480,022, 10,662,468, 11,001,879, 11,549,138, and 11,761,030.</div><div style="margin-top:12pt;text-align:justify;text-indent:27pt">On February 1, 2024, Curio filed a motion to dismiss alleging that the asserted claims are directed to patent ineligible subject matter. The Court denied that motion on May 9, 2024. On May 31 and June 20, 2024, Curio answered the Complaint and filed antitrust and unfair competition counterclaims. The Company filed a motion to dismiss Curio's unfair competition and antitrust counterclaims on July 5, 2024. The Company believes Curio's counterclaims are meritless and intends to vigorously defend itself. Trial is scheduled for May 2026.</div></div></div>

Shareholder Return (TSR) of the Company's common stock as compared to the TSR of the members of the Russell 3000 Medical Equipment and Services Sector Index over a three-year performance period from January 1, 2024 to December 31, 2026. Depending on the results relative to the TSR market condition, the holders may earn from 0% to 200% of the target amount of shares which will vest at the end of the performance period.

The PSU's will be forfeited if the performance conditions are not achieved at the end of the relative performance periods as described above. The vesting of the PSU's can also be triggered upon certain change in control events or in the event of death or disability.

The weighted average grant date fair values of the PSU's relating to CAGR and TSR components were \$37.43 and \$44.80 per share respectively. Stock-based compensation expense recognized for these awards was approximately \$0.7 million and \$0.8 million for the three and six months ended June 30, 2024, respectively.

The Company estimated the fair values of shares granted under the market-based TSR PSU's using a Monte Carlo simulation model with the following assumptions:

Expected volatility	66%
Expected dividend yield	0%
Risk-free interest rate	4.5%

In March 2023, the Company granted 172,842 PSU's under the 2019 Plan to certain members of management, which are subject to the achievement of certain stock price thresholds established by the Company's Compensation Committee of the Board of Directors.

As of June 30, 2024, the performance periods for the 2024 PSU's were not completed and none of the stock price thresholds for the 2023 PSU's had been met resulting in no shares vesting or becoming exercisable.

During the three months ended June 30, 2024 and 2023, 192,869 and 117,280 shares of Class A common stock, respectively, were issued under the ESPP. There were no shares of Class A common stock were issued under the ESPP during the three months ended March 31, 2024 and 2023. As of June 30, 2024, there were 2,898,194 shares available for issuance under the ESPP.

The price at which Class A common stock is purchased under the ESPP is equal to 85% of the fair market value of the common stock on the first day of the offering period or purchase date, whichever is lower.

Three Months Ended -> June 30, 2023	2023
Cost of revenue	\$2,247
Cost of goods sold	\$1,835
Operating expenses	\$4,280
Research and development	\$3,296
Selling, general and administrative	\$3,296
Interest expense	\$3,296
Income tax expense	\$3,296
Other income	\$3,296
Other expense	\$3,296
Net income	\$3,296

Net income available to common shareholders was \$3,296 for the three months ended June 30, 2024 and 2023.

